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Introduction 
 
The first successful kidney transplantation dates back to the year 1954. A healthy 
adult donated a kidney to his identical twin brother with life-threatening kidney 
disease. No immunosuppressive medication was used. The recipient lived for nine 
more years, got married, had children, and had a job to his liking.1 This event raised 
the hopes of all patients with end stage kidney disease. It took another five years 
before the first kidney transplantation in a child succeeded, with a kidney donated by 
his identical twin.2  
 
Transplantation is the ultimate modality of renal replacement therapy for end stage 
renal failure in children. It replaces most of the lost functions of the native kidneys, in 
contrast to any form of dialysis. Transplantation may restore kidney function within 
normal ranges, whereas with dialysis no more than 10% of normal clearance is 
reached. Moreover, dialysis is associated with high morbidity and even mortality. 
Chronic dialysis in children is therefore not considered as a permanent solution, but 
as a bridge to transplantation. In the Netherlands kidney transplantation in children is 
an accepted and feasible option since 1973.  
 
In our country the procedure is thought to be feasible in children with a minimum age 
of 3 years, or a minimum body weight of 12 kg. Either a pediatric or a vascular 
surgeon performs the transplantation, in some centers together with a pediatric 
urologist. The grafted kidney is usually placed in the iliac fossa; in case of a small 
child receiving an adult kidney, the abdomen may be the graft site. The renal blood 
vessels are anastomosed with the recipient’s external or commune iliac vessels, or, 
in case of intra-abdominal placement, with the aorta and inferior caval vein. The 
donor ureter is implanted in the recipient’s bladder. In most centers a temporary intra-
ureteral splint is placed to enable the urine to drain without resistance from the 
transplanted kidney. 
 
Table 1. Differences between pediatric and adult kidney transplantation (adapted from Ettenger ‘92 3) 
  1 Different spectrum of primary kidney disease 
  2 Different pharmacokinetics of immunosuppressive agents  
  3 Higher risk of vascular thrombosis in children 
  4 Longer anastomosis times with resulting delayed graft function in children  
  5 Immunologic responsiveness different in young children  
  6 Diagnosis of acute rejection more difficult in disproportionate graft size 
  7 Non-compliance with medication, especially in adolescents 
  8 More recurrence of original disease  
  9 Impaired growth before as well as after transplantation 
10 Negative effect of renal failure on children’s neurodevelopment 
11 Children more often naïve to viral infections (CMV, EBV) 
 
Pediatric kidney transplantation differs from adult transplantation in a number of 
aspects, as summarized in Table 1. Many of these factors will be discussed below. 
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Graft survival in children used to be lower than in adults, but recent outcomes tend to 
converge. A recent report of the OPTN/SRTR a showed a 5 year deceased donor 
graft survival rate of 73% both in recipients aged 6 – 10 years and recipients aged 35 
– 49 years.4,5  
 
Short-term risks of graft loss include acute rejection and thrombosis. Grafts surviving 
the first year may fail due to chronic allograft nephropathy, a gradual, multifactorial 
decline of kidney function.  
 
Once it comes to transplantation, a child may already have a wide range of comorbid 
conditions, e.g. of skeleton, heart and blood vessels. Transplantation will bring 
improvement, but nevertheless is a source of comorbidity of its own, for example 
through the toxic side effects of immunosuppressive medication. The sad truth 
therefore is that patients do not stop being patients. They get saddled with inevitable 
rules of life, first and foremost taking medication: immunosuppressive, 
antihypertensive.  
In spite of all this, renal transplantation is the optimal way to replace kidney function. 
Its ultimate goal is to achieve a higher quality and quantity of life of renal failure 
patients. Reaching this goal in children requires ongoing, scrupulous attention to 
medical and non-medical aspects, notably compliance with medication, psychosocial 
development, and education. 
 
 
End stage renal failure in numbers 
 
The incidence of end stage renal disease in children younger than 16 years in the 
Netherlands has remained rather stable between 1990 and 2006, fluctuating between 
25 and 30 new patients per year (Stichting Renine, www.renine.nl). Until recently this 
figure equalled the annual number of children receiving a kidney transplantation, 
which implies that the number of children on dialysis remained fairly stable. Since 
1972, approximately 800 children have received transplants in the four centers for 
pediatric kidney transplantation in the Netherlands. The proportion of children with 
end stage renal disease is very low relative to the incidence in the total population, 
which over this period surged from 1000 to 1800 patients per year. It is mainly the 
older age groups that explain this increase. The actual annual number of kidney 
transplantations in the Netherlands is below 1000, allowing the waiting list to grow. 
The number of patients enlisted for a deceased donor kidney at Eurotransplant 
increased from 2,000 in the year 1980 to 12,000 in 1998, and did not change 
significantly since then (www.eurotransplant.nl). Proportions of living donor 
transplantation in the entire Eurotransplant cohort increased from 9% in 1990 to 40% 
in 2007.  
 
                                               
a United States Organ Procurement and Transplantation Network / Scientific Registry of Transplant 
Recipients 
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Primary kidney disease (Table 2) 
The spectrum of diseases that lead to end stage renal failure in children differs from 
that in adults. Congenital structural abnormalities of the urinary tract – including 
obstructive uropathy (posterior urethral valves), refluxnephropathy, and renal 
dysplasia – form the larger part. Some of these urological disorders are associated 
with bladder dysfunction. Such dysfunction may seriously complicate the outcome of 
renal transplantation. Focal segmental glomerulosclerosis and hemolytic uremic 
syndrome are difficult to manage, not only before, but also after transplantation. 
These diseases show high recurrence rates and may lead to graft loss (see below).  
 
In contrast to adults, polycystic kidney disease in children is mainly of the autosomal 
recessive type, associated with end stage renal failure within the first decade of life, 
often complicated by liver disease. Metabolic diseases like cystinosis and oxalosis 
are both systemic diseases characterized by enzyme defects.  
Diabetic nephropathy, of growing influence in adult chronic kidney disease, is of 
minor importance in children. 
 
Table 2. Etiology of end stage kidney disease in the NAPRTCS b registry (adapted from 6) 
 % 
Aplasia/hypoplasia/dysplasia 1432 15.9 
Obstructive uropathy 1424 15.8 
Focal segmental glomerulosclerosis 1049 11.7 
Reflux nephropathy 466 5.2 
Chronic glomerulonephritis 307 3.4 
Polycystic disease 262 2.9 
Nephronophthisis/medullary cystic disease 249 2.8 
Hemolytic uremic syndrome 244 2.7 
Membranoproliferative glomerulonephritis 241 2.7 
Prune belly syndrome 239 2.7 
Congenital nephrotic syndrome 230 2.6 
IgA nephritis / Henoch-Schonlein nephritis 223 2.5 
Familial nephritis 200 2.2 
Cystinosis 185 2.1 
Idiopathic crescentic glomerulonephritis 166 1.8 
Pyelo/interstitial nephritis 164 1.8 
SLE nephritis 141 1.6 
Renal infarct 127 1.4 
Denys-Drash syndrome 49 0.5 
Wegener's granulomatosis 48 0.5 
Wilms' tumor 47 0.5 
Oxalosis 45 0.5 
Membranous nephropathy 41 0.5 
Other systemic immunologic diseases 32 0.4 
Sickle-cell nephropathy 15 0.2 
Diabetic glomerulonephritis 10 0.1 
Other  806 9.0 
Unknown 548 6.1 
Total 8990 100.0 
 
                                               
b North American Pediatric Renal Trials and Collaborative Studies 
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Patient survival 
In 1998 the expected life span of pediatric dialysis patients in the USA was 40 to 60 
years shorter than of an age- and race-matched healthy population. For transplanted 
patients it was 20 to 25 years shorter.7 Data on transplantation in childhood are 
limited. In the beginning of this century, Groothoff et al. performed extensive studies 
on outcome of a Dutch cohort of 250 young adult patients who had started renal 
replacement therapy in childhood (LERIC, or Late Effects of Renal Insufficiency in 
Children). The mortality rate of these patients was alarming: 25% had died before the 
age of 30.8 In this study and a similar one in Germany, 41 and 50% of deaths, 
respectively, were ascribed to cardiovascular or cerebrovascular events.8,9  
 
Infections formed the second most frequent cause of death. Mortality was associated 
with hypertension and with prolonged dialysis prior to transplantation. Fortunately, 
the last decade has seen a considerable rise in life expectancy of children with end 
stage renal disease, thanks to better dialysis therapy, immunosuppressive therapy, 
and treatment of infectious complications.8,10 
 
Graft survival 
Primarily thanks to the expansive development of immunosuppressive agents, short-
term graft survival has improved considerably over recent years. Longer term graft 
survival, however, appears to stay behind. Few studies extend 5 years’ follow up, 
and some of these are based upon extrapolation of short-term data. In a study of 
2004 in adults transplanted between 1988 and 1995 Meier-Kriesche et al 
demonstrated only marginal progress in long term deceased donor graft survival.11 
Though the 1 year graft survival rate nicely improved by 7% over this period, the 8 
year graft survival rate had increased only from 66% to 70%. In children, with 
exclusion of the youngest recipients and donors, the 1 year graft survival rate 
improved significantly as well: from 88% in the 1994-1998 cohort registered for the 
UNOSc to 95% in the 1999-2002 cohort.12 Limited to the first 5 years post-transplant 
the NAPRTCS data indicate a similar improvement: the 5 year graft survival rate of 
all deceased donor grafts registered since 1987 is 65%; that for grafts transplanted 
during the last decade is 77%.6 Longer term graft survival has not been published by 
NAPRTCS. Nevertheless, in a large single center in the USA, 10 year graft survival in 
children who received deceased donor grafts, also had hardly improved over the first 
30 years of pediatric kidney transplantation: from 51% in the 1970s to 55% in the 
1980s and 1990s, confirming the findings of Meier-Kriesche.10  
Graft survival in children is related to recipient age, and is worst in adolescents: at 5 
years post-transplant it is 72% in the 1 to 5 year olds, 77% in the 6 to 10 year olds, 
but no more than 60% in the 11-17 year old recipients, according to recent data of 
OPTN/SRTR.13 These differences appear to be based on long-term events, rather 
than events during the first year after transplantation. In addition to recipient age, 
other risk factors for graft loss are poor HLA matching, a prior transplant, multiple 
blood transfusions, prior dialysis, prolonged cold ischemia time, and African-
American race.6 
                                               
c United Network for Organ Sharing 
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Improved short-term graft survival has come at a price. Expansion and intensification 
of immunosuppressive therapy went hand in hand with higher incidence of infections 
– notably caused by cytomegalovirus, Epstein-Barr-virus and BK-polyomavirus –, 
long term toxicity of the immunosuppressive agents, and more malignancies, to 
name a few. Therefore current strategies on immunosuppression focus on 
minimization of these complications, by avoidance or withdrawal protocols. 
 
 
Pre-transplant factors: donor source and duration of dialysis 
 
A range of factors contribute to successful transplantation, including recipient factors 
(e.g. primary kidney disease, age, panel reactive antibodies, modality and duration of 
dialysis), donor factors (living vs. deceased, heart beating vs. non heart beating, age, 
cause of death) and factors relating to the transplantation procedure itself (ischemia 
times, HLA-matching, surgical complications). Here we comment on some of these.  
 
Donor source 
A kidney may be retrieved from a deceased or from a living donor. In the Netherlands 
and in the United Kingdom at present approximately 30 to 35% of pediatric 
transplantations concern a living related donation. this thesis,15 In North America, this 
percentage is higher, 50-60%. 6,14  
Living kidney donation in pediatric transplantation usually involves one of the parents. 
In recent years, grandparents have been added to this source of kidney donors. In 
most countries siblings cannot decide for organ donation until they have reached 
adulthood. Short-term survival of living donor grafts is superior to that of grafts from 
deceased donors, persistent for the first 5 years. The difference seems to decrease 
afterwards: graft survival at 5 years it is 80-85% and 65-66%, and at 10 years 54 and 
51% for living and deceased donors, respectively, in pediatric data from Great Britain 
and North America.15,16  
Allocation of deceased donor organs within the region of Germany, Austria, the 
Benelux, Slovenia and Croatia is entrusted to Eurotransplant. Because longer 
dialysis period interferes with children’s growth and neuropsychological development, 
and leads to less school attendance with permanent gaps in knowledge, most 
countries give children priority on the waiting list. Since the waiting lists grow, the 
average waiting time for children also increases. The Eurotransplant allocation 
system ETKAS, implemented in 1996, favors children on the waiting list for a 
deceased donor graft.17 Since the introduction of this system, the waiting time for 
children averages 1.5 to 2 years in our experience, and is shorter than that for adults. 
Waiting times for young children enlisted exclusively for a pediatric kidney donor, are 
even longer. 
 
Size discrepancy between donor and recipient 
An issue of controversy in kidney transplantation is the question whether pediatric 
patients should be given pediatric donor kidneys preferentially.18,19 Adult kidneys in 
young children have some drawbacks.  
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deceased donor graft.17 Since the introduction of this system, the waiting time for 
children averages 1.5 to 2 years in our experience, and is shorter than that for adults. 
Waiting times for young children enlisted exclusively for a pediatric kidney donor, are 
even longer. 
 
Size discrepancy between donor and recipient 
An issue of controversy in kidney transplantation is the question whether pediatric 
patients should be given pediatric donor kidneys preferentially.18,19 Adult kidneys in 
young children have some drawbacks.  
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First, as children have lower blood pressure, the discrepant size of the kidney carries 
the risk of hypoperfusion of the graft, which is associated with potential nephron loss.  
 
Second, the large organ heavily taxes the child’s circulation, with acute 
cardiovascular risks. In addition, the functional overcapacity of an adult kidney might 
mask complications such as acute rejections, reflected by delayed rise of plasma 
creatinin values.  
Several studies argue in favor of transplantation of pediatric donor kidneys to 
pediatric recipients. Of children receiving a deceased pediatric donor kidney the 
absolute glomerular filtration rate (GFR) gradually rose throughout the first four years 
after transplantation, reflecting the progressive use of reserve capacity.20,21 Increase 
in GFR in pediatric donor kidneys was paralleled by sustained growth of the grafts.22 
In contrast, the absolute GFR of pediatric recipients of adult grafts, living as well as 
deceased, did not increase, and therefore, the relative GFR declined.  
Nevertheless, graft survival of kidneys from donors younger than 10 years 
transplanted into young recipients is lower than that of all other combinations of age 
categories, as established by NAPRTCS and UNOS registries.19,23 The data of the 
Eurotransplant registry, collected for the study described in chapter 8, show a similar 
trend (data not published).  
 
Therefore, NAPRTCS advocates to transplant adult living donor kidney grafts, even 
into the youngest children and claims excellent results. In North America recipients 
aged 1 to 5 years have become the age group with the best graft survival after 5 
years, according to the OPTN/SCTR registry.5 
 
Two of the four centers for pediatric kidney transplantation in the Netherlands provide 
recipients below the age of 6 years only with pediatric donor kidneys. This policy is 
based on the lack of experience with the complicated surgery and anesthesia of adult 
kidney grafts in infants.  
 
Therefore, these children are dependent on deceased pediatric donors. In the 
Eurotransplant region, the number of pediatric donors is decreasing annually. Until 
recently, children did not get priority for pediatric donor kidneys. France and, since a 
few years the USA as well, offer organs of donors younger than 30 and 35 years 
respectively, preferentially to pediatric candidates.24,25 Only patients with 0 HLA 
mismatches and those who are highly sensitized have higher priority. The waiting 
time for children in these countries is less than 6 months. Eurotransplant also 
recognized the benefit of allocating pediatric kidneys to pediatric recipients and 
recently launched a program called ‘Young for young’, advocating organs of donors 
younger than 10 years to be given to recipients younger than 6 years, given full HLA-
DR matching. Nine months later no transplantations have been realized in this 
program yet.  
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Strategies to expand the donor pool 
A major issue in transplantation practice is the falling number of deceased donors 
over the years in combination with increasing numbers of patients in need for a 
transplantation. Road traffic in the Eurotransplant region has become safer, which 
has changed donor profiles. While 20 years ago the typical donor would have died 
from traumatic cerebral injury, nowadays the cause of death more often is intracranial 
hemorrhage. Due to this shift in cause of death, in the Eurotransplant region mean 
donor age has risen from 30 years to 50 years. Graft survival is negatively correlated 
with adult donor age; therefore, the shift in age has repercussions for graft survival.26  
 
In the Netherlands a national registry of potential organ donors was instituted in 
2001. Registration is on a voluntary, ‘informed consent’, basis. Surprisingly, since 
then fewer effective organ donations have been effectuated, and waiting time for 
candidates on the waiting list increased. Especially the large pool of unregistered 
people yielded less donors. Countries like Belgium, Austria, and Spain, which have 
the ‘presumed consent’ system, which implies that someone who dies is a donor 
unless he registered as non-donor, yield more donors resulting in shorter waiting 
times than in the Netherlands.  
 
The scarcity of organs calls for widening of the donor criteria. One approach that 
raised the number of potential donors is a gradual rise in donor upper age limit. 
Another option would be more active stimulation of living donation, for pediatric as 
well as adult recipients. 
In addition to heart beating donors, organs from non heart beating donors are 
increasingly being used in the Netherlands, despite the higher risk of delayed graft 
function and even primary non-function.27 Numbers of non heart beating donation 
have largely increased in recent years, however at the expense of heart beating, 
brain dead donation.  
Given the donor shortage, even ABO incompatible donor-recipient combinations are 
considered for transplantation nowadays, provided specific precautions be taken. 
The use of immunoadsorption has yielded reasonable results.28 Small-scale 
experience within the pediatric age group has recently been reported from the United 
States.6 
Many centers discard organs from donors under the age of 5 years. However, the 
use of these kidneys en bloc may expand the donor pool, especially for older children 
or adults. The outcome is better than that of single kidneys of these young donors in 
adult recipients, according to two reports from large United States registries, and is 
similar to that of ‘ideal’ donors.29,30 Still, this procedure carries higher risk of surgical 
complications and early graft loss due to thrombosis. Once the graft survives the first 
three months, long term graft survival may be similar to that of live adult 
transplantation.29,31 The glomerular filtration rate may increase over the first post 
transplant year.31 We reported good results with en bloc transplantations in pediatric 
recipients as well.32  
 
A new program for the exchange of living donor kidneys was introduced in 2004 in 
our country, the ‘cross-over’ program. In short, of two incompatible donor-recipient 
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pairs the donor kidney from one pair is transplanted to the recipient of the other pair, 
and vice versa, given a negative cross match.33 This new system already effectuated 
100 extra living organ donations so far, with good results.  
 
Pre-emptive transplantation 
One of the determinants of transplantation success is duration of the dialysis episode 
prior to the transplantation. Shorter dialysis leads to better transplantation results. In 
adults, this was shown by comparing kidney pairs transplanted into recipient pairs of 
whom one had dialyzed maximally 6 months and the other at least 2 years.34 This 
would seem to imply that pre-emptive transplantation, without prior dialysis, gives 
even better results. Indeed a NAPRTCS survey reported that LD graft survival in pre-
emptively transplanted or short-time dialyzed children was by far superior to that in 
the longer dialyzed recipients.35 This effect could not be demonstrated for deceased 
donor transplantations. Adolescents, who show the worst graft survival, may benefit 
most from pre-emptive transplantation, as shown from Australian data.36 The reason 
for better graft survival is not evident. One could speculate that pre-emptively 
transplanted patients will be fitter at the time of transplantation than those who have 
undergone prolonged dialysis. Also, the healthier cardiovascular system of such 
recipients has been suggested to adapt more properly to the circulatory demands of 
the new organ. Pre-emptively transplanted patients more often have immediate graft 
function than dialyzed patients.35  
In Europe, rates of pre-emptively performed pediatric kidney transplantations vary 
with country and donor source: Scandinavian countries, with high numbers of living 
donors, report high figures, in contrast to Greece, Belgium, and the Netherlands.37 
 
 
Immunologic processes in kidney transplantation 
 
A grafted organ elicits an immune response to the foreign antigens in the recipient, 
which may result in rejection of the organ. Therefore, the central issue in organ 
transplantation remains suppression of allograft rejection, or, better still, induction of 
tolerance.38 Human Leukocyte Antigens (HLA) play a major role in the immune 
responses that cause rejection of transplanted organs. They are controlled by highly 
polymorphic genes, encoding groups of antigens in two categories, class-I (HLA-A, -
B, and -C) and class-II (HLA-DR and -DQ). The spectrum of expressed HLA antigens 
is specific for each individual. These antigens are expressed on the membranes of 
allogen presenting cells and are instrumental in the generation of humoral and 
cellular immune responses.39 Avoiding HLA mismatches between donor and recipient 
of an organ transplantation appears to be relevant to its success. 
In allograft rejection naïve T cells and memory T cells are stimulated by antigen 
presenting cells (Figure 1). Naïve T cells are stimulated optimally by dendritic cells in 
secondary lymphoid tissue; antigen experienced cells also by other cell types, like 
endothelial cells of the graft. Three signals from outside the T-cells are necessary to 
initiate and continue the alloimune response.  
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Only one of these is antigen specific, i.e. signal 1: the antigen-presenting cell 
presents an antigen in connection with HLA-antigen, to engage with a T cell via the T 
cell receptor. This binding has no effect until it is parallelled by a costimulatory signal 
from the antigen presenting cell to the T cell (signal 2). Signals 1 and 2 together 
activate three pathways in the T cell, i.e. the calcineurin pathway, the mitogen-
activated protein kinase pathway, and the protein kinase C- nuclear factor κB 
pathway. These pathways trigger the transcription factors nuclear factor of activated 
T-cells (NFAT), activating protein 1, and NF- κB.  
This will lead to the expression of numerous molecules, including several 
interleukins, that result in a cascade of reactions. Interleukin-2 and -15, 
extracellularly, bind to the membrane-bound IL-2 receptor (CD25) of activated T-
cells, forming signal 3, leading to activation of mTOR (‘mammalian target of 
rapamycin’) and phosphoinositide-3-kinase, with subsequent initiation of the cell 
cycle. This results in T cell proliferation and differentiation. In lymfoid tissue B cells 
are activated as well by their antigen receptors, to produce alloantibodies against 
donor HLA antigens. 38  
 
Figure 1. Sites of action of immunosuppressive drugs in the three-signal model 
From: P. Halloran, NEJM 2004 38 
 
Lymphocytes require synthesis of purine- and pyrimidine nucleotides for replication, 
regulated by inosine monophosphate dehydrogenase (IMPDH) and dihydro-orotate 
dehydrogenase (DHODH), respectively. Effector T-cells infiltrate the graft and create 
typical rejection lesions such as tubulitis, and, in more advanced rejection, 
endothelial arteritis. 
 
Immunosuppressive therapy  
Immunosuppressive therapy aims to prevent or treat acute rejection episodes of the 
allograft. Its mechanisms of action are depletion of the responsible cells, diverting 
lymphocyte traffic, or interfering with lymphocyte response pathways.38  
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During the past decades the effectiveness of immunosuppressive medication has 
increased dramatically, both in numbers of available drugs and in their 
effectiveness.40 The first immunosuppressive agents were azathioprine and 
corticosteroids. At that time 5 year kidney graft survival was 30-50%. The introduction 
of cyclosporine in the 1980s was rewarded with a fall in the incidence of acute 
rejections and large improvement of graft survival 41. Since then, many 
immunosuppressive agents have been developed, the most widely spread of which 
are mycophenolic acid and tacrolimus.  
Polyclonal and monoclonal immunoglobulins found their way into induction therapy 
and anti-rejection therapy. Immunosuppressive prophylaxis usually consists of 
several immunosuppressive agents simultaneously. Currently, frequently used 
combinations are prednisolone, a calcineurin inhibitor and mycophenolate mofetil, 
sometimes in combination with an induction agent. The ultimate goal of research in 
immunosuppression is induction of complete or ‘prope’ tolerance to the organ, 
necessitating treatment with only a minimal amount of immunosuppression.42 
 
Immunosuppressive drugs in general have three different pharmacological effects: 1. 
prevention and suppression of allograft rejection, 2. undesired immunosuppression 
leading to (opportunistic) infections and malignancies, and 3. nonimmune toxicity to 
other tissues. 
 
Table 3. Classification of immunosuppressive agents (from P.Halloran, 2004 38) 
Small molecular drugs 
 Corticosteroids 
 Immunophilin-binding drugs 
  Calcineurin inhibitors 
   Cyclophilin-binding drugs: cyclosporine 
  FKBP12-binding drugs: tacrolimus, modified-release tacrolimus 
  Target-of-rapamycin inhibitors: sirolimus, everolimus 
 Inhibitors of nucleotide synthesis 
  Purine synthesis (IMPDH) inhibitors 
   Mycophenolate mofetil 
   Enteric-coated mycophenolic acid 
   Mizoribine (only used in Japan) 
  Pyrimidine synthesis (DHODH) inhibitors 
   Leflunomide 
   FK778 
 Antimetabolites: azathioprine 
 Sphingosine-1-phosphate-receptor antagonists: FTY720 
Protein drugs 
 Cell depleting antibodies (T-cells and/or B-cells) 
  Polyclonal antibody: horse or rabbit antithymoglobulin 
  Mouse monoclonal anti CD3 antibody (muromonab-CD3) 
  Humanized monoclonal anti-CD52 antibody: alemtuzumab 
  B-cell-depleting monoclonal anti-CD20 antibody: rituximab 
 Nondepleting antibodies and fusion proteins 
  Humanized or chimeric monoclonal anti-CD25 antibody (daclizumab, basiliximab) 
  Fusion protein with natural binding properties: CTLA-4-Ig 
 Intravenous immune globulin 
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Description of immunosuppressive agents currently in use in 
pediatric kidney transplantation (Table 3) 
 
Corticosteroids  
The effects of glucocorticoids on immunoresponsive cells are complex and not 
completely understood. After entering the immunoresponsive cell and binding to 
intracellular glucocorticoid receptors, steroids are phosphorylated and transported to 
the nucleus, where they activate or repress various genes. This results in either a 
release or a decrease in a vast number of interleukins and growth factors, ultimately 
resulting in dramatic immunosuppression.43 
The toxic side effects of glucocorticoids are as diverse as its immunosuppressive 
actions: hypertension, overweight, cushingoid appearance, acne vulgaris, 
osteopenia, psychosis, behavioral disturbances and sleeping disorders, cataracts, 
and gastric ulceration. Growth failure is one of the most impressive side effects in 
children. A possible remedy is decreasing the dosage or bringing down the frequency 
of administration from daily to alternate daily. 
 
Calcineurin inhibitors 
The benefits of calcineurin inhibitors of reducing acute rejection and better short-term 
graft survival are counteracted by a wide range of toxic effects. 
 
Cyclosporine acts by binding to cyclophilin; the complex inhibits calcineurin.44 By 
blocking calcineurin, cyclosporine ultimately inhibits the production of interleukin 2. 
The drug’s effects are proportional to degree of exposure to the drug, which makes 
monitoring of blood levels essential. 
Adverse effects of cyclosporine depend on degree of exposure as well, and include 
nephrotoxicity, neurotoxic effects like tremor and convulsions, hypertension, 
hyperlipidemia, hypomagnesemia, cosmetic side effects including hirsutism and 
gingiva hyperplasia. Furthermore, hemolytic uremic syndrome and post-transplant 
diabetes mellitus may occur. 
Cyclosporine is metabolized by CYP3A4 and CYP3A5, and therefore interacts with 
other drugs that need these enzymes for metabolism.45  
Pharmacokinetics: Serum trough levels are the easiest way to assess the drug’s 
pharmacokinetics and adjust the dosage accordingly. These levels do not correlate 
well, however, with total exposure and bioavailability over time. The level at 2 hours 
after ingestion, or levels at several time points, correlate better with the area under 
the concentration-time curve.46, 47 
Pediatric aspects: clearance of cyclosporine in young children is faster than in adults. 
Thrice daily administration therefore may be better than twice daily in this group of 
patients. This has been confirmed by studying the AUC.48, 49 Neoral® (cyclosporine) 
capsules are larger than the small pills of Prograft® and are smelly. These aspects, 
together with the cosmetic side effects of cyclosporine may lead to non-compliance, 
especially for adolescent girls. 
 
Tacrolimus inhibits calcineurin after binding to another immunophilin: FKBP12. In 
adults as well as children the use of tacrolimus has gradually taken over that of 
cyclosporine.  
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children. A possible remedy is decreasing the dosage or bringing down the frequency 
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monitoring of blood levels essential. 
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gingiva hyperplasia. Furthermore, hemolytic uremic syndrome and post-transplant 
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Cyclosporine is metabolized by CYP3A4 and CYP3A5, and therefore interacts with 
other drugs that need these enzymes for metabolism.45  
Pharmacokinetics: Serum trough levels are the easiest way to assess the drug’s 
pharmacokinetics and adjust the dosage accordingly. These levels do not correlate 
well, however, with total exposure and bioavailability over time. The level at 2 hours 
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Tacrolimus inhibits calcineurin after binding to another immunophilin: FKBP12. In 
adults as well as children the use of tacrolimus has gradually taken over that of 
cyclosporine.  
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A meta-analysis of 30 trials comparing tacrolimus and cyclosporine showed a higher 
efficacy of tacrolimus in preventing acute rejection, and improved graft survival of 
tacrolimus treated patients.50 In children co-treated with azathioprine and 
corticosteroids, tacrolimus yielded fewer acute rejections, and superior graft survival 
and glomerular filtration rate at four years post-transplant as compared with 
cyclosporine.51, 52  
Regrettably, tacrolimus has serious toxic effects: hypomagnesemia, neurological and 
gastrointestinal side-effects are more pronounced than with cyclosporine.50 
Nephrotoxicity is similar. De novo diabetes mellitus occurs more often as well, 
especially if tacrolimus is combined with higher doses of glucocorticoids.53  
In recent years, however, with further refinement of tacrolimus-based regimens the 
incidence of diabetes has declined.54 Tacrolimus does not have the cosmetic side-
effects of cyclosporine, and also hyperlipidemia and hypertension are usually milder.  
 
mTOR inhibitors 
Both sirolimus and everolimus bind to the same immunophilin as tacrolimus, 
FKBP12. This complex blocks the effect of the 3rd signal. By inhibiting the target of 
rapamycin (mTOR) it prevents the IL-2 IL-2-receptor complex to activate the cell 
cycle. Favorable properties of this drug include the lack of nephrotoxicity,55 and the 
potentially beneficial role in the prevention of malignancies.56 mTOR inhibitors have 
been evaluated in different primary immunosuppressive algorithms, either as 
replacement for calcineurin inhibitors or anti-metabolites, or in combination with 
calcineurin inhibitors at low or high doses.  
In children sirolimus is especially used to reduce side effects of calcineurin inhibitors. 
mTOR inhibitors generally favor surrogate endpoints for graft survival, e.g. 
glomerular filtration rate, but have a deleterious effect on some surrogate endpoints 
for patient outcome, like bone marrow depression and lipid disturbance.57 The mTOR 
inhibitors have a wide range of toxic effects: hyperlipidemia, thrombocytopenia, 
mouth ulcers, skin lesions, aggravation of proteinuria. Their use shortly after 
transplantation is relatively contraindicated due to delay of wound healing and 
increased occurrence of lymphoceles.58 In addition, sirolimus used in adult males has 
been reported to result in decreased testosterone levels, disruption of 
spermatogenesis and deleterious effects on the testis.59 This effect of sirolimus has 
not been investigated in children yet, but may be even more important in this age 
group.  
 
Mycophenolate mofetil (MMF)  
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic acid. It acts as an 
inhibitor of inosin monophosphate dehydrogenase, a key enzyme in purine synthesis 
in lymphocytes.60 It was developed in the nineties. In combination with corticosteroids 
and cyclosporine, it led to lower incidences of acute rejections as compared with 
placebo or azathioprine,61,62 which was confirmed by a meta-analysis of trials.63 It has 
achieved widespread use, due to both its immunosuppressive action and its mild 
toxicity profile. Side effects affect the gastrointestinal tract (mainly diarrhea) and bone 
marrow (anemia, leukopenia). In addition, MMF may increase the incidence of viral 
infections.  
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The dosage of MMF in children is derived from that in adults and based on body 
surface area, 600 mg/m2 twice daily.64 MMF dosage is dependent on co-medication: 
in combination with tacrolimus the dose should be lower than in combination with 
cyclosporine.65-67 With tapering of steroids, the availability of mycophenolic acid 
increases and the dosage should be adapted.68 Young children need higher relative 
dosage of MMF than older children.69 All these interactions stress the value of 
therapeutic drug monitoring.70  
As an alternative for MMF, enteric coated capsules of mycophenolic acid are 
available. The gastrointestinal side effects of these tablets might be lower. Children 
seldom have trouble swallowing the large tablets of Cellcept®. 
 
Azathioprine 
After corticosteroids, azathioprine was the first immunosuppressive drug used during 
the first 20 years of transplantation. Azathioprine acts by converting 6-
mercaptopurine, which leads to interference with DNA synthesis. Its 
immunosuppressive effect in transplant patients is inferior when compared to that of 
calcineurin inhibitors or MMF. Toxic effects are of a gastrointestinal (nausea) or bone 
marrow suppressive (anemia, leukopenia) nature. 
 
IL2-receptor antagonists 
Both daclizumab and basiliximab block the IL-2 receptors expressed on activated T-
cells. Its addition to a combination of cyclosporine, azathioprine and prednisolone, or 
of tacrolimus and steroids, respectively, reduces the incidence of acute rejections in 
both adults and children.71,72 Basiliximab has no proven beneficial effect on patient or 
graft survival. Its administration carries low risk, and is associated with fewer adverse 
events than T-cell depleting agents, like anti-thymocyte globulin (ATG). In recipients 
retransplanted after graft loss, however, life-threatening reactions were reported 
following re-exposure to basiliximab.(see 73) 
 
Alemtuzumab 
A recently introduced immunosuppressive agent, although not yet in Dutch pediatric 
kidney transplantation, is alemtuzumab. Alemtuzumab is a humanized monoclonal 
antibody against CD52, present on all B- and T-cells, monocytes, macrophages and 
natural killer cells. Applied in adults as induction therapy, it causes cell lysis and 
prolonged depletion of all affected cells. Though alemtuzumab was thought to play a 
role in the development of tolerance, recent studies contradict this.74 
 
Minimization of immunosuppressive therapy 
Confronted with the toxicity of the powerful immunosuppressive therapies of recent 
years, clinicians now attempt to minimize or even completely avoid administration of 
these drugs, immediately or later after transplantation, yet without compromising their 
immunosuppressive effects. The most important toxic effects to be avoided are 
cardiovascular toxicity (steroids and calcineurin inhibitors), nephrotoxicity (calcineurin 
inhibitors), growth inhibition, overweight, osteopenia and avascular bone necrosis 
(steroids), and cosmetic side effects that may lead to diminished compliance 
(steroids and calcineurin inhibitors).  
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Minimizing protocols therefore focus on eventual withdrawal of corticosteroids and 
calcineurin inhibitors in particular. Ideally, safety of this strategy should be 
guaranteed by careful monitoring of immunologic reactivity during tapering off. 
Recent studies have shown that this is well feasible.75 
Broyer reported the favorable effect on children’s growth of reducing the cumulative 
steroid dosage, i.e. by switching from a daily to an alternate daily schedule.76 Such 
switch in adults, or to half the daily dose of prednisolone, resulted in a clinically 
significant reduction of overweight, blood pressure, antihypertensive medication, and 
HbA1c. No further benefit was registered after complete withdrawal.77 The drawback 
of an alternate daily schedule is the risk of accidental non-compliance. The only 
randomized study of complete steroid withdrawal in children was prematurely 
stopped due to too many adverse events of the used immunosuppressive regimen 
(basiliximab, calcineurin-inhibitor, sirolimus and steroids), not because of steroid 
withdrawal itself. (see 78) A meta-analysis of steroid withdrawal studies in adults 
showed a higher risk of graft loss; however, no such difference was detected in the 
subset of trials containing MMF.79,80 In children even complete avoidance has been 
possible in the presence of extended daclizumab induction, tacrolimus and MMF.81 A 
prospective, randomized multicenter steroid-based versus steroid-free trial in 
pediatric kidney transplantation is currently underway in the United States.78 
Minimizing exposure to calcineurin inhibitors aims to reduce the toxic effects. A meta-
analysis of numerous relatively small, randomized, controlled trials – designed to 
evaluate the replacement of cyclosporine by azathioprine or the withdrawal of 
cyclosporine from an azathioprine containing regimen – concluded that elective CsA 
withdrawal increases the risk of acute rejection by about 11%, but does not reduce 
graft survival.79 Replacement of a calcineurin inhibitor by sirolimus immediately after 
transplantation has to be weighed against the considerable toxicity profile of sirolimus 
at this stage. In the long term, however, a combination of sirolimus and 
mycophenolate mofetil may exert a beneficial effect on GFR, graft survival, blood 
pressure and malignancies.82,83 It would be advisable, however, to first evaluate the 
effects of sirolimus on male fertility, especially important in youth. 
 
 
Factors threatening the survival of the grafted kidney 
 
Renovascular thrombosis  
Unfortunately, transplanted kidneys may be lost within days due to thrombosis of the 
anastomosed blood vessels. Some predisposing factors are specifically present in 
pediatric recipients. For example, transplant surgery can be complicated by small 
diameters of blood vessels of recipient or donor and by calibre differences between 
donor and recipient vessels. Moreover, when a large adult kidney is transplanted into 
a young child, blood pressure and blood flow will be considerably lower than what 
that kidney was used to. These factors in combination with the usual post-surgery 
hypercoagulable state predisposes particularly small children to thrombosis of the 
graft. In adults the reported incidence is 2%, in children most reported percentages 
are higher, i.e. 2 - 10%.6,23,84,85  
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Early graft loss due to thrombosis is associated with previous treatment with 
peritoneal dialysis, with prolonged cold ischemia time, and donor age below 6 
years.23,84,86,87 It occurs more often in deceased donor grafts than in living donor 
grafts, and more in retransplants than in first transplants.84,88 Recently, the use of IL-
2 receptor antagonists has been reported to decrease the risk of renal allograft 
thrombosis.89  
 
Apart from the usual post-surgical hypercoagulable state, thrombosis may originate 
from inherited or acquired thrombophilia. Patients with ESRD have greater risk of 
thrombophilia due to higher levels of homocystein and clotting factors VIII and IX as 
compared with the normal population.  
 
Also, within the framework of their primary kidney disease they may have acquired 
anti-phospholipid antibodies or lupus anti-coagulans, a strong risk factor for arterial 
and venous thrombosis. Furthermore, relatively high incidences of inherited causes 
of thrombophilia have been reported in patients with ESRD: 13% in adults and 27% 
in a relatively small population of pediatric patients.90,91 The causes in question were 
deficiency of protein C, S and antithrombin III, factor V Leiden mutation, and 
prothombin gene G20210 polymorphism.92 Patients with thrombophilia may lose their 
grafts in the first weeks due to thrombosis of the anastomosed blood vessels, but 
also long term graft survival can be hampered by sequential infarction of smaller 
artery branches.92 Cyclosporine and corticosteroids both have procoagulable 
properties, but clinical trials evaluating their effects on thrombosis have yielded 
conflicting results.93-95 
 
Different forms of prophylactic therapy to prevent thrombosis have been reported as 
successful: low dose aspirin in adults,96 low dose heparin or low molecular weight 
heparin in children,97,98 and in patients with a persisting risk of thrombosis heparin 
followed by aspirin during at least 12 months.91 Nevertheless, others reported lack of 
any impact of low dose heparin on the incidence of graft loss by thrombosis.85 Any 
benefit of treatment with (low molecular weight) heparin shortly after surgery must be 
balanced against the risk of bleeding, which may necessitate blood transfusions or 
surgical re-exploration. 
 
Delayed graft function 
Delayed development of graft function (DGF) has a detrimental effect on long term 
graft function and graft survival in both children and adults.99-102 It is largely caused 
by ischemic injury to the allograft in the period without blood circulation. Of these, the 
first warm ischemic period is the most harmful followed by the cold ischemia time, 
when the organ is perfused with protective cold preservation solution and stored on 
ice. In contrast to heart beating donation, non heart beating donation procedures are 
associated with a considerable first warm ischemia time, between cardiac arrest of 
the donor and perfusion of the organs. Moreover, the circulation of the donor will not 
be optimal prior to cardiac arrest. Non heart beating donor grafts, therefore, more 
often show DGF than do heart beating donor grafts.  
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often show DGF than do heart beating donor grafts.  
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On the other hand, organs from heart beating donors may suffer from ischemic injury 
as well, as a result of circulatory and hormonal disturbances and inflammatory 
processes in the donor.12 Organ quality could be improved by extended intensive 
care treatment of the donor, i.e. insulin therapy for strict glycemic control, adequate 
inotropic support, and possibly anti-inflammatory and cytoprotective treatments. 
Finally, at transplantation, reperfusion of the ischemically damaged organ activates a 
sequence of events that sustain renal injury, e.g. by the induction of reactive oxygen 
species.103 Preservation fluids aim to limit ischemia and reperfusion damage to the 
graft.104 In Dutch pediatric kidney transplantation practice mannitol is given 
immediately before removing the vessel clamps, based on its combined properties as 
a diuretic and an oxygen radical scavenger.  
 
Both in adults and children, DGF is associated with prolonged cold ischemia 
time.101,102 Other predictors in adults are higher donor age and higher donor 
creatinine levels; in North American children HLA-DR incompatibility and African-
American race.101,102 Evidently, grafts from living donors carry lower risk of DGF than 
do grafts from deceased donors, since the living donor is in good health at the time of 
donation, and the cold ischemia time is much shorter. In a NAPRTCS report the 
incidence of DGF in pediatric recipients was 6% for living donor grafts and 19% for 
deceased donor grafts.101 
 
Cyclosporine, with its vasoconstrictive action, may aggravate DGF. Attempts have 
been made, therefore, to postpone start of cyclosporine and replace it by a form of 
immunoglobulin induction. The findings of several investigators were not 
unanimous.105 A sequential therapy with ATG as induction therapy successfully 
prevented DGF in children.106,107 
 
Acute rejection 
The immune reaction against the foreign cells of an allograft can result in an acute 
rejection. Clinically, this presents as elevation of serum creatinine level, sometimes in 
combination with hypertension, fever, and haematuria and proteinuria. The diagnostic 
golden standard is kidney biopsy. The degree of acute rejection has been 
standardized in consensus meetings in Banff, defined as Banff criteria.108 
 
It has been suggested that children experience more allograft rejections than adult 
patients. Incidences of rejections may have been overestimated, however, by 
inclusion of rejections not proven by renal biopsy. Another explanation for the 
observed higher frequency of rejections may be the often relatively late introduction 
of new immunosuppressive drugs in pediatric programs. On the other hand, the 
diagnosis of acute rejection may be delayed in small children with relatively large 
grafts due to considerable functional reserve capacity of the donor kidneys. Only few 
pediatric transplant centers perform protocol biopsies, either for suspected rejections 
or as surveillance biopsies at fixed time points during the first year after 
transplantation. Consequently, to date there is still insufficient evidence to ascertain 
whether young age really is a risk factor for allograft rejection.  
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The incidence of acute rejection episodes gradually declined since the expansion of 
the arsenal of immunosuppressive drugs: cyclosporine in the 1980s, mycophenolate 
mofetil, tacrolimus and interleukin-2 receptor antagonists in the 1990s; viz. from 69% 
in 1988 to 16% in 2004 as reported by the NAPRTCS.6 Noteworthily, the more recent 
data are flattered by the high (50%) percentage of living donor transplantations, 
which are associated with a lower incidence of acute rejections.  
 
Acute rejection remains one of the main determinants of long term graft survival. 
Survival tends to be better in patients free from acute rejection episodes. Chronic 
allograft nephropathy, the most frequent cause of kidney allograft loss, remains to be 
associated with previous acute rejection episodes in children, particularly if these 
occur late in follow-up, or are repetitive.109  
 
Chronic allograft nephropathy 
Chronic allograft nephropathy is defined as a state of impaired renal allograft function 
at least three months post-transplant, independent of acute rejection, acute drug 
toxicity, and recurrent or de novo specific disease entities, and with typical features 
on biopsy, i.e. fibrotic changes of vascular endothelium, renal tubules, interstitium 
and glomeruli.110 It is the major cause of failure of kidney transplants after the first 
year. Sadly, its incidence has hardly declined, despite decreased incidence of acute 
rejection as a result of improved immunosuppression.  
 
This kind of transplant nephropathy is predicted by many factors. These include 
donor factors (aging, hypertension, brain death with hypocirculation), immunologic 
factors (HLA-matching, panel reactive antibodies, host responsiveness, effectiveness 
of and adherence to immunosuppressive therapy) and exogenous stressors on the 
graft (hypertension, donor-recipient size-disparity, hyperlipidemia, drug toxicity, and 
infectious agents).110 The pathogenesis is only partly understood. It is thought that 
endothelial activation in response to one or more of the aforementioned factors 
stimulates leukocyte activation and recruitment. These leukocytes activate effector 
cells, resulting in the secretion of an excessive amount of abnormal extracellular 
matrix, leading to fibrosis.111 Chronic allograft nephropathy resembles an accelerated 
normal aging process of the kidney.110 
 
Non-compliance 
Transplantations in adolescents have the lowest long term graft survival of all 
pediatric age groups. Specific properties of this age group include hormonal and 
behavioral changes of puberty. To the best of our knowledge, the effects of hormonal 
changes on graft survival have never been studied. The natural zest for 
independency of the adolescent would naturally seem to conflict with the prospect of 
lifelong dependency on and pampering by the medical system. Transplantation 
brings along a therapeutic regimen of continuous drug therapy, including drugs for 
immunosuppression, prophylactic antibiotics, and often for the treatment of 
hypertension and other comorbid diseases as well. And then, the youngsters are 
instructed to avoid risk factors for cardiovascular disease and cancer (sun protection, 
not smoking).  
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Non-compliance has been defined as failure or refusal to conform and adapt one’s 
actions to a rule, or to another person’s wishes.112 For young children it will be less of 
a problem, because living to the rules is primarily dependent on the parents. Parents 
generally are concerned for their children and are anxious to comply with doctors’ 
orders. Adolescents, however, are different. For several reasons they find it hard to 
adhere to the prescriptions. They like to see immediate results of what they are 
doing, and are not well able to conceptualize future consequences of present actions. 
Furthermore, they abhor the visible side effects of especially cyclosporine (hirsutism, 
gingiva hyperplasia, hand tremor) and corticosteroids (moon face, acne vulgaris, 
binge eating, overweight). In addition, they hate the smell of certain pills, or find them 
difficult to swallow. Finally, and not least importantly, they cannot face being different 
from their peers. All these are good reasons for some of the adolescents to revolt to 
the medication, overtly or silently.113  
 
Measuring the extent of non-compliance is virtually impossible. Often non-
compliance will out when trough concentrations of cyclosporine appear to be highly 
variable, unexpectedly low, or consistently lower when measured in the outpatient 
clinic than during admissions. Sometimes the clue might be provided by the 
pharmacy registry or more high-tech by electronic monitoring devices in the lids of 
the medication jars.114 
 
Some adolescents will be open about non-compliance and others will not, often 
dependent on the person who puts the question to them. A nurse or a social worker 
may be more capable than a physician of convincing them that the rules will work out 
well in the long run. Better compliance might be achieved e.g. through discussion 
groups with fellow patients coached by a social worker or psychologist.115  
 
A notorious moment to quit complying is the transition from pediatric to adult 
care.116,117 It is important therefore to prepare the patients for this event, and the 
medical and social teams at both the institutions of pediatric and adult care should be 
able to provide a high level of special support focused on this issue. 
 
 
Complications related to the primary kidney disease 
 
A few diseases leading to end stage kidney disease may harm the allograft as well.  
 
Dysfunction of the lower urinary tract 
Several urologic abnormalities are associated with dysfunction of the lower urinary 
tract. These include posterior urethral valves, prune belly syndrome, 
meningomyelocele, sinus urogenitalis and cloacal malformation. In those cases the 
graft may be connected to a malfunctioning bladder, which raises the risk of urinary 
drainage problems and urinary tract infections. Nonetheless, long term graft survival 
in these cases is similar to that in patients with normal bladder function 118-120.  
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Pre-transplantation urodynamic studies should ensure adequate management of the 
lower urinary tract. Augmentation cystoplasty before as well as after transplantation 
is reported to be without major complications.121 
 
Focal segmental glomerulosclerosis 
Focal segmental glomerulosclerosis (FSGS) is one of the frequently recurring 
diseases, especially if the original disease set on before the age of 6 years, and 
progressed rapidly to end stage disease. FSGS accounts for 11% of pediatric 
patients on renal replacement therapy. The recurrence rate is up to 50%.122 
Recurrence usually presents as proteinuria, and usually within 2 weeks from 
transplantation. Nephrectomy of the native kidneys has been recommended to detect 
proteinuria originating from the graft. Nephrotic range proteinuria within 2 weeks after 
transplantation is associated with a 50% risk of graft loss. Therapies such as plasma-
exchange and high dosed CsA have been successful in some cases to save the 
graft.123-125 Pre-emptive plasmapheresis for 2 to 8 sessions, starting immediately 
following transplantation, has been reported to reduce recurrence in children and 
high-risk adult patients.123,126 The use of a living donor kidney allows the start of 
plasmapheresis already during the preceding week. Prospective studies are required 
to delineate the optimal approach to prevent and/or treat the recurrence of FSGS. 
 
Hemolytic uremic syndrome 
Atypical, diarrhea negative hemolytic uremic syndrome (HUS) has been reported to 
recur in up to 50% of pediatric cases after transplantation, especially if related to 
factor H deficiency.122,127 Some cases can be treated successfully with 
plasmapheresis, but HUS will recur again in many cases after plasmapheresis 
tapering off.128,129 
 
IgA nephropathy 
Recurrence of IgA nephropathy, in terms of mesangial IgA deposits and 
hypercellularity, can be demonstrated in up to 50 - 60% of patients, though not 
always clinically significant. Graft loss due to recurrent disease has been reported in 
1.3 - 16% of patients with IgA nephropathy.130 
 
Membranoproliferative glomerulonephritis 
Membranoproliferative glomerulonephritis types 1 and 2 both recur frequently in 
kidney allografts, but only rarely are associated with graft loss. 
 
Primary hyperoxaluria type 1 
Primary hyperoxaluria type 1, resulting from the absent or dysfunctional hepatic 
enzyme alanine glyoxylate aminotransferase, is associated with renal failure on 
account of the deposition of calcium oxalate crystals. After transplantation the 
circulating oxalate crystals may continue to deposit in the kidney allograft, leading to 
graft failure. Intensive haemofiltration and/or haemodialysis, before and after 
transplantation, has improved graft survival.131 In some patients this metabolic 
disorder responds well to treatment with high dose vitamin B6.  
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Patients who do not respond to vitamin B6 can only be treated with liver 
transplantation to replace the missing enzyme. 
 
Finnish type of congenital nephrotic syndrome and Alport syndrome 
In the Finnish type of congenital nephrotic syndrome and Alport syndrome another 
phenomenon may occur after transplantation. Both diseases are associated with the 
hereditary absence of a structural component in the glomerulus: lack of nephrin 
between the epithelial cells in the former disease, and lack of a component of the 
collagen of the glomerular basement membrane in the latter. The transplanted kidney 
will possess these components, and in some cases the recipient develops antibodies 
against the foreign components. This may result in a recurrent nephrotic syndrome in 
the congenital nephrotic syndrome, and in a form of anti-glomerular basement 
syndrome in Alport syndrome.132 
 
 
Extrarenal comorbidity  
 
The child with chronic kidney disease is at risk for extrarenal complications, including 
cardiovascular and bone disease, and growth retardation. Some of these may be 
overcome when renal function is restored following transplantation. Other 
complications may aggravate as side effect of medication such as corticosteroids. 
Some comorbid conditions, such as infections and malignancies, directly result from 
the immunosuppressive medication. 
 
Cardiovascular changes 
Cardiovascular death is by far the most frequent cause of death in patients who 
started renal replacement therapy in childhood. Cardiovascular morbidity therefore 
has to be prevented or counteracted in an early phase of chronic renal failure.  
Insight into the pathophysiologic mechanisms leading to cardiovascular damage in 
children with renal failure gradually has grown during recent years. 
 
Cardiac morbidity in pediatric dialysis patients is different from that in adults. 
Arrhythmia, cardiomyopathy, valvular disease, and cardiac arrest prevail, whereas 
ischemic heart disease is rare in this age group.133 Risk factors that make children 
with renal disease prone to cardiovascular disease include hypertension, 
dyslipidemia, anemia, disturbed calcium-phosphate metabolism, malnutrition and 
hyperhomocysteinemia.134,135 Hypertension occurs in a large proportion of patients 
with chronic renal failure, and its prevalence is generally not lower after 
transplantation. It is a toxic side effect of several immunosuppressive agents, 
including corticosteroids, and calcineurin inhibitors. Furthermore, two processes have 
a detrimental effect on structure and function of the blood vessels. First, in the phase 
of chronic renal failure, high serum phosphate levels and hyperparathyroidism, the 
treatment of which may cause hypercalcemia, result in an increased calcium 
phosphate product. Calcium phosphate, subsequently, can precipitate in the medial 
wall of the blood vessels resulting in stiffening and thickening of the arterial walls; 
arteriosclerosis.134,136  
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This process may be aggravated by a low serum level of the potent inhibitor of serum 
calcium-phosphate complex formation fetuin-A, which may occur in combination with 
inflammation and malnutrition in patients with CRF.137 Second, blood vessels may be 
harmed by atherosclerotic plaques. Dyslipidemia and endothelial dysfunction are two 
of the main factors contributing to atherosclerosis, and were demonstrated in both 
children and adults on dialysis as well as after transplantation.138  
 
These degenerative changes in the vessel walls, together with the frequently 
occurring volume overload and metabolic disturbances in the dialysis phase, may 
lead to cardiac hypertrophia and replacement of the myocardium by fibrous tissue.136 
The increase in mass and the change in composition of the ventricle wall may cause 
disturbances of the heart rhythm and a fall in compliance of the ventricle wall, 
resulting in functional changes. Diastolic function of the heart usually deteriorates 
first: early diastolic filling of the ventricle is injured followed by the late diastolic filling 
by atrial contraction. Later the systolic function is at risk as well. Both diastolic and 
systolic dysfunction lead to congestive heart disease.136 Left ventricular hypertrophy 
and cardiac dysfunction have their onset early in chronic renal disease, and are 
progressive throughout the dialysis period.139  
 
After transplantation certain risk factors will disappear. The calcium phosphate 
metabolism usually normalizes, but other factors may now exert their influence, such 
as hypertension and toxicity of immunosuppressive drugs. Left ventricular 
hypertrophy decreases, but does not disappear: many pediatric patients still show left 
ventricular hypertrophy after transplantation.134,140 
 
Growth retardation 
Growth retardation is a major concern in children with chronic renal insufficiency. It 
originates from metabolic disturbances, malnutrition and dysfunction of the growth 
hormone axis. Even despite the use of growth hormone before transplantation to 
increase final height of growth retarded children with renal failure, around 60% of 
young adults with chronic renal disease since childhood had an adult height below -2 
standard deviation score.143,144 After transplantation some catch-up growth may 
occur, dependent on the child’s age and body height at transplantation, graft function, 
and dose and frequency of corticosteroids.141,142 
 
One way to improve longitudinal growth after transplantation is by reducing the 
frequency of administration of corticosteroids from once daily to alternate daily.76,145 
Prolonging of treatment with growth hormone is another option. Haffner et al studied 
patients with chronic kidney disease, including renal replacement therapy, who were 
treated with growth hormone for an average of 5 years. Their standard deviation 
score for body height increased from -3.2 to -1.7 at final height, as opposed to a 
decrease from -1.4 to -2.1 in patients who did not use growth hormone.146 Controlled 
studies of growth hormone treatment after transplantation similarly reported 
significantly improved growth in pre-pubertal and pubertal children.  
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These studies showed that growth hormone treatment does not affect renal function 
nor increases occurrence of acute rejections, though earlier reports suggested 
this.147-149 Currently in the Netherlands growth hormone therapy is reimbursed only 
for children with chronic renal failure and a GFR of less than 50 ml/min.1.73m2. Mean 
GFR one year post-transplant is 60 ml/min.1.73m2. This implies that many of these 
children have to wait for their GFR to decrease before treatment can be continued.  
 
Bone disease 
As in adults, chronic renal failure in childhood is often accompanied with renal 
osteodystrophy, a type of bone disease associated with osteopenia and 
osteomalacia, caused by disturbances in the calcium phosphate metabolism and 
hyperparathyroidism. These factors are especially hard to control in young children 
who have a relatively high intake of protein and phosphate. Prevention of renal 
osteodystrophy by means of dietary measures, phosphate binders and vitamin D 
analogues is feasable in many, but not all children. After successful transplantation 
this form of bone disease may improve, but a new kind of bone disorder may arise. In 
the first place corticosteroid therapy is associated with osteopenia, which may be 
monitored using dual energy X-ray absorptiometry (DEXA).150,151 However, DEXA 
results need to be corrected for bone age and pubertal stage, since transplanted 
children are often growth retarded and do not fit well in the normal values for age and 
sex.152 Secondly, avascular necrosis of the femoral head and condyles, and of the 
talus, may develop as a serious complication after transplantation. This may hardly 
be reversible and may well lead to crippling of the patient. It is associated with 
cumulative corticosteroid dose. In a recent cross-sectional study in Finland 3.6% of 
pediatric solid organ recipients had signs of osteonecrosis of the hip. All patients 
were older than 12 years at the time of diagnosis.153 In the LERIC study, 13% of 
patients with renal replacement therapy since childhood had experienced avascular 
bone necrosis, and 18% mentioned disabling bone disease in young adulthood.144 
Metabolic bone disease after transplantation is a solid argument to search for long 
term immunosuppressive regimens with only low steroids dosage.  
 
Infection 
Apart from preventing rejection of the allograft, immunosuppression suppresses the 
healthy response to infective agents as well, with more risk of serious infections. 
Infections in the first month after transplantation are generally caused by bacteria, 
and are associated with surgery, indwelling drains and catheters. The next five 
months notably bring viral diseases. Cytomegalovirus (CMV), Epstein Barr virus 
(EBV), varicella zoster virus (VZV, or chicken pox) and polyomaviruses then are the 
most threatening to immunosuppressed children.154 Furthermore, human herpes 
viruses 6 and 8 are associated with acute rejection and Kaposi sarcoma, 
respectively. In contrast to adults, children often still are naïve for some of these viral 
infections at the time of transplantation. It is therefore important that vaccinations are 
started already prior to transplantation, all the more because vaccination during 
immunosuppressive therapy is less effective. Unfortunately, vaccines for CMV and 
EBV are not available yet.  
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Finally, immunosuppressed patients are at risk of opportunistic infections, e.g. by 
Pneumocystis pneumoniae, toxoplasma, and certain fungi. Antibiotic prophylaxis with 
trimetoprim - sulfamethoxazol during the first three months could prevent most 
urinary tract infections, as well as some of the above mentioned opportunistic 
infections.155 
 
CMV 
CMV disease in a transplant patient is most commonly associated with fever, 
weakness and depression of bone marrow, and may include end-organ disease as 
well: nephritis, pneumonitis, colitis, esophagitis, hepatitis, retinitis and 
encephalopathy. CMV infection can also induce allograft rejection. The combination 
of CMV seropositive donors with CMV seronegative recipients has been reported to 
give a 4 times higher incidence of CMV disease, a non-significant increase in acute 
rejection incidence, and more than 20% increase in graft loss as compared with 
seronegative donors.156 Not only overt, but also subclinical CMV disease may be 
deleterious to the graft.157  
 
CMV may also increase susceptibility to co-infection with other viruses, like EBV. 
CMV disease is treated with gancyclovir.154 In kidney transplant patients resistance of 
CMV to gancyclovir is rare. Prophylactic treatment during the first three or six months 
after transplantation is usually instituted when either the donor or the recipient, or 
both, are seropositive at transplantation. 
 
EBV 
EBV infection due to transplantation of EBV-positive grafts into EBV-seronegative 
children is associated with post-transplant lymfoproliferative disease (PTLD). 
Infection or PTLD may present as unexplained fever, a mononucleosis-like 
syndrome, gastrointestinal bleeding, abdominal-mass lesions, central nervous 
system disease, but also as infiltrative disease of the allograft.154 Regular EBV-PCR 
surveillance and carefully monitored reduction of immunosuppression remain the 
mainstay of treatment. This may be followed by the administration of rituximab, and 
in case of atypical lymphoma, of chemotherapy. Antiviral prophylaxis may provide 
some protection against EBV disease as well as CMV disease. 
 
VZV 
The course of a primary VZV disease may be violent and atypical.158 Some patients 
have even died from disseminated VZV infection. Renal transplant patients who are 
seronegative for VZV antibodies, should receive zoster immunoglobulin if they have 
had contact with a child with chicken pox. Preferably, seronegative patients should 
be vaccinated before transplantation. 
 
BK-polyomavirus 
BK-polyomavirus may cause nephropathy with the risk of graft loss or ureteral 
obstruction.154 Histologic evidence of nephropathy precedes renal allograft 
dysfunction in more than 50% of cases.155  
Chapter 1 
30 
These studies showed that growth hormone treatment does not affect renal function 
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immunosuppressive therapy is less effective. Unfortunately, vaccines for CMV and 
EBV are not available yet.  
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Finally, immunosuppressed patients are at risk of opportunistic infections, e.g. by 
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It has been suggested to test all kidney transplant patients every three months for 
viruria by cytology (decoy-cells) or quantitative PCR. If viremia measured by PCR 
exceeds 10,000 copies per ml, a renal biopsy can confirm the diagnosis of BK-
nephropathy. Unfortunately, no effective antiviral treatment is available for BK 
disease. Less immunosuppression is currently the only chance of recovery, but 
consequently increases the risk of acute rejection and graft loss.  
 
Malignancies 
Malignancy is a major cause of morbidity and mortality in adult renal transplant 
patients. In long term follow-up studies incidences range between 2 and 20%.159-161 
Non-melanoma skin cancer is the most frequent malignancy in adults. Incidence of 
malignancies in children are still fairly low (1 - 4%), but have increased parallel to 
expansion of immunosuppressive therapy.162,163 In a 1994 report from the Cincinnati 
Transplant Tumor Registry, 53% of post renal transplant tumors occurring during 
childhood were lymphomas, followed by 19% skin and lip carcinomas. Ninety-eight 
percent of lymphomas were non-Hodgkin lymphoma, of which 90% of B-cell type, 
especially those occurring in the first year post-transplant.164 Most lymphomas 
occurred in adolescents, with a mean of 3 years post-transplant. Lymphomas are 
strongly associated with EBV infection (see above).  
 
In young Dutch adults on renal replacement therapy since childhood an overall 8.4% 
incidence of malignancies has been reported. Fifty-nine percent of these 
malignancies were skin cancers, and 23% non-Hodgkin lymphoma.165 The probability 
of developing a malignancy within 25 years after starting renal replacement therapy 
in childhood was estimated to be 17%.165 
 
 
Organisation of pediatric kidney transplantation in the Netherlands 
 
Renal replacement therapy in children in the Netherlands – both dialysis and kidney 
transplantation – is limited on a statutory basis to four institutions, in Amsterdam 
(Emma Children’s Hospital / Academic Medical Center), Utrecht (Wilhelmina 
Children’s Hospital / University Medical Center Utrecht), Nijmegen (University 
Medical Center St. Radboud), and Rotterdam (Erasmus MC / Sophia Children’s 
Hospital). The yearly number of kidney transplantations is stable, i.e. between 25 and 
30, distributed over the four centers. Due to the small numbers of cases per 
institution, single center evaluations and randomized controlled trials performed are 
hardly feasible within a reasonable time frame. Therefore, in 1997 the pediatric 
kidney transplant departments of the four Dutch centers set up a collaboration with 
that of the University Hospital Antwerp, Belgium. During the past ten years I had the 
privilege to coordinate our collaborative efforts. We had frequent contacts, and met 
formally at least four times per year. Consensus protocols were defined and clinical 
data were pooled. The collaboration served three goals. It allowed us to evaluate the 
results of these protocols, to perform prospective clinical trials, and to exchange 
individual experiences in the day to day care for renal transplant patients.  
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The ultimate goal of these efforts obviously was to improve the prospects of children 
with end stage renal disease.  
 
Since 1998 the centers use a shared immunosuppressive regimen. It has been 
agreed to adjust the immunosuppressive therapy after every transplanted 100 
patients, considering the results of the latter regimen and recent publications. The 
results of the first two cohorts are documented in this thesis. In addition we reached 
consensus on protocols for CMV prophylaxis and thrombosis prophylaxis. Currently 
we are working on consensus protocols for perioperative fluid management and for 
control of hypertension during follow up. Application of such standardized protocols is 
thought to enable further detailed assessment of transplant results in our pooled 
population.  
 
The collaborative database was developed in cooperation with the Dutch Organ 
Transplant Registry (NOTR). It contains the medical data of all pediatric kidney 
transplantations performed since the start of the first immunosuppressive protocol, 1 
January 1998. A research nurse regularly visits the different institutions and retrieves 
data from medical charts and digital databases. Data include detailed clinical data 
and medical events, like acute rejections, infections and other complications, growth, 
medication, education, and social environment. In addition, laboratory data are 
recorded. The Dutch Kidney Foundation supported the database financially during 
the first years, and since then Roche Nederland and Novartis Pharma Nederland 
have kindly provided financial sponsorship. Without this support, we would not have 
been able to set up and maintain the database, the core of the collaborative studies. 
 
It is my conviction that the improved outcome of our patients – as shown by fewer 
acute rejections and improved graft survival – is largely due to our joined efforts in 
developing new treatment strategies. The benefits of this cooperation are reflected in 
the research outcomes described in this thesis.  
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Outline of the thesis 
 
This thesis is a compilation of joint studies in pediatric kidney transplantation in and 
around the Netherlands. Most were within the framework of the Netherlands - 
Antwerp collaboration, one at Eurotransplant level, and one at interdepartmental level 
within one institution.  
 
 
Part I describes the two retrospective studies of transplantations in Dutch children 
that formed the point of departure for the collaboration between the pediatric kidney 
transplantation centers in the Netherlands and Antwerp. 
Chapter 2 reviews the short and intermediate term results of the transplantations 
performed between 1985 and 1995, the decade preceding the start of shared 
protocols. By then, every institution used a different protocol, the results of which did 
not allow firm conclusions due to relatively small numbers of cases.  
Chapter 3 deals with the clinical evaluation of Dutch young adults after they had 
undergone kidney transplantation in childhood, both retrospectively and cross-
sectionally. It forms part of the extensive investigations on Late Effects of Renal 
Insufficiency in Childhood, by Jaap Groothoff and coworkers.  
 
 
Part II reports the effect of different immunosuppressive protocols on outcome, both 
retrospectively and prospectively. These studies were conducted within the 
framework of the Netherlands - Antwerp collaboration. 
Chapter 4 compares the outcome of one shared immunosuppressive regimen, 
consisting of corticosteroids, cyclosporine and mycophenolate mofetil, without 
induction therapy, with that of the historic group described in Chapter 2. 
Chapter 5 compares the outcome of a modification of the initial immunosuppressive 
regimen with that of the cohort of Chapter 4. This modification aimed to reduce the 
incidences of delayed graft function and acute rejection episodes, and comprised 
sequential quadruple therapy starting with an IL-2 receptor antagonist, corticosteroids 
and mycophenolate mofetil; cyclosporine was added only after graft function was 
established.  
Chapter 6 describes a randomized controlled trial in which dual immunosuppressive 
therapy with MMF and prednisolone was compared with cyclosporine and 
prednisolone therapy. This trial started at the end of the first year post-transplant, and 
had 2 years of follow-up. The objective of this study was to reduce long term toxicity 
of cyclosporine.  
 
 
Part III studies the influences of pre-transplant factors on the outcome. 
Chapter 7 is a retrospective report from the Eurotransplant community describing the 
effect of avoiding dialysis treatment prior to transplantation on transplantation 
outcome. 
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Part IV deals with comorbid conditions in pediatric kidney transplantation. 
Chapter 8 reports five cases with a rare pulmonary complication after kidney or liver 
transplantation, i.e. bronchiectasis. 
Chapter 9 brings the results of the evaluation of respiratory complaints and 
pulmonary function in children with a functioning kidney transplant. This study was 
initiated after we became aware of bronchiectasis in some of our patients.  
Chapter 10 reports the prevalence in a single center of diastolic dysfunction of the 
left ventricular of the heart in children with a functioning kidney transplant. 
 
Chapter 1 
34 
Outline of the thesis 
 
This thesis is a compilation of joint studies in pediatric kidney transplantation in and 
around the Netherlands. Most were within the framework of the Netherlands - 
Antwerp collaboration, one at Eurotransplant level, and one at interdepartmental level 
within one institution.  
 
 
Part I describes the two retrospective studies of transplantations in Dutch children 
that formed the point of departure for the collaboration between the pediatric kidney 
transplantation centers in the Netherlands and Antwerp. 
Chapter 2 reviews the short and intermediate term results of the transplantations 
performed between 1985 and 1995, the decade preceding the start of shared 
protocols. By then, every institution used a different protocol, the results of which did 
not allow firm conclusions due to relatively small numbers of cases.  
Chapter 3 deals with the clinical evaluation of Dutch young adults after they had 
undergone kidney transplantation in childhood, both retrospectively and cross-
sectionally. It forms part of the extensive investigations on Late Effects of Renal 
Insufficiency in Childhood, by Jaap Groothoff and coworkers.  
 
 
Part II reports the effect of different immunosuppressive protocols on outcome, both 
retrospectively and prospectively. These studies were conducted within the 
framework of the Netherlands - Antwerp collaboration. 
Chapter 4 compares the outcome of one shared immunosuppressive regimen, 
consisting of corticosteroids, cyclosporine and mycophenolate mofetil, without 
induction therapy, with that of the historic group described in Chapter 2. 
Chapter 5 compares the outcome of a modification of the initial immunosuppressive 
regimen with that of the cohort of Chapter 4. This modification aimed to reduce the 
incidences of delayed graft function and acute rejection episodes, and comprised 
sequential quadruple therapy starting with an IL-2 receptor antagonist, corticosteroids 
and mycophenolate mofetil; cyclosporine was added only after graft function was 
established.  
Chapter 6 describes a randomized controlled trial in which dual immunosuppressive 
therapy with MMF and prednisolone was compared with cyclosporine and 
prednisolone therapy. This trial started at the end of the first year post-transplant, and 
had 2 years of follow-up. The objective of this study was to reduce long term toxicity 
of cyclosporine.  
 
 
Part III studies the influences of pre-transplant factors on the outcome. 
Chapter 7 is a retrospective report from the Eurotransplant community describing the 
effect of avoiding dialysis treatment prior to transplantation on transplantation 
outcome. 
 
 
Background: current state of affairs 
35 
Part IV deals with comorbid conditions in pediatric kidney transplantation. 
Chapter 8 reports five cases with a rare pulmonary complication after kidney or liver 
transplantation, i.e. bronchiectasis. 
Chapter 9 brings the results of the evaluation of respiratory complaints and 
pulmonary function in children with a functioning kidney transplant. This study was 
initiated after we became aware of bronchiectasis in some of our patients.  
Chapter 10 reports the prevalence in a single center of diastolic dysfunction of the 
left ventricular of the heart in children with a functioning kidney transplant. 
 
Chapter 1 
36 
References 
 
1. Morris PJ. Transplantation--a medical miracle of the 20th century. N Engl J Med 
2004;351(26):2678-80. 
2. Goodwin WE, Mims MM, Kaufman JJ. Human renal transplantation. III. Technical problems 
encountered in six cases of kidney homotransplantation. Trans Am Assoc Genitourin Surg 
1962;54:116-125. 
3. Ettenger RB. Children are different: the challenges of pediatric renal transplantation. American 
Journal of Kidney Diseases 1992;20:668-672. 
4. Salvatierra O, Alfrey E, Tanney DC, et al. Superior outcomes in pediatric renal transplantation. 
Arch Surg 1997;132(8):842-7; discussion 847-9. 
5. U.S Organ Procurement and Transplantation Network and the Scientific Registry of Transplant 
Recipients (OPTN/SCTR). Annual report 2006; Transplant data 1996 - 2005; 2006. 
6. Smith JM, Stablein DM, Munoz R, et al. Contributions of the Transplant Registry: The 2006 
Annual Report of the North American Pediatric Renal Trials and Collaborative Studies 
(NAPRTCS). Pediatr Transplant 2007;11(4):366-73. 
7. Disease NKFTFoC. Controlling the epidemic of cardiovascular disease in chronic renal disease: 
what do we know? Special report from the National Kidney Foundation Task Force on 
Cardiovascular disease. Am J Kidney Dis 1998;32(suppl 3):1-121. 
8. Groothoff JW, Gruppen MP, Offringa M, et al. Mortality and causes of death of end-stage renal 
disease in children: a Dutch cohort study. Kidney Int 2002;61(2):621-9. 
9. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults 
with childhood-onset chronic renal failure. Circulation 2002;106(1):100-5. 
10. Papalois VE, Najarian JS. Historical notes. In: Fine RN, Webber SA, Olthoff KM, Kelly DA, 
Harmon WE, editors. Pediatric solid organ transplantation: Blackwell Publishing; 2007. p. 139-
145. 
11. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made 
significant progress or is it time to rethink our analytic and therapeutic strategies? Am J 
Transplant 2004;4(8):1289-95. 
12. Hwang AH, Cho YW, Cicciarelli J, et al. Risk factors for short- and long-term survival of primary 
cadaveric renal allografts in pediatric recipients: a UNOS analysis. Transplantation 
2005;80(4):466-70. 
13. Magee JC, Bucuvalas JC, Farmer DG, et al. Pediatric transplantation. Am J Transplant 2004;4 
Suppl 9:54-71. 
14. Rees L, Shroff R, Hutchinson C, et al. Long-term outcome of paediatric renal transplantation: 
follow-up of 300 children from 1973 to 2000. Nephron Clin Pract 2007;105(2):c68-76. 
15. Shapiro R. Living donor kidney transplantation in pediatric recipients. Pediatr Transplant 
2006;10(7):844-50. 
16. Seikaly M, Ho PL, Emmett L, et al. The 12th Annual Report of the North American Pediatric 
Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr 
Transplant 2001;5(3):215-31. 
17. Persijn GG, Smits JM, Smith M, et al. Five-year experience with the new Eurotransplant Kidney 
Allocation System, 1996 to 2001. Transplant Proc 2002;34(8):3072-4. 
18. Pape L, Ehrich JH, Offner G. Young for young! Mandatory age-matched exchange of paediatric 
kidneys. Pediatr Nephrol 2007;22(4):477-9. 
19. Bresnahan BA, McBride MA, Cherikh WS, et al. Risk factors for renal allograft survival from 
pediatric cadaver donors: an analysis of united network for organ sharing data. Transplantation 
2001;72(2):256-61. 
20. Dubourg L, Cochat P, Hadj-Aissa A, et al. Better long-term functional adaptation to the child's 
size with pediatric compared to adult kidney donors. Kidney Int 2002;62(4):1454-60. 
21. Pape L, Offner G, Ehrich JH, et al. Renal allograft function in matched pediatric and adult 
recipient pairs of the same donor. Transplantation 2004;77(8):1191-4. 
22. Pape L, Hoppe J, Becker T, et al. Superior long-term graft function and better growth of grafts in 
children receiving kidneys from paediatric compared with adult donors. Nephrol Dial Transplant 
2006;21(9):2596-600. 
23. Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal 
transplantation: a special report of the North American Pediatric Renal Transplant Cooperative 
Study. Transplantation 1997;63(9):1263-7. 
Background: current state of affairs 
37 
24. Loirat C, Chalem Y, Golmard JL. Organ allocation in pediatric transplantation in France. Pediatr 
Nephrol 2001;16(12):964-70. 
25. Sweet SC, Wong HH, Webber SA, et al. Pediatric transplantation in the United States, 1995-
2004. Am J Transplant 2006;6(5 Pt 2):1132-52. 
26. Opelz G. Factors influencing long-term graft loss. The Collaborative Transplant Study. Transplant 
Proc 2000;32(3):647-9. 
27. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, et al. Non-heart-beating donor kidneys in the 
Netherlands: allocation and outcome of transplantation. Transplantation 2005;79(9):1195-9. 
28. Tyden G, Donauer J, Wadstrom J, et al. Implementation of a Protocol for ABO-incompatible 
kidney transplantation--a three-center experience with 60 consecutive transplantations. 
Transplantation 2007;83(9):1153-5. 
29. Pelletier SJ, Guidinger MK, Merion RM, et al. Recovery and utilization of deceased donor kidneys 
from small pediatric donors. Am J Transplant 2006;6(7):1646-52. 
30. Dharnidharka VR, Stevens G, Howard RJ. En-bloc kidney transplantation in the United states: an 
analysis of united network of organ sharing (UNOS) data from 1987 to 2003. Am J Transplant 
2005;5(6):1513-7. 
31. Sureshkumar KK, Reddy CS, Nghiem DD, et al. Superiority of pediatric en bloc renal allografts 
over living donor kidneys: a long-term functional study. Transplantation 2006;82(3):348-53. 
32. Bergmeijer JH, Cransberg K, Nijman JM, et al. Functional adaptation of en bloc-transplanted 
pediatric kidneys into pediatric recipients. Transplantation 1994;58(5):623-5. 
33. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, et al. A highly efficient living donor kidney 
exchange program for both blood type and crossmatch incompatible donor-recipient 
combinations. Transplantation 2006;82(12):1616-20. 
34. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for 
renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002;74(10):1377-81. 
35. Vats AN, Donaldson L, Fine RN, et al. Pre-transplant dialysis status and outcome of renal 
transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal 
Transplant Cooperative Study. Transplantation 2000;69(7):1414-9. 
36. Kennedy SE, Mackie FE, Rosenberg AR, et al. Waiting time and outcome of kidney 
transplantation in adolescents. Transplantation 2006;82(8):1046-50. 
37. van der Heijden BJ, van Dijk PC, Verrier-Jones K, et al. Renal replacement therapy in children: 
data from 12 registries in Europe. Pediatr Nephrol 2004;19(2):213-21. 
38. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 
2004;351(26):2715-29. 
39. Takemoto S, Port FK, Claas FH, et al. HLA matching for kidney transplantation. Hum Immunol 
2004;65(12):1489-505. 
40. Dharnidharka VR. Renal transplantation: the present and the future. Indian J Pediatr 
2005;72(9):785-8. 
41. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 
1983;309(14):809-15. 
42. Calne RY. Prope tolerance-the future of organ transplantation from the laboratory to the clinic. 
Transpl Immunol 2004;13(2):83-6. 
43. Buckbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new 
therapeutic opportunities. Curr Drug Targets Inflamm Allergy 2002;1(2):127-36. 
44. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-
lymphocyte activation. Nature 1992;357(6380):695-7. 
45. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a 
cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains 
interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43(6):630-5. 
46. Ferraresso M, Citterio F, Ghio L, et al. C2 is an age-independent parameter for optimal 
cyclosporine exposure in long-term kidney transplant recipients. Transplant Proc 
2004;36(9):2656-8. 
47. Dello Strologo L, Campagnano P, Federici G, et al. Cyclosporine A monitoring in children: 
abbreviated area under curve formulas and C2 level. Pediatr Nephrol 1999;13(2):95-7. 
48. Buchler M, Johnston A. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit 
2005;27(1):3-6. 
49. Hoyer PF, Brodehl J, Ehrich JH, et al. Practical aspects in the use of cyclosporin in paediatric 
nephrology. Pediatr Nephrol 1991;5(5):630-8. 
Chapter 1 
36 
References 
 
1. Morris PJ. Transplantation--a medical miracle of the 20th century. N Engl J Med 
2004;351(26):2678-80. 
2. Goodwin WE, Mims MM, Kaufman JJ. Human renal transplantation. III. Technical problems 
encountered in six cases of kidney homotransplantation. Trans Am Assoc Genitourin Surg 
1962;54:116-125. 
3. Ettenger RB. Children are different: the challenges of pediatric renal transplantation. American 
Journal of Kidney Diseases 1992;20:668-672. 
4. Salvatierra O, Alfrey E, Tanney DC, et al. Superior outcomes in pediatric renal transplantation. 
Arch Surg 1997;132(8):842-7; discussion 847-9. 
5. U.S Organ Procurement and Transplantation Network and the Scientific Registry of Transplant 
Recipients (OPTN/SCTR). Annual report 2006; Transplant data 1996 - 2005; 2006. 
6. Smith JM, Stablein DM, Munoz R, et al. Contributions of the Transplant Registry: The 2006 
Annual Report of the North American Pediatric Renal Trials and Collaborative Studies 
(NAPRTCS). Pediatr Transplant 2007;11(4):366-73. 
7. Disease NKFTFoC. Controlling the epidemic of cardiovascular disease in chronic renal disease: 
what do we know? Special report from the National Kidney Foundation Task Force on 
Cardiovascular disease. Am J Kidney Dis 1998;32(suppl 3):1-121. 
8. Groothoff JW, Gruppen MP, Offringa M, et al. Mortality and causes of death of end-stage renal 
disease in children: a Dutch cohort study. Kidney Int 2002;61(2):621-9. 
9. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults 
with childhood-onset chronic renal failure. Circulation 2002;106(1):100-5. 
10. Papalois VE, Najarian JS. Historical notes. In: Fine RN, Webber SA, Olthoff KM, Kelly DA, 
Harmon WE, editors. Pediatric solid organ transplantation: Blackwell Publishing; 2007. p. 139-
145. 
11. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made 
significant progress or is it time to rethink our analytic and therapeutic strategies? Am J 
Transplant 2004;4(8):1289-95. 
12. Hwang AH, Cho YW, Cicciarelli J, et al. Risk factors for short- and long-term survival of primary 
cadaveric renal allografts in pediatric recipients: a UNOS analysis. Transplantation 
2005;80(4):466-70. 
13. Magee JC, Bucuvalas JC, Farmer DG, et al. Pediatric transplantation. Am J Transplant 2004;4 
Suppl 9:54-71. 
14. Rees L, Shroff R, Hutchinson C, et al. Long-term outcome of paediatric renal transplantation: 
follow-up of 300 children from 1973 to 2000. Nephron Clin Pract 2007;105(2):c68-76. 
15. Shapiro R. Living donor kidney transplantation in pediatric recipients. Pediatr Transplant 
2006;10(7):844-50. 
16. Seikaly M, Ho PL, Emmett L, et al. The 12th Annual Report of the North American Pediatric 
Renal Transplant Cooperative Study: renal transplantation from 1987 through 1998. Pediatr 
Transplant 2001;5(3):215-31. 
17. Persijn GG, Smits JM, Smith M, et al. Five-year experience with the new Eurotransplant Kidney 
Allocation System, 1996 to 2001. Transplant Proc 2002;34(8):3072-4. 
18. Pape L, Ehrich JH, Offner G. Young for young! Mandatory age-matched exchange of paediatric 
kidneys. Pediatr Nephrol 2007;22(4):477-9. 
19. Bresnahan BA, McBride MA, Cherikh WS, et al. Risk factors for renal allograft survival from 
pediatric cadaver donors: an analysis of united network for organ sharing data. Transplantation 
2001;72(2):256-61. 
20. Dubourg L, Cochat P, Hadj-Aissa A, et al. Better long-term functional adaptation to the child's 
size with pediatric compared to adult kidney donors. Kidney Int 2002;62(4):1454-60. 
21. Pape L, Offner G, Ehrich JH, et al. Renal allograft function in matched pediatric and adult 
recipient pairs of the same donor. Transplantation 2004;77(8):1191-4. 
22. Pape L, Hoppe J, Becker T, et al. Superior long-term graft function and better growth of grafts in 
children receiving kidneys from paediatric compared with adult donors. Nephrol Dial Transplant 
2006;21(9):2596-600. 
23. Singh A, Stablein D, Tejani A. Risk factors for vascular thrombosis in pediatric renal 
transplantation: a special report of the North American Pediatric Renal Transplant Cooperative 
Study. Transplantation 1997;63(9):1263-7. 
Background: current state of affairs 
37 
24. Loirat C, Chalem Y, Golmard JL. Organ allocation in pediatric transplantation in France. Pediatr 
Nephrol 2001;16(12):964-70. 
25. Sweet SC, Wong HH, Webber SA, et al. Pediatric transplantation in the United States, 1995-
2004. Am J Transplant 2006;6(5 Pt 2):1132-52. 
26. Opelz G. Factors influencing long-term graft loss. The Collaborative Transplant Study. Transplant 
Proc 2000;32(3):647-9. 
27. Keizer KM, de Fijter JW, Haase-Kromwijk BJ, et al. Non-heart-beating donor kidneys in the 
Netherlands: allocation and outcome of transplantation. Transplantation 2005;79(9):1195-9. 
28. Tyden G, Donauer J, Wadstrom J, et al. Implementation of a Protocol for ABO-incompatible 
kidney transplantation--a three-center experience with 60 consecutive transplantations. 
Transplantation 2007;83(9):1153-5. 
29. Pelletier SJ, Guidinger MK, Merion RM, et al. Recovery and utilization of deceased donor kidneys 
from small pediatric donors. Am J Transplant 2006;6(7):1646-52. 
30. Dharnidharka VR, Stevens G, Howard RJ. En-bloc kidney transplantation in the United states: an 
analysis of united network of organ sharing (UNOS) data from 1987 to 2003. Am J Transplant 
2005;5(6):1513-7. 
31. Sureshkumar KK, Reddy CS, Nghiem DD, et al. Superiority of pediatric en bloc renal allografts 
over living donor kidneys: a long-term functional study. Transplantation 2006;82(3):348-53. 
32. Bergmeijer JH, Cransberg K, Nijman JM, et al. Functional adaptation of en bloc-transplanted 
pediatric kidneys into pediatric recipients. Transplantation 1994;58(5):623-5. 
33. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, et al. A highly efficient living donor kidney 
exchange program for both blood type and crossmatch incompatible donor-recipient 
combinations. Transplantation 2006;82(12):1616-20. 
34. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for 
renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002;74(10):1377-81. 
35. Vats AN, Donaldson L, Fine RN, et al. Pre-transplant dialysis status and outcome of renal 
transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal 
Transplant Cooperative Study. Transplantation 2000;69(7):1414-9. 
36. Kennedy SE, Mackie FE, Rosenberg AR, et al. Waiting time and outcome of kidney 
transplantation in adolescents. Transplantation 2006;82(8):1046-50. 
37. van der Heijden BJ, van Dijk PC, Verrier-Jones K, et al. Renal replacement therapy in children: 
data from 12 registries in Europe. Pediatr Nephrol 2004;19(2):213-21. 
38. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 
2004;351(26):2715-29. 
39. Takemoto S, Port FK, Claas FH, et al. HLA matching for kidney transplantation. Hum Immunol 
2004;65(12):1489-505. 
40. Dharnidharka VR. Renal transplantation: the present and the future. Indian J Pediatr 
2005;72(9):785-8. 
41. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 
1983;309(14):809-15. 
42. Calne RY. Prope tolerance-the future of organ transplantation from the laboratory to the clinic. 
Transpl Immunol 2004;13(2):83-6. 
43. Buckbinder L, Robinson RP. The glucocorticoid receptor: molecular mechanism and new 
therapeutic opportunities. Curr Drug Targets Inflamm Allergy 2002;1(2):127-36. 
44. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-
lymphocyte activation. Nature 1992;357(6380):695-7. 
45. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a 
cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains 
interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43(6):630-5. 
46. Ferraresso M, Citterio F, Ghio L, et al. C2 is an age-independent parameter for optimal 
cyclosporine exposure in long-term kidney transplant recipients. Transplant Proc 
2004;36(9):2656-8. 
47. Dello Strologo L, Campagnano P, Federici G, et al. Cyclosporine A monitoring in children: 
abbreviated area under curve formulas and C2 level. Pediatr Nephrol 1999;13(2):95-7. 
48. Buchler M, Johnston A. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit 
2005;27(1):3-6. 
49. Hoyer PF, Brodehl J, Ehrich JH, et al. Practical aspects in the use of cyclosporin in paediatric 
nephrology. Pediatr Nephrol 1991;5(5):630-8. 
Chapter 1 
38 
50. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary 
immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of 
randomised trial data. Bmj 2005;331(7520):810. 
51. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin 
microemulsion in renal transplantation. Pediatr Nephrol 2002;17(3):141-9. 
52. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a 
randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005;9(4):498-
503. 
53. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial 
comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J 
Transplant 2007;7(6):1506-14. 
54. First MR. Improving long-term renal transplant outcomes with tacrolimus: speculation vs 
evidence. Nephrol Dial Transplant 2004;19 Suppl 6:vi17-vi22. 
55. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to 
cyclosporine in renal transplant recipients. Am J Transplant 2002;2(5):436-42. 
56. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic 
tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 
2002;8(2):128-35. 
57. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and 
everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review 
and meta-analysis of randomized trials. Transplantation 2006;81(9):1234-48. 
58. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal 
transplant. Pediatr Transplant 2005;9(4):520-2. 
59. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and 
everolimus) in male patients: an overview. Transpl Int 2007;20(4):305-11. 
60. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester 
prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28. 
61. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, 
randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in 
cadaveric renal transplantation. Transplantation 1996;61(7):1029-37. 
62. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of 
mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute 
rejection. Lancet 1995;345(8961):1321-5. 
63. Wang K, Zhang H, Li Y, et al. Efficacy of mycophenolate mofetil versus azathioprine after renal 
transplantation: a systematic review. Transplant Proc 2004;36(7):2071-2. 
64. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for 
total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: 
a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil 
Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999;21(5):498-506. 
65. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid 
pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in 
combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5(3):225-32. 
66. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by 
concomitant immunosuppression. Pediatric Nephrology 2000;14:100-104. 
67. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of 
mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000;14(2):95-9. 
68. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil 
bioavailability in kidney transplantation. Kidney Int 2002;62(3):1060-7. 
69. Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in 
combination with tacrolimus after pediatric renal transplantation. Transplant Proc 
2004;36(5):1327-31. 
70. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil 
in transplantation. Ther Drug Monit 2006;28(2):145-54. 
71. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent 
acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 
1998;338(3):161-5. 
72. Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of 
renal transplants in children and adolescents. Pediatr Nephrol 2001;16(9):693-6. 
Background: current state of affairs 
39 
73. Boggi U, Vistoli F, Signori S, Del Chiaro M, et al. Efficacy and safety of basiliximab in kidney 
transplantation. Expert Opin Drug Saf 2005;4(3):473-90. 
74. Ciancio G, Burke GW, 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J 
Transplant 2008;8(1):15-20. 
75. van de Wetering J, van der Mast BJ, de Kuiper P, et al. Reduction of immunosuppressive load in 
renal transplant recipients with a low donor-specific cytotoxic T-lymphocyte precursor frequency 
is safe. Transplant Proc 2005;37(2):779-81. 
76. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid 
treatment after kidney transplantation. J Pediatr 1992;120(5):721-5. 
77. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in 
renal transplant recipients. Am J Kidney Dis 2001;37(6):1162-9. 
78. Sarwal M, Pascual J. Immunosuppression minimization in pediatric transplantation. Am J 
Transplant 2007;7(10):2227-35. 
79. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal 
trials in renal transplantation. J Am Soc Nephrol 2000;11(10):1910-7. 
80. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple 
therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, 
controlled trials. Transplantation 2004;78(10):1548-56. 
81. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and 
lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric 
renal transplantation. Transplantation 2003;76(9):1331-9. 
82. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal 
transplantation. Am J Transplant 2006;6(9):1991-9. 
83. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based 
therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 
2005;5(7):1748-56. 
84. McDonald RA, Smith JM, Stablein D, et al. Pretransplant peritoneal dialysis and graft thrombosis 
following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003;7(3):204-
8. 
85. Nagra A, Trompeter RS, Fernando ON, et al. The effect of heparin on graft thrombosis in 
pediatric renal allografts. Pediatr Nephrol 2004;19(5):531-5. 
86. van der Vliet JA, Barendregt WB, Hoitsma AJ, et al. Increased incidence of renal allograft 
thrombosis after continuous ambulatory peritoneal dialysis. Clin Transplant 1996;10(1 Pt 1):51-4. 
87. Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult 
renal transplant recipients. Kidney Int 1999;55(5):1952-60. 
88. Snyder JJ, Kasiske BL, Gilbertson DT, et al. A comparison of transplant outcomes in peritoneal 
and hemodialysis patients. Kidney Int 2002;62(4):1423-30. 
89. Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with 
interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006;6(3):585-8. 
90. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with 
thrombophilia. Transplantation 1998;65(7):936-9. 
91. Kranz B, Vester U, Nadalin S, et al. Outcome after kidney transplantation in children with 
thrombotic risk factors. Pediatr Transplant 2006;10(7):788-93. 
92. Andrassy J, Zeier M, Andrassy K. Do we need screening for thrombophilia prior to kidney 
transplantation? Nephrol Dial Transplant 2004;19 Suppl 4:iv64-8. 
93. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic 
changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1(8436):999-
1002. 
94. Brunkwall J, Bergqvist D, Bergentz SE, et al. Postoperative deep venous thrombosis after renal 
transplantation. Effects of cyclosporine. Transplantation 1987;43(5):647-9. 
95. van den Dorpel MA, Levi M, JN IJ, et al. Beneficial effects of conversion from cyclosporine to 
azathioprine on fibrinolysis in renal transplant recipients. Transplant Proc 1999;31(1-2):329. 
96. Robertson AJ, Nargund V, Gray DW, et al. Low dose aspirin as prophylaxis against renal-vein 
thrombosis in renal-transplant recipients. Nephrol Dial Transplant 2000;15(11):1865-8. 
97. Broyer M, Gagnadoux MF, Sierro A, et al. Preventive treatment of vascular thrombosis after 
kidney transplantation in children with low molecular weight heparin. Transplantation Proceedings 
1991;23:1384-1385. 
Chapter 1 
38 
50. Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary 
immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of 
randomised trial data. Bmj 2005;331(7520):810. 
51. Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin 
microemulsion in renal transplantation. Pediatr Nephrol 2002;17(3):141-9. 
52. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a 
randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005;9(4):498-
503. 
53. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial 
comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J 
Transplant 2007;7(6):1506-14. 
54. First MR. Improving long-term renal transplant outcomes with tacrolimus: speculation vs 
evidence. Nephrol Dial Transplant 2004;19 Suppl 6:vi17-vi22. 
55. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to 
cyclosporine in renal transplant recipients. Am J Transplant 2002;2(5):436-42. 
56. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic 
tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 
2002;8(2):128-35. 
57. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and 
everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review 
and meta-analysis of randomized trials. Transplantation 2006;81(9):1234-48. 
58. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal 
transplant. Pediatr Transplant 2005;9(4):520-2. 
59. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and 
everolimus) in male patients: an overview. Transpl Int 2007;20(4):305-11. 
60. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester 
prodrug, mycophenolate mofetil. Immunol Rev 1993;136:5-28. 
61. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, 
randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in 
cadaveric renal transplantation. Transplantation 1996;61(7):1029-37. 
62. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of 
mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute 
rejection. Lancet 1995;345(8961):1321-5. 
63. Wang K, Zhang H, Li Y, et al. Efficacy of mycophenolate mofetil versus azathioprine after renal 
transplantation: a systematic review. Transplant Proc 2004;36(7):2071-2. 
64. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for 
total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: 
a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil 
Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999;21(5):498-506. 
65. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid 
pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in 
combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5(3):225-32. 
66. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by 
concomitant immunosuppression. Pediatric Nephrology 2000;14:100-104. 
67. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of 
mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000;14(2):95-9. 
68. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil 
bioavailability in kidney transplantation. Kidney Int 2002;62(3):1060-7. 
69. Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in 
combination with tacrolimus after pediatric renal transplantation. Transplant Proc 
2004;36(5):1327-31. 
70. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil 
in transplantation. Ther Drug Monit 2006;28(2):145-54. 
71. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent 
acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 
1998;338(3):161-5. 
72. Swiatecka-Urban A, Garcia C, Feuerstein D, et al. Basiliximab induction improves the outcome of 
renal transplants in children and adolescents. Pediatr Nephrol 2001;16(9):693-6. 
Background: current state of affairs 
39 
73. Boggi U, Vistoli F, Signori S, Del Chiaro M, et al. Efficacy and safety of basiliximab in kidney 
transplantation. Expert Opin Drug Saf 2005;4(3):473-90. 
74. Ciancio G, Burke GW, 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J 
Transplant 2008;8(1):15-20. 
75. van de Wetering J, van der Mast BJ, de Kuiper P, et al. Reduction of immunosuppressive load in 
renal transplant recipients with a low donor-specific cytotoxic T-lymphocyte precursor frequency 
is safe. Transplant Proc 2005;37(2):779-81. 
76. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid 
treatment after kidney transplantation. J Pediatr 1992;120(5):721-5. 
77. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in 
renal transplant recipients. Am J Kidney Dis 2001;37(6):1162-9. 
78. Sarwal M, Pascual J. Immunosuppression minimization in pediatric transplantation. Am J 
Transplant 2007;7(10):2227-35. 
79. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal 
trials in renal transplantation. J Am Soc Nephrol 2000;11(10):1910-7. 
80. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple 
therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, 
controlled trials. Transplantation 2004;78(10):1548-56. 
81. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and 
lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric 
renal transplantation. Transplantation 2003;76(9):1331-9. 
82. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal 
transplantation. Am J Transplant 2006;6(9):1991-9. 
83. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based 
therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 
2005;5(7):1748-56. 
84. McDonald RA, Smith JM, Stablein D, et al. Pretransplant peritoneal dialysis and graft thrombosis 
following pediatric kidney transplantation: a NAPRTCS report. Pediatr Transplant 2003;7(3):204-
8. 
85. Nagra A, Trompeter RS, Fernando ON, et al. The effect of heparin on graft thrombosis in 
pediatric renal allografts. Pediatr Nephrol 2004;19(5):531-5. 
86. van der Vliet JA, Barendregt WB, Hoitsma AJ, et al. Increased incidence of renal allograft 
thrombosis after continuous ambulatory peritoneal dialysis. Clin Transplant 1996;10(1 Pt 1):51-4. 
87. Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult 
renal transplant recipients. Kidney Int 1999;55(5):1952-60. 
88. Snyder JJ, Kasiske BL, Gilbertson DT, et al. A comparison of transplant outcomes in peritoneal 
and hemodialysis patients. Kidney Int 2002;62(4):1423-30. 
89. Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with 
interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006;6(3):585-8. 
90. Fischereder M, Gohring P, Schneeberger H, et al. Early loss of renal transplants in patients with 
thrombophilia. Transplantation 1998;65(7):936-9. 
91. Kranz B, Vester U, Nadalin S, et al. Outcome after kidney transplantation in children with 
thrombotic risk factors. Pediatr Transplant 2006;10(7):788-93. 
92. Andrassy J, Zeier M, Andrassy K. Do we need screening for thrombophilia prior to kidney 
transplantation? Nephrol Dial Transplant 2004;19 Suppl 4:iv64-8. 
93. Vanrenterghem Y, Roels L, Lerut T, et al. Thromboembolic complications and haemostatic 
changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;1(8436):999-
1002. 
94. Brunkwall J, Bergqvist D, Bergentz SE, et al. Postoperative deep venous thrombosis after renal 
transplantation. Effects of cyclosporine. Transplantation 1987;43(5):647-9. 
95. van den Dorpel MA, Levi M, JN IJ, et al. Beneficial effects of conversion from cyclosporine to 
azathioprine on fibrinolysis in renal transplant recipients. Transplant Proc 1999;31(1-2):329. 
96. Robertson AJ, Nargund V, Gray DW, et al. Low dose aspirin as prophylaxis against renal-vein 
thrombosis in renal-transplant recipients. Nephrol Dial Transplant 2000;15(11):1865-8. 
97. Broyer M, Gagnadoux MF, Sierro A, et al. Preventive treatment of vascular thrombosis after 
kidney transplantation in children with low molecular weight heparin. Transplantation Proceedings 
1991;23:1384-1385. 
Chapter 1 
40 
98. Alkhunaizi AM, Olyaei AJ, Barry JM, et al. Efficacy and safety of low molecular weight heparin in 
renal transplantation. Transplantation 1998;66(4):533-4. 
99. Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and 
long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004;65(5):1906-13. 
100. Boom H, Mallat MJ, de Fijter JW, et al. Delayed graft function influences renal function, but not 
survival. Kidney Int 2000;58(2):859-66. 
101. Tejani AH, Sullivan EK, Alexander SR, et al. Predictive factors for delayed graft function (DGF) 
and its impact on renal graft survival in children: a report of the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation 1999;3:293-300. 
102. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia 
time on renal allograft survival. Nephrol Dial Transplant 2006;21(6):1689-96. 
103. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet 
2004;364(9447):1814-27. 
104. Ahmad N, Pratt JR, Potts DJ, et al. Comparative efficacy of renal preservation solutions to limit 
functional impairment after warm ischemic injury. Kidney Int 2006;69(5):884-93. 
105. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal 
transplantation: a review. Clin Transplant 2005;19(6):705-10. 
106. Cravedi P, Codreanu I, Satta A, et al. Cyclosporine prolongs delayed graft function in kidney 
transplantation: are rabbit anti-human thymocyte globulins the answer? Nephron Clin Pract 
2005;101(2):c65-71. 
107. Muller T, Ruffingshofer D, Bidmon B, et al. Reduction of delayed renal allograft function using 
sequential immunosuppression. Pediatr Nephrol 2001;16(8):613-7. 
108. Solez K, Hansen HE, Kornerup HJ, et al. Clinical validation and reproducibility of the Banff 
schema for renal allograft pathology. Transplant Proc 1995;27(1):1009-11. 
109. Tejani A, Ho PL, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft 
failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS). Am J Transplant 2002;2(2):142-7. 
110. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of 
accelerated senescence. J Am Soc Nephrol 1999;10(1):167-81. 
111. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. 
Transpl Immunol 2006;16(3-4):148-57. 
112. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant 
recipients. Drugs 2007;67(10):1463-81. 
113. Habwe VQ. Posttransplantation quality of life: more than graft function. Am J Kidney Dis 
2006;47(4 Suppl 2):S98-110. 
114. Blowey DL, Hebert D, Arbus G, et al. Compliance with cyclosporine in adolescent renal transplant 
recipients. Pediatric Nephrology 1997;11:547-551. 
115. Smith JM, McDonald RA. Renal transplantation in adolescents. Adolesc Med Clin 
2005;16(1):201-14. 
116. Remorino R, Taylor J. Smoothing things over: the transition from pediatric to adult care for kidney 
transplant recipients. Prog Transplant 2006;16(4):303-8. 
117. Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 
2000;14(6):469-72. 
118. Groenewegen AA, Sukhai RN, Nauta J, et al. Results of renal transplantation in boys treated for 
posterior urethral valves. J Urol 1993;149(6):1517-20. 
119. Salomon L, Fontaine E, Gagnadoux MF, et al. Posterior urethral valves: long-term renal function 
consequences after transplantation. J Urol 1997;157(3):992-5. 
120. Luke PP, Herz DB, Bellinger MF, et al. Long-term results of pediatric renal transplantation into a 
dysfunctional lower urinary tract. Transplantation 2003;76(11):1578-82. 
121. Fontaine E, Gagnadoux MF, Niaudet P, et al. Renal transplantation in children with augmentation 
cystoplasty: long-term results. J Urol 1998;159(6):2110-3. 
122. Smith JM, McDonald RA. Post-transplant management. In: Fine RN, Webber SA, Olthoff KM, 
Kelly DA, Harmon W, editors. Pediatric solid organ transplantation: Blackwell Publishing; 2007. p. 
174-184. 
123. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS 
in high-risk renal transplant recipients. Am J Transplant 2005;5(12):2907-12. 
124. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal 
transplantation in children. Pediatr Nephrol 2007;22(4):496-502. 
Background: current state of affairs 
41 
125. Nathanson S, Cochat P, Andre JL, et al. Recurrence of nephrotic syndrome after renal 
transplantation: influence of increased immunosuppression. Pediatr Nephrol 2005;20(12):1801-4. 
126. Ohta T, Kawaguchi H, Hattori M, et al. Effect of pre-and postoperative plasmapheresis on 
posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 
2001;71(5):628-33. 
127. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal 
transplantation in children. Pediatr Nephrol 2003;18(11):1095-101. 
128. Davin JC, Olie KH, Verlaak R, et al. Complement factor H-associated atypical hemolytic uremic 
syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am 
J Kidney Dis 2006;47(2):e27-30. 
129. Zimmerhackl LB, Besbas N, Jungraithmayr T, et al. Epidemiology, clinical presentation, and 
pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 
2006;32(2):113-20. 
130. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J 
Transplant 2006;6(11):2535-42. 
131. Scheinman JI. Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int 
1991;40(3):389-99. 
132. Patrakka J, Ruotsalainen V, Reponen P, et al. Recurrence of nephrotic syndrome in kidney grafts 
of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. 
Transplantation 2002;73(3):394-403. 
133. Chavers BM, Li S, Collins AJ, et al. Cardiovascular disease in pediatric chronic dialysis patients. 
Kidney Int 2002;62(2):648-53. 
134. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 
2006. 
135. Lilien M, Duran M, Van Hoeck K, et al. Hyperhomocyst(e)inaemia in children with chronic renal 
failure. Nephrol Dial Transplant 1999;14(2):366-8. 
136. Scharer K, Schmidt KG, Soergel M. Cardiac function and structure in patients with chronic renal 
failure. Pediatr Nephrol 1999;13(9):951-65. 
137. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular 
death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67(6):2383-92. 
138. Lilien MR, Stroes ES, Op't Roodt J, et al. Vascular function in children after renal transplantation. 
Am J Kidney Dis 2003;41(3):684-91. 
139. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 
1997;4(3):212-24. 
140. Bullington N, Kartel J, Khoury P, et al. Left ventricular hypertrophy in pediatric kidney transplant 
recipients: long-term follow-up study. Pediatr Transplant 2006;10(7):811-5. 
141. Hokken-Koelega AC, van Zaal MA, van Bergen W, et al. Final height and its predictive factors 
after renal transplantation in childhood. Pediatr Res 1994;36(3):323-8. 
142. Qvist E, Marttinen E, Ronnholm K, et al. Growth after renal transplantation in infancy or early 
childhood. Pediatr Nephrol 2002;17(6):438-43. 
143. Fine RN, Ho M, Tejani A. The contribution of renal transplantation to final adult height: a report of 
the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 
2001;16(12):951-6. 
144. Groothoff JW, Offringa M, Van Eck-Smit BL, et al. Severe bone disease and low bone mineral 
density after juvenile renal failure. Kidney Int 2003;63(1):266-75. 
145. Hokken-Koelega AC, de Muinck Keizer-Schrama SM, Drop SL. Effects of alternate-day or daily 
prednisone treatment on GH and cortisol levels in growth-retarded children after renal 
transplantation. J Pediatr Endocrinol 1994;7(2):119-25. 
146. Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of 
children with chronic renal failure. German Study Group for Growth Hormone Treatment in 
Chronic Renal Failure. N Engl J Med 2000;343(13):923-30. 
147. Maxwell H, Rees L. Randomised controlled trial of recombinant human growth hormone in 
prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology. 
Arch Dis Child 1998;79(6):481-7. 
148. Fine RN, Stablein D, Cohen AH, et al. Recombinant human growth hormone post-renal 
transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 
2002;62(2):688-96. 
Chapter 1 
40 
98. Alkhunaizi AM, Olyaei AJ, Barry JM, et al. Efficacy and safety of low molecular weight heparin in 
renal transplantation. Transplantation 1998;66(4):533-4. 
99. Siddiqi N, McBride MA, Hariharan S. Similar risk profiles for post-transplant renal dysfunction and 
long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004;65(5):1906-13. 
100. Boom H, Mallat MJ, de Fijter JW, et al. Delayed graft function influences renal function, but not 
survival. Kidney Int 2000;58(2):859-66. 
101. Tejani AH, Sullivan EK, Alexander SR, et al. Predictive factors for delayed graft function (DGF) 
and its impact on renal graft survival in children: a report of the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation 1999;3:293-300. 
102. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia 
time on renal allograft survival. Nephrol Dial Transplant 2006;21(6):1689-96. 
103. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet 
2004;364(9447):1814-27. 
104. Ahmad N, Pratt JR, Potts DJ, et al. Comparative efficacy of renal preservation solutions to limit 
functional impairment after warm ischemic injury. Kidney Int 2006;69(5):884-93. 
105. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal 
transplantation: a review. Clin Transplant 2005;19(6):705-10. 
106. Cravedi P, Codreanu I, Satta A, et al. Cyclosporine prolongs delayed graft function in kidney 
transplantation: are rabbit anti-human thymocyte globulins the answer? Nephron Clin Pract 
2005;101(2):c65-71. 
107. Muller T, Ruffingshofer D, Bidmon B, et al. Reduction of delayed renal allograft function using 
sequential immunosuppression. Pediatr Nephrol 2001;16(8):613-7. 
108. Solez K, Hansen HE, Kornerup HJ, et al. Clinical validation and reproducibility of the Banff 
schema for renal allograft pathology. Transplant Proc 1995;27(1):1009-11. 
109. Tejani A, Ho PL, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft 
failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS). Am J Transplant 2002;2(2):142-7. 
110. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of 
accelerated senescence. J Am Soc Nephrol 1999;10(1):167-81. 
111. Yates PJ, Nicholson ML. The aetiology and pathogenesis of chronic allograft nephropathy. 
Transpl Immunol 2006;16(3-4):148-57. 
112. Morrissey PE, Flynn ML, Lin S. Medication noncompliance and its implications in transplant 
recipients. Drugs 2007;67(10):1463-81. 
113. Habwe VQ. Posttransplantation quality of life: more than graft function. Am J Kidney Dis 
2006;47(4 Suppl 2):S98-110. 
114. Blowey DL, Hebert D, Arbus G, et al. Compliance with cyclosporine in adolescent renal transplant 
recipients. Pediatric Nephrology 1997;11:547-551. 
115. Smith JM, McDonald RA. Renal transplantation in adolescents. Adolesc Med Clin 
2005;16(1):201-14. 
116. Remorino R, Taylor J. Smoothing things over: the transition from pediatric to adult care for kidney 
transplant recipients. Prog Transplant 2006;16(4):303-8. 
117. Watson AR. Non-compliance and transfer from paediatric to adult transplant unit. Pediatr Nephrol 
2000;14(6):469-72. 
118. Groenewegen AA, Sukhai RN, Nauta J, et al. Results of renal transplantation in boys treated for 
posterior urethral valves. J Urol 1993;149(6):1517-20. 
119. Salomon L, Fontaine E, Gagnadoux MF, et al. Posterior urethral valves: long-term renal function 
consequences after transplantation. J Urol 1997;157(3):992-5. 
120. Luke PP, Herz DB, Bellinger MF, et al. Long-term results of pediatric renal transplantation into a 
dysfunctional lower urinary tract. Transplantation 2003;76(11):1578-82. 
121. Fontaine E, Gagnadoux MF, Niaudet P, et al. Renal transplantation in children with augmentation 
cystoplasty: long-term results. J Urol 1998;159(6):2110-3. 
122. Smith JM, McDonald RA. Post-transplant management. In: Fine RN, Webber SA, Olthoff KM, 
Kelly DA, Harmon W, editors. Pediatric solid organ transplantation: Blackwell Publishing; 2007. p. 
174-184. 
123. Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS 
in high-risk renal transplant recipients. Am J Transplant 2005;5(12):2907-12. 
124. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal 
transplantation in children. Pediatr Nephrol 2007;22(4):496-502. 
Background: current state of affairs 
41 
125. Nathanson S, Cochat P, Andre JL, et al. Recurrence of nephrotic syndrome after renal 
transplantation: influence of increased immunosuppression. Pediatr Nephrol 2005;20(12):1801-4. 
126. Ohta T, Kawaguchi H, Hattori M, et al. Effect of pre-and postoperative plasmapheresis on 
posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation 
2001;71(5):628-33. 
127. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal 
transplantation in children. Pediatr Nephrol 2003;18(11):1095-101. 
128. Davin JC, Olie KH, Verlaak R, et al. Complement factor H-associated atypical hemolytic uremic 
syndrome in monozygotic twins: concordant presentation, discordant response to treatment. Am 
J Kidney Dis 2006;47(2):e27-30. 
129. Zimmerhackl LB, Besbas N, Jungraithmayr T, et al. Epidemiology, clinical presentation, and 
pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 
2006;32(2):113-20. 
130. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J 
Transplant 2006;6(11):2535-42. 
131. Scheinman JI. Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int 
1991;40(3):389-99. 
132. Patrakka J, Ruotsalainen V, Reponen P, et al. Recurrence of nephrotic syndrome in kidney grafts 
of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. 
Transplantation 2002;73(3):394-403. 
133. Chavers BM, Li S, Collins AJ, et al. Cardiovascular disease in pediatric chronic dialysis patients. 
Kidney Int 2002;62(2):648-53. 
134. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 
2006. 
135. Lilien M, Duran M, Van Hoeck K, et al. Hyperhomocyst(e)inaemia in children with chronic renal 
failure. Nephrol Dial Transplant 1999;14(2):366-8. 
136. Scharer K, Schmidt KG, Soergel M. Cardiac function and structure in patients with chronic renal 
failure. Pediatr Nephrol 1999;13(9):951-65. 
137. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular 
death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67(6):2383-92. 
138. Lilien MR, Stroes ES, Op't Roodt J, et al. Vascular function in children after renal transplantation. 
Am J Kidney Dis 2003;41(3):684-91. 
139. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 
1997;4(3):212-24. 
140. Bullington N, Kartel J, Khoury P, et al. Left ventricular hypertrophy in pediatric kidney transplant 
recipients: long-term follow-up study. Pediatr Transplant 2006;10(7):811-5. 
141. Hokken-Koelega AC, van Zaal MA, van Bergen W, et al. Final height and its predictive factors 
after renal transplantation in childhood. Pediatr Res 1994;36(3):323-8. 
142. Qvist E, Marttinen E, Ronnholm K, et al. Growth after renal transplantation in infancy or early 
childhood. Pediatr Nephrol 2002;17(6):438-43. 
143. Fine RN, Ho M, Tejani A. The contribution of renal transplantation to final adult height: a report of 
the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 
2001;16(12):951-6. 
144. Groothoff JW, Offringa M, Van Eck-Smit BL, et al. Severe bone disease and low bone mineral 
density after juvenile renal failure. Kidney Int 2003;63(1):266-75. 
145. Hokken-Koelega AC, de Muinck Keizer-Schrama SM, Drop SL. Effects of alternate-day or daily 
prednisone treatment on GH and cortisol levels in growth-retarded children after renal 
transplantation. J Pediatr Endocrinol 1994;7(2):119-25. 
146. Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of 
children with chronic renal failure. German Study Group for Growth Hormone Treatment in 
Chronic Renal Failure. N Engl J Med 2000;343(13):923-30. 
147. Maxwell H, Rees L. Randomised controlled trial of recombinant human growth hormone in 
prepubertal and pubertal renal transplant recipients. British Association for Pediatric Nephrology. 
Arch Dis Child 1998;79(6):481-7. 
148. Fine RN, Stablein D, Cohen AH, et al. Recombinant human growth hormone post-renal 
transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int 
2002;62(2):688-96. 
Chapter 1 
42 
149. Hokken-Koelega AC, Stijnen T, de Ridder MA, et al. Growth hormone treatment in growth-
retarded adolescents after renal transplant. Lancet 1994;343(8909):1313-7. 
150. Boot AM, Nauta J, de Jong MC, et al. Bone mineral density, bone metabolism and body 
composition of children with chronic renal failure, with and without growth hormone treatment. 
Clin Endocrinol (Oxf) 1998;49(5):665-72. 
151. van der Sluis IM, Boot AM, Nauta J, et al. Bone density and body composition in chronic renal 
failure: effects of growth hormone treatment. Pediatr Nephrol 2000;15(3-4):221-8. 
152. Goksen D, Darcan S, Kara P, et al. Bone mineral density in pediatric and adolescent renal 
transplant patients: how to evaluate. Pediatr Transplant 2005;9(4):464-9. 
153. Helenius I, Jalanko H, Remes V, et al. Avascular bone necrosis of the hip joint after solid organ 
transplantation in childhood: a clinical and MRI analysis. Transplantation 2006;81(12):1621-7. 
154. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357(25):2601-14. 
155. Acott PD, Hirsch HH. BK virus infection, replication, and diseases in pediatric kidney 
transplantation. Pediatr Nephrol 2007;22(9):1243-50. 
156. Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing 
with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral 
ganciclovir CMV prophylaxis. Am J Transplant 2003;3(4):445-51. 
157. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless 
cytomegalovirus infection. Lancet 1994;344(8939-8940):1737-8. 
158. Geel AL, Landman TS, Kal JA, et al. Varicella zoster virus serostatus before and after kidney 
transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 
2006;38(10):3418-9. 
159. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 
1995;346(8972):403-6. 
160. Behrend M, Kolditz M, Kliem V, et al. Malignancies in patients under long-term 
immunosuppression after kidney transplantation. Transplant Proc 1997;29(1-2):834-5. 
161. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J 
Cancer 1997;71(4):517-20. 
162. Offner G, Latta K, Hoyer PF, et al. Kidney transplanted children come of age. Kidney 
International 1999;55:1509-1517. 
163. Wingen AM, Wiesel M, Mohring K, et al. Malignancies in children with renal replacement therapy. 
Transplant Proc 1994;26(1):5-6. 
164. Penn I. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc 
1994;26(5):2763-5. 
165. Coutinho HM, Groothoff JW, Offringa M, et al. De novo malignancy after paediatric renal 
replacement therapy. Arch Dis Child 2001;85(6):478-83. 
 
 
Part I
Pediatric kidney 
transplantation in the 
Netherlands: outcome of 
earlier cohorts
Chapter 1 
42 
149. Hokken-Koelega AC, Stijnen T, de Ridder MA, et al. Growth hormone treatment in growth-
retarded adolescents after renal transplant. Lancet 1994;343(8909):1313-7. 
150. Boot AM, Nauta J, de Jong MC, et al. Bone mineral density, bone metabolism and body 
composition of children with chronic renal failure, with and without growth hormone treatment. 
Clin Endocrinol (Oxf) 1998;49(5):665-72. 
151. van der Sluis IM, Boot AM, Nauta J, et al. Bone density and body composition in chronic renal 
failure: effects of growth hormone treatment. Pediatr Nephrol 2000;15(3-4):221-8. 
152. Goksen D, Darcan S, Kara P, et al. Bone mineral density in pediatric and adolescent renal 
transplant patients: how to evaluate. Pediatr Transplant 2005;9(4):464-9. 
153. Helenius I, Jalanko H, Remes V, et al. Avascular bone necrosis of the hip joint after solid organ 
transplantation in childhood: a clinical and MRI analysis. Transplantation 2006;81(12):1621-7. 
154. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357(25):2601-14. 
155. Acott PD, Hirsch HH. BK virus infection, replication, and diseases in pediatric kidney 
transplantation. Pediatr Nephrol 2007;22(9):1243-50. 
156. Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing 
with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral 
ganciclovir CMV prophylaxis. Am J Transplant 2003;3(4):445-51. 
157. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless 
cytomegalovirus infection. Lancet 1994;344(8939-8940):1737-8. 
158. Geel AL, Landman TS, Kal JA, et al. Varicella zoster virus serostatus before and after kidney 
transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc 
2006;38(10):3418-9. 
159. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 
1995;346(8972):403-6. 
160. Behrend M, Kolditz M, Kliem V, et al. Malignancies in patients under long-term 
immunosuppression after kidney transplantation. Transplant Proc 1997;29(1-2):834-5. 
161. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J 
Cancer 1997;71(4):517-20. 
162. Offner G, Latta K, Hoyer PF, et al. Kidney transplanted children come of age. Kidney 
International 1999;55:1509-1517. 
163. Wingen AM, Wiesel M, Mohring K, et al. Malignancies in children with renal replacement therapy. 
Transplant Proc 1994;26(1):5-6. 
164. Penn I. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc 
1994;26(5):2763-5. 
165. Coutinho HM, Groothoff JW, Offringa M, et al. De novo malignancy after paediatric renal 
replacement therapy. Arch Dis Child 2001;85(6):478-83. 
 
 
Part I
Pediatric kidney 
transplantation in the 
Netherlands: outcome of 
earlier cohorts
  
Chapter 2
Pediatric renal 
transplantations in the 
Netherlands
Karlien Cransberg
Jan D van Gool
Jean Claude Davin 
Maria C J W de Jong
Muriel Darby
Marjolijn E Boendermaker
Johan de Meester
Theo Stijnen
Eric D Wolff
Jeroen Nauta
Pediatr Transplantation 2000;4:72-81
  
Chapter 2
Pediatric renal 
transplantations in the 
Netherlands
Karlien Cransberg
Jan D van Gool
Jean Claude Davin 
Maria C J W de Jong
Muriel Darby
Marjolijn E Boendermaker
Johan de Meester
Theo Stijnen
Eric D Wolff
Jeroen Nauta
Pediatr Transplantation 2000;4:72-81
Chapter 2 
46 
Abstract 
 
Introduction 
In the Netherlands, pediatric kidney transplantation programs are available in four 
centers. We retrospectively analyzed the results obtained over the past decade.  
 
Methods 
Between 1985 and 1995 231 patients (139 boys) received 269 transplants, including 
61 repeat. The recipients were aged 1.9 - 21.8 years (mean 10.9), the donors 0.3 - 
63.3 years (median 11.4, mean 19.7). Immunosuppression consisted of 
corticosteroids, cyclosporine A and azathioprine, in various combinations and 
dosages.  
 
Results 
The patient survival during follow up was 97%. The overall graft survival was 73% at 
1 year and 60% at 5 years after transplantation. Major causes of graft loss were 
acute rejection (21%), thrombosis (12%), and chronic rejection (28%). Acute rejection 
episodes were noted in 74% of all grafts. First acute rejection episodes had a 
moderate predictive value for graft loss (relative risk (RR), compared to rejection free 
grafts, 5.9). First rejection episodes occurring later than 3 months after 
transplantation were considerably more predictive (RR 18.3) than early ones. Grafts 
from living related donors (n=35) yielded a superior 5 year graft survival (77%) and 
remained free of rejection more often than grafts from adult cadaveric donors (43% 
vs 25%). The results of pre-emptive transplants were excellent (n=13, 5 year survival 
100%). Repeat transplants had the same results as primary transplants. Recipients 
younger than 4 years showed a poor 5 year graft survival of 38% (n=13). Single 
kidney grafts from donors younger than 4 years (n=35) had a 5 year graft survival of 
44%. In contrast, kidneys from these young donors did well if transplanted en bloc 
(n=10, 5 year graft survival 89%).  
 
Conclusion 
These overall results are in line with those of others. The results may be improved by 
expansion of immunosuppressive therapy in the first year and by thrombosis 
prophylaxis in high-risk patient-donor combinations. Better results may be expected 
from more extensive use of living related donations, pre-emptive transplantations and 
en bloc transplantation instead of single kidneys of young donors.  
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Introduction 
 
Renal transplantation is a firmly established mode of renal replacement therapy in 
children. Since its introduction in the early 1970s the success rate gradually 
increased.1, 2 The development of new immunosuppressive drugs has contributed to 
the prevention of acute rejection and therefore to better graft survival. In the first half 
of the 1980s cyclosporine A was introduced and took a central place in 
immunosuppressive therapy. Recently, new drugs have been introduced, such as 
mycophenolate mofetil 3, 4 and tacrolimus. 5  
In the Netherlands the first kidney transplantation in a child was performed in 1973. 
There are four pediatric renal transplantation centers. All four started their programs 
before 1977. The annual number of transplantations stabilized from 1980 onwards to 
between 25 and 30, distributed over the four centers. The centers used to work 
independently, and each developed an immunosuppressive regimen of its own. The 
limited number of patients per center impeded the development of experience with a 
certain immunosuppressive protocol and the possibility to evaluate it. Therefore, 
recently the four centers decided to join forces and to design a shared 
immunosuppressive regimen, as well as a single database for the clinical information 
of all children transplanted in the Netherlands. The current retrospective analysis 
provided the basis for this Dutch consensus protocol.  
 
Patients and methods 
 
Clinical data were collected from patient records by two medical students (M.B. and 
M.D.), on specially designed data forms. Included were all renal transplantations 
performed in the four pediatric transplantation centers in the Netherlands between 
1985 and 1995. From 1985 on, all centers used prednisone and cyclosporin as the 
pivot of immunosuppressive therapy. Acute rejection was defined as a full course of 
anti-rejection therapy, consisting of methylprednisolone in pulse therapy, high dosed 
prednisone, antithymocyte globulin (ATG) or OKT3. Graft failure was defined as the 
start of any other form of renal replacement therapy, or a glomerular filtration rate 
(GFR) of less than 10 mL/min/1,73m2. Death with functioning graft was considered as 
graft failure. 
 
Statistics 
Actuarial patient and graft survival were calculated according to the Kaplan-Meier 
method. Comparisons between curves were performed with the log rank test. In 
survival studies with multiple subgroups, figures were cut off at 6 years because of 
the small numbers of patients beyond this time point. Relative risks (RR) of graft 
failure were calculated with Cox proportional hazards regression model, adjusted for 
selected parameters. To investigate whether the risk of graft failure is affected by the 
occurrence of a rejection episode and the timing of the first rejection episode, Cox 
regression with time dependent co-variates was employed. Means were compared 
using Student’s two-sample t-test or Wilcoxon’s two-sample test where appropriate. 
In all statistical tests, a p-value below 0.05 was considered significant. 
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Results 
 
Patient and graft characteristics (Tables 1 and 2) 
In the 10 year period 269 kidney transplantations were performed in 231 patients 
(139 boys). The age at transplantation ranged from 1.9 to 21.8 years, with a mean of 
10.9 and a median of 11.3. In 208 cases, this was the first transplantation, in 53 a 
second and in 8 a third. 
The primary renal diseases leading to end-stage renal failure are shown in Table 1.  
The largest group of patients (n=81) had a urological malformation or dysfunction. Of 
these patients 62 (77%) were boys, explaining the preponderance of boys in the 
whole population. Differentiation within the group of urological diagnoses was 
difficult: it was not always clear whether dysplastic kidneys or vesico-ureteral reflux 
were associated with urethral valves or not. 
The modes of renal replacement therapy (RRT) at the time of transplantation 
included chronic intermittent hemodialysis (n=144), continuous ambulatory or cycling 
peritoneal dialysis (n=102) and a graft with residual function (n=8). Thirteen patients 
(5%) did not receive RRT before transplantation and thus were transplanted pre-
emptively. 
In 35 cases (13%) a living related donor (LRD) procedure was performed. In 33 
cases, the donor was a parent and in two an adult brother. Seven of the 35 LRD 
cases concerned a repeat transplantation.  
 
Table 1. Primary renal disease 
  n % 
Patients 231 100 
Glomerular disease 62 27 
 FSGS 29  
 MPGN 9  
 IgA nephropathy 4  
 RPGN 7  
 Alport syndrome 3  
 Other/not specified 10  
Congenital nephrotic syndrome 13 6 
Congenital structural abnormalities 81 35 
Tubulointerstitial nephritis, not specified 3 1 
Cystic diseases 19 8 
Metabolic diseases 7 3 
Vascular and systemic diseases 25 11 
 HUS 17  
Renal malignancy 5 2 
Other / unknown 15 7 
Missing 1 0 
FSGS, focal segmental glomerulosclerosis;  
MPGN, membranoproliferative glomerulonephritis;  
RPGN, rapidly progressive, or crescentic, glomerulonephritis;  
HUS, hemolytic uremic syndrome 
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The kidneys from cadaveric donors (n=234; 87%) were HLA-matched and obtained 
in the framework of the Eurotransplant Organ Exchange Organisation. The donor age 
varied from 0.3 years to 63.3 years. The mean donor age was 19.7 years, median 
11.4. Of 10 cadaveric donors, all younger than 4 years, the kidneys were 
transplanted en bloc. The cold ischemia time of the cadaveric kidneys ranged from 6 
to 46 hours, with a mean and a median of 29 hours. The number of HLA-B/DR-
mismatches of cadaveric donors are shown in Table 2.  
 
Table 2. Transplantation characteristics 
   n % 
Transplantations   269 100 
Rankorder 1st 208 77 
 repeat 61 23 
Recipient age (yrs) 0 - 2 1 0 
 2 - 4 12 5 
 4 - 9 88 33 
 9 - 18 151 56 
  > 18  17 6 
Donor age (yrs) 0 - 4 45 17 
 4 - 9 65 24 
 9 - 18 52 19 
 18 - 40 54 20 
 40 - 50 38 14 
 > 50 14 5 
  missing 1 0 
Donor source CAD 234 87 
  LRD 35 13 
RRT prior to this transplantation hemodialysis 144 54 
 peritoneal dialysis 102 38 
 transplantation 8 3 
 none  13 5 
  missing 2 1 
PRA pre-transplantation (%) 0 - 10 210 78 
 10 - 40 28 10 
 > 40 20 7 
  missing 11 4 
HLA-B/DR-mismatches (CAD) (234) (100) 
 0 30 13 
 1 - 2 183 78 
 3 - 4 20 9 
  missing 1 0 
Cold ischemia time (CAD)  (234) (100) 
 < 24 hr 49 21 
 24 - 36 hr 159 68 
 > 48 hr 0 0 
  missing 26 11 
CAD=cadaveric 
LRD=living related donor  
RRT=renal replacement therapy 
PRA=panel reactive antibodies 
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Perioperative management 
All grafts were implanted in the iliac fossa with the donor vessels connected to the 
external or common iliac vessels of the recipient. In two centers the ureter was 
implanted in the bladder with an anti-reflux procedure, in two centers without. The 
peri-operative fluid administration was generous in all centers. Prophylactic heparin 
was not routinely administered throughout the observation period.  
 
Immunosuppressive therapy (Table 3) 
During the observation period all centers prescribed corticosteroids, azathioprine and 
cyclosporine A. No ATG or OKT3 induction therapy was used, except for nine 
patients treated in one center. All centers used high-dose corticosteroids starting 
preoperatively and rapidly tapered in the first 6 to 12 weeks to 0.25 mg/kg/day. 
Prednisone was given daily during the first postoperative months in all centers. A 
proportion of the patients were subsequently switched to an alternate-day schedule. 
This switch was made routinely at 3 months in one center, and at a later stage in 
others. At 3 years after transplantation overall half the patients received prednisone 
on alternate days. The mean daily dosage of prednisone was equal when given once 
daily or on alternate days. 
The time-point at which cyclosporine A was started, and the dosage, varied among 
the centers and within the observation period. In one center, cyclosporine A was only 
started when the creatinine level was below 100 µmol/L. In the absence of 
cyclosporine A, azathioprine was administered.  
Maintenance immunosuppressive therapy consisted of prednisone and cyclosporine 
A for the majority of patients. The percentage of patients treated with triple therapy 
(prednisone, azathioprine, cyclosporine) increased through the years. It was 
prescribed either from transplantation onwards as standard therapy, or, at a later 
stage, when cyclosporine A toxicity was suspected and the cyclosporine A dosage 
needed to be lowered. In this situation in some cases prednisone / cyclosporine A 
was converted to prednisone / azathioprine.  
 
Table 3. Immunosuppressive regimens throughout the years 
 1985 – 1990 (n=130)  1990 – 1995 (n=139) 
    
Years after transplantation 1 4  1 4 
      
Transplants at risk: 88 (100)a 68 (100)  99 (100) 51 (100) 
Pred/AZA 47 (53) 34 (50)  10 (10) 7 (14) 
Pred/CsA 34 (39) 16 (24)  46 (47) 14 (27) 
Pred/CsA/AZA 5 (6) 17 (25)  43 (43) 29 (57) 
Other/missing 2 (2) 1 (1)  0 1 (2) 
a number of grafts (percentage) 
Pred= prednisone; AZA= azathioprine; CsA= cyclosporine A 
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Patient survival 
Eight patients died with a functioning graft. Causes of death included a 
cerebrovascular accident (n=3), infection (sepsis, n=1, and toxoplasmosis, n=1), 
myocardial infarction (n=1) and sudden death, most likely from cardiovascular origin 
(n=1). In one case the cause of death remained unknown. The mean age at 
transplantation for the deceased patients (9.1 years) was comparable to that of the 
surviving patients. The majority of the deaths (n=6) occurred during the first 6 months 
after transplantation. 
 
Graft survival 
The overall graft survival rate at 1 year was 73%, at 3 years 67%, and at 5 years 
60%. The slight difference in results of the cohort transplanted between 1990 and 
1995 compared to that transplanted between 1985 and 1990 (5 year survival of 64% 
vs. 56%) was not statistically significant.  
In the investigated period 107 of the 269 grafts failed. Table 4 shows the causes of 
the graft failure according to survival time. Graft loss within the first month after 
transplantation occurred in 14% of all transplants and was largely due to acute 
allograft rejection and vascular thrombosis. Graft failure after the first months was 
mainly due to chronic rejection. 
Thrombosis was responsible for 12% of all failures. The lower age of the donors of 
these thrombosed grafts was the only factor associated with a higher risk of 
thrombosis (median 7.1 vs. 10.1 years for the grafts failed for another reason, 
p=0.06). In contrast to the suggestion by Van Lieburg et al.,6 patients with dys- and 
hypoplastic kidneys were not over-represented in the group with vascular thrombosis 
compared to the total population (36 vs. 32%).  
 
Table 4. Causes of graft failure according to time (months) after transplantation 
 0 - 1 1 - 6 6 - 12 12 - 60 > 60 Total 0 - 60 
Grafts at risk (n) 269 231 209 188 87 269 
 Acute rejection 12 5 4 0 0 21 
 Thrombosis 12 1 0 0 0 13 
 Primary non function 5 0 0 0 0 5 
 Death 3 3 1 1 0 8 
 Recurrence 2 0 3 3 0 8 
 Infection 1 0 0 0 0 1 
 Chronic rejection 0 3 7 18 2 30 
 Other/missing 3 6 2 7 3 21 
Grafts failed (n) 38 18 17 29 5 107 
 
Living related donor transplants (LRD) (Figure 1) 
In the group with LRD transplants (n=35), early failures occurred with approximately 
the same frequency as in the group with cadaveric (CAD) kidneys. Two of these early 
failures (n=7) were due to accelerated acute rejection. Once the first month after 
transplantation had passed, only one graft was lost, after 39 months, because of 
recurrence of the original disease.  
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Comparing the results of LRD grafts that survived the first month after transplantation 
with those of CAD grafts from adult donors that survived this period (n=72), the 
difference in graft survival was strongly in favor of the LRD (p<0.01). The age at 
transplantation and the number of HLA-mismatches did not differ significantly 
between recipients of LRD and CAD kidneys. Of the LRD grafts 43% did not show 
any rejection episode, compared to 25% of the grafts from adult cadaveric donors 
(not significant). 
 
Figure 1. Cumulative graft survival of living related vs. cadaveric kidneys 
Figure 2. Cumulative graft survival according to prior RRT (p<0.05) 
 
Prior renal replacement therapy (Figure 2) 
Transplantation prior to any mode of RRT was performed in 13 patients. These grafts 
did considerably better than grafts in dialyzed children (n=246) (p<0.05). The 5 year 
patient and graft survival was 100%. Within this pre-emptively transplanted group of 
patients, a relative overrepresentation of LRD transplants (31% vs. 12% in the group 
with prior dialysis) was noted as well as of an original disease of congenital structural 
abnormalities (62% vs. 35%).  
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Thirteen patients did not receive any 
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However, when compared to a dialyzed control group matched for age, donor source 
and primary renal disease (n=28), the 5 year survival was significantly better (100% 
vs. 63%, p<0.05). The pre-emptive and post-dialysis groups were not different 
regarding donor age, panel reactive antibodies (PRA), number of mismatches, cold 
ischemia in the CAD kidneys, or number of rejection episodes. The slight difference 
in graft survival between patients on hemodialysis and those on peritoneal dialysis 
was not statistically significant.  
 
Retransplantation 
Comparing the results of repeat CAD transplantations (n=54) with first CAD 
transplantations (n=180), we noticed a similar 5 year graft survival (53% vs. 58%, not 
significant). The repeat grafts had better matching (mean number of HLA–B/DR 
mismatches 1.2 vs. 1.6 in the first CAD grafts, p<0.05), with higher antibodies prior to 
transplantation (mean 26% vs. 5%, p<0.001).  
The recipients as well as the donors were slightly older (mean recipient age 12.1 vs. 
10.4 years, p<0.01, median donor age 16.9 vs. 10.0 years). The repeat grafts 
showed fewer rejection episodes (0.84 vs. 1.1 episodes per graft in the 1st year, 
p<0.05), which may be explained by the better matching, the older age of donors and 
recipients, and the negative cross-matching despite circulating PRA.  
When correcting for the above-mentioned factors by Cox proportional hazards model, 
still no significant difference was seen between the survival of first and repeat 
transplantations. 
 
Young recipients (< 4 years) 
Although the graft survival in recipients younger than 4 years (54% at 1 year, 38% at 
5 years after transplantation) was worse than in older patients, the difference was not 
statistically significant in this small group of patients (n=13). They received kidneys of 
younger donors (median age 4.3 vs. 12.2, p<0.01). Young patients tended to have 
more acute rejection episodes than older recipients. Of the 13 recipients aged < 4 
years, 2 did not have any rejection episode (15%), compared to 29% of older 
recipients (p<0.05).  
 
Young donors (< 4 years) 
Forty-five patients received a kidney from a donor younger than 4 years. The donor 
age varied between 1.6 and 4 years, with the exception of one very young single 
kidney donor aged 0.3 year. The recipients of these young kidneys were slightly 
younger than the overall group: mean age 8.5 vs. 10.9 years.  
Causes of graft failure in this group included thrombosis (n=3, 16% of all failures in 
this group), acute rejection (n=3, 16%), and chronic rejection (n=5, 26%). The 
survival of the grafts from young donors was equal to that from older CAD donors 
(69% at 1 year, 54% at 5 years after transplantation). However, when within the 
young donor group a distinction was made between en bloc transplanted kidneys 
(n=10) and single kidneys (n=35), the graft survival was significantly different: the 5 
year survival was 89% vs. 44% (Figure 3, p<0.05).  
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Comparing the results of LRD grafts that survived the first month after transplantation 
with those of CAD grafts from adult donors that survived this period (n=72), the 
difference in graft survival was strongly in favor of the LRD (p<0.01). The age at 
transplantation and the number of HLA-mismatches did not differ significantly 
between recipients of LRD and CAD kidneys. Of the LRD grafts 43% did not show 
any rejection episode, compared to 25% of the grafts from adult cadaveric donors 
(not significant). 
 
Figure 1. Cumulative graft survival of living related vs. cadaveric kidneys 
Figure 2. Cumulative graft survival according to prior RRT (p<0.05) 
 
Prior renal replacement therapy (Figure 2) 
Transplantation prior to any mode of RRT was performed in 13 patients. These grafts 
did considerably better than grafts in dialyzed children (n=246) (p<0.05). The 5 year 
patient and graft survival was 100%. Within this pre-emptively transplanted group of 
patients, a relative overrepresentation of LRD transplants (31% vs. 12% in the group 
with prior dialysis) was noted as well as of an original disease of congenital structural 
abnormalities (62% vs. 35%).  
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However, when compared to a dialyzed control group matched for age, donor source 
and primary renal disease (n=28), the 5 year survival was significantly better (100% 
vs. 63%, p<0.05). The pre-emptive and post-dialysis groups were not different 
regarding donor age, panel reactive antibodies (PRA), number of mismatches, cold 
ischemia in the CAD kidneys, or number of rejection episodes. The slight difference 
in graft survival between patients on hemodialysis and those on peritoneal dialysis 
was not statistically significant.  
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The recipients of single and of en bloc kidneys did not differ in age, original disease, 
number of mismatches, PRA, or cold ischemia time. The function of surviving grafts 
at 1 year after transplantation was significantly better for en bloc grafts (n=9) than for 
single kidney grafts (n=16): the estimated GFR7 amounted to 87 vs 64 
mL/min/1.73m2, p<0.05. 
Young donor kidneys tended to induce more rejection episodes than older ones: a 
rejection-free follow up was observed in 20% of grafts from donors younger than 4 
years, 26% of grafts from donors 4 to 10 years old and 32% of grafts from donors 
older than 10 years (n.s.). 
 
Figure 3. Cumulative cadaveric graft survival according to donor age (p<0.05) 
 
Acute rejections 
A biopsy confirmed the diagnosis of acute rejection in 47% of all episodes.  
The occurrence of any acute rejection episode affected the graft survival substantially 
(RR 5.9, p<0.001). With an increasing number of rejections per patient the long-term 
outcome became worse. Chronic rejection was the main cause of graft loss in the 
long term, and occurred in 30 cases. Looking only at the grafts that did not fail by 
other causes than chronic rejection (n=192), the difference in graft survival between 
the groups without any acute rejection episode (5 year survival 100%), with one 
(90%) and with more than one episode (72%) was highly significant (p<0.001). 
In the majority of cases the first acute rejection episode occurred within the first 3 
months after transplantation (Table 5). The small number of grafts with first rejection 
episodes occurring later than 3 months after transplantation (31 out of 189 episodes) 
had a significantly worse prognosis than early rejections, compared to the grafts 
without any rejection episode.  
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Table 5. Relative risk of graft failure according to timing of first rejection episode 
 timing of 1st acute rejection episode na (%) RR of graft failure b p  
days 0 - 14 102 (54)   
after transpl.  5.1 < 0.001 
 14 - 30 22 (12)   
          
months 1 - 3 34 (18) 3.6 < 0.01 
after transpl.    
 3 - 6 12 (6)   
   18.3 < 0.001 
 6 - 12 9 (5)   
     
  > 12 10 (5) 12.7 < 0.001 
a Of 9 rejection episodes the date of occurrence was missing. 
b relative risk (RR) of graft failure compared to grafts without any acute rejection 
 
Malignancies 
In our series one case of malignancy was registered. It concerns a Kaposi sarcoma 
in a patient treated with chemotherapy for a bilateral Wilms tumor, who had therapy-
resistant rejection episodes in the 4 months she had her graft. After graftectomy and 
cessation of the immunosuppressive medication the Kaposi sarcoma vanished. 
 
Discussion 
 
The results of renal transplantations in Dutch children over the past decade were 
similar to those reported for North American8 and European children1, when 
comparing the CAD grafts. We noticed a slight statistically not significant 
improvement over time. Our multi-center graft survival was comparable to that 
reported a decade earlier from a retrospective analysis in one of the centers.9 The 
causes of graft failure in our population were distributed similarly as in the most 
recent report of the North American database.8 Early graft loss was predominantly 
caused by thrombosis (12%) and acute rejection (20%). We will discuss the major 
complications that determine graft loss and highlight the potential benefits of LRD 
transplantation, of pre-emptive transplantation and of transplanting young donor 
kidneys en bloc. 
 
Thrombosis 
In our population, the only factor significantly associated with a high risk of 
thrombosis was young age of the donor. In contrast to other reports, no correlation 
could be found between the incidence of thrombosis and prolonged cold ischemia 
time, low recipient age, or a primary renal disease with high urine production at the 
time of transplantation.6, 10, 11 The most evident factors increasing the risk of 
thrombosis may be summarized as those circumstances where blood flow problems 
are to be expected, as in young donors and small recipients, or in donor kidneys with 
multiple arteries. Thrombosis may be prevented in these high-risk situations by the 
administration of low molecular weight heparin during 2 - 3 weeks post-transplant.12 
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Acute rejection episodes 
A large proportion of grafts was lost directly due to acute rejections. It has been 
suggested that acute rejection episodes in young children may lead to graft failure 
more often than in older ones. According to the North-American data on CAD grafts, 
21% of all rejection episodes in children 0-1 years of age ended in graft loss, 15% in 
children aged 2-5 years, and 7-8% in older children.13 The number of young children 
in our population was too small to influence the failure rate by acute rejection of our 
population as a whole. Apart from this direct effect, our results confirm the data of 
others, that acute rejections substantially increase the risk of graft failure in the 
longer term, especially by chronic rejection.14, 15 Important determinants of this risk 
appear to be the number of the rejection episodes per patient, and the timing of the 
first rejection. Although low in number, first rejections occurring more than 3 months 
after transplantation have a significantly worse prognosis. These observations 
parallel those of others.16, 17, 18 Whether this graft loss long after a late acute rejection 
is related to a relatively low immunosuppressive effect of the drug regimen and/or to 
compliance problems cannot be concluded from our data.  
 
Living related donations 
The long-term survival of LRD grafts in our series is good. This is consistent with the 
results of others.8, 19 The direct post-operative period, however, was less favorable, 
resulting in the loss of one patient and 20% of the grafts. Two losses by accelerated 
acute rejection might have been prevented by applying a donor specific transfusion 
prior to transplantation and cross-matching. Another explanation could be that the 
relatively low number of LRD transplantations was performed in a negatively selected 
patient population. It is likely that, in some of the patients, dialysis problems and 
other medical and social complications contributed to the decision to plan an LRD in 
order to shorten the waiting time.  
 
The low proportion of LRD transplantations in our series is in contrast to the general 
policy in other parts of the world.8, 19 Historically it reflects a low need for LRD grafts 
in our country, since sufficient CAD grafts were available from the service of 
Eurotransplant. The waiting time for CAD kidneys was relatively short and the cold 
ischemia time acceptable. Reluctance towards the use of LRD grafts was based on 
the awareness of the impact on the psychosocial environment of the patient and his 
family, on the physical risks for the donor, as well as on the notion that potential 
family donors might be saved as a “backup” for later. Recent evidence regarding 
LRD transplants, however, indicates that the physical risks are relatively low,20 the 
psychosocial circumstances may even be positively affected21 and the “backup” 
parents may be lost as a potential donor as a result of antibody formation following a 
preceding transplantation. The waiting time is shorter, the time of transplantation can 
be chosen and the outcome is better. Based on these considerations we now 
encourage LRD transplantations more. 
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Young donors 
Transplantation of single kidneys from donors younger than 4 years yielded poor 
results, confirming the data of several other groups22, 23 but contradicting a recent 
single center report.24 In particular, the use of kidneys from young donors in young 
recipients accumulates risk factors for graft failure22 and should therefore be avoided. 
If the small kidney is severely affected by long warm ischemia caused by the 
technical difficulty of the anastomoses, or acute rejection, the tissue reserve is 
limited. Hyperfiltration damage and chronic rejection may follow. The favorable 
circumstance of mass equivalence between recipient and donor appears not to 
counterbalance these increased risks.  
On the other hand, good long-term results have been reported for young donor 
kidneys into adult recipients. Single kidneys from donors aged 1 year grafted into 
adult recipients yielded acceptable results for both graft survival and GFR.25 Early 
acute rejections threatened the survival of the graft however, resulting in the need for 
aggressive immunosuppressive induction and rejection therapy.  
 
In another study comparing transplant results of donors younger than 7 years with 
adult donors, it was found that grafts from young donors did equally well in terms of 
graft survival, GFR, incidence of acute rejections and incidence of proteinuria.26 
Therefore, the risk for chronic rejection, reflected by proteinuria, seems not to be 
increased, and the growth in volume seen in these kidneys seems to reflect 
accelerated normal maturation growth, as has been demonstrated before.27, 28 
 
In contrast to the findings with single kidneys, our results of en bloc kidneys of the 
youngest donors were good.  
These data expand on an earlier report by one of the centers.29 Two factors may 
contribute to this favorable outcome. The wider caliber of the blood vessels leads to 
both safer anastomoses and better flow properties of the arterial bed. In addition, the 
double transplanted renal mass implies a doubling of the functional capacity and 
potentially less damage from compensatory hyperfiltration.30 En bloc kidneys are also 
suitable for adults.31-34 An obvious drawback of the en bloc use of young donor 
kidneys is that fewer patients are being helped. However, in the Eurotransplant area 
many centers (49 out of 68) do not accept kidneys from these very young donors at 
all, neither single nor en bloc (De Meester, personal communication). 
Although our overall results with young donors are disappointing as in other studies, 
we are encouraged by the results of en bloc transplanted kidneys. If these findings 
are substantiated, then this approach may become worthwhile in these times of 
organ scarcity. 
 
Pre-emptive transplantations 
Pre-emptive transplantations were remarkably successful in our series. Some 
authors have suggested that pre-emptive transplantations will do worse than post-
dialysis transplantations due to an assumed immunologically protective effect of 
uremia and the greater motivation to take medication in the post-dialysis group.35 
However, favorable results similar to ours were reported by other authors.1, 36 
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Several groups found an equal success rate for pre-emptive and post-dialysis 
transplantations, both in adults37-39 and children.35, 40, 41, 42 Schurman and McEnergy, 
on the other hand, noted an adverse effect of pre-emptive transplantations in children 
receiving CAD grafts, in contrast to LRD grafts.43 LRD graft were used in a high 
proportion of all described pre-emptively transplanted patients. In addition to this 
favorable graft survival, transplantation before the need of dialysis has a number of 
other potential advantages. The better physical condition of the patient when 
compared to most dialyzed adult patients has been associated with quicker recovery 
from surgery38 and with a better cardiovascular patient survival.44 An enormous 
advantage obviously is the avoidance of the burden of dialysis and its complications. 
This will undoubtedly lead to better conditions for growth and psychosocial 
development and ultimately to a better quality of life for these children. In addition to 
these advantages, two potential drawbacks of pre-emptive transplantations need to 
be addressed. First, in many cases the timing of transplantation is not easy. Renal 
failure due to congenital disorders of the renal architecture tends to progress very 
slowly, implying a considerable risk that transplantation is carried out years before 
actually needed. Second, the compliance to drug therapy after transplantation might 
be better for children with dialysis experience. Compliance is well recognized as a 
major determinant of long-term outcome of renal transplantations in children.45 
 
In conclusion, our results are in line with those of others. The success rate may be 
enhanced by decreasing the incidence of acute rejection and thrombosis. Prevention 
of acute rejection is expected to postpone extinction of the graft by chronic rejection 
as well.  
 
The centers now share a new and potentially more effective immunosuppressive 
regimen, as well as default thrombosis prophylaxis in high-risk patients. In most 
centers LRD transplantations are promoted more actively, as is pre-emptive grafting.  
In this way, we hope to improve the graft survival and quality of life of our patients 
without considerable increase of the incidence of infections and malignancies. 
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Several groups found an equal success rate for pre-emptive and post-dialysis 
transplantations, both in adults37-39 and children.35, 40, 41, 42 Schurman and McEnergy, 
on the other hand, noted an adverse effect of pre-emptive transplantations in children 
receiving CAD grafts, in contrast to LRD grafts.43 LRD graft were used in a high 
proportion of all described pre-emptively transplanted patients. In addition to this 
favorable graft survival, transplantation before the need of dialysis has a number of 
other potential advantages. The better physical condition of the patient when 
compared to most dialyzed adult patients has been associated with quicker recovery 
from surgery38 and with a better cardiovascular patient survival.44 An enormous 
advantage obviously is the avoidance of the burden of dialysis and its complications. 
This will undoubtedly lead to better conditions for growth and psychosocial 
development and ultimately to a better quality of life for these children. In addition to 
these advantages, two potential drawbacks of pre-emptive transplantations need to 
be addressed. First, in many cases the timing of transplantation is not easy. Renal 
failure due to congenital disorders of the renal architecture tends to progress very 
slowly, implying a considerable risk that transplantation is carried out years before 
actually needed. Second, the compliance to drug therapy after transplantation might 
be better for children with dialysis experience. Compliance is well recognized as a 
major determinant of long-term outcome of renal transplantations in children.45 
 
In conclusion, our results are in line with those of others. The success rate may be 
enhanced by decreasing the incidence of acute rejection and thrombosis. Prevention 
of acute rejection is expected to postpone extinction of the graft by chronic rejection 
as well.  
 
The centers now share a new and potentially more effective immunosuppressive 
regimen, as well as default thrombosis prophylaxis in high-risk patients. In most 
centers LRD transplantations are promoted more actively, as is pre-emptive grafting.  
In this way, we hope to improve the graft survival and quality of life of our patients 
without considerable increase of the incidence of infections and malignancies. 
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Abstract  
 
Background  
Few data exist on long-term morbidity, overall survival and graft survival of pediatric 
renal transplantation. 
 
Methods 
The authors performed a long-term cohort study in all Dutch patients, born before 
1979, with onset of end-stage renal disease (ESRD) between 1972 and 1992 at age 
0 to 15 years. Data on graft survival and determinants of outcome were obtained by 
reviewing all medical charts. The health status was assessed by cross-sectional 
examination of surviving patients.  
 
Results 
Three hundred ninety-seven transplantations were performed in 231 of all 249 
patients, of whom 25 died with a functioning graft. Cardiovascular disease was the 
most prominent cause of death. Graft survival estimates for all transplantations were 
59.2%, 45.3%, 35.4%, and 30.3% at 5, 10, 15 and 20 years, respectively. In 
comparison with azathioprine, cyclosporine as immunosuppressant was associated 
with increased graft survival in retransplantations but not in first transplantations. 
Cross-sectional examination was performed on 110 patients. In 44 patients, the most 
recent graft survival exceeded 15 years. Comorbidity was found in 40% of all 
patients; motor, hearing or visual disabilities in 19%. Bone disease, headaches, 
itching and tremors were the most reported disabling problems. Cyclosporine use 
was associated with hypertension and a history of epilepsy. Compared to all age-
matched Dutch inhabitants, the educational attainment was low, and unemployment 
and parental dependency were high.  
 
Conclusions 
The authors’ results emphasize the need for reducing cardiovascular disease and 
metabolic bone disease in pediatric ESRD, a policy towards less toxic antirejection 
therapy, a more strict treatment of hypertension and more attention for schooling and 
social development towards independency. 
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Introduction 
 
Over the past 20 years, transplantation has become routine treatment for children 
with end-stage renal disease. To increase the rate of graft survival, more potent 
immunosuppressive regimens have been introduced over the past decade. However, 
concern has risen regarding the side effects of these new immunosuppressive drugs. 
In the discussion about the optimal immunosuppressive regimen in children 
undergoing transplantation, there is need for more information about the long-term 
effects of the earliest immunosuppressive treatment with respect to graft survival as 
well as comorbidity. To date, only few data exist on these long-term outcomes. Our 
purpose was to investigate the long-term overall survival, graft survival, and 
morbidity, and the effect of introduction of cyclosporine as immunosuppressive 
therapy on these outcomes. For this purpose, we used data from the Late Effects of 
Renal Insufficiency in Children (LERIC) study, a national Dutch long-term follow-up 
study that aimed to evaluate late physical, social, and psychological effects of renal 
insufficiency in children. 
 
Patients and methods 
 
Study design 
The study was designed as a cohort study and consisted of a cross-sectional part 
and a retrospective part. The aim of the cross-sectional study was to establish the 
current health status of the patients. The aim of the retrospective part of the study 
was to evaluate the influence of a set of predefined determinants on outcome 
parameters. The study covered the total period of renal replacement therapy (RRT) 
for each patient. The end of the study was marked by the day of last chart review for 
potential non-participants in the cross-sectional study and the day of the cross-
sectional examination for participants. The medical ethical committees of all 
participating centers approved the study. 
 
Formation of the cohort 
The LERIC cohort comprises all Dutch patients who had started chronic RRT at age 
0 to 15 years between 1972 and 1992, and who were born before 1979. Patients in 
whom renal function recovered within 4 months after commencing dialysis were 
excluded. Patients who underwent transplantation pre-emptively were included. Data 
on gender, date of birth, initiation of RRT, and date of death of all the patients who 
fulfilled the inclusion criteria were provided by the National Dutch Registry of patients 
on RRT (RENINE, Rotterdam, The Netherlands). RENINE, founded in 1985, is the 
Dutch source of the European Dialysis and Transplantation Association. The 
completeness approaches 100% as registration is compulsory for reimbursement of 
RRT. We checked the accuracy of data on these patients by comparing RENINE 
data with the databases of all four Dutch centers for pediatric dialysis and kidney 
transplantation and with the databases of all centers for adult dialysis and 
transplantation. The cohort formation has previously been described in detail.1 
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Data collection 
Between November 1998 and August 2000, members of the LERIC-team visited 37 
hospitals in The Netherlands. They collected information about the period, duration 
and onset of renal replacement therapy, the total number and duration of dialysis and 
transplant periods; and all immunosuppressive drugs that were used. The date of 
graft failure was defined as the day of onset of chronic dialysis or a next 
transplantation after the particular transplantation. An analysis was made of the effect 
of the introduction of cyclosporine on the long-term graft survival by comparing two 
groups of transplantations: one characterized by an initial immunosuppressive 
regimen consisting of azathioprine and prednisone (the AZA group), and one 
characterized by an initial immunosuppressive regimen consisting of cyclosporine, 
prednisone with or without azathioprine (the CsA group). Immunosuppressive 
regimens, in which cyclosporine was introduced within 1 month after transplantation, 
were included in the CsA group. Transplantations with initial immunosuppressive 
regimens containing other drugs, such as mycophenolate mofetil, tacrolimus, 
antithymocyte globulin, cyclophosphamide or OKT3, were excluded from this 
analysis. All medical charts of all patients, participants as well as non-participants in 
the cross-sectional study, were reviewed. Emigrated patients were located and 
medical information was obtained from their current physician. 
 
All patients who were alive were invited for examination in our hospital. Data were 
gathered on health, current medication, current renal function and social status, by 
using questionnaires, reviewing medical charts, and performing a physical 
examination. Data on renal function and comorbidity were gathered from the medical 
charts. A systolic blood pressure above140 mmHg was considered to be systolic 
hypertension; a diastolic blood pressure above 90 mmHg was considered to be 
diastolic hypertension. The glomerular filtration fraction (GFR) was estimated on 
basis of the serum-creatinine, using the Cockroft–Gault formula.2 Comorbidity was 
considered to be present in the event of the occurrence of one or more of the clinical 
diseases as defined by Davies et al. (i.e. malignancy, clinical apparent ischemic heart 
disease, peripheral vascular disease, clinical apparent left ventricular dysfunction, 
diabetes mellitus, systemic collagen vascular disease, cerebrovascular disease, 
chronic obstructive airway disease, or other significant abnormality).3 Disabilities 
were considered present in case of severe deafness, blindness or disability resulting 
from motor function disorders. For quality of life assessment, the RAND-36 Health 
Survey was used;4 data were compared to data derived from a Dutch age-matched 
control group.5 Data on social status included employment, educational attainment 
and residence.  
 
Statistical analysis 
We used Kaplan-Meier analysis to calculate graft survival probabilities. Survival 
curves were compared using the log-rank test. Logistic regression analysis was used 
to establish associations between comorbidity and disabilities on one side and 
patient characteristics (i.e. GFR, gender, duration of dialysis, duration of renal 
replacement therapy, and duration of transplantation) on the other side.  
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We used the Student t test to analyze the effect of cyclosporine therapy on mean 
blood pressure. Chi square test was used to analyze the association between 
cyclosporine therapy and binominal dichotomous outcomes.  
We performed a stratified analysis for linear trend in proportions (EpiInfo, Centers for 
Disease Control and Prevention, Atlanta, GA) to analyze the difference in educational 
attainment and the general Dutch population. SPSS 10.0.07 was used for all other 
statistical calculations. 
 
Results  
 
Patient characteristics 
The LERIC cohort consisted of 249 subjects. Of these, 62 had died at time of 
investigation, leaving 187 alive. One patient died 4 months after the cross-sectional 
investigation and is included in the analysis of mortality. For 82 patients (33%), the 
follow up was more than 20 years. At the end of the study no patients were lost to 
follow up. 
The mean total duration of RRT was 15.5 years (range 0.3-28), the mean total 
duration of transplantation was 11.3 years (range 0-29.9), the mean total duration of 
hemodialysis 3.3 years (range 0-25.6), and the mean total duration of peritoneal 
dialysis 0.8 years (range 0-14.7). Patients changed from therapy modality (i.e. 
dialysis or functioning graft) from one to nine times during the study period. Of all 187 
living patients, 140 participated in the cross-sectional part of the study, of whom 110 
had a functioning graft at time of investigation. The main characteristics of the total 
cohort and the participants in the cross-sectional study are given in Table 1. 
 
Table 1. Patient characteristics of the LERIC cohort 
 LERIC cohort Participants cross-sectional 
study with a functioning 
graft 
Number of patients (male/female) 249 (136/113) 110 (54/56) 
Primary disease (n)   
 Glomerulopathy % 90 (36.1)  40 (36.4) 
 Obstructive uropathy % 70 (28.1)   32 (29.1) 
 Congenital renal malformation %a 44 (17.7)   22 (20) 
 Hemolytic Uremic Syndrome % 18 (7.2)    9 (8.2) 
 Metabolic diseaseb   8 (3.2)    0  
 SLE %  5 (2.0)    2 (1.8) 
 Other % 14 (5.6)    0  
Mean follow up time from start of RRT, yrs (range)    15.5 (0.2-30.0)     18.2 (6.2-30.0) 
Mean age at start of RRT, yrs (range)    10.6 (1.9-14.9)     11.0 (1.9-14.9) 
Mean age at first transplantation, yrs (range)    12.6 (3.9-27.0)     12.6  (6.6-27.0) 
Mean age of all patients alive at the end of the 
study, yrs (range) 
   29.5 (20.7-1.7)     29.3  (20.7-41.7) 
Number of deaths    63  
Number of patients ever transplanted   231  
Number of patients never transplanted    18  
Number of pre-emptive transplantations      7  
a dysplasia (15), nephronophtisis (22), autosomal recessive polycystic kidney disease (3), Alport’s 
syndrome (1), congenital nephrotic syndrome (2), prune belly syndrome (1) 
b cystinosis (5), oxalosis (3) 
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Data collection 
Between November 1998 and August 2000, members of the LERIC-team visited 37 
hospitals in The Netherlands. They collected information about the period, duration 
and onset of renal replacement therapy, the total number and duration of dialysis and 
transplant periods; and all immunosuppressive drugs that were used. The date of 
graft failure was defined as the day of onset of chronic dialysis or a next 
transplantation after the particular transplantation. An analysis was made of the effect 
of the introduction of cyclosporine on the long-term graft survival by comparing two 
groups of transplantations: one characterized by an initial immunosuppressive 
regimen consisting of azathioprine and prednisone (the AZA group), and one 
characterized by an initial immunosuppressive regimen consisting of cyclosporine, 
prednisone with or without azathioprine (the CsA group). Immunosuppressive 
regimens, in which cyclosporine was introduced within 1 month after transplantation, 
were included in the CsA group. Transplantations with initial immunosuppressive 
regimens containing other drugs, such as mycophenolate mofetil, tacrolimus, 
antithymocyte globulin, cyclophosphamide or OKT3, were excluded from this 
analysis. All medical charts of all patients, participants as well as non-participants in 
the cross-sectional study, were reviewed. Emigrated patients were located and 
medical information was obtained from their current physician. 
 
All patients who were alive were invited for examination in our hospital. Data were 
gathered on health, current medication, current renal function and social status, by 
using questionnaires, reviewing medical charts, and performing a physical 
examination. Data on renal function and comorbidity were gathered from the medical 
charts. A systolic blood pressure above140 mmHg was considered to be systolic 
hypertension; a diastolic blood pressure above 90 mmHg was considered to be 
diastolic hypertension. The glomerular filtration fraction (GFR) was estimated on 
basis of the serum-creatinine, using the Cockroft–Gault formula.2 Comorbidity was 
considered to be present in the event of the occurrence of one or more of the clinical 
diseases as defined by Davies et al. (i.e. malignancy, clinical apparent ischemic heart 
disease, peripheral vascular disease, clinical apparent left ventricular dysfunction, 
diabetes mellitus, systemic collagen vascular disease, cerebrovascular disease, 
chronic obstructive airway disease, or other significant abnormality).3 Disabilities 
were considered present in case of severe deafness, blindness or disability resulting 
from motor function disorders. For quality of life assessment, the RAND-36 Health 
Survey was used;4 data were compared to data derived from a Dutch age-matched 
control group.5 Data on social status included employment, educational attainment 
and residence.  
 
Statistical analysis 
We used Kaplan-Meier analysis to calculate graft survival probabilities. Survival 
curves were compared using the log-rank test. Logistic regression analysis was used 
to establish associations between comorbidity and disabilities on one side and 
patient characteristics (i.e. GFR, gender, duration of dialysis, duration of renal 
replacement therapy, and duration of transplantation) on the other side.  
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Transplantations 
A total of 397 transplantations were performed in 231 out of 249 patients, 45 of which 
were from a family-related donor and 352 from a cadaveric donor. Only seven 
patients underwent transplantation pre-emptively.  
The number of transplantations per patient was 1 in 112 patients, 2 in 79 patients, 3 
in 33 patients and 4 in 7 patients. Living related donation (LRD) transplantations were 
performed significantly more often as retransplantation than as primary 
transplantation (17% [29 of 166] vs 7% [16 of 231], p=0.001). In 206 (52.3%) of all 
397 transplantations, only azathioprine and prednisone were used as initial anti-
rejection regimen (AZA-group).  
In 160 transplantations (40.7%) the combination of cyclosporine and prednisone with 
or without azathioprine was used as anti-rejection therapy (CsA-group) (Table 2).  
 
Table 2. Initial Immunosuppressive regimens all transplantations 
Regimens All Tx 
(n=397) 
First Tx 
(n=231) 
Second Tx 
(n=119) 
Third Tx 
(n=40) 
Fourth Tx 
(n=7) 
AZA/p 206 161 41   3 1 
CsA/p  90   33 43 14 0 
CsA/AZA/p  70   23 29 15 3 
ATG/OKT3+ 14    8  3  3 3 
MMF/CsA/p 10    0  2  5 7 
Other  7    6  1  0 1 
Tx = transplantation; AZA/p =azathioprine & predniso(lo)ne; CsA/p = cyclosporine & predniso(lo)ne; 
CsA/AZA/p = cyclosporine & azathioprine & predniso(lo)ne; ATG/OKT3 + = ATG or OKT3 & other 
drugs; other = cyclophosphamide/azathioprine/prednisone, or radiotherapy/azathioprine/prednisone 
 
Graft survival 
Graft survival estimates of all transplantations were 59.9%, 46.2%, 36.1%, and 
30.9% at 5, 10, 15 and 20 years, respectively. The survival of all first transplantations 
of the AZA group and the CsA group were similar. The survival of all 
retransplantations was significantly higher in the CsA group than in the AZA group 
(p=0.016; Figure 1 & Table 3). 
Graft survival estimates for all family-related transplantations (n=45) were 
significantly higher than for all post-mortem transplantations: 77.7%, 74.5%, 65.7% 
and 49.3% at 5, 10, 15 and 20 years, respectively, versus 58.0%, 43.3%, 33.3% and 
28.9% (p=0.003) (Figure 2). Overall, 219 of 397 transplantations were complicated by 
a complete graft failure. In 29.7% this was caused by acute rejection, in 52.2% by 
chronic graft nephropathy, and in 9.1% by thrombosis (Table 4). We found no 
influence on the cause of the graft failure of the period of transplantation, the 
immunosuppressive regimen (AZA group vs. CsA group), or the consecutive number 
of transplantation within one patient.  
 
Mortality 
Of the 63 patients who died, 25 died with a functioning renal graft. Of these 25 
patients, 7 (28%) died within 4 months after transplantation and 13 (52%) died within 
one year, at a mean age of 18.0 years (range 4.6-33.5 years).  
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Figure 1. Kaplan-Meier survival estimates of all first transplantations (1a) and all retransplantations  
(1b) with either azathioprine and prednisone (=azathioprine, dotted line), or cyclosporine, 
(azathioprine) and prednisone (=cyclosporine) as initial immunosuppressants 
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From the onset of transplantation, patient survival was 91%, 86%, 83% and 78% at 
5, 10, 15 and 20 years respectively (Figure 3). Causes of death of the 25 patients 
who died with a functioning graft were the following: cerebral bleeding (n=4), 
congestive heart failure (n=4), non-Hodgkin lymphoma (n=3), Pneumocystis carinii 
infection (n=2), cytomegalovirus infection (n=2), refusal of further treatment at the 
time of graft failure (n=2), myocardial infarction (n=1), septicemia (n=1), dengue 
(n=1), fibrosarcoma (n=1), ruptured aortic aneurysm (n=1), gastro-intestinal bleeding 
(n=1), acute rejection complicated by cardiac arrest (n=1) and unknown cause (n=1). 
In the first year after transplantation, infectious disease was the most common cause 
of death (38.5%). Mortality and causes of death in the LERIC cohort are described in 
detail elsewhere.1 
 
Table 3. Transplant survival 
 Total no 5 yr survival 10 yr 
survival 
15 yr 
survival 
20 yr 
survival 
All TX a 397 60% 46% 36% 31% 
 AZA 206 57% 43% 33% 28% 
 Censored 72(35%) 14 (5%) 19 (9%) 30 (14%) 42 (20%) 
 CsA 160 66% 56% 48%  
 Censored 90 (56%) 24 (15%) 51 (32%) 83 (52%)  
First Tx a 231 61% 46% 36% 32% 
 AZA 161 60% 46% 35% 31% 
 Censored 59 (36%) 11 (6%) 13 (8%) 22 (8%) 32 (20%) 
 CsA 56 66% 51% 44%  
 Censored 28 (50%) 4 (7%) 8 (14%) 23 (41%)  
Secound-Fourth TX a 166 59% 48% 39% 27% 
 AZA 45 44% 37% 28% 19% 
 Censored 13 (29%) 3 (7%) 5 (11%) 8 (18%) 10 (22%) 
 CsA 104 65% 54% 45%  
 Censored 62 (60%) 20 (19%) 43 (41%) 50 (58%)  
Tx = transplantation; AZA = azathioprine & prednisone; CsA = cyclosporine, (azathioprine) & 
prednisone; a including those on other immunosuppressive regimens 
 
Health state at cross-sectional examination 
 
Patient characteristics 
Of all 187 patients who were alive, 140 participated in the cross-sectional study 
(75%). Of these 140, 110 patients, 54 male and 56 female, were living with a 
functioning graft. Previously, we have shown that the clinical characteristics of 
participants and non-participants in the cross-sectional study were similar.6 The 
mean age of the cross-sectionally investigated patients was 29.3 years (range 20.7-
41.7). The mean duration of the last transplant period was 12.3 years (range 0.3-
26.3, median 11.7) (Table 1). In 44 patients, the survival of the latest graft exceeded 
15 years. In 7 patients, the GFR was less than 25 mL/min/1.73m² at the time of 
investigation. On 106 of 110 patients, data on health and social status could be 
obtained. Cyclosporine was used by 38 (34.5%) of all patients at time of 
investigation; 35 patients (31.8%) had never used cyclosporine. Tacrolimus was used 
by 7 (6.4%) patients. Anti-hypertensive medication was used by 64 (58.2%) patients; 
24 (21.8%) used angiotensin-converting enzyme inhibitors, 31 (28.2%) calcium-
antagonists, 39 (35.5%) beta-blockers and 7 (6.4%) diuretics.  
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Figure 2. Kaplan-Meier survival estimates of all family related (n=45) and all post-mortem 
transplantations (n=352) 
time after transplantation in years
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Figure 3. Kaplan-Meier patient survival estimates of all transplanted patients 
time after transplantation in years
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Table 4. Diagnosis of graft failure of all transplantations, and of all transplantations with initial 
azathioprine/prednisone therapy (AZA Tx) and of those with cyclosporine / (azathioprine) / prednisone (CsA Tx) 
 all Tx  all AZA Tx  all CsA Tx   
 n (% ) n (%) n (%) 
No failure 178 (44.8) 72 (35.0) 90 (56.3) 
Acute rejection 65 (16.4) 35 (17.0) 21 (13.1) 
Chronic allograft nephropathy 115 (29.0) 69 (33.5) 41 (25.6) 
Thrombosis 20 (5.0) 15 (7.3) 4 (2.5) 
Renal artery stenosis 3 (0.8) 2 (1.0) 1 (0.6) 
Urethral obstruction/Obstructive uropathy 2 (0.5) 2 (1.0) 0  
Primary disease 9 (2.3) 7 (3.4) 2 (1.3) 
Unknown 2 (0.5) 2 (1.0) 0  
Bleeding 2 (0.5) 1 (0.5) 1 (0.6) 
Reduction immunosuppressive therapy 
because of a lymphoma 
1 (0.3) 1 (0.5) 0  
Total 397a  206  160  
Tx = transplantation;a 31 transplantations with other immunosuppressive regimens than the combination of 
azathioprine/prednisone or cyclosporine /prednisone/(azathioprine) 
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Table 4. Diagnosis of graft failure of all transplantations, and of all transplantations with initial 
azathioprine/prednisone therapy (AZA Tx) and of those with cyclosporine / (azathioprine) / prednisone (CsA Tx) 
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Table 5. Health status in patients with a functioning graft (n=106) 
General condition:  
 Comorbidity 40.0% 
 Motor, visual or auditive  disabilities 19.1% 
General Health Perception  
 >50% healthy, no disabilities 58.7% 
 >50% healthy, “disabled” 29.3% 
 < 50% healthy 11.9% 
Fatigue:  
 Never or sometimes 65.1% 
 Often 11.9% 
 Daily 22.9% 
 Limitation of daily activities 27.3% 
 Inactivity 37.3% 
Bone disorders 34.5% 
 Disabling bone disorders 17.3% 
 Aseptic bone necrosis 11.8% 
 Height <-2SD  60.9% 
Skin disorders:  
 Itching 27.3% 
 Warts 59.1% 
Fertility women (n=56):  
 Amenorrhoea   5.6% 
 Ever been pregnant 16.4% 
 Offspring 16.4% 
 Infertility established   3.6% 
Cardiovascular symptoms:  
 Exercise intolerance  18.2% 
 Ankle edema 14.5% 
 Angina pectoris   8.2% 
 Intermittent claudication   7.3% 
Neurological symptoms:  
 Severe headache 49.5% 
  Once a month 32.1% 
  Weekly 17.4% 
 Sensory disorders 16.4% 
 Epilepsy   8.2% 
 Dysbalance 11.8% 
 Paresis 15.5% 
 Restless legs 21.8% 
 Tremors 38.2% 
Fertility men (n=54)  
 No erection   7.1% 
 No ejaculation 17.8% 
 Offspring 16.1% 
 Infertility established   5.4% 
Quality of lifea  
 Physical Component Summary 47.5 (10.1)b 
 Mental Component Summary 49.9 (9.1) 
a RAND-36 questionnaire, scores for general population of Physical Component Summary and Mental 
Component summary both 50 with SD 10; b significantly lower than found in the general population 
(p=0.05); mean score general population for both Physical and Mental Component summary is 50. 
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Health state 
Of all patients, 60% reported a good overall health state. Comorbidity was reported in 
40%, skeletal disabilities, impaired vision or hearing were reported in 19% (Table 5). 
Clinical signs of bone disease (i.e. chronic joint and bone pain, disabling 
malformations, pathological fractures, aseptic bone necrosis), severe headaches, 
severe itching and tremors were the most frequently occurring disabling problems. 
Systolic and diastolic hypertensions at cross-sectional examination were found in 
31% and 22%, respectively. The mean educational attainment of all patients was 
significantly lower than that of the general Dutch population (Chi-square for linear 
trend p<0.001). Also, compared to the age-matched general Dutch population, 
significantly more patients lived without a partner (58.8% versus 29.8%; Table 6). 
 
Table 6. Social status (n=106) 
 Patients Dutch populationa 
Educational attainment     
Low vocational training 57.0%   27.2%b 
Intermediate vocational training 30.8% 47.0% 
High vocational training 12.1% 25.9% 
Unemploymentc 25.5%   11.1%d 
Domestication   
 Living alone  29.4% 20.7% 
 With partner 38.5% 64.8% 
 With parents 29.4% 12.7% 
  Institution   2.7%   5.4% 
a Dutch population 20-44 years old: N =5.975.843; bChi-square for linear trend: p<0.001; c students 
excluded; d 381.900 people Unemployment Benefit (Werkloosheid Wet) or on Employment Unfitness 
Benefit (Wet Arbeids Ongeschiktheid) (6.39%) &  283.260 people on Employment Unfitness Benefit 
(4.74%). Data from Central Bureau for National Statistics, 1999 (Centraal Bureau voor de Statistiek: 
www.cbs.nl).  
 
Associations between disease characteristics, medication and outcome 
Overall comorbidity was associated with a low actual GFR and male gender 
(adjusted odds ratios 14.1 (p=0.02) and 2.5 (p=0.03), respectively). We found no 
association between the appearance of disabilities and patient characteristics. Being 
on cyclosporine at time of investigation was associated with a higher mean systolic 
blood pressure (135±17.9 mmHg vs. 128±19.0 mmHg; p=0.05), severe warts 
(p=0.02), hypertrichosis (p<0.001), complaints of general fatigue (p=0.03) and a 
history of epilepsy (p=0.05). Of all patients on cyclosporine therapy, 75% used anti-
hypertensive drugs, compared to 50% of those without cyclosporine (p=0.01). We 
found no associations between other outcome measurements and the use of 
cyclosporine.  
 
Discussion  
 
This is the first study with detailed information reporting on pediatric kidney 
transplantations with a follow up in nearly one third of more than 15 years. In Europe, 
only a few reports on the long term follow up of the early kidney transplantations in 
children have been published over the past decade.7-9  
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The large North American databases on kidney transplantations (the United Network 
for Organ Sharing and the North American Pediatric Renal Transplant Cooperative 
Study) started to collect their data in 1987. Thus, their follow-up is shorter than in the 
current cohort, and their patients have been treated with more modern 
immunosuppressive therapy.10-12 
 
Graft survival: the effect of cyclosporine therapy  
The overall 20 year graft survival of 31% that we found in our cohort is in accordance 
with the report of a single European center.9 The fact that no patient of our historical 
cohort was lost to follow-up made it possible to compare the effect of the introduction 
of cyclosporine as immunosuppressive therapy on graft survival in the long run. As 
expected, we found that cyclosporine therapy was associated with a higher mean 
graft survival than azathioprine. However, to our surprise, this only counted for 
retransplantations. We found no beneficial effect of cyclosporine on graft survival in 
all first transplantations. Moreover, the number of graft losses resulting from acute 
rejection was not different in the AZA group compared to that in the CsA group. 
These are important observations, because azathioprine has clear advantages above 
cyclosporine. The cross-sectional part of the study showed that survivors on 
cyclosporine suffered from more side effects than those on azathioprine (i.e. a higher 
mean blood pressure and more cosmetic and neurological problems). Nevertheless, 
the apparent better results of the cyclosporine group with respect to graft survival in 
the retransplantations could be biased as a result of the strategy of some Dutch 
centers in the late 1980s. Their protocols prescribed a conversion from azathioprine 
to cyclosporine only after a decrease in serum creatinine below a certain value (i.e. 
100 mol/L) in most centers. The same policy is described by Chavers et al.8 
Because some patients never reached this value and remained on azathioprine, this 
protocol led to a selection of grafts with worse function compared to the AZA group in 
the current study. The fact that cyclosporine was found to be beneficial only in 
retransplantations suggests that its additional immunosuppressive action only 
overrules its nephrotoxicity with respect to graft function in the more immunogenic 
circumstances that obviously come with retransplantations. During the first years 
after the introduction of cyclosporine in renal transplantation, most regimens 
prescribed very high dosages of the drug, inducing severe renal toxicity. Chavers et 
al made the same observations with respect to the effect of cyclosporine on first and 
repeat transplantations.8 
 
Post-mortem versus living related transplantations 
Compared to reports of the North American Pediatric Renal Transplant Cooperative 
Study database, the proportion of living related transplantations was relatively 
small.12 Between 1970 and 1983, only 7 LRD transplantations in children have been 
performed in the Netherlands. This low figure could partly be explained by the 
excellent allocation system in Europe of Eurotransplant, which has resulted in a 
relatively short waiting time for postmortem grafts. In the Netherlands, this situation 
has induced a policy to postpone LRD kidneys to a later stage, in which finding a 
suitable cadaveric donor can be expected to be more difficult.  
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The far more favorable survival of LRD grafts as compared with cadaveric grafts that 
we found has been confirmed by others. However, in The Netherlands, the proportion 
of LRD transplantations has remained low until the late 1990s. Lately, the scarcity of 
cadaveric organs and the changed attitude of the teams towards LRD 
transplantations have pushed its proportion up to 30%.13 Our findings underline the 
need for a further increase in LRD transplantations. 
 
Outcome 
Cardiovascular disease was the most common cause of death, a remarkable feature 
considering the young age at which our patients died. Previously, we reported on 
cardiac and vascular disease in the LERIC cohort.6,14 We found a high incidence of 
left ventricular hypertrophy, calcification of the aortic valve, and on average an 
increased arterial wall stiffness of the carotid wall.  
Strikingly, we found these abnormalities to the same extent in transplanted patients 
with good renal function, as in patients on dialysis at the time of investigation. 
Hypertension was strongly associated with most of these cardiovascular 
abnormalities, all of which have proved to be mortality risk factors.15 
 
Health status at cross-sectional investigation 
Although most patients appeared to be in good health at cross-sectional 
investigation, still 40% of all patients suffered from concomitant diseases and nearly 
20% had disabilities. Skeletal, neurological, and skin disorders were most frequently 
reported. In an earlier report of the European Dialysis and Transplant Association 
database concerning young adult transplanted patients with pediatric end-stage renal 
disease, 20% of the patients had one disability and 11% more than one.16 Like in our 
cohort, musculoskeletal disorders were most frequently reported (15%), followed by 
vision (8%) and the hearing (8%) problems. In their long-term follow-up study on 
adult kidney transplant recipients, Lee et al described a high prevalence of skin, 
skeletal, and cardiovascular comorbidity in the 20 patients surviving at least 25 years 
after transplantation.17 Our data are in line with these observations. Whereas 
cardiovascular disease is the most prominent life-threatening problem, bone disease 
is the most disabling problem in young transplanted patients with pediatric ESRD.  
 
Quality of life and social outcome 
The subjective health perception of our patients was very good, despite the 
disabilities and comorbidity. Other authors also found a favorable quality of life in 
these patients.17-19 It seems that graft recipients do not feel that their health status 
interferes with their social life and that they often understate the degree of their 
disabilities in questionnaires.20 At the same time however, life career milestones of 
social independency and development (i.e. living without parents and having a 
partner) were significantly different from the normal population. Also, we found 
involuntary unemployment in our patients to be more than twice as high as in the 
age-matched population. The fact that some American reports have shown a more 
favorable outcome with respect to employment could reflect the difference in social 
security of both societies.17-18  
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Other European studies are in line with our data, confirming the relatively high social 
dependency and low grade of employment as compared to with healthy peers or 
patients with another chronic disease, such as diabetes mellitus.16,20,21 Our finding 
emphasizes the need for a psychosocial approach in children with ESRD that will 
stimulate them to become a socially well-adapted and independent individual in 
adulthood. 
 
Suggestions for improvement of therapy 
Although efforts to reduce the incidence of graft failure should be continued, more 
attention should be given to the prevention and reversal of cardiovascular, skeletal, 
and neurological comorbidity. Replacing cyclosporine by less vascular toxic 
medication and a more strict anti-hypertensive treatment are mandatory to reduce 
cardiovascular disease. The beneficial role of statins in young renal transplant 
recipients in this respect needs to be investigated. Last but not least, attention should 
be paid to the psychosocial development of children with ESRD, especially with 
respect to schooling and development towards social independency.  
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Abstract 
 
Background  
Collaboration of the Dutch centers for kidney transplantation in children started in 
1997 with a shared immunosuppressive protocol, aimed at improving graft survival by 
diminishing the incidence of acute rejections. This study compares the results of 
transplantations in these patients to those in a historical reference group. 
 
Methods 
Ninety-six consecutive patients receiving a first kidney transplant were treated with 
an immunosuppressive regimen consisting of mycophenolate mofetil, cyclosporine 
and corticosteroids. The results were compared to those of historic controls (first 
transplants between 1985 and 1995, n=207), treated with different combinations of 
corticosteroids, cyclosporine A and/or azathioprine. Cytomegalovirus prophylaxis was 
prescribed to high-risk patients in the study group, and only a small proportion of the 
reference group.  
 
Results  
The graft survival at 1 year improved significantly: 92% in the study group, vs 73% in 
the reference group (p<0.001). In the study group 63% of patients remained 
rejection-free during the first year; in the reference group 28% (p<0.001). After 
statistical adjustment of differences in baseline data, as cold ischemia time, the 
proportion of LRD, pre-emptive transplantation, and young donors, the difference 
between study and reference group in graft survival (RR 0.33, p=0.003) and 
incidence of acute rejection (RR 0.37, p<0.001), as the only factor, remained 
statistically significant, indicating the effect of the immunosuppressive therapy. In the 
first year 1 case of malignancy occurred in each group. CMV disease occurred less 
frequently in the study group (11%) than in the reference group (26%, p=0.02). As a 
new complication in 4 patients bronchiectasis was diagnosed.  
 
Conclusion  
A new consensus protocol, including the introduction of mycophenolate mofetil, 
considerably improved the outcome of pediatric kidney transplantation in the 
Netherlands, measured as reduction of the incidence of acute rejection and improved 
graft survival.  
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Introduction 
 
In 1997 the Dutch centers for pediatric kidney transplantation together with the one in 
Antwerp, Belgium, started sharing treatment and research protocols. The first project 
was a shared immunosuppressive regimen, primarily aimed at ameliorating long-term 
graft survival by diminishing the incidence of acute rejection episodes (AREs) in the 
first year. 
This aim originated from results of transplantation performed in the Netherlands 
between 1985 and 1995, which were recently reviewed.1 In this cohort, which 
included 13% living related (LRD) transplantation, the one-year graft survival was 
73%. Similar cohorts of children in other countries showed higher one-year graft 
survival rates: in post-mortally donated (PMD) grafts 79% in Great Britain2, 78% in 
Scandinavia3, and 81% in North America4; in LRD grafts 88% in Scandinavia3 and 
91% in North America4. In the Dutch cohort 22% of the graft losses in the first year 
was due to acute rejection, equivalent to 7% of all transplants. During subsequent 
years graft failure was primarily caused by chronic allograft nephropathy.1 In the 
course of time acute rejection has become less important as a cause of direct graft 
loss. Chronic allograft nephropathy, however, has acquired a leading role in the loss 
of grafts in the long run.4, 5  
To improve graft survival, the development of chronic allograft nephropathy should 
therefore be prevented. Several authors showed that acute rejection is the major risk 
factor for chronic allograft nephropathy: without a previous acute rejection episode 
the incidence of chronic allograft nephropathy is very low. One rejection episode 
contributes to chronic allograft nephropathy, but multiple rejection episodes carry a 
higher relative risk.6-9 Late occurrence of the first rejection episode (later than 6 
months) is also an independent risk factor for chronic allograft nephropathy.7-9 No 
fewer than 63% of North American pediatric patients with a PMD graft still have one 
or more acute rejection episodes within 4 years after transplantation,10 this proportion 
is 51% in patients with a LRD graft.11  
Having to design an immunosuppressive regimen for all Dutch centers, we aimed at 
reducing the graft losses caused by acute rejection and chronic allograft nephropathy 
by way of diminishing the incidence of acute rejection. In adult kidney transplantation, 
adding mycophenolate mofetil (MMF) to the immunosuppressive regimen consisting 
of corticosteroids and cyclosporine (CsA) significantly reduced the incidence of acute 
rejection.12-14 This is why we decided on a combination of MMF, CsA and 
corticosteroids as immunosuppressive treatment of our pediatric kidney transplant 
patients during the first year after transplantation. In order to be able to assess the 
efficacy and safety of this regimen, we agreed upon a standard protocol for additional 
treatment variables. Here we present the results of this new protocol in the first 
cohort of pediatric transplant patients, using the 1985-1995 cohort as a reference 
group. 
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Patients and methods 
 
Patients 
All patients receiving a kidney transplant in the Netherlands and Antwerp, Belgium 
were treated with the same immunosuppressive protocols from October 1997. Until 
December 2001, 121 transplants had been performed; data were collected for at 
least one year after transplantation. The results were compared to those from 
transplants performed in the Netherlands between 1985 and 1995, the retrospective 
evaluation of which has been published earlier.1 To enable comparison, only first 
transplants were analyzed. 
 
Immunosuppressive regimen 
The immunosuppressive regimen consisted of three drugs: corticosteroids, CsA and 
MMF. Of each drug a loading dose was given 1 to 6 hours pre-operatively: of 
methylprednisolone 300 mg/m2 intravenously, of CsA 10 mg/kg orally, and of MMF 
600 mg/m2 orally. Post-transplant (methyl)prednisolone was prescribed at 40 mg/m2 
twice daily, with weekly tapering off the dosage to 7.5 mg/m2, once daily, at week 6. 
Six months post-transplant it was further decreased to 5 mg/m2. From 6 hours after 
recirculation CsA was administered intravenously for 24 hours in a dosage of 3 
mg/kg/24 hr, followed by oral administration titrated towards a trough level of 150-250 
mg/L during the first 6 weeks, of 150-200 mg/L during the second 6 weeks, and 100-
150 mg/L thereafter. MMF was administered as soon as oral intake was possible, in 
a dosage of 600 mg/m2 twice daily. Triple therapy was scheduled to be continued 
during the first year.  
In the reference group patients had been treated with various combinations of 
corticosteroids, CsA and azathioprine (AZA). In both groups no induction therapy with 
ATG or monoclonals had been applied. 
 
Acute rejection 
An acute rejection was defined as a sudden increase of serum creatinine to more 
than 115% of the previous values with no other identifiable cause, followed by the 
prescription of a full course of anti-rejection treatment. In the study group anti-
rejection treatment consisted of one or two courses of intravenous 
methylprednisolone. If this treatment failed, a course of rabbit ATG was instituted. 
Prior to ATG treatment a kidney biopsy was taken. In the reference group the choice 
of antirejection treatment had been determined by hospital policy. Complete recovery 
was defined as a creatinine level of <115% of the pre-rejection value 2 weeks after 
treatment. 
 
Chronic allograft nephropathy 
Chronic allograft nephropathy was defined as slowly progressive renal failure with no 
other identifiable cause, at least 3 months after transplantation. Renal biopsies were 
performed in some, but not all cases of chronic allograft nephropathy.  
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Delayed graft function 
Delayed graft function was defined as the need of dialysis treatment in the first week 
after transplantation. 
 
Graft survival 
Start of any form of chronic dialysis or a new transplant or death with a functioning 
graft was considered as graft loss.  
 
Thrombosis prophylaxis 
All patients in the study group with a high risk of vascular thrombosis of the graft – 
recipients younger than 6 years of age, donors younger than 10 years, multiple renal 
arteries or veins to the graft, or a history of thrombosis – received anti-thrombotic 
therapy during 2 weeks, either low dose heparin or low molecular weight heparin. 
Data on prophylaxis in the reference group were not available. 
 
CMV prophylaxis 
In the study group all CMV seropositive patients, and seronegative patients with a 
seropositive donor (D+R-, D+R+, D-R+) received prophylaxis against CMV during  
the first 3 months after transplantation, consisting of (val)acyclovir, or gancyclovir in 
high-risk patients, in two centers in combination with hyperimmune globulin every 
other week. In the reference group (for the CMV data restricted to the patients 
transplanted between 1990 and 1995) only one center prescribed hyperimmune 
globulin only to CMV seronegative recipients with seropositive donors (D+R-). 
 
CMV disease 
CMV disease was defined as CMV-infection (PCR in plasma or pp65 in leukocytes 
positive) together with clinical symptoms, with admission to the hospital for treatment 
with i.v. gancyclovir. 
 
Statistics 
Primary endpoints were the incidence of acute rejection during the first year and the 
graft survival during the first 2 years. The difference between Kaplan Meier survival 
curves, used for patient and graft survival, and time to first acute rejection, was 
tested for its statistical significance with a log rank test. Differences in other 
parameters were tested with the following tests: chi-square, or Fisher’s exact test if 
appropriate, for categorical variables, Student’s t-test for continuous variables. Cox’ 
regression analysis was used to adjust the comparison between study and reference 
group for possibly confounding factors. 
 
Results 
 
Between 1997 and 2001, 121 kidney transplants were performed in 117 patients, 
with a minimum follow-up of 12 months. Ninety-six patients received a first graft. The 
reference group consisted of 269 transplantations in 231 patients, of which 207 were 
a first graft. Baseline demographic and clinical data of the patients are shown in 
Table 1.  
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Table 1. Baseline demographic and clinical characteristics 
   Triple therapy Reference group p 
   n (%) n (%)  
Transplantations  96 (100) 207 (100)  
        
Primary kidney disease     ns 
 congenital struct. abnorm. 45 (47) 74 (36)  
 glomerulonephritis 15 (16) 54 (26)  
 cystic disease 9 (9) 18 (9)  
 HUS  4 (4) 12 (6)  
 TIN/Alport/Goodpasture 7 (7) 7 (3)  
 cystinosis/oxalosis 4 (4) 7 (3)  
 cong. nephrotic syndr. 5 (5) 10 (5)  
 miscellaneous 4 (4) 14 (7)  
 unknown  3 (3) 11 (5)  
        
Recipient age (yr)      ns 
 < 6  16 (17) 41 (20)  
 6 - 10  23 (24) 56 (27)  
 10 - 14  33 (34) 67 (32)  
 > 14  24 (25) 43 (21)  
        
Donor age (yr)      <0.001 
 0 - 10  8 (8) 104 (50)  
 10 - 20  15 (16) 30 (15)  
 20 - 45  42 (44) 50 (24)  
 > 45  30 (32) 22 (11)  
 missing  1  1   
        
Donor source      0.001 
 PMD  68 (71) 179 (86)  
 LRD  28 (29) 28 (14)  
        
Renal replacement therapy prior to this transplantation    <0.001 
 haemodialysis 43 (46) 96 (47)  
 peritoneal dialysis 31 (33) 97 (47)  
 none  20 (21) 13 (6)  
 missing  2  1   
        
PRA pre-transplantation     ns 
 0 - 10  90 (99) 179 (89)  
 10 - 40  1 (1) 17 (8)  
 > 40  0 (0) 6 (3)  
 missing  5  5   
        
HLA-mismatches (only PMD transplantation)    ns 
 0  6 (9) 13 (7)  
 1 - 2  34 (52) 74 (41)  
 3 - 4  26 (39) 88 (49)  
 5 - 6  0 (0) 3 (2)  
 missing  2  1   
        
Cold ischemia time (only PMD transplantation)    <0.001 
 < 24 hr  39 (67) 58 (32)  
 24 - 36 hr  18 (31) 89 (50)  
 > 36 hr  1 (2) 32 (18)  
 missing  10     
HUS = hemolytic uremic syndrome, TIN=tubulo-interstitial nephropathy, PRA=panel reactive 
antibodies, PMD=postmortal donation 
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Differences include the increased proportion of grafts from living related donors and a 
higher percentage of pre-emptive transplants. Of the pre-emptive transplants, 5 out 
of 20 in the study group were from PMD, as compared to 9 out of 13 in the reference 
group (p=0.012). The proportion of young donors was lower in the study group. The 
cold ischaemia time in the study group was lower than that in the reference group. 
 
Patient survival 
After one year survival in the study group is 100%, in the reference group 96% 
(p=0.07). In the reference group 7 patients died within the first year, due to 
cerebrovascular accident (3), cardiac death (2), toxoplasmosis (1), unknown cause 
(1).1 
 
Graft survival 
Mean duration of follow-up is 20 months (range 0-61) in the study group and 45 
months (range 0-137) in the reference group. The graft survival rate for both LRD 
and PMD transplants is presented in Figure 1.  
The one-year graft survival of the study group is 92% overall, i.e. 96% for LRD and 
90% for PMD. In the reference group these values are 73%, 78% and 72%, 
respectively (p<0.0001 for all transplants; p=0.08 for LRD; p=0.0003 for PMD). The 
proportion of grafts lost due to acute rejection in the first year was 2.1% in the study 
group and 7.2% in the reference group (p=0.044) (Table 2).  
 
Table 2. Causes of graft loss in the 1st year after transplantation. ‘Other’ causes include in the 
reference group: death with functioning graft (6), primary non function (4), recurrence of primary renal 
disease (4), surgical problem (1) and miscellaneous (9); in the study group miscellaneous (2) 
 Triple therapy Reference group p 
 n (%) n (%)  
Number of transplants 96 (100) 207 (100)  
Acute rejection 2 (2.1) 15 (7.2) 0.044 
Chronic rejection 1 (1.0) 6 (2.8) n.s. 
Thrombosis 2 (2.1) 12 (5.8) n.s. 
Other 2 (2.1) 24 (11.5) 0.006 
      
Total 7 (7.3) 56 (27.1) <0.001 
 
Chronic allograft nephropathy caused graft loss during the first 2 years after 
transplantation in 2.1% in the study group vs 5.8% in the reference group (n.s.). 
Thrombosis caused graft loss in 2.1% in the study group and 5.3% in the reference 
group (n.s.). Graft failure was not observed in any of the 32 pre-emptive transplants. 
In Cox regression analysis we adjusted for the possible confounding effect of the 
following factors: pre-emptive vs post-dialysis transplantation, donor source, primary 
kidney disease, donor and recipient age at transplantation. The result was an 
adjusted RR for graft loss for study vs reference group of 0.33 (p=0.003). Adding 
CMV disease to the list of confounding factors, selecting the transplants that survived 
3 months, did not change the results for the other variables: the influence of CMV 
disease on graft survival was not statistically significant, and the difference between 
study and reference group remained statistically significant (RR=0.22, p=0.028). 
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Table 1. Baseline demographic and clinical characteristics 
   Triple therapy Reference group p 
   n (%) n (%)  
Transplantations  96 (100) 207 (100)  
        
Primary kidney disease     ns 
 congenital struct. abnorm. 45 (47) 74 (36)  
 glomerulonephritis 15 (16) 54 (26)  
 cystic disease 9 (9) 18 (9)  
 HUS  4 (4) 12 (6)  
 TIN/Alport/Goodpasture 7 (7) 7 (3)  
 cystinosis/oxalosis 4 (4) 7 (3)  
 cong. nephrotic syndr. 5 (5) 10 (5)  
 miscellaneous 4 (4) 14 (7)  
 unknown  3 (3) 11 (5)  
        
Recipient age (yr)      ns 
 < 6  16 (17) 41 (20)  
 6 - 10  23 (24) 56 (27)  
 10 - 14  33 (34) 67 (32)  
 > 14  24 (25) 43 (21)  
        
Donor age (yr)      <0.001 
 0 - 10  8 (8) 104 (50)  
 10 - 20  15 (16) 30 (15)  
 20 - 45  42 (44) 50 (24)  
 > 45  30 (32) 22 (11)  
 missing  1  1   
        
Donor source      0.001 
 PMD  68 (71) 179 (86)  
 LRD  28 (29) 28 (14)  
        
Renal replacement therapy prior to this transplantation    <0.001 
 haemodialysis 43 (46) 96 (47)  
 peritoneal dialysis 31 (33) 97 (47)  
 none  20 (21) 13 (6)  
 missing  2  1   
        
PRA pre-transplantation     ns 
 0 - 10  90 (99) 179 (89)  
 10 - 40  1 (1) 17 (8)  
 > 40  0 (0) 6 (3)  
 missing  5  5   
        
HLA-mismatches (only PMD transplantation)    ns 
 0  6 (9) 13 (7)  
 1 - 2  34 (52) 74 (41)  
 3 - 4  26 (39) 88 (49)  
 5 - 6  0 (0) 3 (2)  
 missing  2  1   
        
Cold ischemia time (only PMD transplantation)    <0.001 
 < 24 hr  39 (67) 58 (32)  
 24 - 36 hr  18 (31) 89 (50)  
 > 36 hr  1 (2) 32 (18)  
 missing  10     
HUS = hemolytic uremic syndrome, TIN=tubulo-interstitial nephropathy, PRA=panel reactive 
antibodies, PMD=postmortal donation 
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Differences include the increased proportion of grafts from living related donors and a 
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of 20 in the study group were from PMD, as compared to 9 out of 13 in the reference 
group (p=0.012). The proportion of young donors was lower in the study group. The 
cold ischaemia time in the study group was lower than that in the reference group. 
 
Patient survival 
After one year survival in the study group is 100%, in the reference group 96% 
(p=0.07). In the reference group 7 patients died within the first year, due to 
cerebrovascular accident (3), cardiac death (2), toxoplasmosis (1), unknown cause 
(1).1 
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Table 2. Causes of graft loss in the 1st year after transplantation. ‘Other’ causes include in the 
reference group: death with functioning graft (6), primary non function (4), recurrence of primary renal 
disease (4), surgical problem (1) and miscellaneous (9); in the study group miscellaneous (2) 
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Other 2 (2.1) 24 (11.5) 0.006 
      
Total 7 (7.3) 56 (27.1) <0.001 
 
Chronic allograft nephropathy caused graft loss during the first 2 years after 
transplantation in 2.1% in the study group vs 5.8% in the reference group (n.s.). 
Thrombosis caused graft loss in 2.1% in the study group and 5.3% in the reference 
group (n.s.). Graft failure was not observed in any of the 32 pre-emptive transplants. 
In Cox regression analysis we adjusted for the possible confounding effect of the 
following factors: pre-emptive vs post-dialysis transplantation, donor source, primary 
kidney disease, donor and recipient age at transplantation. The result was an 
adjusted RR for graft loss for study vs reference group of 0.33 (p=0.003). Adding 
CMV disease to the list of confounding factors, selecting the transplants that survived 
3 months, did not change the results for the other variables: the influence of CMV 
disease on graft survival was not statistically significant, and the difference between 
study and reference group remained statistically significant (RR=0.22, p=0.028). 
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Acute rejections  
During the first year 46 acute rejection episodes occurred in the study group, 
amounting to 0.5 episodes per patient; 235 in the reference group, 1.1 episodes per 
patient (p<0.001). About 50% in both groups were proven by biopsy. Figure 2 shows 
the time to first ARE in the study and the reference group, classified by donor source. 
   
Figure 1.     Figure 2. 
 
In the study group 58 patients (63%) remained rejection-free during the first year, in 
LRD 77%, PMD 59%. This was significantly better than in the reference group: 56 
patients (28%) remained rejection-free, in LRD 52%, PMD 26% (p<0.001). The 
incidence of steroid-resistant acute rejection was 16% in the study group, compared 
to 30% in the reference group (p=0.055). The trend towards a higher degree of 
complete recovery in the study group was not significant (Table 3). 
After correction for possibly confounding factors (pre-emptive versus post-dialysis 
transplantation, donor source, primary kidney disease, donor and recipient age at 
transplantation) in Cox regression analysis the adjusted relative risk for an ARE for 
study versus reference group was 0.37 (p<0.001).  
 
Delayed graft function 
In both the study group and the reference group delayed graft function occurred in 
17% of cases. The one-year graft survival rate after delayed graft function is 
significantly lower than after immediate function, in the study group 79% vs 99% 
(p=0.001), in the reference group 50% vs. 76% (p<0.001). 
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Graft function 
The average GFR, calculated according to Schwartz et al,15 modified by Morris et 
al,16 of the functioning grafts at the end of the first year was 63 mL/min.1.73m2 in 
both groups. In the study group patients who had experienced at least one acute 
rejection episode, had a GFR of 52 mL/min.1.73m2 at the end of the first year; 
patients without a rejection episode had a GFR of 69 mL/min.1.73m2 (p<0.001). In 
the reference group these values were 58 and 75 mL/min.1.73m2 respectively 
(p<0.001).  
 
Table 3. Acute rejection episodes (ARE) within 1st year 
 Triple therapy Reference group  
 n (%) n (%) p 
Number of transplants 96 (100) 207 (100)  
Number of AREs per patient      
 0 58 (63) 56 (28) <0.001 
 1 24 (26) 77 (39)  
 2 8 (9) 40 (20)  
 3 or more 2 (2) 25 (13)  
 Missing 4  9 9  
       
Total of ARE in 1st year (n) 46 (100) 235 (100)  
Biopsy proven AR 21 (46) 118 (50) ns 
Mean nr of ARE per patient 0.5  1.1  <0.001 
Recovery      
 Completea 29 (69) 120 (62) ns 
 Partialb 11 (11) 63 (32)  
 Graft loss 2 (5) 15 (8)  
 Missing 4  37   
       
Steroid sensitivity of ARE (1st treatment 
methylprednisolone)    
 Number with data 45 (100) 171 (100)  
 Sensitive 38 (84) 120 (70)  
 Resistant 7 (16) 51 (30) 0.055 
aComplete recovery is defined as serumcreatinine value 2 weeks after end of treatment of less than   
 115% of pre-rejection value 
bPartial recovery as more than 115% 
 
Use of antihypertensive medication  
In the study group 50 out of 89 (61%) patients did not use any antihypertensive drug 
at the end of the first year, in the reference group 51 out of 144 (35%, p=0.002). 
 
Adverse events 
In both groups one case of malignancy was registered during the first 2 years, i.e. in 
the study group a case of lymphoproliferative disease, associated with primary EBV-
infection, and in the reference group a HHV8-related Kaposi sarcoma (n.s.). CMV 
disease with hospitalisation for intravenous treatment with gancyclovir occurred in 9 
out of 81 patients in the study group (11%) and in 20 out of 78 cases in the reference 
group (26%, Table 4).  
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disease with hospitalisation for intravenous treatment with gancyclovir occurred in 9 
out of 81 patients in the study group (11%) and in 20 out of 78 cases in the reference 
group (26%, Table 4).  
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The data were incomplete in 15 patients of the study group, and in 21 of the 
reference group, these patients were not included in this analysis. The two groups 
showed similar distribution of serologic CMV status of donor (D) and recipient (R) at 
transplantation. In the study group 5 patients with a CMV status D+R- (n=26) 
developed CMV disease (19%), 1 with D-R+ (10%), and 3 with D-R- (8%). In the 
reference group the distribution was as follows: 10 cases with D+R- (45%), 3 with 
D+R+ (38%), 3 with D-R+ (33%) and 4 with D-R- (10%). The differences between the 
groups are significant (p=0.017). Five of the 6 patients with CMV disease in the study 
group who had received prophylaxis, developed the disease within the first 3 months. 
In 4 patients in the study group a new complication was described: persistent 
respiratory complaints, with bronchiectasis on high resolution CT-scan.17 
 
Table 4. Symptomatic CMV disease during the first year after transplantation, according to CMV 
serology at transplantation (cases with incomplete data in the study group n=15, in the reference 
group n=21, have been left out) 
 Study group Reference group  
    (1990-1995)  
CMV-status n Disease No disease n Disease No disease  
D+R- 26   5 (19)a 21 22 10 (45) 12 p = 0.05 
D+R+ 9 0 (0) 9 8 3 (38) 5 
D-R+ 10  1 (10) 9 9 3 (33) 6 
p = 0.02 
D-R- 36 3 (8) 33 39 4 (10) 35  
Total 81  9 (11) 72 78 20 (26) 58 p = 0.02 
a numbers (percentages) 
 
Change of therapy 
At the end of the first year data on immunosuppressive therapy were available in 80 
of 89 patients in the study group. Sixty five of these 80 patients (81%) were still on 
triple therapy, 55 on the initial Pred/CsA/MMF, in 10 patients the CsA was switched 
to tacrolimus (TCL). In 9 patients the MMF had been stopped: 8 of them were treated 
with Pred/CsA, 1 with Pred/TCL. Reasons for the interruption of MMF were side 
effects (diarrhea), CMV disease, lymphoproliferative disease or inclusion in another 
study. Six patients were treated with Pred/MMF, because they had entered into 
another study 6 months after transplantation. Switching from CsA to TCL was 
precipitated because of the cosmetic side effects of CsA. 
In the reference group at the end of the first year 28% of patients were on 
Pred/CsA/AZA, 29% on Pred/AZA, 43% on Pred/CsA. 
 
Discussion 
 
In this study the one-year graft survival rate showed a spectacular, highly significant 
improvement: from 73% in the historical reference group to 92% in the more recent 
study group with a new immunosuppressive protocol, consisting of corticosteroids, 
CsA and MMF. The differences were recognizable both in LRD and in PMD 
transplants. In a comparable German study with Pred/CsA/MMF in pediatric kidney 
transplantation the 3 year graft survival in the study group was 98%, compared to 
80% in the historical reference group.18  
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91 
In the pooled placebo- and AZA controlled studies in adults on the same triple 
therapy the one-year graft survival improved only slightly and not significantly, from 
88% to 90%.14 The difference between the 2 pediatric studies and the adult studies 
may reflect the difference between children and adults, but also between the use of a 
historical and a randomized control group.  
As was our primary objective, the harm done to the grafts by ARE was evidently less 
in the study group than in the reference group, measured in several ways. First, the 
incidence of ARE strongly diminished. The lower incidence of CMV disease may 
have contributed to this effect.19 Second, the graft losses that were the direct 
consequence of ARE, decreased. Third, the ARE episodes tended to be less 
aggressive in the MMF group, as suggested by a two-fold reduction of the frequency 
of steroid resistance. No significant improvement in reversibility is shown. The 
German Pediatric Renal Transplantation Study Group reported a similar incidence of 
ARE at 6 months posttransplant, i.e. 28% of patients treated with Pred/CsA/MMF, 
compared to 59% in the historical reference group on Pred/CsA/AZA.20 In the large 
placebo and azathioprine controlled studies on MMF in adults the incidence of ARE 
during the first 6 months significantly decreased from 31-46% to 13-20%.12,13 
 
However, as mentioned above, part of the improvement may be the result of the use 
of a historical control group. Primarily the new immunosuppressive protocol was 
developed not as a study protocol, but rather as a shared treatment protocol, of 
which the results would be compared to those of transplantations in the past years. 
But, the values of several baseline parameters differed between the study and the 
reference group. Therefore, the recent improvement will reflect contributions of a 
number of factors. First, there was a general trend over time towards a higher 
proportion of LRD transplants. As LRD grafts obviously yield better graft survival than 
PMD grafts, both were analyzed separately. Second, partly due to the higher 
LRD/PMD ratio the proportion of pre-emptive transplants was higher in the study 
group, because an LRD transplantation can be arranged more easily. The graft 
survival of pre-emptive transplants was excellent. Third, in recent years the Dutch 
centers used fewer kidneys from pediatric donors, especially from those under 5 
years old. Inquiry with Eurotransplant revealed a strongly decreased contribution of 
children in the donor pool over the studied period (G. Persijn, pers. communication). 
Apart from the smaller pediatric donor supply the use of small pediatric kidneys for 
pediatric recipients may be restricted by publications reporting the increased risk of 
combining young donors with young recipients.4 Fourth, the cold ischemia time 
fortunately became shorter over time, reflecting more efficient logistics of organ 
exchange. And finally, the incidence of CMV disease decreased as a result of the 
simultaneous introduction of a shared protocol for the prophylaxis of CMV. However, 
after statistical correction for all the above mentioned factors by Cox’ regression 
analysis, the results of the study group still remained significantly better than those of 
the reference group, indicating the influence of the introduction of MMF. A part of the 
improvement in graft survival in the earlier mentioned German pediatric study18 may 
be due to the same change in baseline data over time as we saw, e.g. cold ischemia 
time, since the German centers obtain their post-mortal donor kidneys from the same 
source as we do, Eurotransplant.  
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Our results do not show an improvement in kidney function in the study group 
compared to the reference group, in contrast to the German study group data which 
report better GFR values in the study group than in the reference group. Taking the 
GFR as a surrogate marker for graft survival, the increased number of recipients who 
remained rejection-free, and the finding that rejection-free patients had a better GFR, 
support the hypothesis that this regimen will benefit the long-term graft survival.  
 
One of the major side effects of many immunosuppressive drugs is high blood 
pressure. The introduction of MMF led to the use of less antihypertensive therapy. 
The same trend was reported by the German study.18 
 
More potent immunosuppression could lead to a higher incidence of malignancies 
and of (opportunistic) infections. We chose to compare the incidence of malignancies 
and CMV disease as indicators of overimmunosuppression. Fortunately the 
incidence of malignancies was fairly small. In both study and reference group only 
one case of malignancy occurred, both virus-associated, each within the first six 
months after transplantation. To detect differences in incidence a larger population 
and a long term follow up is required. In the NAPRTCS database the reported 
incidence of malignancies in pediatric kidney transplantation is 1.5%.4 In the adult 
MMF studies at 3 years post-transplant an incidence of lymphoproliferative disease 
of 1.2% after 3 years was reported in the MMF group (2 g daily), compared to 0.6% 
in the control group, of skin cancer of 11.1% in the MMF group and 13.6% in the 
control group.21 These figures suggest that following the introduction of MMF the 
incidence of malignancies did not increase. 
 
The finding that the proportion of transplanted children with CMV disease in our study 
(18%) is much higher than that reported in adult patients, e.g. from the USRDS 
between 1994 and 1998 (2.2%),22 relates to the larger proportion of D+R- patients in 
the pediatric age group. A high incidence of CMV disease in MMF treated children 
has been reported in an early uncontrolled study, creating fear of an increase of CMV 
disease caused by MMF.23 In the above mentioned USRDS report, among the 
factors independently associated with a higher risk of CMV-disease, maintenance 
therapy with MMF was one with a slightly elevated relative risk (RR 1.75).22 In this 
study by far the most important factor was the D+R- status (RR 5.19), followed by 
D+R+ (RR 2.04). In the adult MMF studies no significant increase in CMV disease in 
MMF patients was shown compared to the control groups: 3.6% vs 2.4%,12 7.0% vs 
6.8%.13 In the German pediatric study 16% of the patients who used MMF, showed 
tissue-invasive CMV disease.20 Whether or not CMV-prophylaxis was prescribed, is 
not mentioned. Remarkably, in our study the incidence of CMV-disease in the study 
group was significantly lower (11%) than in the reference group (26%). For a large 
part this may  be explained by the fact that CMV prophylaxis was given to all patients 
in the MMF group with CMV status D+R+, D+R-, and D-R+, in contrast to therapy 
with only hyperimmunoglobulin in a small selection of patients in the reference group.  
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Withholding CMV prophylaxis to D+R- graft recipients treated with Pred/CsA/MMF 
has been reported to result in a high incidence of CMV disease, compared to patients 
treated with Pred/CsA.24 Our results confirm the efficacy of CMV prophylaxis in the 
Pred/CsA/MMF group.  
 
Conclusion 
 
In our study group treated with corticosteroids, cyclosporine and mycophenolate 
mofetil, compared to a historical reference group treated with different combinations 
of corticosteroids, cyclosporine and azathioprine, in both LRD and PMD grafts the 
incidence of ARE has decreased, and the short term survival of pediatric kidney 
transplantation improved considerably. Also the graft loss due to ARE has been 
reduced. Apart from the effect of the immunosuppressive regimen the change in 
baseline data and the introduction of CMV prophylaxis may have contributed in this 
improvement, though not significant in Cox’ regression analysis. The finding that 
patients without ARE have better GFR than those who have ARE, together with the 
increased proportion of patients who remain rejection-free, suggests improvement of 
the graft survival in the long run. Whether the diminished incidence of ARE effectively 
will lead to the reduction of chronic allograft nephropathy can only be determined 
during long-term follow up. 
 
Chapter 4 
92 
Our results do not show an improvement in kidney function in the study group 
compared to the reference group, in contrast to the German study group data which 
report better GFR values in the study group than in the reference group. Taking the 
GFR as a surrogate marker for graft survival, the increased number of recipients who 
remained rejection-free, and the finding that rejection-free patients had a better GFR, 
support the hypothesis that this regimen will benefit the long-term graft survival.  
 
One of the major side effects of many immunosuppressive drugs is high blood 
pressure. The introduction of MMF led to the use of less antihypertensive therapy. 
The same trend was reported by the German study.18 
 
More potent immunosuppression could lead to a higher incidence of malignancies 
and of (opportunistic) infections. We chose to compare the incidence of malignancies 
and CMV disease as indicators of overimmunosuppression. Fortunately the 
incidence of malignancies was fairly small. In both study and reference group only 
one case of malignancy occurred, both virus-associated, each within the first six 
months after transplantation. To detect differences in incidence a larger population 
and a long term follow up is required. In the NAPRTCS database the reported 
incidence of malignancies in pediatric kidney transplantation is 1.5%.4 In the adult 
MMF studies at 3 years post-transplant an incidence of lymphoproliferative disease 
of 1.2% after 3 years was reported in the MMF group (2 g daily), compared to 0.6% 
in the control group, of skin cancer of 11.1% in the MMF group and 13.6% in the 
control group.21 These figures suggest that following the introduction of MMF the 
incidence of malignancies did not increase. 
 
The finding that the proportion of transplanted children with CMV disease in our study 
(18%) is much higher than that reported in adult patients, e.g. from the USRDS 
between 1994 and 1998 (2.2%),22 relates to the larger proportion of D+R- patients in 
the pediatric age group. A high incidence of CMV disease in MMF treated children 
has been reported in an early uncontrolled study, creating fear of an increase of CMV 
disease caused by MMF.23 In the above mentioned USRDS report, among the 
factors independently associated with a higher risk of CMV-disease, maintenance 
therapy with MMF was one with a slightly elevated relative risk (RR 1.75).22 In this 
study by far the most important factor was the D+R- status (RR 5.19), followed by 
D+R+ (RR 2.04). In the adult MMF studies no significant increase in CMV disease in 
MMF patients was shown compared to the control groups: 3.6% vs 2.4%,12 7.0% vs 
6.8%.13 In the German pediatric study 16% of the patients who used MMF, showed 
tissue-invasive CMV disease.20 Whether or not CMV-prophylaxis was prescribed, is 
not mentioned. Remarkably, in our study the incidence of CMV-disease in the study 
group was significantly lower (11%) than in the reference group (26%). For a large 
part this may  be explained by the fact that CMV prophylaxis was given to all patients 
in the MMF group with CMV status D+R+, D+R-, and D-R+, in contrast to therapy 
with only hyperimmunoglobulin in a small selection of patients in the reference group.  
Improved outcome after the introduction of MMF 
93 
Withholding CMV prophylaxis to D+R- graft recipients treated with Pred/CsA/MMF 
has been reported to result in a high incidence of CMV disease, compared to patients 
treated with Pred/CsA.24 Our results confirm the efficacy of CMV prophylaxis in the 
Pred/CsA/MMF group.  
 
Conclusion 
 
In our study group treated with corticosteroids, cyclosporine and mycophenolate 
mofetil, compared to a historical reference group treated with different combinations 
of corticosteroids, cyclosporine and azathioprine, in both LRD and PMD grafts the 
incidence of ARE has decreased, and the short term survival of pediatric kidney 
transplantation improved considerably. Also the graft loss due to ARE has been 
reduced. Apart from the effect of the immunosuppressive regimen the change in 
baseline data and the introduction of CMV prophylaxis may have contributed in this 
improvement, though not significant in Cox’ regression analysis. The finding that 
patients without ARE have better GFR than those who have ARE, together with the 
increased proportion of patients who remain rejection-free, suggests improvement of 
the graft survival in the long run. Whether the diminished incidence of ARE effectively 
will lead to the reduction of chronic allograft nephropathy can only be determined 
during long-term follow up. 
 
Chapter 4 
94 
References 
 
1. Cransberg K, van Gool JD, Davin JC, et al. Pediatric renal transplantation in the Netherlands. 
Pediatric Transplantation 2000;4:72-81. 
2. Postlethwaite RJ, Johnson RJ, Armstrong S, et al. The outcome of pediatric cadaveric renal 
transplantation in the UK and Eire. Pediatr Transplant 2002;6:367-377. 
3. Tyden G, Berg U. Pediatric renal transplantation in the Nordic countries: a report of the Nordic 
Pediatric Renal Transplant Study Group. Pediatr Transplant 1998;2(3):240-3. 
4. Benfield MR, McDonald R, Sullivan EK, et al. The 1997 annual renal transplantation in children 
report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric 
Transplantation 1999;3:152-167. 
5. Matas AJ. Impact of acute rejection on development of chronic rejection in pediatric renal 
transplant recipients. Pediatric Transplantation 2000;4:92-99. 
6. Birk PE, Matas AJ, Gillingham KJ,et al. Risk factors for chronic rejection in pediatric renal 
transplant recipients - a single center experience. Pediatric Nephrology 1997;11:395 - 398. 
7. Guyot C, Nguyen J-M, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft 
recipients. Pediatric Nephrology 1996;10:723-727. 
8. Tejani AH, Stablein DM, Sullivan EK, et al. The impact of donor source, recipient age, 
preoperative immunotherapy and induction therapy on early and late acute rejections in children: a 
report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric 
Transplantation 1998;2:318-324. 
9. Vanrenterghem Y. Role of acute rejection in chronic rejection. Transplantation 1998;30:1210-
1211. 
10. Elshihabi I, Chavers B, Donaldson L, et al. Continuing improvement in cadaver donor graft survival 
in North American children: the 1998 annual report of the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation 2000;4:235-246. 
11. McDonald R, Donaldson L, Emmett L, et al. A decade of living donor transplantation in North 
American children: the 1998 annual report of the North American Pediatric Renal Transplant 
Cooperative Study (NAPRTCS). Pediatric Transplantation 2000;4:221-234. 
12. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids 
for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. 
Lancet 1995;345(8961):1321-5. 
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in 
cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation 
Study Group. Transplantation 1996;61(7):1029-37. 
14. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a 
pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of 
rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. 
Transplantation 1997;63(1):39-47. 
15. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating 
glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 
1987;34(3):571-90. 
16. Morris MC, Allanby CW, Toseland P, et al. Evaluation of a height/plasma creatinine formula in the 
measurement of glomerular filtration rate. Arch Dis Child 1982;57(8):611-5. 
17. Pijnenburg MWH, Cransberg K, Wolff ED, et al. Bronchiectasis in children after renal or liver 
transplantation: a report of five cases. Pediatric Transplantation 2004;8:71-74. 
18. Jungraithmayr T, Staskewitz A, Kirste G, et al. Pediatric renal transplantation with mycophenolate 
mofetil-based immunosuppression without induction: results after three years. Transplantation 
2003;75(4):454-61. 
19. Sageda S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on 
rejection episodes in renal allograft recipients. Am J Transplant 2002;2(9):850-6. 
20. Staskewitz A, Kirste G, Tonshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation 
without induction therapy: results after 12 months of treatment. German Pediatric Renal 
Transplantation Study Group. Transplantation 2001;71(5):638-44. 
21. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in 
cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal 
Transplantation Study Group. Transplantation 1998;65(11):1450-4. 
 
Improved outcome after the introduction of MMF 
95 
22. Abbott KC, Hypolite IO, Viola R, et al. Hospitalizations for Cytomegalovirus disease after renal 
transplantation in the United States. Annals of Epidemiology 2002;12(6):402-409. 
23. Ettenger R, Cohen A, Nast C, et al. Mycophenolate mofetil as maintenance immunosuppression in 
pediatric renal transplantation. Transplantation Proceedings 1997;29:340 - 341. 
24. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the 
incidence and severity of primary cytomegalovirus infections and disease after renal 
transplantation. Nephrol Dial Transplant 2000;15(5):711-4. 
Chapter 4 
94 
References 
 
1. Cransberg K, van Gool JD, Davin JC, et al. Pediatric renal transplantation in the Netherlands. 
Pediatric Transplantation 2000;4:72-81. 
2. Postlethwaite RJ, Johnson RJ, Armstrong S, et al. The outcome of pediatric cadaveric renal 
transplantation in the UK and Eire. Pediatr Transplant 2002;6:367-377. 
3. Tyden G, Berg U. Pediatric renal transplantation in the Nordic countries: a report of the Nordic 
Pediatric Renal Transplant Study Group. Pediatr Transplant 1998;2(3):240-3. 
4. Benfield MR, McDonald R, Sullivan EK, et al. The 1997 annual renal transplantation in children 
report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric 
Transplantation 1999;3:152-167. 
5. Matas AJ. Impact of acute rejection on development of chronic rejection in pediatric renal 
transplant recipients. Pediatric Transplantation 2000;4:92-99. 
6. Birk PE, Matas AJ, Gillingham KJ,et al. Risk factors for chronic rejection in pediatric renal 
transplant recipients - a single center experience. Pediatric Nephrology 1997;11:395 - 398. 
7. Guyot C, Nguyen J-M, Cochat P, et al. Risk factors for chronic rejection in pediatric renal allograft 
recipients. Pediatric Nephrology 1996;10:723-727. 
8. Tejani AH, Stablein DM, Sullivan EK, et al. The impact of donor source, recipient age, 
preoperative immunotherapy and induction therapy on early and late acute rejections in children: a 
report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatric 
Transplantation 1998;2:318-324. 
9. Vanrenterghem Y. Role of acute rejection in chronic rejection. Transplantation 1998;30:1210-
1211. 
10. Elshihabi I, Chavers B, Donaldson L, et al. Continuing improvement in cadaver donor graft survival 
in North American children: the 1998 annual report of the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS). Pediatric Transplantation 2000;4:235-246. 
11. McDonald R, Donaldson L, Emmett L, et al. A decade of living donor transplantation in North 
American children: the 1998 annual report of the North American Pediatric Renal Transplant 
Cooperative Study (NAPRTCS). Pediatric Transplantation 2000;4:221-234. 
12. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids 
for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. 
Lancet 1995;345(8961):1321-5. 
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in 
cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation 
Study Group. Transplantation 1996;61(7):1029-37. 
14. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a 
pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of 
rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. 
Transplantation 1997;63(1):39-47. 
15. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating 
glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 
1987;34(3):571-90. 
16. Morris MC, Allanby CW, Toseland P, et al. Evaluation of a height/plasma creatinine formula in the 
measurement of glomerular filtration rate. Arch Dis Child 1982;57(8):611-5. 
17. Pijnenburg MWH, Cransberg K, Wolff ED, et al. Bronchiectasis in children after renal or liver 
transplantation: a report of five cases. Pediatric Transplantation 2004;8:71-74. 
18. Jungraithmayr T, Staskewitz A, Kirste G, et al. Pediatric renal transplantation with mycophenolate 
mofetil-based immunosuppression without induction: results after three years. Transplantation 
2003;75(4):454-61. 
19. Sageda S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on 
rejection episodes in renal allograft recipients. Am J Transplant 2002;2(9):850-6. 
20. Staskewitz A, Kirste G, Tonshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation 
without induction therapy: results after 12 months of treatment. German Pediatric Renal 
Transplantation Study Group. Transplantation 2001;71(5):638-44. 
21. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in 
cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal 
Transplantation Study Group. Transplantation 1998;65(11):1450-4. 
 
Improved outcome after the introduction of MMF 
95 
22. Abbott KC, Hypolite IO, Viola R, et al. Hospitalizations for Cytomegalovirus disease after renal 
transplantation in the United States. Annals of Epidemiology 2002;12(6):402-409. 
23. Ettenger R, Cohen A, Nast C, et al. Mycophenolate mofetil as maintenance immunosuppression in 
pediatric renal transplantation. Transplantation Proceedings 1997;29:340 - 341. 
24. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the 
incidence and severity of primary cytomegalovirus infections and disease after renal 
transplantation. Nephrol Dial Transplant 2000;15(5):711-4. 
  
 
Chapter 5
Induction with basiliximab 
allows delayed introduction 
of cyclosporine in pediatric 
kidney transplantation
Karlien Cransberg
Antonia H Bouts
Elisabeth A M Cornelissen
Marc R Lilien
Koen J M van Hoeck
Wim C J Hop
Jeroen Nauta
Submitted
  
 
Chapter 5
Induction with basiliximab 
allows delayed introduction 
of cyclosporine in pediatric 
kidney transplantation
Karlien Cransberg
Antonia H Bouts
Elisabeth A M Cornelissen
Marc R Lilien
Koen J M van Hoeck
Wim C J Hop
Jeroen Nauta
Submitted
Chapter 5 
98 
Abstract  
 
Background 
Delayed graft function and acute rejections adversely affect the long-term survival of 
kidney transplantation. In order to decrease the incidences of these phenomena we 
changed the initial immunosuppressive protocol in pediatric kidney transplantation in 
the Netherlands. 
 
Methods 
We compared a 4 year cohort (n=123) treated with basiliximab and delayed onset 
cyclosporine (CsA), to the preceding cohort (n=110) in which CsA was started 
already pre-operatively. Both cohorts were treated with mycophenolate mofetil (MMF) 
and corticosteroids as well. All consecutive transplantations were included.  
 
Results 
The incidence of delayed graft function did not significantly differ between the cohorts 
(10% and 13%, in basiliximab and control group). Significantly fewer patients in the 
basiliximab group had acute rejection episodes (20% vs. 36% in control group, 
p=0.007). The mean estimated glomerular filtration rate at 1 year and graft survival at 
2 years post-transplant did not differ between groups (62 vs. 64 ml/min.1.73m2, and 
89% vs. 92% respectively).  
 
Conclusion 
Adding basiliximab to triple initial immunosuppressive therapy (corticosteroids, CsA 
and MMF) while delaying the onset of CsA did not reduce the incidence of delayed 
graft function in pediatric kidney transplantation. Yet, fewer acute rejections were 
noted. However, long-term favorable effects could not be detected in this study. 
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Introduction  
 
Delayed development of graft function (DGF) has adverse long-term effects, both in 
children and adults,1-3 and increases the risk of acute rejections.4 The incidence of 
DGF is approximately 30% in adult kidney transplantation and has been relatively 
stable over recent years.5 In pediatric transplantation, its incidence is 15-20%, and 
higher in deceased than in living donated transplantations.3, 6 In the Netherlands, this 
incidence has not changed significantly between 1985 and 2000.6 The use of 
cyclosporine (CsA) has been shown to prolong delayed graft function, in adults as 
well as in young children.7-9 
 
The incidence of DGF could therefore perhaps be reduced by delaying exposure of 
the graft to CsA. This nephrotoxic agent has a vasoconstrictive effect in the grafted 
kidney, thereby aggravating the ischemic injury of the transplantation procedure. This 
strategy proved beneficial in an adult population at high risk for DGF treated with 
steroids, MMF and basiliximab.10, 11 Basiliximab, an interleukin-2 (IL-2) receptor 
antagonist, allowed delayed introduction of CsA, a suppressor of IL2 synthesis. It is a 
chimeric mouse-human monoclonal antibody to the IL-2 alpha receptor on the 
surface of activated T-lymphocytes. The addition of IL-2 receptor antagonists to 
double (CsA and corticosteroids) or triple (CsA, azathioprine and corticosteroids) 
immunosuppressive therapy has led to significantly fewer acute rejection episodes.12-
14 
 
The early post-transplant period may additionally be complicated by acute rejection 
episodes.15 In the Netherlands 37% of children with a kidney transplant treated with 
triple immunosuppressive therapy – CsA, mycophenolate mofetil, and corticosteroids 
– experienced at least one acute rejection episode.6 
 
Five years ago we added basiliximab to our initial triple immunosuppressive regimen, 
aiming to start CsA only when graft function was established. We hypothesized that 
this would decrease the incidence of DGF without increasing the risk of acute 
rejection episodes in the first year. Ultimately this might improve long-term graft 
function, assessed in terms of glomerular filtration rate (GFR) at various time points. 
 
Methods  
 
Design 
This was a retrospective multicenter open-label cohort study conducted in five 
institutions for pediatric kidney transplantation, i.e. four in the Netherlands and one in 
Belgium, comparing two regimens for initial immunosuppression in consecutive 
cohorts. 
 
Patients 
Enrolled were all consecutive patients receiving a kidney transplant in the 
participating centers between 01-01-1998 and 01-01-2006, with a follow-up of at 
least 1 year and ending at the transfer to the adult care.  
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The primary endpoint of the study was the incidence of DGF. Secondary endpoints 
were the incidence of acute rejection episodes, the estimated GFR (eGFR) at 3 
months and 1 to 3 years post-transplant, and graft survival. 
 
Immunosuppression 
The participating centers shared the same initial immunosuppressive regimen for 
pediatric recipients of a kidney transplant. The first cohort (control group), 
transplanted between 01-01-1998 and 01-01-2002, received corticosteroids, CsA and 
mycophenolate mofetil (MMF). Preoperative loading doses were: 300 mg/m2 
methylprednisolone intravenously, 10 mg/kg CsA orally, 600 mg/m2 MMF orally. 
Post-operatively they received 40 mg/m2 (methyl)prednisolone twice daily. 
Thereafter, the dose was tapered to 7.5 mg/m2, once daily, at week 6, and 5 mg/m2 
at 6 months post-transplant. From 6 h after revascularisation CsA was administered 
intravenously for 24 h in a dosage of 3 mg/kg/24 h, followed by an oral dose adjusted 
to a trough level of 150–250 mg/L during the first 6 weeks, of 150–200 mg/L during 
the second 6 weeks, and of 100–150 mg/L thereafter. A dose of 600 mg/m2 MMF 
was administered twice daily as soon as oral intake was possible.  
From 2002 onwards patients were treated with a revised protocol (second cohort, 
basiliximab group). This involved administration of two doses of basiliximab, the first 
1-6 hours preoperatively, the second on the fourth day post-transplant. The dose was 
10 mg in children weighing less than 35 kg, and 20 mg in children weighing more. 
CsA was introduced after the creatinine level reached 50% of the pre-transplant and 
pre-dialysis value. The initial dose was 4 mg/kg twice daily, adjusted to a trough level 
of 150-200 mcg/l, after 6 weeks adjusted to 100-150 mcg/l. Treatment with 
corticosteroids and MMF was according to the earlier protocol. If DGF occurred, 
tapering of steroid dosage was postponed and CsA was withheld. 
In both cohorts triple therapy was scheduled to be continued at least during the first 
year. 
 
Definitions 
DGF was assessed with two methods. The need for dialysis therapy in the first week 
after transplantation, with subsequent recovery of kidney function, was a 
dichotomous criterion for DGF. In order to construct a time-dependent variable, the 
time to reach 50% of the pre-transplant plasma creatinine value (creat t½) was 
calculated in periods of 24 hours post-transplant.  
Acute rejection: a sudden rise in creatinine to more than 115% of the previous stable 
value with no other identifiable cause, followed by the prescription of a full course of 
anti-rejection treatment consisting of methylprednisolone IV 10-20 mg/kg, 3 to 5 
times on consecutive or alternate days. Taking a biopsy in case of a suspected acute 
rejection episode was left to the discretion of the local physician. However, in case of 
a steroid resistant acute rejection, a graft biopsy was taken per protocol and a 10-14 
days course of rabbit ATG was instituted.  
Glomerular filtration rate (eGFR) was estimated according to the Schwartz formula, 
modified according to local laboratory practices.16, 17  
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Graft loss 
Graft loss start of any form of chronic dialysis, a new transplant, or death with a 
functioning graft. 
 
Hypertension 
Hypertension: scored with a scale assessing two parameters: a. systolic or diastolic 
blood pressure below (score 0) or above (score 1) the 95th percentile for age and 
sex;18 and b. number of antihypertensive and diuretic drugs (no drugs = 0, 1 drug = 1, 
2 or more drugs = 2). Scores could thus range from 0 to 3, from no hypertension to 
serious hypertension. 
 
Other treatment aspects 
Thrombosis prophylaxis: All patients with a high risk of vascular thrombosis of the 
graft – i.e. recipients younger than 6 yr of age, donors younger than 10 yr, multiple 
renal arteries or veins to the graft, or a history of thrombosis – received 
antithrombotic therapy during 2 weeks. This consisted of either low-dosed heparin or 
low-molecular weight heparin.  
CMV prophylaxis: seronegative recipients with a seropositive donor (D+R-) and CMV 
seropositive recipients (D+R+, D-R+) received prophylaxis against CMV infection 
during the first 3 months after transplantation. Seropositive patients received 
valacyclovir; seronegative patients with seropositive donors valgancyclovir. In the first 
cohort two centers used acyclovir and megalotect as CMV-prophylaxis instead.  
 
Statistical analysis 
The data were analysed on an intention-to-treat-basis. Differences between Kaplan–
Meier survival curves, used for patient and graft survival, time to first acute rejection 
and creat t½, were tested for statistical significance with the log rank test. Differences 
in other parameters were tested with either chi-square for categorical variables, 
Student’s t-test for continuous variables with a normal distribution or Mann Whitney 
test for continuous variables without a normal distribution. Cox regression analysis 
was used to adjust the comparison between cohorts for possible confounding factors. 
Repeated measurements ANOVA by SAS statistical software was used to detect 
differences in GFR over time between the groups. For the multivariate analyses 
potential independent predictors of outcome were identified by univariate analysis. 
Variables correlated to the outcome variable of interest with a significance level 
p<0.10 were included in the multivariate model and the factor of primary interest, 
cohort, was forced into the model. Two-sided p-values less than 0.05 were 
considered to indicate statistical significance.  
 
 
Results 
 
Included in the study were 215 patients, who received 233 kidneys, 123 in the control 
and 110 in the basiliximab group. The baseline characteristics are shown in Table 1.  
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The primary endpoint of the study was the incidence of DGF. Secondary endpoints 
were the incidence of acute rejection episodes, the estimated GFR (eGFR) at 3 
months and 1 to 3 years post-transplant, and graft survival. 
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Graft loss 
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Table 1. Baseline characteristics 
  control  basiliximab   
  n = 123  n = 110   
   
available 
n  
available 
n p 
Age at transplantation a 11.6 (3.4-18.0) 123 12.6 (2.7-18.1) 109 ns 
Age at start RRT a 9.5 (0.02-17.9) 116 10.9 (0.04-17.6)    99 ns 
Recipient gender (female (%)) 52 (42%) 123 45 (41%) 110 ns 
Primary kidney disease c  119  107  
 Congenital structural abnormalities 63 (53%)  51 (48%)   
 Acquired disease  33 (28%)  37 (35%)   
 Other 19 (16%)  14 (13%)   
 Unknown 4 (3%)  5 (5%)  ns 
       
First transplant d 95 (79%) 121 92 (84%) 109 ns 
No previous RRT 22 (18%) 123 25 (23%) 109 ns 
Type of previous dialysis 
(PD/HD/both/none) 36/35/14/22 107 40/21/11/25    97 ns 
Duration previous RRT (yr) a 1.2 (0.0 – 12.8) 120 1.0 (0.0 – 16.4) 102 ns 
      
Donor source living e 33 (27%) 123 38 (35%) 110 ns 
Mismatches HLA - DR b 0.6 ± 0.6 102 0.6 ± 0.5 101 ns 
Mismatches HLA - A, B, DR b 2.2 ± 1.2 102 2.2 ± 1.2 101 ns 
Donor age (only DD) a 39 (2-62)   88 41 (3-63)   71 ns 
Cold ischemia time (only DD) b 21 ± 7   69 19 ± 5   64 ns 
       
Donor/recipient CMV serological status  111    91  
 Positive/negative 31 (28%)  33 (36%)   
 Positive/positive 10 (9%)  15 (17%)   
 Negative/positive 19 (17%)  15 (17%)   
 Negative/negative 51 (46%)  28 (31%)  ns 
Data shown as: a median (range), b mean ± SD, other parameters n (%)  
c Congenital nephrotic syndrome is included in acquired disease 
d Of subsequent transplants, 3 in the control group and 0 in the basiliximab group were third 
e Of the DD grafts 1 in the control and 2 in the basiliximab group were from non heart beating donors 
Abbreviations: DD deceased donor, PRA panel reactive antigens, RRT renal replacement therapy 
 
No relevant differences between the groups were detected. The basiliximab group 
tended to contain more CMV positive donors. 
 
DGF, defined as the need for dialysis in the first week after transplantation, occurred 
in 16 patients of the control group (13%) and 11 of the basiliximab group (10%) (n.s.). 
The cohorts did not significantly differ in creat t½ either (Figure 1, n.s.). Cold 
ischemia time, donor source, recipient age group and pre-transplant dialysis were 
significantly associated with a longer creat t½, using univariate analysis (Table 2a). 
Type of dialysis before transplantation (PD vs. HD), donor age (< 10 vs. > 10 years) 
and serologic CMV status of donor and recipient (D+R- vs. other) were not 
significantly associated with creat t½. In Cox regression analysis, recipient age (older 
than 6 compared to younger) and donor source (DD compared to LD) were the major 
independent predictors of DGF.  
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Figure 1. Half life of pre-transplant plasma creatinine after transplantation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control group solid line, basiliximab group dotted line 
 
Acute rejection 
As indicated in Figure 2, at the end of the first year after transplantation 36% of 
patients in the control group had experienced at least one acute rejection episode, 
compared to 20% of patients in the basiliximab group (p=0.007). Two patients in the 
control group, and one in the basiliximab group, lost their graft due to an acute 
rejection (n.s.).  
 
Figure 2. Incidence of acute rejections during the first year after transplantation 
Control group solid line, basiliximab group dotted line 
p-value = 0.007 
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Univariate as well as multivariate analysis by Cox regression (Table 2b) identified 
cohort and donor source to be factors independently predicting the occurrence of 
acute rejections. Recipient age, donor age, transplantation pre-emptively or following 
dialysis, DR-mismatches and previous PRA did not show a significant association 
with the incidence of acute rejections. Cox regression showed no significant 
differences between the 5 centers. Also the difference between cohorts did not differ 
between centers. Grafts with a creat t½ < 3 days and a survival of more than 14 days 
remained rejection free during the first year more often than transplants with a longer 
creat t½ (77% vs. 62%, p=0.043). Of the suspected acute rejection episodes, 16% 
were steroid resistant in both the control group and basiliximab group. Forty-one per 
cent of the acute rejection episodes in the control group and 52% in the basiliximab 
group were biopsy-proven (n.s.). 
 
eGFR values at several time points are shown in Figure 3. Repeated measurements 
ANOVA demonstrated a significant decrease over time in both groups (p=0.004). The 
difference between the groups was not significant, neither regarding the mean level 
at each time point nor the mean decrease over time. At one year post-transplant the 
eGFR was 62 in the control and 64 ml/min.1.73m2 in the basiliximab group. 
Predictors of eGFR were analysed in 197 transplants that were followed at least 1 
year (107 control and 90 basiliximab patients) (Table 2c). Creat t½, incidence of 
acute rejection and recipient age were significant determinants of eGFR at 1 year 
(p<0.05). The factor cohort was not predictive. After DGF a mean one-year eGFR of 
47 ml/min.1.73m2 was seen, compared to 65 in patients with immediate function 
(p<0.001). Likewise, eGFR was lower in patients with acute rejections in the first 
year: 51 vs. 67 ml/min.1.73m2 in patients without acute rejections (p<0.001).  
 
Graft survival at one year, censored for death, was similar: 92% in the control group, 
and 89% in the basiliximab group (n.s., Figure 4). 
 
Figure 3. Estimated GFR (mean ± SEM) along time, at 3 months, 1, 2 and 3 years post-transplant, by 
study group (solid squares – control; open squares – basiliximab) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Induction with basiliximab and delayed onset of cyclosporine 
105 
Graft survival at 3 years was 88% and 87% respectively. Thrombosis of the renal 
vessels caused graft loss in the first year in four cases (3.3%) in the control group, 
and in six cases (5.5%) in the basiliximab group (n.s.). Grafts with a creat t½ of less 
than 3 days that survived at least 14 days, had a significantly better two-year graft 
survival than grafts with a longer creat t½: 99% and 87%, respectively (p<0.001). The 
absence or presence of an acute rejection episode in the first year had a similar 
effect: 98% vs. 91%, p=0.004. Regarding patient survival: four patients died, i.e. one 
in the control group, due to a cerebrovascular accident, and three in the basiliximab 
group, 1 due to a cerebrovascular accident, one to an infectious cause and one with 
an uncertain cause of death.  
 
Figure 4: Graft survival, censored for death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control group solid line, basiliximab group dotted line 
 
Comorbidity 
CMV disease occurred in 11 patients in the first year post-transplant, three in the 
control and eight in the basiliximab group (p=0.046). None of these were associated 
with acute rejection or graft loss. Four cases of malignancy were registered (1.7%), 
all within the first two years after transplantation: three in the control group and one in 
the basiliximab group. All four concerned lymphoproliferative disease. 
Other treatment aspects did not change evidently over the years. The 
immunosuppressive regimens used after the initial treatment did not differ 
significantly between the two groups. Within the cohorts, however, the regimens 
gradually changed over time, as delineated in Table 3. After the first year, double 
therapy replaced triple therapy to become the most prevalent form. The proportion of 
patients using tacrolimus instead of cyclosporine increased. Between 3 months and 2 
years after transplantation the dose of prednisolone decreased from 8.3 ± 2.9 to 5.4 ± 
2.3 mg/m2 body surface area in the control group, and from 8.1 ± 4.1 to 4.8 ± 2.6 
mg/m2 in the basiliximab group (n.s. between the groups). The hypertension score 
changed over time in the control group from 2.0 to 1.7 between 3 months and 2 
years, in the basiliximab group from 1.9 to 1.5 (n.s. between the groups).  
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Comorbidity 
CMV disease occurred in 11 patients in the first year post-transplant, three in the 
control and eight in the basiliximab group (p=0.046). None of these were associated 
with acute rejection or graft loss. Four cases of malignancy were registered (1.7%), 
all within the first two years after transplantation: three in the control group and one in 
the basiliximab group. All four concerned lymphoproliferative disease. 
Other treatment aspects did not change evidently over the years. The 
immunosuppressive regimens used after the initial treatment did not differ 
significantly between the two groups. Within the cohorts, however, the regimens 
gradually changed over time, as delineated in Table 3. After the first year, double 
therapy replaced triple therapy to become the most prevalent form. The proportion of 
patients using tacrolimus instead of cyclosporine increased. Between 3 months and 2 
years after transplantation the dose of prednisolone decreased from 8.3 ± 2.9 to 5.4 ± 
2.3 mg/m2 body surface area in the control group, and from 8.1 ± 4.1 to 4.8 ± 2.6 
mg/m2 in the basiliximab group (n.s. between the groups). The hypertension score 
changed over time in the control group from 2.0 to 1.7 between 3 months and 2 
years, in the basiliximab group from 1.9 to 1.5 (n.s. between the groups).  
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Table 2. Univariate and multivariate analysis 
A  univariate analysis multivariate analysis  
Creatinine t 1/2      
Factor  
% of patients with 
creat t½ 
3 days or longera 
 
p 
hazard 
ratio 
confidence 
interval p 
Cohort  
(control vs. basiliximab) 37 vs 41 0.432 1.3 1.0 to 1.8 0.088 
Donor source  
(LD vs. DD) 15 vs 50 <0.001 1.8 1.2 to 2.6 0.002 
Recipient age  
(< 6 vs. > 6 yr) 29 vs 41 0.04 1.5 1.0 to 2.3 0.041 
Cold ischemia time  
(< 19 vs. > 19 hr) 26 vs 61 <0.001 1.4 1.0 to 2.1 0.079 
Previous dialysis  
(yes vs. no) 41 vs 30 0.051 --- --- --- 
 
B     
Occurrence of acute rejection      
Factor   
% of patients 
rejection-free at 1 yrb p 
hazard 
ratio 
confidence 
interval p 
Cohort  
(control vs. basiliximab) 64 vs 79 0.012 1.7 1.0 to 3.0 0.038 
Donor source  
(LD vs. DD) 81 vs 66 0.036 0.5 0.3 to 1.0 0.031 
Recipient age 
(< 6 vs. > 6 yr) 83 vs 69 0.144 0.4 0.2 to 1.0 0.05 
Donor age  
(< 10 vs. older) 73 vs 70 0.831 --- --- --- 
Previous dialysis  
(yes vs. no) 71 vs 80 0.187 --- --- --- 
Ranking order  
(1st transplant vs. later) 74 vs 66 0.585 --- --- --- 
Creat t½  
(< 3 days vs. longer) 82 vs 72 0.178 --- --- --- 
 
C     
eGFR at 1 year post-transplant      
Factor   
mean per group 
(ml/min.1.73m2) p 
regression 
coefficient 
confidence 
interval p 
Cohort  
(Control vs. basiliximab) 62 vs 64 0.383 1.0 -7.9 to 2.6 0.316 
Acute rejection  
(vs no rejection) 50 vs 66 <0.001 --- --- --- 
Creatinine half-life 
 (< 3 d vs longer) 68 vs 53 < 0.001 22.9 8.4 to 20.1 < 0.001 
Recipient age  
(< 6 vs > 6 yr) 61 vs 70 0.016 4.4 0.4 to 14.6 0.038 
Donor source  
(LD vs DD) 66 vs 61 0.097 0.2 -4.6 to 7.4 0.654 
Ranking order  
(1 vs > 1) 64 vs 58 0.128 --- --- --- 
a Kaplan-Meier estimates of percentage of patients not having reached half of pre-transpl. creatinine before 3   
  days 
b Kaplan-Meier estimates of percentage of patients with no acute rejection within the 1st year 
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Table 3. Immunosuppressive regimens over time after transplantation 
 M3 Y1 Y2 
 control basiliximab control basiliximab control basiliximab  
pred-CsA-MMF 99 (93%) 76 (84%) 81 (76%) 60 (71%) 27 (28%) 12 (18%) 
pred-TCL-MMF 3 (3%) 4 (4%) 9 (8%) 9 (11%) 10 (10%) 5 (8%) 
pred-CsA 3 (3%) 3 (3%) 7 (7%) 7 (8%) 30 (31%) 24 (36%) 
pred-MMF 1 (1%) 4 (4%) 7 (7%) 3 (4%) 20 (21%) 14 (21%) 
pred-TCL 0 (0%) 4 (4%) 3 (3%) 4 (5%) 8 (8%) 10 (15%) 
other 0 (0%) 0 (0%) 0 (0%) 1 (1%) 2 (2%) 2 (3%) 
n 106 91 107 84 97 67 
 
Discussion 
 
In this retrospective cohort study we examined the influence of the addition of 
basiliximab and the delayed introduction of CsA on delayed graft function and acute 
rejections in pediatric kidney transplantation. We also assessed the effects of this 
strategy on longer-term graft function and survival. The modified immunosuppressive 
treatment did not significantly decrease creat t½ nor the need for post-transplant 
dialysis, two markers for delayed graft function. In the first cohort, 13% of patients 
needed dialysis post-transplant, a figure lower than expected, based upon earlier 
results.6 In view of its confidence limits - 8 to 21% -, however, this low incidence does 
not conflict with the previously reported incidence of 19%.19 The decline to 10% in the 
second cohort could not reach statistical significance in this study. A possible 
drawback of defining DGF as need of dialysis in the first week post-transplant is the 
rather crude discriminatory capacity, since the graft function development may be 
well slowed down without dialysis being necessary. Furthermore, individual doctors 
will assess the need for dialysis differently, and patients may be dialyzed for other 
reasons than lack of graft function, e.g. in hyperoxaluria. By measuring the half life of 
the pre-transplant creatinine value, we tried to find a more objective criterion. Still, 
time to reach 50% of baseline creatinine value did not differ between the two cohorts. 
Previous studies on effects of the addition of basiliximab on DGF incidence are not 
equivocal.14, 20, 21 In a study including adults with long ischemia time, older donors 
and/or recipients, and a lower degree of HLA-matching, the trend towards a positive 
effect appeared to be more outspoken in high risk patients.11 A possibly favorable 
effect of sequential immunosuppression was found in a small study with very young 
recipients, although the agent was ATG rather than an IL2-receptor antagonist.9 All in 
all, our findings and those from the literature do not support delayed introduction of 
CsA – with basiliximab added to cover the immunosuppressive gap in the first days 
after transplantation – to decrease the incidence of DGF in a non-selected pediatric 
renal recipient population. 
 
The change in immunosuppression resulted in fewer acute rejection episodes, with 
an incidence comparable to that achieved by the introduction of IL2 receptor 
antagonists with concurrent CsA therapy in adults.12-14 In contrast, a large 
multinational pediatric study comparing a tacrolimus-based regimen with and without 
basiliximab found no difference in incidences of acute rejection.22  
Chapter 5 
106 
Table 2. Univariate and multivariate analysis 
A  univariate analysis multivariate analysis  
Creatinine t 1/2      
Factor  
% of patients with 
creat t½ 
3 days or longera 
 
p 
hazard 
ratio 
confidence 
interval p 
Cohort  
(control vs. basiliximab) 37 vs 41 0.432 1.3 1.0 to 1.8 0.088 
Donor source  
(LD vs. DD) 15 vs 50 <0.001 1.8 1.2 to 2.6 0.002 
Recipient age  
(< 6 vs. > 6 yr) 29 vs 41 0.04 1.5 1.0 to 2.3 0.041 
Cold ischemia time  
(< 19 vs. > 19 hr) 26 vs 61 <0.001 1.4 1.0 to 2.1 0.079 
Previous dialysis  
(yes vs. no) 41 vs 30 0.051 --- --- --- 
 
B     
Occurrence of acute rejection      
Factor   
% of patients 
rejection-free at 1 yrb p 
hazard 
ratio 
confidence 
interval p 
Cohort  
(control vs. basiliximab) 64 vs 79 0.012 1.7 1.0 to 3.0 0.038 
Donor source  
(LD vs. DD) 81 vs 66 0.036 0.5 0.3 to 1.0 0.031 
Recipient age 
(< 6 vs. > 6 yr) 83 vs 69 0.144 0.4 0.2 to 1.0 0.05 
Donor age  
(< 10 vs. older) 73 vs 70 0.831 --- --- --- 
Previous dialysis  
(yes vs. no) 71 vs 80 0.187 --- --- --- 
Ranking order  
(1st transplant vs. later) 74 vs 66 0.585 --- --- --- 
Creat t½  
(< 3 days vs. longer) 82 vs 72 0.178 --- --- --- 
 
C     
eGFR at 1 year post-transplant      
Factor   
mean per group 
(ml/min.1.73m2) p 
regression 
coefficient 
confidence 
interval p 
Cohort  
(Control vs. basiliximab) 62 vs 64 0.383 1.0 -7.9 to 2.6 0.316 
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(vs no rejection) 50 vs 66 <0.001 --- --- --- 
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Donor source  
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Ranking order  
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  days 
b Kaplan-Meier estimates of percentage of patients with no acute rejection within the 1st year 
 
Induction with basiliximab and delayed onset of cyclosporine 
107 
Table 3. Immunosuppressive regimens over time after transplantation 
 M3 Y1 Y2 
 control basiliximab control basiliximab control basiliximab  
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pred-MMF 1 (1%) 4 (4%) 7 (7%) 3 (4%) 20 (21%) 14 (21%) 
pred-TCL 0 (0%) 4 (4%) 3 (3%) 4 (5%) 8 (8%) 10 (15%) 
other 0 (0%) 0 (0%) 0 (0%) 1 (1%) 2 (2%) 2 (3%) 
n 106 91 107 84 97 67 
 
Discussion 
 
In this retrospective cohort study we examined the influence of the addition of 
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effect appeared to be more outspoken in high risk patients.11 A possibly favorable 
effect of sequential immunosuppression was found in a small study with very young 
recipients, although the agent was ATG rather than an IL2-receptor antagonist.9 All in 
all, our findings and those from the literature do not support delayed introduction of 
CsA – with basiliximab added to cover the immunosuppressive gap in the first days 
after transplantation – to decrease the incidence of DGF in a non-selected pediatric 
renal recipient population. 
 
The change in immunosuppression resulted in fewer acute rejection episodes, with 
an incidence comparable to that achieved by the introduction of IL2 receptor 
antagonists with concurrent CsA therapy in adults.12-14 In contrast, a large 
multinational pediatric study comparing a tacrolimus-based regimen with and without 
basiliximab found no difference in incidences of acute rejection.22  
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Another study introduced IL-2 receptor antagonist with low dosed CsA (trough level 
50-100 mcg/l) at transplantation, together with MMF and steroids. This strategy did 
not result in fewer acute rejection episodes at 6 months as compared with standard 
CsA dosage therapy without the IL2 receptor antagonist.23 It would seem, therefore, 
that adding an IL-2 receptor antagonist is most effective in studies using a control 
group receiving less immunosuppression: double instead of triple therapy, and 
cyclosporine instead of tacrolimus.  
 
Creatinine level at 1 year post-transplant in adults has been associated with long 
term graft survival.1 As Filler and colleagues suggested, the eGFR calculated as a 
function of body height and serum creatinine, could be used as surrogate marker for 
long term graft survival in children.24 Despite fewer acute rejection episodes in the 
first year in the basiliximab group, the change in initial immunosuppressive therapy 
was not beneficial in terms of estimated GFR over the first 3 years. In line with our 
findings, Ekberg and colleagues reported that low dose CsA combined with an IL2-
receptor antagonist gave no better graft function at one year after transplantation 
than did standard CsA dose without an IL-2 receptor antagonist. But, as mentioned 
above, these authors also found no difference in the incidence of acute rejections.23 
 
CMV disease was more frequent in the basiliximab cohort, but still, this incidence 
was low. This cohort tended towards a higher proportion of CMV D+R- combination 
compared to the control cohort. Schnitzler and colleagues found a 4 times higher 
incidence of CMV disease, a non-significant increase in acute rejection incidence, but 
more than 20% increase in graft loss for the seronegative recipient receiving a kidney 
from a seropositive donor as compared with a seronegative donor.25 
 
A limitation of a retrospective cohort study is the possibility that changes in other 
aspects of care than the ones studied underlie differences between cohorts. In the 
present study, we could point at the (non-significant) higher rate of biopsies to prove 
acute rejection in the later cohort – suggesting that physicians over time have 
become less reluctant to perform biopsies. Judging from the higher proportion of 
biopsy proven acute rejection episodes, the diagnosis of acute rejection tends to be 
stricter in the second cohort, thus attenuating the found difference in incidences of 
acute rejection in the two cohorts.  
As far as other treatment schedules are concerned, the antihypertensive and 
maintenance immunosuppressive treatment remained similar in both cohorts. 
 
In conclusion, the addition of basiliximab to triple initial immunosuppressive 
prophylaxis, in combination with delayed start of CsA, reduced the incidence of acute 
rejections, but not that of delayed graft function in this unselected population of 
children with a kidney transplant. Effects on graft function and survival at one year 
post-transplant could not be detected.  
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Abstract 
 
Background 
Aiming at reducing cyclosporine toxicity, we investigated safety and efficacy of 
mycophenolate mofetil (MMF) as an immunosuppressive drug in pediatric kidney 
transplantation compared to cyclosporine, both in combination with corticosteroids.  
 
Methods 
One year after kidney transplantation, children on triple immunosuppression, having 
experienced no more than one, steroid-sensitive, acute rejection episode, were 
randomized to withdrawal of either cyclosporine (CsA) or MMF, and were followed for 
2 years.  
 
Results 
In each group, 2 patients had an acute rejection episode during withdrawal. 
Treatment failure occurred in 3 of 21 MMF and 5 of 23 CsA patients. Final analysis 
was for 18 patients in either group. A larger than 10 mL/min.1.73m2 decrease in 
glomerular filtration rate was seen in more patients on CsA than on MMF (73 vs. 
29%, p=0.019). No differences in blood pressure or nightly drop of blood pressure 
were noted. Hypercholesterolism improved in the MMF (-16%), but not the CsA 
group (+5%, p<0.05), over the first, but not over both study years. Differences in 
triglycerid levels between groups were not shown. At study end, MMF patients 
tended to have lower hemoglobin levels than patients on CsA. Two MMF patients 
experienced a first acute rejection episode during the second study year, resulting in 
chronic transplant glomerulopathy with graft loss in one and deterioration of kidney 
function in the other. 
 
Conclusion 
In pediatric kidney transplantation, maintenance immunosuppression with MMF 
together with corticosteroids has short-term benefits for kidney function and lipid 
pattern compared to CsA, but is not without risk of complications.  
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane trial registration number ISRCTN89278733 
The Dutch Kidney Foundation funded the study 
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Introduction  
 
Mycophenolate mofetil (MMF) has gained a place in the immunosuppressive 
treatment of kidney transplantation, either added to a regimen of corticosteroids and 
cyclosporine (CsA), or replacing azathioprine in the triple regimen corticosteroids, 
CsA and azathioprine. Its introduction has reduced the incidence of acute rejection 
episodes, both in adults1,2 and in children.3 In addition, it considerably improved 
short-term graft survival in children in the Netherlands.4 MMF, like azathioprine 
(AZA), inhibits lymphoproliferation. Reported side-effects are gastrointestinal 
discomfort, diarrhea, and bone-marrow depression; it has no known negative effects 
on blood vessels or lipids. In contrast, CsA negatively affects the cardiovascular 
system and the kidneys: it causes vasoconstriction and increases of blood pressure, 
nephrotoxicity, and corroborates the dyslipidemia caused by corticosteroids.5 
Furthermore its use produces cosmetic changes, which may induce non-compliance, 
especially in adolescent girls. We felt it would be better, therefore, to restrict CsA 
treatment to the first year after transplantation. In the present prospective, open-
label, study we investigated the safety and efficacy of MMF as an 
immunosuppressive drug in the maintenance phase of pediatric kidney 
transplantation as compared to CsA, both in combination with corticosteroids.  
 
Patients and methods 
 
This prospective, open-label, clinical trial was conducted in the 5 centers of the Dutch 
pediatric kidney transplantation group and was approved by the medical ethical 
committees of the participating hospitals. Since 1998 all patients receiving a kidney 
transplant in one of these centers have been treated with initial immunosuppressive 
triple therapy consisting of corticosteroids, CsA and MMF. In detail: 
(methyl)prednisolone (pre-operatively 300 mg/m2, first week after transplant 40 
mg/m2 b.i.d., weekly dose-reduction to 7.5 mg/m2 once daily at 6 weeks, and 5 
mg/m2 6 months after transplant); CsA (trough level in the first 6 weeks of 200-250 
mcg/l, 150-200 mcg/l at 6 weeks and 100-150 mcg/l 3 months after transplant) and 
MMF (600 mg/m2 b.i.d.). In 2001 the protocol was modified by adding basiliximab to 
the triple therapy on day 0 and day 4, while CsA was not given until the graft had 
started to function.  
 
Eligible for the study were patients who at one year after transplant had not 
experienced more than one, steroid-sensitive, acute rejection episode, received triple 
immunosuppression as per protocol and showed stable kidney function. All 
participating patients and/or their parents gave informed consent. After enrolment 
they were randomized to the MMF group or the CsA group. Randomization was 
conducted by randomly permuted blocks stratified by center. The third drug was 
tapered off over 3 months and then discontinued. During these 3 months the dose of 
prednisolone was doubled. The dosage of MMF remained unchanged; that of CsA 
was adjusted to a trough level of 100-150 mcg/l. All patients were followed for at least 
2 years. 
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Introduction  
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episodes, both in adults1,2 and in children.3 In addition, it considerably improved 
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Patients and methods 
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mg/m2 b.i.d., weekly dose-reduction to 7.5 mg/m2 once daily at 6 weeks, and 5 
mg/m2 6 months after transplant); CsA (trough level in the first 6 weeks of 200-250 
mcg/l, 150-200 mcg/l at 6 weeks and 100-150 mcg/l 3 months after transplant) and 
MMF (600 mg/m2 b.i.d.). In 2001 the protocol was modified by adding basiliximab to 
the triple therapy on day 0 and day 4, while CsA was not given until the graft had 
started to function.  
 
Eligible for the study were patients who at one year after transplant had not 
experienced more than one, steroid-sensitive, acute rejection episode, received triple 
immunosuppression as per protocol and showed stable kidney function. All 
participating patients and/or their parents gave informed consent. After enrolment 
they were randomized to the MMF group or the CsA group. Randomization was 
conducted by randomly permuted blocks stratified by center. The third drug was 
tapered off over 3 months and then discontinued. During these 3 months the dose of 
prednisolone was doubled. The dosage of MMF remained unchanged; that of CsA 
was adjusted to a trough level of 100-150 mcg/l. All patients were followed for at least 
2 years. 
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Primary endpoints were change of GFR, number of acute rejection episodes (ARE), 
serumlipids, blood pressure and number of antihypertensive drugs. Secondary 
endpoints were patient and graft survival, change of hemoglobin level and the 
incidence of malignancies. Time-points of measurement were before withdrawal of 
MMF or CsA, and at 1 and 2 years after randomization. The blood tests were 
performed in a fasting state: creatinine, hemoglobin level, concentrations of total 
cholesterol, HDL- and LDL-cholesterol, and homocystein. However, LDL-cholesterol 
was measured in only few patients. Therefore, the concentration of the lower density 
lipoprotein bound cholesterol was also estimated by subtracting HDL-cholesterol 
from total cholesterol. The glomerular filtration rate (GFR) was measured using either 
the inulin single injection6 or the inulin urine collection technique, according to local 
hospital policy. With survival analysis differences between the groups were studied in 
number of patients surviving without a decrease in GFR of more than 10 
ml/min.1.73m2. For this analysis GFR values were used estimated by a modified 
calculation according to Schwartz,7,8 by which method complete data could be 
obtained. The 24 hour ambulatory blood pressure was measured yearly. Incidences 
of acute rejection episodes and numbers of antihypertensive drugs were registered. 
 
Hypertension 
High blood pressure was treated according to local policy, with ACE-inhibitors, Ca-
entry blockers, beta-blockade, and/or diuretics. The mean daytime blood pressure of 
the 24 hour ambulatory recording was used for analysis. If missing (6 measurements 
in the MMF group, 5 in the CsA group), this was filled in by the mean of triple office 
measured blood pressures. Hypertension scores were arrived at by adding values of 
two parameters: mean daytime systolic or diastolic blood pressure below (score 0) or 
above (score 1) the 95th percentile for age,9 and number of antihypertensive and 
diuretic drugs (no drugs = 0, 1 drug = 1, 2 or more drugs = 2). Scores could thus 
range from 0 to 3. Differences between mean day and night blood pressure were 
calculated.  
 
Definitions 
Graft failure was defined as the start of any form of chronic dialysis, repeat kidney 
transplant, or death with functioning graft. Acute rejection was defined as the 
prescription of a course of anti-rejection therapy, consisting of methylprednisolone, or 
ATG. Graft biopsies were taken only in case of steroid resistent rejection. Treatment 
failure was defined as the replacement of the intended immunosuppressive drug, or 
addition of another one. 
 
Design and statistics 
The study began 12 months after transplantation. To detect a difference in GFR of 
15% at a power of 80% 50 patients were needed, calculated according to a historic 
population.10 To measure the net effect of the treatment with pred/MMF compared to 
pred/CsA, patients in whom treatment failed were excluded from the final analysis. 
The reason for treatment failure is described in the Results section. Changes of 
variables were calculated as percentage of the value at start of the study, except for 
the blood pressure score which was measured as absolute difference.  
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Differences between the groups were tested with Pearson’s chi-square for 
categorical variables, Student’s t-test for continuous variables, and Wilcoxon-Gehan 
test in the survival analysis. A p-value below 0.05 was considered statistically 
significant. 
 
Results 
 
Forty-four patients were included (Figure 1). Randomization resulted in 21 patients in 
the MMF and 23 in the CsA group. Only one patient, in the CsA group, had 
experienced an acute rejection episode in the first year after transplantation. 
Treatment failure resulted in exclusion from analysis in three patients in the MMF 
group, two in the first study year, one in the second year, all caused by acute 
rejection. Four patients in the CsA group were excluded because of treatment failure, 
one in the first study year, because of acute rejection, and three in the second year 
because of cosmetic side-effects. One patient in this group withdrew from the study. 
Thus, 18 patients in the MMF group (86%) and 18 in the CsA group (78%) completed 
the study with the intended medication.  
 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow-chart of the study. One year after transplantation randomisation takes place, which is the starting 
point of the study, t=0. The numbers of available patients per group at yearly intervals are indicated 
 
Acute rejections during withdrawal 
Four patients, two of 21 MMF and two of 23 CsA patients, had acute rejection 
episodes during tapering off the other drug. In one of the MMF patients, this was 
caused by overt non-compliance with immunosuppressive therapy. All of these 
rejection episodes were steroid sensitive. They were reason to change 
immunosuppressive therapy for both MMF cases and one of the two CsA patients; 
these cases were excluded from further analysis (see in the section above).  
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Baseline data 
Table 1 shows baseline data for the 18 remaining patients in each group. Boys were 
overrepresented in the CsA group; in association this group also showed a greater 
proportion of urologic primary kidney disease. Glomerular disease was evenly 
distributed between the groups. At start of the study, HDL- and LDL-cholesterol, 
homocystein and hemoglobin levels were within normal limits. Cholesterol was 
slightly above normal in the MMF group; triglycerid level was above normal in both 
groups. At start of the study no statistically significant differences between the groups 
were noted in mean age, glomerular filtration rate, blood pressure and difference in 
blood pressure between day and night, and hemoglobin level, nor in the distribution 
of donor source. Cholesterol and LDL-cholesterol levels were different, with higher 
values in the MMF group. Dosage of MMF was significantly higher in the MMF group 
than in the CsA group, dosage of prednisolone and CsA were similar. 
 
Table 1. Baseline data 
 MMF group CsA group normal 
 n=18 n=18    
Age at start study, yr 11.9 10.9  
GFR (measured) 73.2 69.1 80 – 120 mL/min.1.73m2 
GFR (estimated) 72.1 67.4  
Hypertension score 1.4  0.9 0.0 
MAP day-night 7.7  8.6 10.0 mmHg 
Cholesterol 5.8  5.0 3.0 - 5.5 mmol/L 
HDL-cholesterol 1.4  1.5 0.9 - 2.7mmol/L 
LDL-cholesterol 4.2    2.7a < 4.2 mmol/L 
Triglycerids 2.0  1.7 0.4 - 1.6 mmol/L 
Homocystein 14.9 16.7 6 – 18 mcmol/L 
Hemoglobin 7.3 7.4 6.6 – 9 mmol/L 
    
Primary kidney disease (n)    
 Urologic/dysplasia 5   12  
 Glomerular 6     6  
 Metabolic 5     0  
 Cystic 2      0a   
Gender (M/F) 8/10      14/4a  
Donor source (LD/DD) 7/11        8/10  
    
Dose prednisolone 7.5      7.6 mg/m2.day 
Dose MMF 1047 881a  mg/m2.day 
Dose CsA 5.6      5.9 mg/kg.day 
The continuous variables are expressed as mean values  
a p < 0.05 
 
Dosage of immunosuppressive drugs 
In the MMF group the dosage of MMF decreased from 1047 mg/m2.day at start of the 
study to 989 at 12 months and 833 at 24 months. In the CsA group, the dosage of 
CsA decreased from 5.9 mg/kg.day to 4.9 and 4.7, with mean CsA trough levels of 
129, 125, and 126 mg/L. The prednisolone doses gradually decreased in both 
groups: at start 7.5 and 7.6, at 12 months 5.6 and 4.8, and at 24 months 5.9 and 4.6 
mg/m2.day in the MMF and CsA group, respectively (n.s. at all time points). 
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Patient and graft survival 
No patients died during follow-up. One graft in the MMF group failed at the end of the 
study due to chronic rejection. No malignancies were registered. 
 
Glomerular filtration rate 
Figures 2a en 2b show the individual GFR values measured by inulin clearance in 
patients with complete data at least at start and at the end of the first year of the 
study. Median values are 72, 76, and 72 at start of the study, 12 months and 24 
months in the MMF group, and 69, 62, and 61 in the CsA group, respectively. Figure 
3 illustrates the proportion of patients surviving without decrease of estimated GFR of 
more than 10 ml/min.1.73m2. This was seen in 27% of CsA vs. 71% of MMF patients 
at 24 months after start of the study (p=0.0197).  
 
Figure 2. 
The individual GFR values with indication of the median GFR in patients with complete data at least at 
start and at the end of the first year of the study: (A) 72, 76, 72 ml/min.1.73m2 at year 0, 1 and 2 in the 
MMF group, and (B) 69, 62, 61 ml/min 1.73 m2  at year 0,1 and 2 in the CsA group 
 
Figure 3. 
Life table showing proportion of patients without decrease of GFR more than 10 ml/min.1.73m2  
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Blood pressure 
The mean blood pressure decreased by 9.7% in the MMF group over the first 12 
months, compared to +0.8% in the CsA group (p=0.056); over 24 months these 
values were –6.2 and +2.8% (p=0.074). The change in blood pressure score did not 
differ significantly between the groups over the first 12 months (mean value in the 
MMF group –0.1 ± 0.2; CsA group +0.1 ± 0.3), nor over 24 months:–0.2 ± 0.3; and 
+0.1 ± 0.2, respectively. Two patients in the MMF, and six in the CsA group had a 
score 0 to begin with, and therefore could not improve. The proportion of patients 
with decreasing hypertension score tended to be greater in the MMF group, yet did 
not reach statistical significance: over 12 months 3/16 (21%) in the MMF group and 
2/18 (11%) in the CsA group (n.s.), over 24 months 5/14 (36%) in the MMF group 
and 2/12 (17%) in the CsA group (n.s.). The mean nightly dip in blood pressure did 
not differ significantly between the groups at all time points: at start +5 in both 
groups, at 1 year +9 and +4 , and at 2 years +4 and +3 mmHg in the MMF and CsA 
group, respectively. The proportion of non-dipping patients (MAP day - night < 10 
mmHg) at start of the study was 8/11 (73%) and 9/12 (75%), after 12 months 6/11 
(55%) and 12/15 (80%) and at 24 months 9/11 (82%) in the MMF and 11/12 (92%) in 
the CsA group (at all time points n.s.). 
 
Laboratory parameters 
Table 2 shows the mean changes over the first 12 months and over the full 24 
months of the study. Cholesterol levels, as shown in Figure 4, over the first 12 
months significantly decreased in the MMF group (-16%), compared to a slight 
increase in the CsA group (+6%, p=0.002); over the full 24 months the difference did 
not reach statistical significance (-13 and +3%, respectively). However, LDL-
cholesterol levels showed a similar pattern, for lower numbers of measurements 
however (n=7 and 8, respectively). The changes in non-HDL-bound cholesterol in the 
complete groups were in the same range. HDL-cholesterol levels decreased slightly 
in the MMF group and increased in the CsA group over 12 months, with less 
pronounced figures over the full 24 months. Triglycerid levels did not significantly 
differ between the groups. Remarkably, we noted widely ranging triglycerid levels in 
the MMF group, particularly over the full 24 months, resulting in large changes in 
mean values. Median levels, however, did not differ between the groups (at start 1.6 
vs. 1.6, after 12 months 1.7 vs. 1.4 and at 24 months 1.9 vs. 1.4 mmol/L). 
Homocystein levels tended to decrease more in the MMF than in the CsA group 
(n.s.).  
Mean hemoglobin level remained fairly constant for both groups and for both study 
periods, as shown in Table 2. At 12 months, 5/18 (28%) MMF and 1/18 (6%) CsA 
patients had a hemoglobin level below 6.6 mmol/L (p=0.05), at 24 months the 
difference was not significant (5/18 (28%) MMF vs. 2/17 CsA (12%), p=0.237). The 
absolute levels at 24 months levels were 6.8 ± 0.5 and 7.6 ± 0.3 mmol/L in the MMF 
and the CsA group, respectively (n.s.). 
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Adverse events 
During the second year of the study, two patients in the MMF group had a first, 
biopsy-proven, acute rejection episode. For one of them this lead to graft loss due to 
chronic rejection 6 months later. The other patient had a C4d positive acute humoral 
rejection, which was treated with plasmapheresis and high-dose corticosteroids. It 
resulted in chronic proteinuria and deteriorated graft function. 
 
Table 2. Change in laboratory values over the first and both study years 
 year 1 year 1+2 
  %(SEM) n p value %(SEM) n p value 
Cholesterol  0.002  0.065 
  MMF -16(4) 16  -13(6) 16  
 CsA +6(5) 17  +3(6) 16  
LDL-cholesterol  0.045  0.650 
  MMF -25(8)  7  -4(25)  6  
 CsA +7(10)  8  +12(24)  6  
Non-HDL-cholesterola  0.013  0.379 
 MMF -19(5) 13  -13(10) 15 
  CsA +3(7) 13  0(10) 11  
HDL-cholesterol  0.014  0.522 
  MMF -7(6) 13  +5(8) 16  
 CsA +22(9) 14  +13(7) 13  
Triglycerids  0.166  0.185 
  MMF -13(8) 15  +21(20) 16  
 CsA +8(12) 17  -5(6) 17  
Homocystein  0.146  0.462 
  MMF -17(5) 14  -10(10) 12  
 CsA -5(6) 12  0(9) 10  
Hemoglobin  0.218  0.369 
 MMF -2(3) 16  -5(6) 18  
 CsA +3(2) 18  +1(3) 17  
The values are given as mean change as percentage of original value; in brackets the standard error 
of the mean 
a In all patients: calculated as cholesterol minus HDL-cholesterol 
 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
Change in cholesterol levels (percentage of original value, ± SEM), left panel: change over the first 
year of the study, p=0.002; right panel over both study years, p=0.065 
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Laboratory parameters 
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months significantly decreased in the MMF group (-16%), compared to a slight 
increase in the CsA group (+6%, p=0.002); over the full 24 months the difference did 
not reach statistical significance (-13 and +3%, respectively). However, LDL-
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complete groups were in the same range. HDL-cholesterol levels decreased slightly 
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pronounced figures over the full 24 months. Triglycerid levels did not significantly 
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vs. 1.6, after 12 months 1.7 vs. 1.4 and at 24 months 1.9 vs. 1.4 mmol/L). 
Homocystein levels tended to decrease more in the MMF than in the CsA group 
(n.s.).  
Mean hemoglobin level remained fairly constant for both groups and for both study 
periods, as shown in Table 2. At 12 months, 5/18 (28%) MMF and 1/18 (6%) CsA 
patients had a hemoglobin level below 6.6 mmol/L (p=0.05), at 24 months the 
difference was not significant (5/18 (28%) MMF vs. 2/17 CsA (12%), p=0.237). The 
absolute levels at 24 months levels were 6.8 ± 0.5 and 7.6 ± 0.3 mmol/L in the MMF 
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Adverse events 
During the second year of the study, two patients in the MMF group had a first, 
biopsy-proven, acute rejection episode. For one of them this lead to graft loss due to 
chronic rejection 6 months later. The other patient had a C4d positive acute humoral 
rejection, which was treated with plasmapheresis and high-dose corticosteroids. It 
resulted in chronic proteinuria and deteriorated graft function. 
 
Table 2. Change in laboratory values over the first and both study years 
 year 1 year 1+2 
  %(SEM) n p value %(SEM) n p value 
Cholesterol  0.002  0.065 
  MMF -16(4) 16  -13(6) 16  
 CsA +6(5) 17  +3(6) 16  
LDL-cholesterol  0.045  0.650 
  MMF -25(8)  7  -4(25)  6  
 CsA +7(10)  8  +12(24)  6  
Non-HDL-cholesterola  0.013  0.379 
 MMF -19(5) 13  -13(10) 15 
  CsA +3(7) 13  0(10) 11  
HDL-cholesterol  0.014  0.522 
  MMF -7(6) 13  +5(8) 16  
 CsA +22(9) 14  +13(7) 13  
Triglycerids  0.166  0.185 
  MMF -13(8) 15  +21(20) 16  
 CsA +8(12) 17  -5(6) 17  
Homocystein  0.146  0.462 
  MMF -17(5) 14  -10(10) 12  
 CsA -5(6) 12  0(9) 10  
Hemoglobin  0.218  0.369 
 MMF -2(3) 16  -5(6) 18  
 CsA +3(2) 18  +1(3) 17  
The values are given as mean change as percentage of original value; in brackets the standard error 
of the mean 
a In all patients: calculated as cholesterol minus HDL-cholesterol 
 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
Change in cholesterol levels (percentage of original value, ± SEM), left panel: change over the first 
year of the study, p=0.002; right panel over both study years, p=0.065 
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Discussion 
 
This study was designed to test the safety and the efficacy of a dual 
immunosuppressive therapy combining MMF and corticosteroids in pediatric renal 
transplantation. Our results show improvement of GFR over the first year. This 
improvement suggests a reversibility of CsA toxicity, probably more related to its 
vasomotor side effects than to its potency to generate interstitial fibrosis. Adult 
studies also have shown better GFR, i.e. at 6 to 9 months after withdrawal of CsA 
from a triple regimen with MMF 3 to 6 months post-transplant.11-13 In the second year 
a parallel decrease of GFR is demonstrated in both groups, finally resulting in better 
sustained GFR after 2 years in the MMF treated patients, as is illustrated by the 
survival analysis. Hollander et al. reported persistently better GFR with long-term use 
of AZA compared to CsA.14 The second-year decrease of GFR in the MMF group in 
the present study may reflect less effective immunosuppression, with the occurrence 
of chronic rejection, as suggested by Smak Gregoor.15  
 
Acute rejections 
In each group two patients showed acute rejection during the withdrawal period (8-
10%). Most studies in adults report higher incidences after withdrawal of CsA from 
triple therapy at 3 to 6 months post transplant.11, 13, 15 In some of these studies 
withdrawal spanned a shorter period of time; for this reason, we opted for a 3-months 
period. Most reported rejection episodes were steroid sensitive and reversible. 
Hollander et al. reported better long-term graft survival in pred/AZA treated patients 
compared to patients on pred/CsA, despite a higher incidence of acute rejections 
during withdrawal.14 
Nevertheless, the severe adverse events encountered in the MMF group in the 
present study, that is, a humoral rejection episode and graft loss six months after an 
acute rejection episode in the second study year, argue against the safety of 
prednisolone and MMF as maintenance immunosuppressive prophylaxis in children. 
Acute rejections in the third year after transplantation are rare, certainly in therapy-
compliant 10-year-old girls like these. Similarly, Decloux et al. reported a late first 
acute rejection episode in 2 of 31 adult patients withdrawn from CsA and continuing 
on MMF.16 
Another possible complication of long-term MMF treatment is the previously reported 
bronchiectasis.17, 18 
 
Cardiovascular status 
Mortality in pediatric kidney transplantation is largely the result of cardiovascular 
disease, in association with high blood pressure and dyslipidemia.19-22 
Cardiovascular disease must be restricted as much as possible by avoiding 
hypertension and dyslipidemia caused by drugs like CsA and prednisolone, and by 
keeping the GFR optimal. This study aimed at improving cardiovascular status by 
withdrawal of CsA. Dyslipidemia, especially total and LDL-bound cholesterol, in fact 
improved after withdrawal of CsA in the first study year. However, the beneficial 
effect subsided in the second year. None of the patients was treated with statins, as 
these are not generally applied in pediatric nephrology in the Netherlands.  
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A study in adults receiving pred/MMF for 2 years showed decreases in total 
cholesterol and in cholesterol/HDL ratio, notably in the short term, but not any more 
after 2 years.15 Several studies on long-term treatment with pred/AZA in adults 
showed improved lipid pattern, better blood pressure control and lower incidence of 
cardiac death, compared to Pred/CsA treated patients.14, 23 Homocystein levels as 
well showed a trend of improvement over the first study year. Lilien et al. reported 
elevated homocystein levels in children with end-stage renal failure and renal 
transplantation, and these were associated with GFR.24 It is not clear yet whether 
homocystein level is independently associated with atherosclerosis. 
In our study, blood pressure as expected improved after withdrawal of CsA, but only 
over the first 12 months, and improvement did not reach statistical significance. 
Studies in adults showed a slight short-term improvement in blood pressure after 
withdrawal of CsA,12, 13 without taking antihypertensive treatment into account. The 
nocturnal decrease in blood pressure in our study did not change after withdrawal of 
CsA, confirming the findings of Schrama et al.12 Then, we had expected a decreased 
nightly dip of blood pressure in patients treated with CsA, based on previously 
reported findings.25 However, such an effect was not seen, neither at baseline nor at 
12 and 24 months.  
 
Side effects of MMF 
Patients on MMF for one year before start of the study, generally did not show new 
side effects. Hemoglobin levels were slightly lower in the MMF group, with the 
difference more pronounced after 12 months than after 24 months. None of the 
patients participating in the study received erythropoetin.  
 
Statistical power 
For some parameters, for example blood pressure, only a trend of a change, without 
statistical significance, could be shown. The study finally may have become 
underpowered. We had aimed at 25 patients in each group, but failed to enroll these. 
One of the reasons was that many potential candidates switched from CsA to 
tacrolimus in the first year after transplantation. Then, we encountered protocol 
violation in more patients than expected. Because we had decided to analyze only 
the data of patients treated with MMF without a calcineurin inhibitor and patients 
treated with CsA without MMF to measure the differential effect of the drugs, patient 
numbers were smaller than planned.  
 
Conclusion 
 
In conclusion, our study shows that MMF and prednisolone as immunosuppressive 
prophylaxis in pediatric kidney transplantation temporarily improve kidney function 
and dyslipidemia, and therefore may possibly improve graft and patient survival in the 
long-term. However, in view of the two late acute rejection episodes observed in this 
study, and the previously reported cases of bronchiectasis in long-term treatment 
with MMF, we feel this regimen is not without risk of serious adverse advents.  
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Abstract 
 
Background 
Kidney transplantation without prior dialysis may prevent dialysis associated 
morbidity.  
 
Methods 
We analyzed the outcome of 1113 first kidney transplants in children performed 
between 1990 and 2000 in the Eurotransplant community. 
 
Results 
Enlistment for a deceased donor kidney before start of dialysis (127/895, 14%) made 
dialysis redundant in 55% of cases. Mean residual creatinine clearance at 
transplantation of these patients was 8 mL/min.1.73 m2. Pre-emptive transplantations 
of deceased donor kidneys showed less acute rejections (52% vs. 37% rejection-free 
at 3 years, p=0.039), compared to transplantations following dialysis. The difference 
in graft survival between non-dialyzed and dialyzed patients (82% vs. 69% at 6 year) 
did not reach statistical significance (p=0.055). No differences were noted after living 
donor transplantation. Multivariate analysis showed that the period of transplantation 
was the strongest predictor of graft survival (p<0.001). Congenital structural 
abnormalities as primary kidney disease predominated in non-dialyzed patients 
compared to dialyzed patients (p<0.001); this factor did not influence graft survival.  
 
Conclusion 
Based on our conclusion that pre-emptive transplantation is at least as good as post-
dialysis transplantation, as well as on quality of life arguments, we recommend to 
consider pre-emptive transplantation in children with end-stage renal failure.
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Introduction 
 
Dialysis is a well established treatment modality in children with end-stage renal 
disease (ESRD). However, based on both medical and quality of life arguments, its 
place is to bridge the time awaiting a renal transplantation. It is associated with 
cardiovascular damage, impaired cognitive development and retardation of growth.1-4 
Moreover, the quality of life during dialysis is poor. Transplantation without prior 
dialysis, or pre-emptive kidney transplantation (PKT), may therefore be preferable in 
children with ESRD. 
 
However, for PKT to be advantageous, graft survival should at least equal that in 
dialyzed patients. Several publications on PKT with living donor (LD) allografts 
indeed report better graft survival, both in adults5-9 and in children.10,11 Others show 
equal results, in adults12,13 and children.14,15 Most publications on transplantations 
from deceased donors (DD) report equal graft survival in PKT, in adults8,12,16,17 and 
children.11,18 Just a few demonstrated better survival in PKT, predominantly in 
adults.6,19 Two reports on European children with DD grafts could only suggest a 
favorable effect of PKT, using series that were too small to reach statistical 
significance.20,21  
 
Here we report on a retrospective study to determine the outcome of PKT in a large 
pediatric cohort in the Eurotransplant communityd. In addition we investigate the 
extent to which the current Eurotransplant allocation policy allows PKT, and the risk 
that children receiving a PKT were transplanted too early.  
 
Patients and methods 
 
Study design 
A registry-wide retrospective study of all consecutive first kidney transplants 
performed in children younger than 16 years between January 1, 1990 and January 
1, 2000 in the Eurotransplant region. Data were retrieved from the Eurotransplant 
database and the medical files at the 22 participating centers.  
 
Definitions 
 
Graft failure 
The start of any form of chronic dialysis, transplantectomy, repeat kidney transplant, 
or death with functioning graft.  
Acute rejection 
The prescription of a course of antirejection therapy, consisting of 
methylprednisolone, ATG or OKT3.  
                                               
d The Eurotransplant International Foundation is responsible for the mediation and allocation of all 
organs in Austria, Belgium, Germany, Luxemburg, the Netherlands and Slovenia 
(www.eurotransplant.nl). 
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Delayed graft function 
The need of dialysis treatment in the first week after transplantation.  
Creatinine clearance 
Creatinine clearance at enlisting and at transplantation was estimated by a modified 
formula of Schwartz:22 body height (cm) x 40 / serum creatinine (mcmol/L).  
Hypertension 
Hypertension scores 1, 3, and 5 years after transplantation were arrived at by adding 
scores on 2 parameters: systolic or diastolic blood pressure below (score 0) or above 
(score 1) the 95th percentile for age and gender,23 and number of antihypertensive 
and diuretic drugs (no drugs = 0, 1 drug = 1, 2 or more drugs = 2). Scores could thus 
range from 0 to 3. 
 
Statistics 
The difference between Kaplan-Meier survival curves, used for patient and graft 
survival, and time to first acute rejection, was tested for its statistical significance with 
a log rank test. Differences in other parameters were tested with the chi-square test 
for categorical variables, Student’s t-test for continuous variables. Cox regression 
analysis was used to adjust the comparison between study and reference groups for 
potentially confounding factors. A probability of type 1 error less than 0.05 was 
considered the threshold of statistical significance. 
 
Results 
 
The Eurotransplant database contained 1234 first transplants meeting the inclusion 
criteria. Data of 1113 of these were available for analysis, 895 (80%) from DD and 
218 (20%) from LD. PKT were performed with 70 of DD grafts (8%), and 86 of LD 
grafts (39%). Mean as well as median follow-up time was 5.3 years (range 0–14.1). 
For analysis a maximal follow-up time of 6 years was set. The 22 participating 
centers contributed with a median number of 35 transplants (range 17 – 166). 
 
Baseline characteristics  
The PKT group had a relative over-representation of congenital structural 
abnormalities as primary kidney disease, in association with a higher residual 
diuresis. Stratified for donor source, no difference was seen in distribution of recipient 
and donor age, panel reactive antibodies, HLA-mismatches, cold ischemia time, and 
time window of transplantation. In the DD group PKT was associated with a shorter 
waiting time, as expected. The calculated creatinine clearance at enlisting and at 
transplantation were well below 10 mL/min.1.73m2, and did not differ between the 
groups. Dialyzed patients with an LD graft had dialyzed shorter than those with a DD 
graft (Table 1). 
 
Patient survival 
The 6-year patient survival in DD patients was 96% for both the pre-emptive and 
post-dialysis group (n.s.), in LD patients 100% for the pre-emptive and 97% for the 
post-dialysis group (p=0.04). 
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For analysis a maximal follow-up time of 6 years was set. The 22 participating 
centers contributed with a median number of 35 transplants (range 17 – 166). 
 
Baseline characteristics  
The PKT group had a relative over-representation of congenital structural 
abnormalities as primary kidney disease, in association with a higher residual 
diuresis. Stratified for donor source, no difference was seen in distribution of recipient 
and donor age, panel reactive antibodies, HLA-mismatches, cold ischemia time, and 
time window of transplantation. In the DD group PKT was associated with a shorter 
waiting time, as expected. The calculated creatinine clearance at enlisting and at 
transplantation were well below 10 mL/min.1.73m2, and did not differ between the 
groups. Dialyzed patients with an LD graft had dialyzed shorter than those with a DD 
graft (Table 1). 
 
Patient survival 
The 6-year patient survival in DD patients was 96% for both the pre-emptive and 
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post-dialysis group (p=0.04). 
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Table 1. Baseline characteristics 
  LD  DD  
    pre-empt post-dial   pre-empt post-dial   
 Number 86 132 p 70 825 p 
Primary kidney disease a       
 Structural  49 (57) 45 (36)  37 (54) 284 (35)  
 Cystic   13 (15) 23 (19)  12 (17) 114 (14)  
 Glomerular acquired   11 (13) 26 (21)  7 (10) 262 (33)  
 Metabolic disease  6 (7) 7 (6)  5 (7) 43 (5)  
 Cong. nephrotic syndrome  3 (3) 9 (7)  4 (6) 35 (4)  
 Other  2 (2) 8 (7)  2 (3) 54 (7)  
 Unknown  2 (2) 6 (5) 0.001 2 (3) 20 (2) 0.003 
Recipient age at transplant (yr), mean 9.8 8.8 n.s. 9.2 9.9 n.s. 
Panel reactive antibodies, recent (%)       
 < 5 62 (90) 97 (87)  62 (91) 684 (84)  
 5 – 85 7 (10) 14 (13)  5 (7) 125 (15)  
 > 85 0 (0) 0 (0) n.s. 1 (1) 8 (1) n.s. 
 Missing 17 21  2 8  
Rest diuresis (ml per 24 hr)       
 < 250 1 (2) 54 (52)  1 (2) 335 (47)  
 250 - 1000 17 (27) 26 (25)  20 (33) 240 (34)  
 > 1000 45 (71) 23 (22) <0.001 40 (66) 132 (19) <0.001 
 Missing 23 29  9 118  
Creat clearance at enlistment, mean   8.8 7.8 n.s. 
Creat clearance at transplant, mean 7.9 8.5 n.s. 8.4 8.4 n.s. 
  (mL/min.1,73m2)             
Donor age (yr)       
 < 6 0 0  10 (14) 150 (18)  
 6 – 20 0 0  26 (37) 276 (34)  
 20 – 40 53 (62) 90 (70)  18 (26) 202 (25)  
 > 40 33 (38) 39 (30) n.s. 16 (23) 196 (24) n.s. 
 Missing 0 3  0 1  
Duration dialysis (months), mean  14.7   18.7 0.006 
 < 6  51 (39)   130 (16)  
 6 – 24  51 (39)   486 (59)  
 > 24  28 (22)   205 (25) <0.001 
 Missing  2   4  
Waiting time (months), from transplantable urgency     
 0 – 6    50 (71) 439 (53)  
 6 – 12    15 (21) 211 (26)  
 > 12    5 (7) 171 (21) 0.001 
Cold ischemia time (hrs), mean 3.6 3.1 n.s. 21.6 21.7 n.s. 
HLA-A, -B, -DR mismatches (n), mean  2.3 2.1 n.s. 2.6 2.5 n.s. 
Period of transplantation       
 1990 - 1995 43 (50) 63 (48)  27 (39) 368 (45)  
 1995 - 2000 43 (50) 69 (52) n.s. 43 (61) 457 (55) n.s. 
Data are shown as number (percentage), or as mean value. Differences between pre-emptive and post-dialysis 
transplants are tested within the strata of donor source, with 1 exception: duration of dialysis was tested for the 
difference between LD and DD post-dialysis transplants. a Within the primary kidney diseases, differences are 
tested between congenital structural abonormalities and other diagnoses. Abbreviations: LD: graft from living 
donor; DD: graft from postmortal donor; pre-empt: pre-emptive; post-dial: post-dialysis; FSGS: focal segmental 
glomerulosclerosis; HUS: hemolytic uremic syndrome 
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Graft survival 
Overall the 6-year graft survival (LD + DD) was better in the non-dialyzed than in the 
dialyzed patients (82% and 71%, respectively, p=0.008). Figures 1a and 1b show 
graft survival curves stratified for donor source. Only in the group of DD transplants 
PKT was found to be favorable, though not statistically significant (p=0.055). Figure 2 
shows graft survival for patients with DD grafts grouped by duration of dialysis, 
demonstrating a better graft survival for PKT and transplants following less than 6 
months of dialysis (p=0.035). Since patients with PKT had relatively more congenital 
structural abnormalities, we assessed the effect of primary kidney disease on graft 
survival in the DD dialyzed patients. This revealed a similar graft survival for 
structural abnormalities compared to other diagnoses (74% vs. 68% at 6 years, 
p=0.19).  
 
Figure 1. Six year cumulative graft survival of DD (Figure 1a) and LD kidney transplants (Figure 1b), 
comparing pre-emptive to post-dialysis transplants. On the horizontal axis the years post-transplant, 
on the vertical axis the cumulative graft survival 
 
The time frame of transplantation had a distinct effect on DD graft survival: 6 year 
graft survival of dialyzed patients increased from 63% when performed between 1990 
and 1995 to 78% between 1995 and 2000 (p<0.001); and remained unchanged in 
pre-emptively transplanted patients: 82 and 81%, respectively. This resulted in loss 
of the favorable effect of pre-emptive transplantation in the second part of the study-
period. The mean duration of dialysis in both time periods was similar, 18.4 and 18.0 
months, respectively. 
 
Multivariate analysis (Table 2), stratified for donor source, revealed no significant 
association between the factor ‘duration of dialysis’ and graft survival (p=0.054). 
When this factor was replaced by ‘pre-emptive versus post-dialysis’ the significance 
level dropped (p=0.074). The factor strongest associated with graft survival was the 
time window. 
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Figure 2. Effect of duration of dialysis upon graft survival, in DD transplants. On the horizontal axis the 
years post-transplant, on the vertical axis the cumulative graft survival 
 
Acute rejection episodes 
In the DD, but not in the LD group, more patients remained rejection-free after PKT 
than after dialysis (52% vs. 37% at 3 years, p=0.039, Figure 3). In DD grafts the 
incidence of acute rejections correlated with duration of dialysis, with the lowest 
incidence (48%) in PKT patients and the highest (67%) in patients dialyzed more 
than 24 months (p=0.040).  
 
Delayed graft function 
The incidence of delayed graft function of DD grafts in dialyzed and non-dialyzed 
patients was 9% and 14%, respectively (p=0.27). Corresponding figures for the LD 
groups were 2.4% and 3.5% (n.s.). 
 
Table 2. Multivariate analysis of the risk of graft failure within the first 6 years after transplantation 
Factor  exp(B) 95% interval p 
      lower upper   
Duration of dialysis     
 0 1    
 < 6 mnth 1.03 0.57 1.88  
 6 - 24 mnth 1.64 0.99 2.72  
 > 24 mnth 1.67 0.97 2.88    0.054 
      
Period: 1995-2000 vs 1990-1995 0.59 0.43 0.76 < 0.001 
HLA-mismatches 1.12 0.97 1.28    0.084 
Age recipient 1.03 0.99 1.06    0.125 
Primary kidney disease     
 other diagnosis vs cong struct abnorm 1.20 0.89 1.60    0.255 
Creatinine clearance at transplantation 1.00 0.98 1.02    0.714 
Age donor 1.00 0.99 1.01    0.769 
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Immunosuppressive therapy 
The immunosuppressive regimens at transplantation and 1 year later did not 
significantly differ between the groups. However, they showed a highly significant 
difference between time windows (p<0.001), with the appearance of 35% 
corticosteroids - cyclosporine - MMF as initial therapy in the later period, largely 
replacing corticosteroids – cyclosporine (- azathioprine). 
 
Hypertension 
In the DD group severe hypertension, defined as score 2 and 3, was found in PKT 
patients in 58%, 40% and 53%, at 1, 3 and 5 years post-transplant, and in dialyzed 
patients in 69%, 64% and 64% respectively (p-values 0.16 at 1 year, 0.016 at 3 
years, and 0.12 at 5 years post-transplant). No differences were seen in the LD 
group.  
 
Figure 3. The incidence of a first acute rejection episode, in DD (Figure 3a) and LD kidney transplants 
(Figure 3b). On the horizontal axis the days post-transplant, on the vertical axis the risk of a first acute 
rejection episode 
 
 
Policy with regard to pre-emptive transplantation 
Of the 895 DD patients, only 127 had been enlisted before start of dialysis (14%). Of 
these, 70 (55%) in fact were transplanted pre-emptively. Eight of the 22 centers did 
not perform pre-emptive DD transplants at all, the same number as in LD transplants.  
 
Discussion 
 
In this Eurotransplant study the survival of pre-emptively transplanted grafts was 
better than that following dialysis. This confirms our previous observations.21,24 
However, the favorable effect of PKT on graft survival appears to have vanished in 
the second half of the observed decade, when the outcome rates of pre-emptive and 
post-dialysis transplants were equivalent.  
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Immunosuppressive therapy 
The immunosuppressive regimens at transplantation and 1 year later did not 
significantly differ between the groups. However, they showed a highly significant 
difference between time windows (p<0.001), with the appearance of 35% 
corticosteroids - cyclosporine - MMF as initial therapy in the later period, largely 
replacing corticosteroids – cyclosporine (- azathioprine). 
 
Hypertension 
In the DD group severe hypertension, defined as score 2 and 3, was found in PKT 
patients in 58%, 40% and 53%, at 1, 3 and 5 years post-transplant, and in dialyzed 
patients in 69%, 64% and 64% respectively (p-values 0.16 at 1 year, 0.016 at 3 
years, and 0.12 at 5 years post-transplant). No differences were seen in the LD 
group.  
 
Figure 3. The incidence of a first acute rejection episode, in DD (Figure 3a) and LD kidney transplants 
(Figure 3b). On the horizontal axis the days post-transplant, on the vertical axis the risk of a first acute 
rejection episode 
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This resulted largely from an improved outcome of dialyzed patients, an improvement 
which has been attributed to the introduction of new immunosuppressive drugs in this 
period, as has been demonstrated for German as well as Dutch transplanted 
children.25,26 Shorter duration of pre-transplant dialysis had a beneficial effect on the 
incidence of acute rejection episodes, as was previously shown by others.15,18,27 
Whether this contributes to better graft survival, could not be demonstrated with 
statistical significance in our study (p=0.035, univariate; p=0.055, multivariate 
analysis), in contrast to other investigators.17,28 
 
Although in literature most data show an improved outcome of PKT in LD transplants, 
we did not see this in our study.5-11,16 The shorter period of dialysis in our LD, 
compared to our DD recipients, may have contributed to this.  
 
Pre-emptive transplantation will most likely improve long term mortality rates in the 
pediatric patient population. It is to be expected that a shorter exposure to ESRD 
hazards in combination with less hypertension18 after transplantation will yield better 
life expectancy in the long run. Nevertheless, the mortality data in our study were 
hardly informative, maybe due to the relatively short observation period. Adults with 
pre-emptive transplantations show a lower mortality rate, especially from 
cardiovascular conditions, and less morbidity from hypertension and left ventricular 
hypertrophy.8, 17, 28 As in adults, the primary cause of mortality in pediatric end-stage 
renal failure is cardiovascular, associated with hypertension.2,29,30 
 
Congenital structural abnormalities are over-represented in pre-emptively 
transplanted children.11 These patients are particularly suited to undergo 
transplantation without prior dialysis. Their renal failure usually progresses only 
slowly, giving time to find a donor. In our series, structural abnormalities of the 
urogenital tract did not affect graft survival, as confirmed by uni- and multivariate 
analysis. 
 
In this retrospective study, we could not assess the effect of PKT on patients’ quality 
of life. However, the literature is clear on this topic. End-stage renal disease in 
childhood is associated with retarded development of social as well as cognitive 
capacities.4,31 Dialysis leads to prolonged parental dependency into adult age, 
unemployment and a lower level of education, relative to the duration of dialysis1,12,32 
The development of confidence and independency in adolescence is better in 
patients transplanted without prior dialysis.33,34 Therefore, the prospect of a normal 
mental and physical development may be improved when dialysis is avoided or 
minimized.  
 
The allocation system of Eurotransplant privileges children waiting for a kidney graft, 
resulting in shorter waiting times for children than for adults. This makes pediatric 
pre-emptive transplantation with DD grafts possible in certain cases. In our 
experience, half of the children listed before start of dialysis, could be transplanted 
without dialysis.  
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Currently only 14% of patients had been enlisted prior to dialysis. This number might 
at least double, considering the 35% of patients with slowly progressive disease 
based on congenital structural abnormalities. This expectation is confirmed by the 
experience in some centers, where already over one third of patients are enlisted 
prior to dialysis.  
 
Conclusion 
 
Graft survival in pre-emptive pediatric kidney transplantation in the Eurotransplant 
region currently at least equals that in dialyzed patients. In view of the reported 
benefits to quality of life, and possibly to the cardiovascular status in the long run, we 
recommend to promote pre-emptive enlistment and transplantation in children with 
ESRD. Eurotransplant’s current allocation system allows to attain a larger proportion 
of pre-emptive DD transplants. 
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Abstract 
 
Background  
More effective immunosuppressive treatment in children following organ 
transplantation has significantly improved the survival of the grafts. Therefore, quality 
of life, long-term prognosis and adverse drug reactions have become more important. 
One of the main complications of immunosuppressive drugs is infections of the 
respiratory tract, but irreversible damage to the airways has not been described after 
renal or liver transplantation.  
 
Patients  
Five children following transplantation of kidney or liver were referred to the Pediatric 
Pulmonology department because of chronic respiratory complaints. Pulmonary 
function tests and high resolution computed tomographic (HRCT) scan were 
performed as routine patient care.  
 
Results  
Four children with a renal transplant and one with a liver transplant showed chronic 
bronchitis and moderate to severe airways obstruction. HRCT showed bronchiectasis 
in all of them. 
 
Conclusion  
We speculate that the immunosuppressive treatment (in)directly contributes to 
irreversible airway damage. We recommend including follow-up of lung function in 
the post transplantation protocol and considering bronchiectasis in case of 
respiratory symptoms, to try preventing further damage to the lung. 
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Introduction 
 
Survival of transplanted organs and prognosis in general has improved considerably 
in children who receive an organ transplant.1 The improved long-term survival is 
associated with more extensive and more potent immunosuppressive treatment. 
Therefore, the side effects of this treatment need more attention. The most relevant 
side effect of immunosuppressive agents is the increased susceptibility for 
(opportunistic) infections, the lung being one of the vulnerable sites.  
Although not uncommon in developing countries, bronchiectasis is a rare disorder in 
children in the Western world; no recent data are available on the incidence.2 
Common causes of bronchiectasis are infections, and in developed countries, cystic 
fibrosis, immunodeficiencies and ciliary dyskinesia.3 Obstructive lung disease and 
bronchiectasis have been reported after bone marrow transplantation, related to 
graft-versus-host disease (GVHD).4,5 In pediatric heart transplantation. recurrent 
sinopulmonary infections and even bronchiectasis were described in children who 
had their transplant before the age of 4 years. It was speculated that impaired 
maturation of antipolysaccharide responses due to immunosuppression may be 
responsible for recurrent and damaging infections.6 Bronchiectasis as a 
radiographical feature of bronchiolitis obliterans may be seen after lung 
transplantation as part of chronic lung allograft rejection.7 However, no reports on 
bronchiectasis as a complication after liver or kidney transplantation are found in the 
literature. We describe four pediatric patients with a kidney transplant and one with a 
liver transplant, who developed chronic and progressive pulmonary symptoms, 
caused by bronchiectasis. 
 
Patients 
 
Characteristics of all 5 patients are summarized in Table 1. 
 
Patient 1, a boy from a family with high socioeconomic status, received a cadaveric 
renal transplant at the age of 12.5 years because of congenital renal dysplasia with 
vesico-ureteral reflux. Chest X-ray at transplantation was normal. 
Immunosuppressive prophylaxis consisted of corticosteroids, cyclosporine A (CsA) 
and mycophenolate mofetil (MMF); no induction treatment was used. Three months 
after transplantation, the CsA levels were between 75 and 125 mg/L, the MMF levels 
between 1.3 and 7 mg/L. Prednisone doses was 7.5 mg, once daily (0.16 mg/kg). 
Acute rejection episodes did not occur. Three months after transplantation he had 
chickenpox, for which he was treated with intravenous acyclovir. One year after 
transplantation he was treated for a Bordetella pertussis infection (confirmed 
serologically), after which he recovered completely. Eighteen months later he was 
referred to the pediatric pulmonologist because of persistent productive coughing. He 
did not have any prior primary pulmonary complaints. Pulmonary function tests (PFT) 
revealed severe airway obstruction (Table 1). Sputum cultures grew Pseudomonas 
aeruginosa and high resolution computed tomography scan (HRCT) showed 
bronchiectasis in both lower lobes (Figure 1). He was treated with ciprofloxacin, 
nebulized tobramycin and DNase, and Positive Expiratory Pressure (PEP) by mask. 
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bronchiectasis have been reported after bone marrow transplantation, related to 
graft-versus-host disease (GVHD).4,5 In pediatric heart transplantation. recurrent 
sinopulmonary infections and even bronchiectasis were described in children who 
had their transplant before the age of 4 years. It was speculated that impaired 
maturation of antipolysaccharide responses due to immunosuppression may be 
responsible for recurrent and damaging infections.6 Bronchiectasis as a 
radiographical feature of bronchiolitis obliterans may be seen after lung 
transplantation as part of chronic lung allograft rejection.7 However, no reports on 
bronchiectasis as a complication after liver or kidney transplantation are found in the 
literature. We describe four pediatric patients with a kidney transplant and one with a 
liver transplant, who developed chronic and progressive pulmonary symptoms, 
caused by bronchiectasis. 
 
Patients 
 
Characteristics of all 5 patients are summarized in Table 1. 
 
Patient 1, a boy from a family with high socioeconomic status, received a cadaveric 
renal transplant at the age of 12.5 years because of congenital renal dysplasia with 
vesico-ureteral reflux. Chest X-ray at transplantation was normal. 
Immunosuppressive prophylaxis consisted of corticosteroids, cyclosporine A (CsA) 
and mycophenolate mofetil (MMF); no induction treatment was used. Three months 
after transplantation, the CsA levels were between 75 and 125 mg/L, the MMF levels 
between 1.3 and 7 mg/L. Prednisone doses was 7.5 mg, once daily (0.16 mg/kg). 
Acute rejection episodes did not occur. Three months after transplantation he had 
chickenpox, for which he was treated with intravenous acyclovir. One year after 
transplantation he was treated for a Bordetella pertussis infection (confirmed 
serologically), after which he recovered completely. Eighteen months later he was 
referred to the pediatric pulmonologist because of persistent productive coughing. He 
did not have any prior primary pulmonary complaints. Pulmonary function tests (PFT) 
revealed severe airway obstruction (Table 1). Sputum cultures grew Pseudomonas 
aeruginosa and high resolution computed tomography scan (HRCT) showed 
bronchiectasis in both lower lobes (Figure 1). He was treated with ciprofloxacin, 
nebulized tobramycin and DNase, and Positive Expiratory Pressure (PEP) by mask. 
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Despite this treatment he had a severe exacerbation of symptoms at the age of 16.5 
years, when bronchoalveolar lavage fluid (BALF) showed Streptococcus pneumoniae 
and rhinovirus. No other pathogens were found. He was treated with intravenous 
cefuroxim and recovered only slowly and incompletely. Cystic fibrosis and primary 
ciliary dyskinesia were ruled out by appropriate tests. It was hypothesized that the 
bronchiectasis could be explained by the proven Bordetella pertussis infection.  
 
Table 1. Characteristics of 5 children who had kidney or liver transplantation and subsequently 
developed bronchiectasis 
 1. male 
17 yrs 
2. male 
12 yrs 
3. male 
11 yrs 
4. male 
7 yrs 
5. female 
11 yrs 
Age at Tx (yr) 12 10 (2nd Tx) 7 3 0.8 
Age at respiratory 
      symptoms (yr) 
15 11 8 5 7 
Primary diagnosis renal dysplasia asphyxia mes prol GN cong NS biliary atresia 
Transplanted organ kidney kidney kidney kidney liver 
Creatinin (µmol/l) 250 85 65 60  
Immunosuppression P, CsA, MMF P, CsA, MMF P, CsAa, MMF P, CsAa, MMF P, CsA, MMF 
Sputumcultures Pseud. 
aeruginosa 
Str.pneumoniae 
H. influenzae 
 
H. influenzae 
H. parainfluenzae 
St. maltophilia 
Flavobact. sp. 
Pseud.        
aeruginosa 
H. influenzae H.parainfluenzae 
FVC b, c 69 / 91 67 / 100 61 / 92 66 / 101 94 / 88 
FEV1 b, c  59 / 80 56 / 103 51 / 71 72 / 101 88 / 81 
FEV1/ FVC (%) c  71 / 73 69 / 86 70 / 64 93 / 84 80 / 79 
MEF25 b, c  11 / 28 17 / 68 13 / 23 28 / 43 45 / 36 
Location 
bronchiectasis 
both lower 
lobes, 
right upper lobe 
left lower lobe generalized right middle 
lobe, lingula 
both lower lobes, 
lingula 
Abbreviations: mes prol GN: mesangio proliferative glomerulonephritis, cong NS: congenital nephrotic syndrome, 
P: Prednisone, CSA: Cyclosporin, MMF: Mycophenolate Mofetil, FVC: forced vital capacity,  
FEV1: forced expiratory volume in 1 second, MEF 25: maximal expiratory flow at 25% of vital capacity 
a prescribed only during the first half year after transplantation 
b values are percentages predicted for sex and height 
c at referral to the department of pediatric respiratory medicine/ maximal value after treatment 
 
However, within 18 months of this referral, four other patients on immunosuppressive 
treatment following kidney (3) or liver (1) transplantation were referred because of 
similar symptoms. They all presented with chronic productive cough without fever, 
dyspnea and with diminished exercise tolerance. The initial immunosuppressive 
therapy was the same for all 4 kidney transplant patients and consisted of 
corticosteroids, CsA and MMF. No induction therapy was administered. From 6 
months post-transplant the dosage of prednisolone was 5 mg/m2/day, and MMF 600 
mg/m2 b.i.d.; CsA dosage was titrated to a serum concentration of 100 mg/l. In 2 
cases (patient 3 and patient 4) cyclosporine was discontinued at 6 months post-
transplantation in the framework of a study protocol. In patient 5 CsA was 
discontinued and replaced by MMF because of slight impairment of renal function. 
Chest X-rays on the day of transplantation were normal in all patients. Kidney 
transplant patients 1, 2 and 4 received antibiotics continuously for urinary tract 
infection prophylaxis.  
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The diagnostic workup, similar to patient 1, did not reveal any indication for the 
common causes of bronchiectasis. Patients 2 and 3 are from families with low 
income; the families of patient 4 and 5 are prosperous. 
 
Figure 1. Slide of HRCT-scan, showing bronchiectasis in patient 1 
 
Patient number 2 had a renal transplant at the age of 2 because of renal failure after 
perinatal asphyxia. Chronic pyelonephritis lead to failure of this graft at the age of 8 
years, after which he was treated with peritoneal dialysis. A second transplant with a 
kidney from his mother was performed at the age of 9 years. As a toddler the boy 
had recurrent ear, nose and throat infections, treated with adenotonsillectomy and 
bilateral ventilation tubes. Chest X-ray before transplantation was unremarkable. One 
year after his second transplant he presented with chronic productive cough and 
recurrent pansinusitis. Sputum culture revealed Haemophilus influenzae and the 
chest X-ray showed increased markings. On HRCT bronchiectasis in the left lower 
lobe was detected. The boy was treated with amoxicillin, DNase and PEP mask and 
only recovered slowly, partly due to low adherence to treatment. 
 
An 11 years old boy was the third referral to our pediatric pulmonology department. 
He received a kidney transplant from his father at the age of 7 years and presented 
with respiratory symptoms 1 year later. His primary diagnosis was 
mesangioproliferative glomerulonephritis. At first presentation severe airway 
obstruction was present. Sputum cultures revealed Haemophilus influenzae. He was 
treated with antibiotics based on sensitivity tests. However, his lung function did not 
recover and HRCT scan showed bronchiectasis. DNase was added and he was 
treated with a PEP mask. When he presented with an exacerbation of his complaints 
a bronchoscopy was performed and BALF grew Haemophilus influenzae, and no 
opportunistic microorganisms.  
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At 3 years after referral sputum was colonized with Pseudomonas aeruginosa, and 
the patient was treated with ciprofloxacin and tobramycin inhalations. 
Stenotrophomonas infection was treated with cotrimoxazole. At the last follow-up visit 
he had a productive cough and crackles bilaterally on chest auscultation. His 
pulmonary function tests improved significantly, but did not recover fully. 
 
The fourth patient was a 3 year old who received a cadaveric kidney transplant for 
congenital nephrotic syndrome. Two years later he presented with chronic productive 
cough; sputum culture grew Haemophilus influenzae and he was treated with 
amoxicilline/clavulanic acid. As symptoms persisted antibiotics were switched to 
clarithromycin and nebulisations with DNase and PEP therapy were started. Only 
after an intravenous course of cefuroxime did his pulmonary function normalized and 
symptoms disappeared. No other pathogens besides Haemophilus influenzae were 
cultured. Bronchoscopy and BAL were not performed. 
 
An 11 year old girl was the 5th patient who developed bronchiectasis after a solid 
organ transplantation. She received a cadaveric donor liver because of biliary atresia 
when she was 10 months old. Initial immunosuppression consisted of prednisone, 
azathioprine and CsA. CsA was discontinued after 1 year, but restarted at the age of 
6 years because of signs of rejection on a liver biopsy. Five years after 
transplantation azathioprine was replaced with MMF. CsA was withdrawn after 
introduction of MMF. At the age of 9 years she presented with chronic cough and 
diminished exercise tolerance for 1.5 years. Immunosuppression at that time 
consisted of MMF 500 mg bid and prednisone 12 mg on alternate days. MMF levels 
varied between 3.5 and 9.6 mg/L (4.0 mg/L at presentation). Immunoglobulins were 
within normal limits. Her pulmonary history was previously unremarkable, however, 
she had had recurrent ear nose and throat infections. Except for one antibiotic course 
the patient did not receive any antibiotic treatment. In her sputum Haemophilus 
parainfluenzae was cultured. The girl was treated with cotrimoxazole, DNase and 
PEP therapy. However, pulmonary function tests have not improved. 
 
Discussion  
 
This is the first report of bronchiectasis in children who underwent a kidney or liver 
transplant. Airway infection with bronchial obstruction and retention of mucus are 
major factors in the pathogenesis of bronchiectasis.3 Well-known causes of 
bronchiectasis in children in the Western world are cystic fibrosis, mucociliary 
clearance defects, recurrent aspiration and immunodeficiencies, but in up to 50% of 
patients with bronchiectasis no cause is identified8 In our current pediatric renal 
transplant population we diagnosed bronchiectasis in 4 out of 38 patients. 
Bronchiectasis has been reported after pediatric bone marrow, heart, heart-lung and 
lung transplantation.4-7 In bone marrow transplantation bronchiectasis is associated 
with chronic GVHD.4 In adult bone marrow recipients it was shown that ciliary beat 
frequency was severely reduced in those patients who developed bronchiolitis 
obliterans and chronic GVHD.9  
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Impaired maturation of antipolysaccharide responses caused by immunosuppression 
may be responsible for recurrent infections leading to bronchiectasis, especially in 
children transplanted before the age of 4 years, as was shown for pediatric heart 
transplant recipients.6  
 
Several mechanisms may account for the development of bronchiectasis in our 
patients. First, all patients have secondary immunodeficiency due to 
immunosuppressive medication, which may have facilitated pulmonary infections. 
Besides, pulmonary infections may have been masked by the prophylactic antibiotic 
treatment these patients received to prevent urinary tract infections. We cannot 
exclude that the patients had opportunistic infections, but could not identify such 
microorganisms despite bronchoscopy with lavage in 2 patients. Patient 1 had had a 
serologically proven B. pertussis infection, a well-known but rare cause of 
bronchiectasis, 18 months before he presented with bronchiectasis.  
 
As we did not feel lung biopsy would provide us with useful information or would 
change our treatment, lung biopsies were not performed in our patients. An 
alternative hypothesis is that the immunosuppressive drugs were a causative factor. 
All patients used one shared immunosuppressive drug, MMF, a relatively new drug in 
our immunosuppressive regime, for a prolonged period of time. Pulmonary side 
effects of MMF have been described: coughing, bronchitis and shortness of breath. 
Two case reports document acute respiratory failure with pulmonary fibrosis and 
pneumonitis most likely due to MMF, but bronchiectasis is not known as an adverse 
effect of MMF.10,11 In vivo, MMF severely depresses humoral immunity making 
patients more susceptible to infection.12 Before the introduction of MMF in our 
standard immunosuppression regime in 1997, we had not seen any patient with 
bronchiectasis after transplantation. We speculate that MMF may play a role in the 
development of bronchiectasis in our patients by facilitating or masking pulmonary 
infections more than other immunosuppressive drugs or by exerting a direct effect on 
the airway wall. Obviously, the exact mechanism remains to be elucidated and 
requires further research. 
 
Therapeutic levels of CsA are not associated with serious pulmonary toxicity.  
 
In our patients no data on pre-transplant PFT were available nor did we have any 
pre-transplant CT scans. Diminished lung volumes have been described in chronic 
renal failure, but most transplanted patients showed normal spirometry.13,14 We 
cannot exclude pre-transplant abnormalities in PFT in our patients, but there were no 
respiratory symptoms prior to transplantation.  
 
As prognosis and survival of children after organ transplantation increased 
dramatically the past decade, complications of the post-transplant therapy have 
become more and more important and may co-determine long-term prognosis.1 Once 
structural abnormalities of the bronchi are present, even control of infection and 
inflammation may not be sufficient to arrest the progression to disabling irreversible 
airway obstruction.  
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In the presence of respiratory symptoms bronchiectasis should be considered and, 
as spirometry is not sensitive enough in detecting early structural lung damage, 
HRCT should be performed.2,15 However, we recommend including follow-up of lung 
function in the post-transplantation protocol as well, as peripheral airway obstruction 
may be a sign of bronchiectasis. By aggressively treating children with bronchiectasis 
who are receiving immunosuppressive drugs, further damage to the lung may be 
prevented and quality of life and long-term prognosis improved.  
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Abstract 
 
Background 
Recently four of 38 children with a kidney transplant were diagnosed with 
bronchiectasis. The aim of the current study was to identify patients with increased 
risk for pulmonary damage.  
 
Methods 
In this cross-sectional observational study, children with a functioning kidney graft in 
the Netherlands and Antwerp, Belgium, were screened with the use of a symptom 
checklist and spirometry. Maximum score for upper airway complaints was 21 
(normal: <8), for lower airway complaints 28 (<10). Results of forced vital capacity 
(FVC), forced expiratory volume in 1 sec (FEV1) and maximal expiratory flow at 25% 
of vital capacity (MEF25) were expressed as percentage predicted for height and 
sex.  
 
Results 
Hundred and thirty-five patients completed the interview (122) and/or spirometry 
(103); 91 did both. Lower airways symptoms were above acceptable levels in 18 
(14%) patients. Forty-nine patients (48%) had an abnormal lung function test: in 12 
concerning FVC%, in 11 FEV1%, in 24 MEF25%, and in 36 FEV1/FVC. Of 
correlations between symptomatology or spirometry data, and clinical parameters, 
only that between GFR and MEF25% was statistically significant. 
 
Conclusion 
Children with a kidney transplant are at increased risk for obstructive lung disease. 
We recommend to monitor lung function during the follow-up after renal 
transplantation. 
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Introduction 
 
The improved long-term survival of transplanted organs is associated with more 
extensive and potent immunosuppressive treatment. Adverse effects of this 
treatment, therefore, are becoming more apparent. The most relevant one is the 
increased susceptibility for (opportunistic) infections, with the lung among the target 
sites. Since the introduction of mycophenolate mofetil (MMF) in our standard 
immunosuppressive protocol, four out of 38 children with a kidney transplant followed 
in Rotterdam have been diagnosed with bronchiectasis.1 They presented with 
persistent productive cough and showed disturbed lung function. Similarly, a later 
report described bronchiectasis in 5 adults with a kidney transplant.2 Bronchiectasis 
is a rare disorder in children in the Western world, associated with cystic fibrosis, 
immunodeficiencies and ciliary dyskinesia.3 It has been reported after bone marrow 
transplantation, in relation to graft-vs.-host disease,3, 4 and after recurrent pulmonary 
infections in heart transplantation in very young children.5 Bronchiectasis may be 
seen after lung transplantation as part of chronic allograft rejection.6 However, 
pulmonary complications of kidney transplant have not been systematically studied.  
Being alerted, we designed a cross-sectional study, (1) to identify pulmonary 
complaints and/or abnormal lung function in children with a functioning kidney 
transplant, and (2) to identify risk factors for disturbed lung function. In particular, we 
explored the hypothesis that MMF might affect respiratory symptoms and lung 
function.  
 
Methods 
 
All 166 children with a functioning kidney transplant who visited one of the 5 pediatric 
nephrology outpatient clinics in the Netherlands and Antwerp, Belgium during a 3 
month period (between April and July) were asked to participate. The index-patients 
with bronchiectasis were excluded. In these institutions a shared initial 
immunosuppressive protocol was applied, consisting of corticosteroids, MMF and 
cyclosporine, after 2001 in combination with basiliximab. After a year the regimen 
generally was reduced to two drugs, either prednisolone and a calcineurin inhibitor or 
prednisolone and MMF. CMV prophylaxis consisted of a 3 months course of 
valganciclovir in CMV-positive donor with negative recipient combination, and 
valaciclovir in CMV-positive recipients. In most institutions, cotrimoxazol prophylaxis 
was prescribed for the first three months after transplant. 
 
The parents were interviewed on upper and lower airway complaints of the children 
using a modified validated questionnaire designed to assess respiratory symptoms in 
patients with bronchiectasis (Table 1).7 Items were scored on a 4-point scale, ranging 
from 0 (never), 1 (sometimes), 2 (often), to 3 (always). The use of antibiotics was 
scored as 0 (none) or 1. The maximum total score possible for upper airway 
complaints was 21, for lower airway complaints 28.  
Item scores 0 or 1 were accepted as normal, resulting in a maximum acceptable 
score for complaints of the upper airways of 7, of the lower airways of 9; patients 
were categorized according to these cut-off values.  
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Table 1. Symptom checklist 
Did your child during the last 3 months complain of following symptoms 
Upper airway complaints: 
Nose obstruction 
Nasal mucus clear 
Nasal mucus yellow or green  
Snoring 
Impaired hearing 
Ear ache 
Otitis 
 
Lower airway complaints: 
Cough, hacking 
Cough in the morning 
Cough at night 
Cough at laughing/crying 
Cough during exercise 
Cough with mucus production 
Dyspnea at rest 
Dyspnea during exercise 
Did your child get antibiotics for pulmonary complaints?  
(no=0, yes=1) 
How often did episodes of coughing and dyspnea occur?  
(0=0, 1=1, 2=2, >2=3) 
 
Spirometry was performed in each institution according to guidelines of the American 
Thoracic Society by authorized lung function technicians used to encourage the 
children to make the ultimate effort in expiration. After maximal inspiration, three 
reproducible loops with a maximum variability in FVC of 10% were obtained. The best 
of the three curves is selected for analysis. Results of spirometry were interpreted by 
pediatric pulmonologists at each local site. FVC, FEV1 and MEF25 were expressed 
as percentage predicted for height and sex (FVC%, FEV1%, MEF25%). The lower 
borders of normal values (-2 SD) were 80% of predicted for FVC, 85% for FEV1, 
70% for MEF25.8 FEV1/FVC ratio, as the most sensitive indicator of airway 
obstruction, was calculated; a value < 0.85 was interpreted as airways obstruction. 
Collected patient data included: age, height and weight at time of the investigation, 
time on renal replacement therapy and after transplantation, and the 
immunosuppressive therapy through the years. Serum creatinine levels at the time of 
the study were collected, and, in one center, serum immunoglobulin levels. 
Since these children did not have major complaints, we considered CT-scanning of 
all patients as unethical, and refrained from it.  
 
Definitions 
Acute rejection was defined as the prescription of a course of antirejection therapy, 
consisting of methylprednisolone or ATG. The glomerular filtration rate (GFR) was 
calculated according to a modified formula of Schwartz.9, 10 
 
Statistical analysis 
Correlations between spirometry findings and clinical parameters were assessed for 
statistical significance with Pearson’s test. Correlations between complaints and 
clinical parameters were tested for statistical significance with logistic regression. 
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Comparison of means between 2 groups was performed by t-test. A p-value < 0.05 
was considered significant. 
 
Results  
 
Of 166 eligible children, 135 completed the interview (122) and/or performed 
spirometry successfully (103); 91 did both. Clinical data of these 135 children are 
shown in Table 2.  
 
Table 2. Clinical characteristics of 135 patients who performed lung function test and/or filled in the 
symptom checklist  
 Mean Median Range 
Age (yr)      13.9   14.6     (4.4 - 19.9) 
Time from start RRT (yr)        6.8      6.2     (0.4 - 15.6) 
Time from transplantation (yr)        4.3      3.9     (0.2 - 13.7) 
GFR (ml/min.1.73m2)   57 57   (12 - 113) 
Creatinine (mcmol/l) 122 99   (43 - 439) 
IgG (n=26, mmol/l)        8.7     8.9     (3.1 - 16.4) 
Height SD score      -2.1    -2.1    (-5.7 - 1.2) 
Body mass index (kg/m2)   21 20  (15 - 39) 
    
Pre-emptive/post-dialysis (n) 15/120   
Rank order 1/2/3 (n) 114/16/5   
Sexe m/f (n) 80/55   
Acute rejection incidence 0/1/>1 (n) 66/33/14 (missing 22)  
Donor source LD/DD (n) 29/96 (missing 10)  
    
MMF currently yes/no      63/45 (missing 27)  
Years on pred     4.1 3   (0 - 13) 
Years on CsA   3 2   (0 - 13) 
Years on MMF     1.7 1 (0 - 8) 
Years on TCL     0.6 0 (0 - 5) 
Pred: prednisolone, CsA: cyclosporine, MMF mycophenolate mofetil, RRT: renal replacement therapy, 
GFR: glomerular filtration rate, TCL: tacrolimus, LD: living donor, DD: deceased donor 
 
Their median age was 14.6 years, they had been on renal replacement therapy for a 
median of 6.2 years, and received their kidney transplant a median of 3.9 years ago. 
As pre-existent pulmonary disease is concerned, no cases with Wegener’s or 
Goodpasture’s disease as primary kidney disease were registered, one patient had 
SLE.  
No overt respiratory problems were present before transplantation; however, a 
previous history of atopy or asthma has not been registered.  
The median creatinine level was 99 mcmol/L, with a mean and median GFR of 57 
mL/min/1.73m2. Forty five percent of patients were still receiving MMF at the time of 
the study, of whom 66% had used it for more than 12 months. Immunosuppressive 
therapy at time of the study consisted of double therapy in 51% of patients (37% on 
prednisolone and a calcineurin inhibitor, and 14% on prednisolone and MMF) and 
44% on triple therapy (prednisolone, a calcineurin inhibitor and MMF). No patients 
were on sirolimus. 
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The symptom checklist scores revealed complaints of upper and lower airways 
above acceptable level in 15 (13%), and in 17 (15%) patients, respectively (Table 3).  
 
Table 3. Spirometry and interview data, mean and median values, range, and number and percentage 
of patients with abnormal values 
 
Mean 
 
Range 
 
< -2SD 
n (%) 
FVC (% of predicted) 104 (55 - 143)   12 (11.5%) 
FEV1 (% of predicted) 107 (56 - 142) 10 (9.6%) 
MEF25 (% of predicted) 89 (32 - 198)   24 (23.8%) 
FEV1/FVC        0.87 (0.48 – 1.00)   36 (34.6%) 
    
Interview score of Median Range 
> Acceptable 
n (%) 
Upper airways 3 (0 - 14) 15 (12.8%) 
Lower airways 4 (0 - 20) 17 (15.4%) 
 
A clear correlation between lower and upper airway complaints was found (r=0.60, 
p<0.001). No statistically significant correlation was found between on the one hand 
checklist scores of either upper or lower airway complaints, and on the other hand 
age, time after transplantation, time on renal replacement therapy, rank order of 
transplant, presence of acute rejection episodes, current use and duration of MMF 
therapy, GFR and IgG. Of the patients currently treated with MMF the proportion with 
lower airway complaints did not differ from those not treated with MMF (6/35 vs. 7/56, 
p=0.453). 
 
Lung function tests revealed at least one lung function parameter value less than -2 
SD in 49 out of 103 patients (48%), in 12 (12%) concerning the FVC%, in 11 (11%) 
the FEV1%, in 36 (35%) the FEV1/FVC ratio, and in 24 (24%) the MEF25% (Table 
3). The mean FVC%, FEV1%, FEV1/FVC ratio and MEF25% were within the normal 
range. No correlations were found between on the one hand lung function 
parameters (in percentage predicted) and on the other hand age, time after 
transplantation, time on renal replacement therapy, rank order of transplant, 
presence of acute rejections, serum IgG, level of immunosuppression (double vs 
triple), and current use and duration of MMF treatment (Table 4). A significant but 
weak correlation was shown between GFR and MEF25% (r=0.216, p=0.036). The 
proportion of patients with below-normal MEF25% was lower in those on MMF 
therapy than in those not on MMF (5/34 vs. 18/49, p=0.045); no difference between 
these groups was noted for the FEV1/FVC ratio. Lung function parameters 
expressed as percentage of predicted for height and sex were not significantly 
correlated with body mass index (BMI). 
 
Of the 26 patients with known IgG levels at the time of the study, 13 were currently 
treated with MMF. IgG levels did not significantly differ between patients with and 
without MMF (7.4 vs 9.3 g/L, p=0.201). Neither did lymphocyte count significantly 
differ between patients with and without MMF (1.9 and 2.1 x 109/L, respectively, 
p=0.549). 
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Table 4. Correlation of lung function with clinical characteristics 
A. Pearson: correlation fvc%  fev1%  mef25%  fev1/fvc  
 coeff p coeff p coeff p coeff p 
Age  0.133 0.177  0.070 0.483  0.066 0.511 -0.178 0.071 
Time after transplant  0.178 0.071  0.085 0.390 -0.086 0.392 -0.175 0.076 
Time after start RRT  0.110 0.302  0.046 0.665 -0.012 0.909 -0.127 0.233 
Height SDS -0.102 0.301 -0.085 0.408  0.122 0.224  0.072 0.466 
BMI   0.164 0.096  0.179 0.068 -0.006 0.955 -0.004 0.971 
Years on MMF  0.021 0.845  0.131 0.226  0.134 0.215  0.196 0.067 
GFR  0.060 0.562  0.177 0.099  0.216 0.036*  0.231 0.054 
IgG  0.183 0.382  0.193 0.354  0.090 0.667  0.054 0.799 
         
B. t-test: differences of means 
Ranking order         
 first 103  108  89  87  
 later 108 0.332 110 0.588 87 0.769 84 0.139 
Duration MMF therapy         
 max 1 year 107  109  79  86  
 longer 102 0.302 106 0.639 89 0.205 88 0.317 
MMF currently         
 yes 100  105  88  89  
 no 106 0.131 108 0.404 86 0.753 86 0.266 
Nr acute rejections         
 0 100  106  89  90  
 1 or more 107 0.078 108 0.64 83 0.356 85 0.010a 
a p=0.05 
 
Discussion 
 
Children with a renal transplant have functional abnormalities of upper and lower 
airways in a higher proportion than expected, as shown in this multi-center, cross-
sectional and descriptive study. We observed pulmonary dysfunction in a significant 
proportion of our patients, in addition to four cases with clinically significant 
bronchiectasis. The findings from the symptom checklist only give a crude impression 
of the prevalence of airway complaints, as it has not been validated in Dutch patients 
with a kidney transplant. The impression is confirmed, however, by the more 
objective spirometry data: much more patients had disturbed pulmonary function than 
expected from the normal distribution in healthy children. The parameters most often 
aberrant were the FEV1/FVC, reflecting airway obstruction, and the MEF25, which 
may be indicative for obstruction of the more peripheral airways. FEV1/FVC is the 
most sensitive and reproducible of these. A dysbalance in production and clearance 
of pulmonary mucus may provide an explanation for this phenomenon.  
Possible causes of overproduction are: increased infectious load from 
immunosuppressive therapy, or diminished clearance due to damaged ciliary 
clearance or lower muscle power. In this respect, myopathy has been suggested as a 
cause of diminished lung volumes in patients on renal replacement therapy, possibly 
resulting from uremia before, and corticosteroid treatment after transplantation.11, 12 
We cannot rule out the possibility that our patients might have had pre-transplant 
abnormalities in lung function because relevant data are missing.  
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 coeff p coeff p coeff p coeff p 
Age  0.133 0.177  0.070 0.483  0.066 0.511 -0.178 0.071 
Time after transplant  0.178 0.071  0.085 0.390 -0.086 0.392 -0.175 0.076 
Time after start RRT  0.110 0.302  0.046 0.665 -0.012 0.909 -0.127 0.233 
Height SDS -0.102 0.301 -0.085 0.408  0.122 0.224  0.072 0.466 
BMI   0.164 0.096  0.179 0.068 -0.006 0.955 -0.004 0.971 
Years on MMF  0.021 0.845  0.131 0.226  0.134 0.215  0.196 0.067 
GFR  0.060 0.562  0.177 0.099  0.216 0.036*  0.231 0.054 
IgG  0.183 0.382  0.193 0.354  0.090 0.667  0.054 0.799 
         
B. t-test: differences of means 
Ranking order         
 first 103  108  89  87  
 later 108 0.332 110 0.588 87 0.769 84 0.139 
Duration MMF therapy         
 max 1 year 107  109  79  86  
 longer 102 0.302 106 0.639 89 0.205 88 0.317 
MMF currently         
 yes 100  105  88  89  
 no 106 0.131 108 0.404 86 0.753 86 0.266 
Nr acute rejections         
 0 100  106  89  90  
 1 or more 107 0.078 108 0.64 83 0.356 85 0.010a 
a p=0.05 
 
Discussion 
 
Children with a renal transplant have functional abnormalities of upper and lower 
airways in a higher proportion than expected, as shown in this multi-center, cross-
sectional and descriptive study. We observed pulmonary dysfunction in a significant 
proportion of our patients, in addition to four cases with clinically significant 
bronchiectasis. The findings from the symptom checklist only give a crude impression 
of the prevalence of airway complaints, as it has not been validated in Dutch patients 
with a kidney transplant. The impression is confirmed, however, by the more 
objective spirometry data: much more patients had disturbed pulmonary function than 
expected from the normal distribution in healthy children. The parameters most often 
aberrant were the FEV1/FVC, reflecting airway obstruction, and the MEF25, which 
may be indicative for obstruction of the more peripheral airways. FEV1/FVC is the 
most sensitive and reproducible of these. A dysbalance in production and clearance 
of pulmonary mucus may provide an explanation for this phenomenon.  
Possible causes of overproduction are: increased infectious load from 
immunosuppressive therapy, or diminished clearance due to damaged ciliary 
clearance or lower muscle power. In this respect, myopathy has been suggested as a 
cause of diminished lung volumes in patients on renal replacement therapy, possibly 
resulting from uremia before, and corticosteroid treatment after transplantation.11, 12 
We cannot rule out the possibility that our patients might have had pre-transplant 
abnormalities in lung function because relevant data are missing.  
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Lung function disturbance in children and adults with end-stage kidney disease has 
been reported before. It appears to be more pronounced during dialysis than after 
transplantation, and more during peritoneal than during hemodialysis.11-14 Paul et al. 
showed FEV1 in transplanted children to be inversely related to the duration of prior 
dialysis, and to be better than in conservatively treated or dialyzed patients11 So, in 
the event of pulmonary function declining over the dialysis period , with return to 
normal in the transplantation phase, one would expect gradually improving 
spirometry data over time elapsing since transplantation. The absence of a 
correlation in the currently studied population between time after transplantation and 
spirometry data does not support this hypothesis, but a longitudinal survey is needed 
to dismiss it. One longitudinal study in adults on lung function  before, and monthly 
for six months after transplantation, showed normalization of residual volume, but an 
unchanged, normal FVC and FEV1.15 
 
The need for lung function measurements is highlighted by the observation that 
abnormal values are not always accompanied by complaints. Remarkably, we only 
found a statistically significant association between FVC%, not the parameters for 
obstruction, and the level of lower airway complaints. Though the mean FVC% 
differed in patients with and without complaints, it lay well within the normal range in 
both groups. The isolated abnormal FVC% in two patients may reflect restrictive 
disease, or an incomplete expiratory manoeuvre. Lung volume studies are indicated 
to exclude restrictive disease. 
 
Obstructive pulmonary disease might also be caused by asthmatic symptoms. From 
this study it cannot be concluded to what extent asthma might contribute to our 
results, since we did not register its prevalence in our patients. Assuming the same 
prevalence as in the Dutch population (3.5% in 1999) and considering the continuous 
treatment of all patients with low-dose prednisolone, asthma can only have a small 
additional role in the 30% patients with obstructive lung function.16 
 
Body size affects spirometry data. We corrected for the smaller height of transplanted 
children by using the percentage of the spirometry data predicted for height and sex. 
One might argue that dysproportion between sitting height to body height may 
account for the lower pulmonary function values we found in part of the study 
population. However, this is unlikely since the sitting height to body height ratio 
hardly differs between transplanted children and healthy children: at onset of puberty 
this ratio is equal in both populations (0.51), at the end of puberty it is 0.49 in 
transplanted children and 0.52 in healthy children.17, 18 
 
The rationale for the current study was the alarming finding that 4 of 38 renal 
transplant patients in our institution showed bronchiectasis. These cases and the 5 
reported by Rook et al, all had been treated with MMF for a prolonged period of time, 
always in combination with prednisolone, with or without a third immunosuppressive 
drug.1, 2 The above mentioned previous study of lung function in renal transplant 
children was done in the pre-MMF era.11  
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During the 25 years before the introduction of MMF in the standard 
immunosuppression regime, neither of the two centers encountered any patient with 
post-transplantation bronchiectasis (in 200 and 1500 transplants, respectively, 
p<0.001). Pulmonary side-effects of MMF have been described, like coughing, 
bronchitis and shortness of breath.  
 
Two case reports document acute respiratory failure with pulmonary fibrosis and 
pneumonitis most likely due to MMF, but development of bronchiectasis has not been 
reported as an adverse effect of MMF.19, 20 In vivo, MMF depresses humoral 
immunity making patients more susceptible for infections.21 Therefore, one would 
expect lower IgG levels in MMF treated patients. We did not find this in the small 
number of patients in whom this was investigated. An alternative hypothesis 
proposes that MMF itself is a causative factor, e.g. influencing ciliary motility of 
pneumocytes. In both pathogenetic mechanisms retention of mucus in peripheral 
bronchi would be expected, accompanied by disturbance of the MEF25 in particular. 
The four index patients with bronchiectasis all showed a severely disturbed 
MEF25%. Therefore, an early decline in MEF25% should make us aware of potential 
risk for bronchiectasis. 
However, in contrast to our expectation based upon the index patients with 
bronchiectasis, in the current study population no association at all was shown 
between the use of MMF, and pulmonary complaints or lung function.  
 
Once structural abnormalities of the bronchi are present, even control of infection and 
inflammation may fail to arrest the progression to disabling irreversible airways 
obstruction. In contrast, the respiratory symptoms of the four Rotterdam children with 
bronchiectasis after renal transplant fortunately subsided after withdrawal of MMF, 
intensive treatment with antibiotics and DNAse, and physical therapy using a positive 
expiratory pressure (PEP) mask (data not published). The other 5 reported cases 
also clinically recovered, although structural changes seen on CT did not disappear.2 
 
Conclusion 
 
Children with a renal transplant may be at higher risk for respiratory complications, 
with bronchiectasis as a severe outcome. Therefore, we recommend spirometry as a 
useful tool for lung function monitoring during follow-up visits of children with a kidney 
transplant. Early signs of lung function decline should prompt referral to a pulmonary 
specialist for further evaluation by chest imaging studies and institution of aggressive 
management of pulmonary care and airway clearance to prevent progression to 
bronchiectasis. 
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Abstract 
 
Introduction 
Cardiovascular disease is the leading cause of death in children with end-stage renal 
disease. We investigated the presence of diastolic dysfunction in a group of patients 
on peritoneal dialysis or after renal transplantation. 
 
Methods and results  
Fourteen patients on peritoneal dialysis for a median of 1.4 years (range 0.1-5.3) and 
thirty nine patients with a functioning kidney transplant for a median time of 3.3 years 
(range 1.2-14.5) were studied and compared to controls. As assessed by 
echocardiography both groups showed diastolic dysfunction. The contribution of atrial 
contraction (A) to the mitral inflow was relatively high in both patient groups (E/A ratio 
in the controls 2.27 ± 0.61; transplant 1.82 ± 0.58; dialysis 1.57 ± 0.73; p<0.001). The 
ratio of early mitral inflow (E) to the early tissue movement of the mitral annular ring 
(E’) was increased in the patient groups, indicating diastolic dysfunction (E/E’ ratio in 
controls 7.97 ± 1.46; transplant 9.49 ± 1.71; dialysis 11.90 ± 2.11; p<0.001). Left 
ventricular mass was only increased in the transplant patients (controls 61 ± 13 g/m2; 
transplant 105 ± 28 g/m2; p<0.001). High PTH levels, more prevalent in dialysis 
patients, are associated with abnormal E/A ratios. 
 
Conclusions  
Abnormalities in diastolic function are present in both peritoneal dialysis and renal 
transplanted patients. In the dialysis group abnormalities in calcium-phosphate 
metabolism are a major risk factor, whereas the transplanted patients show an 
increased left ventricular mass. 
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Introduction 
 
Cardiovascular disease is the leading cause of death in patients who started renal 
replacement therapy in childhood.1-4 This includes cerebrovascular accident, 
cardiomyopathy, arrhythmias and cardiac arrest from unknown origin. Early signs of 
cardiac disease in renal patients include left ventricular hypertrophy and diastolic 
dysfunction of the left ventricle.3 These abnormalities have been shown to develop in 
children already at the time of mild to moderate chronic renal insufficiency, and 
progress as renal function deteriorates.5,6 They have been described in patients on 
chronic dialysis as well as after renal transplantation. Hypertension and prolonged 
dialysis are predictors for cardiovascular mortality.4 Risk factors for cardiovascular 
disease in children include abnormalities in calcium-phosphate metabolism, nephrotic 
syndrome, anemia and long-term use of immunosuppressive agents, such as 
corticosteroids and calcineurin inhibitors.1,7 Many of these risk factors improve after 
transplantation. In the present study we investigated children on chronic peritoneal 
dialysis or after renal transplantation. All patients underwent both conventional 
echocardiography and measurement of tissue Doppler variables. These may help to 
determine early onset diastolic dysfunction. 
We hypothesized that the cardiovascular abnormalities in transplanted patients may 
be less prominent than in patients on dialysis and that left ventricular hypertrophy is a 
major risk factor in developing diastolic dysfunction. 
 
Methods 
 
A cross-sectional study of dialysis and transplanted patients in a tertiary pediatric 
nephrology department in a single university hospital in Rotterdam, the Netherlands 
was performed. The study population consisted of 53 patients with a median time on 
renal replacement therapy of 4.3 year (range 0.1-16.0), and 88 healthy controls. 
Thirty nine patients had a functioning kidney transplant for a median time of 3.3 years 
(range 1.2-14.5), 14 patients were on peritoneal dialysis for a median of 1.4 years 
(range 0.1-5.3). 
The patients were followed by the outpatient nephrology clinic, and all underwent 
yearly echocardiography as part of their medical follow-up. The controls were healthy 
school children without any medication or illness known to influence renal or cardiac 
function and underwent echocardiography only. The institutional review board of the 
Erasmus Medical Center, Rotterdam, The Netherlands approved the study, and 
written informed consent was obtained from all controls and their parents. Patients’ 
medical records were reviewed for age, cause of renal failure, duration of peritoneal 
dialysis or time after renal transplantation. Calcium-phosphate disturbances were 
prevented as much as possible by the use of dialysate with a physiologic calcium 
concentration (1.25 mmol/l), a protein-restricted diet, phosphate binding medication 
with the meals (usually sevelamer), and alphacalcidol as vitamin D analogue. In 
transplanted patients 24 hr ambulatory blood pressure monitoring was performed at 
the same occasion as the cardiac evaluation, by using an oscillometric device 
(SpaceLabs monitor, 90207; SpaceLabs Medical Inc., Redmond, Washington, USA).  
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dialysis or time after renal transplantation. Calcium-phosphate disturbances were 
prevented as much as possible by the use of dialysate with a physiologic calcium 
concentration (1.25 mmol/l), a protein-restricted diet, phosphate binding medication 
with the meals (usually sevelamer), and alphacalcidol as vitamin D analogue. In 
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the same occasion as the cardiac evaluation, by using an oscillometric device 
(SpaceLabs monitor, 90207; SpaceLabs Medical Inc., Redmond, Washington, USA).  
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Measurements were performed every 30 minutes during daytime and every hour 
during the night. Bed-time of the child was used as night-time. Hypertension was 
scored as a mean blood pressure above the 95th percentile for age and sex8 during 
both systole and diastole and during both day and night.  
 
Serum creatinine, calcium, phosphorus, intact parathyroid hormone (iPTH), and 
haemoglobin determined for each patient at time of echocardiography. GFR was 
estimated using the Schwartz formula, modified to conform with local laboratory 
practice.9,10 
 
Echocardiography was performed using standard techniques on a commercially 
available machine (Philips Sonos 5500, Andover, MA, USA). These included M-mode 
measurement of left ventricular wall and septum, mitral inflow parameters, and 
pulsed Tissue Doppler estimates of the basal part of the left ventricle. 
Left ventricular mass (LVM) was measured by two-dimensional directed M-mode 
echocardiography according to the American Society of Echocardiography criteria11 
LV systolic performance was assessed by calculation of shortening fraction (SF) and 
heart rate-corrected velocity of circumferential shortening. 
Transmitral flow was obtained with pulsed wave Doppler at the leaflet tips. The 
velocity of early mitral inflow (E), the velocity of the mitral inflow during active 
contraction (A), the E/A ratio and the decelaration time (Dt) were also calculated.12 
 
Pulsed wave Doppler tissue velocities were obtained at the cardiac base in the apical 
4-chamber orientation from 3 locations: the lateral mitral annulus; the interventricular 
septum; and the lateral tricuspid annulus. Tissue doppler measurements from each 
of these myocardial wall segments included peak systolic annular velocity (S), peak 
early diastolic annular velocity (E’) and peak late diastolic annular velocity (A) waves. 
The ratio of early mitral inflow measured by Doppler to peak early diastolic annular 
velocity (E/E’) was measured as well.  
 
Statistics 
Statistical analysis was performed with SPSS 11.5 (SPSS, Inc., Chicago, Il). Values 
are presented as mean ± SD unless stated otherwise. A two sample t-test was used 
to compare the means of continuous variables with a normal distribution, and Mann-
Whitney test for continuous variables without normal distribution. Categorical values 
were compared using the chi-square test or Fisher exact test. The correlations 
between variables were assessed by Spearman correlation analysis. A p value < 
0.05 was considered statistically significant.   
 
Results 
 
Patient characteristics (Table 1) 
The peritoneal dialysis patients were significantly younger than the transplant 
patients. Consequently, length and weight were lower as well. The main causes of 
end-stage renal disease in the transplanted patients were congenital anatomic 
abnormalities (n=16, 43%) and glomerulonephritis (n=14, 38%).  
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In the dialysis patients the main causes were congenital anatomic abnormalities 
(n=5, 36%), glomerulonephritis (n=4, 29%), and congenital nephrotic syndrome (n=4, 
29%). Phosphate and iPTH levels were significantly higher in dialysis patients as 
compared to transplant patients, as were urea and creatinine levels. The glomerular 
filtration rate in the transplanted patients had a mean value of 54 ml/min.1.73m2 
(range 16-107). 
 
Table 1. Patient characteristics 
 Controls NTX PD C vs.N C vs. P N vs. P 
Age  11 ± 1  14 ± 4   8 ± 6 ns  <0.01 
Length 149 ± 10  147 ± 25 113 ± 32 ns   <0.001   <0.001 
Weight   40 ± 10    49 ± 19   24 ± 15 <0.01   <0.001   <0.001 
       
Hb (mmol/l)    7.5 ± 1.1   7.2 ± 1.0  ns  
Ht (l/l)    0.35 ± 0.05   0.33 ± 0.05  ns  
Urea (mmol/l)    9.9 ± 3.2 14.7 ± 6.0   <0.001  
Creatinine (µmol/l)  126 ± 60   692 ± 367   <0.001  
Phosphate (mmol/l)    1.39 ± 0.25   1.69 ± 0.48  <0.01  
Calcium (mmol/l)    2.47 ± 0.13   2.45 ±. 015  ns  
Ca.PO4 product    3.42 ± 0.57   4.17 ± 1.40  <0.01  
iPTH (pmol/l)   13.0 ± 9.2   36.7 ± 35.9    <0.001  
 
24 hour ambulatory blood pressure registration  
Twenty-four hour blood pressure monitoring was performed in the transplanted 
patients only. Blood pressure above the 95th percentile was observed in 13 (35%) for 
daytime systolic blood pressure, in 9 (24%) for daytime diastolic blood pressure, in 
13 (37%) for nighttime systolic blood pressure and in 11 (31%) for nighttime diastolic 
blood pressure. In 10 patients mean systolic and diastolic blood pressure during both 
day and night were below p95, in 5 all these values were above p95. 
 
Left ventricular mass (Table 2) 
In the transplanted patients both left ventricular posterior wall and interventricular 
septum were thicker than in the controls. This resulted in an increased left ventricular 
mass. In contrast, mean left ventricular mass of dialysis patients did not differ from 
controls. LV mass above the 95th percentile of the controls was present in 3/14 PD 
patients (22%), and 30/39 NTX patients (73%) (p<0.01). 
 
Table 2. M-mode values of left ventricular function 
 Controls NTX PD C vs.N C vs. P N vs. P 
IVSd   6.6 ± 1.2  10.4 ± 2.3  7.3 ± 2.1 <0.001 ns   <0.001 
LVPWd   5.8 ± 1.3   9.0 ± 2.0  6.7 ± 2.1 <0.001 ns <0.01 
LVmass   61 ± 13 105 ± 28  72 ± 25 <0.001 ns   <0.001 
SF   0.37 ± 0.05   0.38 ± 0.12   0.36 ± 0.11 ns ns ns 
LVED 44 ± 4 45 ± 5 33 ± 9 ns <0.001   <0.001 
LVES 27 ± 3 27 ± 4 20 ± 6 ns <0.001   <0.001 
VCFC   1.17 ± 0.19   1.21 ± 0.22   1.25 ± 0.29 ns ns ns 
IVSd = thickness of the interventricular septum in diastole (mm), LVPWd = thickness of the left 
ventricular posterior wall in diastole (mm), LVmass = left ventricular mass (g/m2), SF = shortening 
fraction (%), LVED = left ventricular enddiastolic dimension (mm), LVES = left ventricular endsystolic 
dimension (mm), VCFC = Velocity of circumferential fiber shortening, corrected for heart rate 
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Systolic function as assessed by shortening fraction was similar between patients 
and controls. There was a significant correlation in the transplanted patients between 
24-hour systolic blood pressure and left ventricular mass (R=0.38; p<0.05). 
 
Doppler parameters (Table 3, Figures 1 and 2) 
Diastolic function as assessed by the mitral E/A ratio was decreased in both 
transplant and dialysis patients. This abnormality was more prominent in the dialysis 
patients. Right ventricular function in all patients was similar to the control population. 
 
Table 3. Mitral inflow parameters 
 Controls NTX PD C vs.N C vs. P N vs. P 
MV-E 1.02 ± 0.16 0.98 ± 0.17 0.97 ± 0.24 ns ns ns 
MV-A 0.47 ± 0.12 0.57 ± 0.14 0.69 ± 0.28   <0.001 <0.05 ns 
MV E/A 2.27 ± 0.61 1.82 ± 0.58 1.57 ± 0.73   <0.001 <0.01 ns 
DecTime 0.16 ± 0.03 0.17 ± 0.04 0.18 ± 0.04 <0.05 ns ns 
       
TV-E 0.73 ± 0.16 0.64 ± 0.13 0.64 ± 0.18 <0.01 ns ns 
TV-A 0.40 ± 0.12 0.39 ± 0.14 0.44 ± 0.21 ns ns ns 
TV E/A 1.94 ± 0.57 1.75 ± 0.54 1.76 ± 0.91 ns ns ns 
DecTime 0.17 ± 0.03 0.17 ± 0.05 0.15 ± 0.05 ns ns ns 
MV-E = early mitral inflow (m/sec), MV-A = active mitral inflow (m/sec), MV E/A = ratio of early mitral 
inflow to active mitral inflow, Dec Time = deceleration time (msec), TV-E = early tricuspid inflow 
(m/sec), TV-A = active tricuspid inflow (m/sec), E/A = ratio of early tricuspid inflow to active tricuspid 
inflow 
 
Figure 1.         Figure 2. 
 
Tissue Doppler velocities (Table 4, Figures 3 and 4) 
All tissue Doppler values were smaller in the patient groups than in the controls, both 
at the basal part of the left ventricular posterior wall as well as at the basal part of the 
interventricular septum. Especially a lower E wave and an increased E/E’ ratio were 
seen in the patients. Also for the tissue Doppler values differences from controls 
were more prominent in the dialysis patients. iPTH was inversely related to E/A ratio 
(R=-0.34; p<0.05). This correlation was not found between iPTH and E/E’ ratio. 
Mitral inflow in a healthy control, 
showing an E-peak of 0.91 m/sec, 
an A-peak of 0.36 m/sec and an E/A 
ratio of 2.5 
Mitral inflow in a patient with a renal 
transplant, showing an E-peak of 1.21 
m/sec, an A-peak of 0.59 m/sec and an 
E/A ratio of 2.0. 
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The E/E’ ratio was significantly higher in patients with blood pressure above the 95th 
percentile (p<0.01). Significance was reached for both systolic and diastolic blood 
pressure during daytime as well as during nighttime. In transplanted patients left 
ventricular mass was significantly correlated with E/E’ ratio (R=0.36, p<0.05).Since 
there was an age difference between dialysis and transplanted patients we tested the 
age effect in the normal controls. Both inflow parameters and tissue Doppler values 
were independent of age. Only left ventricular enddiastolic and endsystolic 
dimensions increased with age and body weight. 
 
Table 4. Tissue Doppler parameters 
 Controls NTX PD C vs.N C vs. P N vs. P 
TDI-sys LV 0.11 ± 0.08 0.08 ± 0.02 0.07 ± 0.02 <0.01 <0.001 ns 
TDI-E LV 0.17 ± 0.04 0.15 ± 0.03 0.13 ± 0.04 <0.001 <0.01 ns 
TDI-A LV 0.05 ± 0.03 0.06 ± 0.02 0.06 ± 0.02 ns ns ns 
TDI E/E’ 6.22 ± 2.49 6.70 ± 1.76 8.20 ± 2.98 ns <0.05 ns 
       
TDI-Sys IVS 0.07 ± 0.01 0.06 ± 0.01 0.06 ± 0.02 <0.001 <0.05 ns 
TDI-E IVS 0.13 ± 0.02 0.10 ± 0.02 0.08 ± 0.02 <0.001 <0.001 <0.001 
TDI-A IVS 0.05 ± 0.02 0.05 ± 0.01 0.05 ± 0.02 ns ns ns 
TDI E/E’ 7.97 ± 1.46 9.49 ± 1.71 11.20 ± 2.11 <0.001 <0.001 <0.01 
TDI-Sys LV = systolic movement of the basal part of the posterior wall of the left ventricle, TDI-E LV = 
early diastolic movement of the basal part of the posterior wall of the left ventricle, TDI-A LV = late 
diastolic movement of the basal part of the posterior wall of the left ventricle, TDI-Sys IVS = systolic 
movement of the basal part of the interventricular septum, TDI-E IVS = early diastolic movement of 
the basal part of the interventricular septum, TDI-A IVS = late diastolic movement of the basal part of 
the interventricular septum  
 
Figure 3.      Figure 4. 
Discussion 
 
In our pediatric patients we noted significant cardiac abnormalities, which may 
underly the well known increased cardiovascular risks associated with end-stage 
renal disease in childhood. The main findings are the preservation of systolic function 
in all patients, an increase in left ventricular mass in the transplanted patients, and 
not in the peritoneal dialysis patients, and diastolic dysfunction of the left ventricle in 
all patients, but more prominent in the dialysis patients.  
Tissue Doppler of the basal part of 
the interventricular septum in a 
healthy control. The E’-wave is 13 
cm/sec. The E/E’ ratio is 7.0. 
Tissue Doppler of the basal part of 
the interventricular septum in a renal 
transplant patient. The E’-wave is 9 
cm/sec. The E/E’ ratio is 13.5 
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A correlation was found between systolic blood pressure and left ventricular mass in 
transplanted patients, and between increased iPTH and diastolic dysfunction. An 
increased E/E’ ratio was found in patients with hypertension, and was correlated to 
left ventricular mass in transplanted patients. 
 
Diastolic dysfunction of the left ventricle, as observed in both transplanted as well as 
dialyzed patients, has been reported previously.5,12,13,14 The underlying mechanisms, 
however, remain unclear. Diastolic dysfunction is one of the first signs of 
cardiovascular disease in renal patients, eventually leading to death in many 
patients.1,4 Correlations between diastolic dysfunction and increased left ventricular 
mass, like the one we found in transplanted patients, have frequently been reported. 
In the present study we found an increased left ventricular mass in the transplanted 
patients, but not in the dialyzed patients, who showed left ventricular hypertrophy in 
only 22%. Others found an increased left ventricular mass already in pre-dialysis 
patients.6,7 The left ventricular mass has been reported to increase gradually before 
and during the time on chronic dialysis treatment.7 During this period left ventricular 
mass is especially related to the presence of systolic hypertension.7 However, most 
studies in children reflect the changes during hemodialysis. In four reports the 
contribution of PD patients to the dialysis population was only 25% (16/61).3,5,13,15 
Further comparison between hemodialysis and peritoneal dialysis patients has to be 
made. Despite the normal LV mass our dialysis patients showed inferior diastolic 
function of the left ventricle compared to the transplanted patients. This suggests that 
left ventricular hypertrophy is not the only cause of diastolic dysfunction. An 
increased PTH level was present in our dialysis patients, and this was associated 
with diastolic dysfunction. Dysregulation of calcium phosphate metabolism in end-
stage renal disease may lead to calcification of arterial walls, resulting in arterial 
stiffness. Mitsnefes et al, who studied cardiovascular disease in children in all phases 
of chronic kidney disease, showed a relationship between arterial stiffness and poor 
diastolic function in dialysis patients.15 Since calcium-phosphate metabolism 
normalises with renal function after kidney transplantation, new vascular 
calcifications are not expected to develop. Nevertheless existing calcified vascular 
lesions are not expected to diminish considerably. 
After renal transplantation a gradual decline of the increased left ventricular mass 
has been reported, although the prevalence of left ventricular hypertrophy remained 
unchanged.16 Others did not find any change in left ventricular hypertrophy or 
diastolic dysfunction after renal transplantation.2,17  
Further studies are necessary to unravel these mechanisms, and to give insight in 
the cardiovascular changes that occur when a dialysis patient receives a kidney 
transplantation. 
 
Limitations of the study 
Since the present investigation is a cross-sectional study, differences between 
dialysis and transplant patients may be due to differences in patient characteristics. 
Only long-term follow-up studies can answer the question if subsequent 
transplantation in dialysis patients will improve left ventricular hypertrophy and 
diastolic dysfunction found in the dialysis patients in the present study. 
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Age differences between the transplant and dialysis patients may influence 
echocardiographic parameters. However, when the youngest and oldest controls 
were compared with each other, corresponding to the age ranges of the dialysis and 
transplanted patients, the only differences found were small increases in left 
ventricular enddiastolic dimension and in left ventricular endsystolic dimension 
according to age and weight, whereas all other inflow and tissue doppler values were 
similar. This makes this factor an unlikely explanation for the found differences 
between dialysis and transplanted patients. 
 
Conclusions 
 
Abnormalities in diastolic function are present in both peritoneal dialysis and renal 
transplant patients. Risk factors associated with these abnormalities are different 
between the groups, abnormalities in calcium phosphate metabolism being most 
prominent in dialysis patients. In the transplant group an increased left ventricular 
mass is prominent, probably related to arterial hypertension and toxicity of 
immunosuppressive agents. Measures to improve cardiovascular function in patients 
with end stage renal disease should account for these differences between dialysis 
and transplant patients. 
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Limitations of the study 
Since the present investigation is a cross-sectional study, differences between 
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Only long-term follow-up studies can answer the question if subsequent 
transplantation in dialysis patients will improve left ventricular hypertrophy and 
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Age differences between the transplant and dialysis patients may influence 
echocardiographic parameters. However, when the youngest and oldest controls 
were compared with each other, corresponding to the age ranges of the dialysis and 
transplanted patients, the only differences found were small increases in left 
ventricular enddiastolic dimension and in left ventricular endsystolic dimension 
according to age and weight, whereas all other inflow and tissue doppler values were 
similar. This makes this factor an unlikely explanation for the found differences 
between dialysis and transplanted patients. 
 
Conclusions 
 
Abnormalities in diastolic function are present in both peritoneal dialysis and renal 
transplant patients. Risk factors associated with these abnormalities are different 
between the groups, abnormalities in calcium phosphate metabolism being most 
prominent in dialysis patients. In the transplant group an increased left ventricular 
mass is prominent, probably related to arterial hypertension and toxicity of 
immunosuppressive agents. Measures to improve cardiovascular function in patients 
with end stage renal disease should account for these differences between dialysis 
and transplant patients. 
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General discussion 
 
Kidney transplantation is the preferred mode of treatment of children with end stage 
renal disease. Unlike dialysis modalities, it replaces most functions of the native 
kidneys. Moreover, the burden of treatment following transplantation is lighter than 
during dialysis. Still, renal replacement therapy is a lifelong affair, at best made up of 
decades of transplantation alternated with months of dialysis. It is notably the 
extrarenal comorbid conditions – such as cardiovascular disease, bone disease, 
disturbed growth, and developmental problems – that determine life expectancy of a 
child on renal replacement therapy. These conditions may improve after 
transplantation, given a good clearance. Nevertheless, transplantation brings along 
comorbidity of its own, not least caused by toxic side effects of immunosuppressive 
therapy. These mostly affect the cardiovascular system and the skeleton. In addition, 
height growth may not catch up as hoped for, resulting in a below normal final height. 
 
The studies compiled in this thesis aimed to improve medical outcome of children 
undergoing kidney transplantation in the Netherlands. Most studies were performed 
within the framework of the Netherlands - Antwerp collaboration. The results support 
the assumption that outcome is determined by 1. the child’s condition at the time of 
transplant (Chapter 5), 2. success of transplantation in terms of improvement of 
patient and graft survival (Chapters 3 and 4), and 3. comorbidity (Chapter 6). Here, 
we will explore how adaptation of protocols, new clinical trials, and organizational 
streamlining may hold promising potential for better outcome of kidney 
transplantation in children. Issues to be considered are: pre-transplant factors, 
source of the allograft, outcome of transplantation, patient survival, comorbidity and 
logistics. 
 
Pre-transplant factors 
 
Many children at the verge of kidney transplantation already have a long and 
complicated medical history. It begins with the primary kidney disease. Some of 
these diseases are likely to recur in the grafted kidney, other may lead to distinctive 
post-transplant complications, such as in diseases with lower urinary tract 
dysfunction, congenital nephrotic syndrome, Alport disease. Chronic severe 
proteinuria, as seen, for example, in focal segmental glomerulosclerosis, raises the 
risk of vascular disease, due to dyslipidemia and hypertension. Patients with chronic 
nephrotic syndrome typically will have been treated with cyclosporine for years. 
Patients with long-standing renal disease, especially those on dialysis and with 
hypertension, are at risk for cardiac and vascular lesions. One of the predictors of 
cardiovascular disease is hyperparathyroidism. Hyperparathyroidism is part of renal 
osteodystrophy, another form of comorbidity of renal disease, which may occur with 
or without skeletal deformities. Growth is frequently disturbed, in many cases despite 
temporary treatment with growth hormone.  
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A number of factors place a heavy psychoemotional burden on these children: 
dietary restrictions, in combination with loss of appetite, and the obligation to take 
medication, loss of freedom due to the dialysis treatment, deteriorating physical 
condition. And then, parents’ anxiety for the well-being of their child may be an 
emotional load for the child as well.Severe renal failure and chronic dialysis – while 
the child is awaiting transplantation – seriously hampers both school performance 
and the development of self-esteem, independency and normal psychosocial skills. 
All these factors together may negatively affect quality of life and social performances 
for life, and make the child dependent on ongoing psychosocial support. 
 
Limiting pre-transplant comorbidity to a minimum would seem all-important for the 
outcome of transplantation. Though not always easy, treatment should aim at 
normalizing blood pressure and biochemical parameters of bone disease. Good 
nutrition, as well as correction of metabolic disturbances such as acidosis and 
hyperparathyroidism, contributes to better growth. Tube feeding may be necessary to 
avoid malnutrition, especially in infants and toddlers. Proper management of bladder 
function, e.g. in children with urethral valves, is essential as well.  
In 2007 a study has started aimed at improving quality of care of patients on renal 
replacement therapy by means of central registration and peer reviewing. This is a 
multicenter cohort study in all pediatric dialysis centers in the Netherlands and 
Belgium, by the name RICH-Q: Renal Insufficiency Therapy in Childhood – Quality 
assessment and improvement (www.rich-q.nl).   
 
Ultimately, the best way to improve comorbidity of end-stage renal disease is to limit 
the duration of it by early transplantation. For children in particular it is critical to keep 
the waiting time for transplantation as short as possible. They are at a critical stage of 
development, both physically and psychosocially, which makes them vulnerable to 
lifelong damage – more than adults. From a health care perspective such damage is 
relatively costly since children’s life expectancy obviously is longer than that of 
adults. The waiting time – from the moment that renal transplantation is indicated 
until the moment the donor kidney becomes available – has gradually increased 
during recent years. A dual cause explains this effect: a drop in number of potential 
donors combined with more and more adult patients requiring transplantation. 
 
Source of the allograft 
The strategy to reduce the waiting time and the dialysis period is threefold: curbing 
the influx of new patients, raising the numbers of donors and striving at pre-emptive 
transplantation in combination with earlier start of searching for a donor.  
 
Concerning the influx of new patients: almost half of cases of end-stage renal 
disease in children are due to congenital disease, some based on consanguinity, and 
half to acquired diseases. Regrettably, better understanding of these disorders has 
not yet reduced the frequency of end-stage renal disease in this age group. Large 
scale international prospective studies are needed to answer the question whether 
general interventions, such as inhibition of the RAAS system, could slow down the 
progression of renal failure in children.  
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Prevention of diabetes mellitus might be more effective, however, as this disease 
causes end-stage renal disease in more and more adults, thereby inflating the 
waiting list. In contrast, improvement in graft survival may gradually reduce numbers 
of patients returning on the waiting list.  
 
Several methods could be proposed to enlarge the donor pool. First of all, by 
increasing the proportion of living donors from the current 30% to the 60% level 
achieved in the USA.1,this thesis This might prove feasible by further encouraging family 
members, including grandparents, by considering ABO incompatible donor-recipient 
combinations, and by including pediatric recipients in the national program for cross-
over exchange of potential living donors.2 Since the start of this program in 2004, 100 
more patients could be transplanted with a living donor graft.3 The total number of 
living donated kidney transplantations last year increased as well, from 278 in 2006 
to 355 in 2007.3  
Second, living adult donors could be allowed for young children, despite the surgical 
implications. Experience with this kind of transplantation is accumulating. These 
youngest recipients will require extra intensive care as the circulating volume must be 
significantly increased in the presence of young children’s relatively low blood 
pressure. In these children, plasma creatinin level will be a less sensitive indicator of 
rejection, due to the large functional reserve of such a kidney. This would mandate 
surveillance biopsies to detect subclinical rejection of the allograft.4 As such 
transplantations will still be rare, it would be desirable to have them performed by a 
single team in the Netherlands, composed of dedicated surgeons, anesthetists, 
intensivists and pediatric nephrologists.  
 
More deceased donors could be acquired in the Netherlands, as demonstrated by 
Ploeg et al.5 Donors may be missed for several reasons. The delicacy of putting a 
donation request to the next of kin just after the death of their relative is one reason. 
The presence of well trained procurement coordinators will facilitate the donation 
request. Currently, in 70% of these cases, however, relatives do not consent in organ 
donation.3 This is related to the fact that less than one third of Dutch inhabitants has 
registered in the donor registry, and fewer still have registered positively for organ 
donation. Repetitive reminders might lead to more potential donors. Regrettably, a 
proposal to change the law from an informed consent system to a presumed consent 
system was rejected. Finally, the need to have a team available to harvest the organs 
heavily draws on human resources. The current organization with regional 
procurement teams on duty aims at improving this situation. Nevertheless, thanks to 
the efforts of the Dutch Transplantation Foundation, recent publicity generated by the 
‘De grote donorshow’ on television, and NIGZe publicity campaigns, more people 
have registered as potential donors. In parallel, numbers of transplantations with 
kidneys from deceased donors rose from 360 in 2006 to 435 in 2007. Numbers of 
non heart beating donors did not change.  
Recently Eurotransplant adopted a ‘Young for young’ policy, implying that kidneys of 
young donors will preferably be used for young recipients.  
                                               
e Nationaal Instituut voor Gezondheidsbevordering en Ziektepreventie 
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However, so far none of the 16 available kidneys from donors younger than 10 years 
has been allocated to a child (personal communication Dr J de Boer, Eurotransplant). 
This policy might become more effective through easing of the HLA-match 
requirement of at least 2 DR-matches and extending the age-criteria for donor and 
recipient up to 16 years. Such measures will be of very little consequence for the 
waiting time of adults, given their at least 30-fold bigger population.  
 
Kidneys from very young donors, from 1 to 5 years of age, can be used more 
effectively. Many centers discard these kidneys. Nevertheless, provided these 
kidneys are of relatively large size, they can be transplanted as single grafts into 
pediatric patients. Relatively small kidneys can still be used for children, when 
transplanted en bloc.6-8 
 
Finally, pre-emptive transplantation and starting the search for a suitable donor prior 
to the actual start of dialysis are measures that will shorten the dialysis episode and 
thus alleviate its impact on children’s physical and psychosocial outcomes. Such pre-
emptive transplantation in Dutch children has been associated with superior graft 
survival (Chapter 5). 
 
Outcome of transplantation 
 
Graft survival 
The past 20 years have seen impressive improvement in graft survival and fall in 
rejection rate (Chapters 2 to 5). Findings parallel those of large registries, e.g. 
NAPRTCS. The latest figure of 1 year graft survival, 92%, corresponds to the 91-92% 
in recent reports of the OPTN/SRTR and NAPRTCS registries.1,9 This improvement 
may largely be explained by the expansion of immunosuppressive treatment and the 
use of more modern agents. In addition, collaboration between the centers, with 
meetings aimed at finding consensus on protocols, and the faster developing 
experience with larger numbers of patients, will have contributed to these results. 
Unfortunately, the extent of this contribution is hardly measurable. The incidence of 
acute rejections is slightly higher than the 16% in the latest NAPRTCS report.1 This 
may be due to the relatively low rates of biopsy proven acute rejection in our studies. 
NAPRTCS surveys for that matter do not report proportions of biopsy proven acute 
rejections. 
The 81% graft survival after 5 years in the cohort 1998-2004 (data not shown) – 
tallies with the 79% reported by the NAPRTCS, if calculated to the same LD/DD 
distribution as in our population.1 
 
Thrombosis of the graft 
We found that 8% of grafts failed within the first year. Most of these graft failures 
were caused by thrombotic events, which partially might have been avoided. 
Incidence of thrombotic events (4.3%) have remained unchanged over the past two 
decades, despite the introduction of a shared protocol on antithrombotic prophylaxis 
in high-risk transplantations.  
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acute rejections is slightly higher than the 16% in the latest NAPRTCS report.1 This 
may be due to the relatively low rates of biopsy proven acute rejection in our studies. 
NAPRTCS surveys for that matter do not report proportions of biopsy proven acute 
rejections. 
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tallies with the 79% reported by the NAPRTCS, if calculated to the same LD/DD 
distribution as in our population.1 
 
Thrombosis of the graft 
We found that 8% of grafts failed within the first year. Most of these graft failures 
were caused by thrombotic events, which partially might have been avoided. 
Incidence of thrombotic events (4.3%) have remained unchanged over the past two 
decades, despite the introduction of a shared protocol on antithrombotic prophylaxis 
in high-risk transplantations.  
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NAPRTCS reports a lower rate of 1.85%, in striking contrast with the 10% observed 
in the Great Ormond Street Hospital for Children in London.1,10,11 In our population 
we could not confirm the previously reported negative association with pre-transplant 
peritoneal dialysis, nor the protective effect of IL-2 receptor antagonists on the 
incidence of thrombosis.10,12-14 We expect that several antithrombotic measures 
might be effective in lowering the rate of graft failure due to thrombosis. For one, 
more aggressive perioperative fluid management seems promising, provided that 
central venous pressure is monitored. Another option is limiting cold and warm 
ischemia times. No longer considered urgent, kidney transplantation usually is 
performed at the end of the surgical program. Together with more efficient allocation 
logistics of Eurotransplant the average cold ischemia time in the deceased donor 
transplants of our last cohort was 20 hours. As graft loss due to thrombosis is 
associated with longer cold ischemia time, surgery should be scheduled such that 
ischemia times are shortened, especially when young donors and/or recipients are 
involved.The second warm ischemia time is dependent on quality of the graft and 
blood vessels and on the surgical technique.  
Widening the criteria for anti-thrombosis prophylaxis might help to prevent 
thrombosis. Pre-transplant evaluation of thrombophilia could identify extra patients at 
risk for thrombosis.15 Another alternative would be prophylaxis for all patients. This 
could result, however, in hemorrhagic complications, also in patients who would not 
need anticoagulation therapy. Summarizing, as possible measures to reduce graft 
loss due to thrombosis we propose extended pre-transplant evaluation of thrombotic 
risk factors, improvement of perioperative fluid management, and reduction of 
ischemia times.  
A report from our group is in preparation on graft thrombosis in our patient 
population, and the effects of two different approaches to thrombosis prophylaxis.  
 
Delayed graft function 
Partly overlapping with the above mentioned problem is that of ischemic injury of the 
donor organs, leading to delayed graft function, which occurred in 10-13% of 
transplants (Chapter 5). Wider donor criteria may have contributed to this 
phenomenon: the use of non heart beating kidneys is associated with delayed graft 
function, and even early graft loss.16 The increase in number of non heart beating 
donation over the last decade unfortunately has been associated with a decrease in 
number of heart beating donors. Non heart beating donor kidneys with a prolonged 
first warm ischemia time of more than 30 minutes are associated with early graft loss 
due to ischemic injury. Moreover, for a certain time before cardiac arrest the donor’s 
circulation will not function optimally. It would seem very important therefore, and the 
trend apparently was set in 2007, to stimulate heart beating donation. Medical teams 
should not decide for non heart beating donation if heart beating donation is a 
feasible option. As in the case of thrombosis, shortening of cold ischemia time and 
more aggressive fluid management may improve delayed graft function as well.  
One would expect that avoiding vasoconstrictive calcineurin inhibitors shortly after 
the ischemia/reperfusion injury should diminish the incidence of delayed graft 
function This was not the case, however, in our study described in chapter 5. 
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Immunosuppressive therapy 
Our study described in Chapter 5, showed fewer acute rejections after induction with 
basiliximab with delayed onset of cyclosporine therapy. Nevertheless, this delay in 
the start of cyclosporine did not affect the occurrence of delayed graft function, nor 
did it improve graft function or graft survival twelve months after transplantation. It is 
too early to tell, however, whether improvement is possible on the longer term. The 
question arises whether initial immunosuppressive therapy for all patients should 
consist of this quadruple, sequential therapy, or whether it should be reserved for 
selected patients, e.g. those receiving deceased donor transplants, or even those 
undergoing retransplants. The addition of basiliximab brings along extra costs, which 
are not counterbalanced by the postponed onset of cyclosporine. Maintenance 
immunosuppressive therapy should ideally be tailored to the patient’s immunological 
profile. We showed that the combination MMF and corticosteroids beyond 1 year 
post-transplant leads to more stable glomerular filtration rate than does treatment 
with cyclosporine and corticosteroids (Chapter 6). Still, as we observed late acute 
rejection episodes in 2 of 18 patients on MMF, there is much to say for restricting this 
regimen to patients at low risk of acute rejection, e.g. recipients of living donor grafts. 
 
Suspected noncompliance to immunosuppressive therapy calls for discussion of the 
patient’s concerns about specific side effects of the medication. If, for instance, 
cosmetic side effects are feared, maintenance therapy could consist of tacrolimus 
and MMF, without corticosteroids or cyclosporine. As an added benefit, this 
combination will also improve blood pressure and bone composition. Noncompliant 
patients will benefit from the once daily formula of tacrolimus that may be available in 
the near future. Minimizing immune therapy requires caution in patients who show 
strong immune reactivity to other HLA-antigens, measured as panel reactive 
antibodies, or in those with a high number of HLA-mismatches with the donor. In 
patients with chronic allograft nephropathy who are on cyclosporine therapy, a 
decrease in dosage of cyclosporine or a switch to sirolimus is recommended.17 
Substitution of calcineurin inhibitors by sirolimus could also be considered in the case 
of toxicity.  
 
Compliance with the prescribed medication 
It has been suggested that adolescent non-compliance lies at the basis of the 
outcome of transplantation in this age group, i.e. the least favorable outcome as 
compared with younger children. Non-compliance covers the spectrum from skipping 
a pill every now and then to systematically refusing to take them. The medical and 
social teams would do well to support the adolescent in taking responsibility for his 
own life, while gradually separating from his parents. Negotiating the appropriate 
extent of parental involvement – neither overprotective, nor lacking support – is a 
challenge for all parties. Acceptable, individualized, immunosuppressive regimens 
could be designed when adolescents are given room to freely talk about aversion to 
certain drugs. Reducing the frequency of drug administration may help. Nurses and 
social workers could be in a better position to dig up the reasons for reluctance or 
negligence. Young persons who have had their disease since early childhood, may in 
their teenage years be regarded as ‘new users’ of medical care.  
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After all, it was the parents who took responsibility until then. Gradually and 
repetitively they should be made acquainted with all aspects of the disease, 
medication, and risks of certain forms of behavior.18 
 
It could be helpful to get the adolescents together in peer groups coached by a social 
worker or psychologist. This would enable them to exchange experiences. Regular 
meetings in hospital are often hard to realize in practice however. A worthwhile 
alternative is inviting them to camps together. Young adults who recently made the 
transition from pediatric to adult care could act as buddies to the younger patients. In 
our experience, camps meet the expectation of bringing patients in contact with each 
other, and several of them have intensive contact since meeting in camp, and visit 
each other during admissions. 
 
Transition 
The transition from pediatric to adult care should be well prepared to meet a number 
of objectives. The health care should be uninterrupted, patient-centered, age and 
developmentally appropriate. It should be flexible and comprehensive. Before and 
after transition, the adolescent should be skilled in communication, decision making, 
assertiveness, self-care and self-advocacy. Furthermore, parents of the young 
person should be supported during transition to enhance their child’s advocacy 
skills.18 The whole team, on the pediatric and the adult side, would do well to 
dedicate themselves to these tasks and let the young person start safely and self-
responsibly at the adult department. 
 
Patient survival 
 
Cardiovascular disease 
While the risk to die early is not large, life expectancy of a child on renal replacement 
therapy is still much shorter than that of a healthy child. Nevertheless it has improved 
over the years.19 It is the patient’s cardiovascular state that mainly determines 
lifespan. This is why prevention or restriction of cardiovascular disease, both pre- and 
post-transplant, should have highest priority. The load of risk factors for 
cardiovascular morbidity appears to be heavier in the dialysis phase than in the 
transplant phase. As mentioned before, one of the best ways to curb cardiovascular 
morbidity, therefore, is to transplant as early as possible, provided it is safe at the 
time. Other steps include optimalization of calcium phosphate metabolism during the 
pre-transplant period. This strategy aims to limit precipitation in the walls of blood 
vessels, which otherwise could lead to stiffening of the vessels. Furthermore, blood 
pressure should be normalized, both pre- and post-transplant, aiming at the 50th 
rather than the 95th percentile for age and sex.20 ACE inhibition may be the treatment 
of choice after transplantation. For, apart from better blood pressure control, its use 
was found to improve graft function both in adults and children, especially those with 
chronic allograft nephropathy.21,22 A large, multicenter, prospective randomized 
controlled trial to determine the effect of ACE-inhibition on blood pressure, graft 
function and mortality will start in 2008 in Canada.23  
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Other risk factors for cardiovascular disease are hypercholesterolemia and 
hyperhomocysteinemia. Statins are known to reduce the risk of atherosclerosis in 
hypercholesterolemia. To date, however. the use of statins in children is still debated, 
and for the time being restricted to older children.24 Folic acid, cyanocobalamin and 
pyridoxin are known to lower homocystein levels. Randomized controlled studies are 
underway to determine whether vitamin therapy is effective in secondary prevention 
of myocardial infarction and stroke.25  
The use of drugs that are toxic to blood vessels and kidneys – such as calcineurin 
inhibitors and corticosteroids – should be restricted as much as possible, both pre- 
and post-transplant. Strategies could aim at limiting doses and/or duration of 
treatment. The study described in Chapter 6 documents an approach to limit the use 
of cyclosporine, i.e. by replacing it with maintenance treatment with MMF. Withdrawal 
of cyclosporine had no effect on blood pressure, however, and only a temporary 
effect on hypercholesterolemia. Sirolimus in combination with MMF is another 
alternative to calcineurin inhibitor, as it is neither nephrotoxic, nor cardiotoxic. Yet it 
has been associated with hyperlipidemia and could possibly lead to fertility 
disturbances in boys.17,26 
 
Comorbidity 
 
Infections and malignancies 
Risks of infections and malignancies apparently have increased over the years, 
parallel to the expansion of immunosuppressive therapy.27 Vaccination before 
transplantation would seem a good strategy to prevent the alarming primary 
infections with EBV and CMV, but is not yet clinically applicable. Post-transplant 
lymfoproliferative disease is the type of malignancy with the highest incidence in 
children after solid organ transplantation. In most cases a primary infection with EBV 
is the underlying cause. Treatment of viral diseases, including the EBV-related PTLD, 
consists first of minimizing immunosuppression as soon as possible, and secondly, of 
starting additional therapy, i.e. gancyclovir for CMV, and rituximab for EBV. 
Monitoring of viral load in the blood is critical to adequate management of these 
infections. 
 
Lung disease 
Our studies (Chapter 7 and 8) showed that pediatric kidney transplant patients are at 
risk for irreversible lung disease, in association with pulmonary infection. It would 
seem important, therefore, not to underestimate respiratory complaints, especially 
persistent coughing, and to monitor lung function yearly. Patients with persistent 
symptoms should be referred to a pediatric pulmonologist who may consider invasive 
diagnostics so as to establish an appropriate antibiotic drugs therapy. Physical 
therapy, with or without mucolytic aerosol therapy, had a positive effect on airway 
clearance: extensive therapy made respiratory symptoms disappear in all patients 
with bronchiectasis. Increased general physical activity could facilitate clearance of 
the airways. 
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Growth 
Most patients on renal replacement therapy show suboptimal growth with stunted 
pubertal growth spurt, even many of those with good renal function. Growth may be 
stimulated by various medical interventions. Several investigators have reported that 
early age at transplantation and good graft function predict a better final height.28,29 
This is one of the considerations to limit dialysis treatment before transplantation as 
much as possible. Treatment with growth hormone has been proven beneficial in 
growth retarded patients with renal disease, before and after transplantation.30-32 
Such treatment achieves maximal effect in the first year of treatment, but each 
subsequent year brings further improvement in the mean standard deviation score.33 
Growth hormone treatment stops at the day of transplantation, because the high 
doses of corticosteroids administered during the first months after transplantation, 
most certainly will antagonize the effect of growth hormone. If the child shows 
insufficient catch-up growth, treatment could be resumed 12 or 18 months after 
transplantation, when corticosteroid dosage is low. Regrettably, the Netherlands 
health care system provides for reimbursement of growth hormone treatment only 
when the child’s glomerular filtration rate is below 50 ml/min.1.73m2. This policy, 
therefore, excludes prescription to patients with a well functioning graft. At the 
moment, final height has a disappointing average of -2 standard deviation score, 
which is in the lower range of normal body height. This would seem to implicate that 
50% of children in need of renal replacement therapy remain as short as or even 
shorter than the 2.5% shortest healthy children. 
 
It is unknown whether extended use of growth hormone both before and after 
transplantation actually improves final height. Most patients in studies received 
growth hormone either before or after transplantation.30,33 Assuming an additional 
effect of extended use, it seems to be justified to offer renal disease patients growth 
hormone treatment from the start of chronic kidney disease until the end of growth, 
with the exception of the first year after transplantation.  
Growth hormone treatment has additional benefits in children with chronic kidney 
disease. First, it may improve bone structure, by enhancing bone mineral density.34,35 
Secondly, it has been reported to alleviate endothelial dysfuction as described in 
renal failure patients as well as in patients with endothelial dysfunction due to growth 
hormone deficiency.36 Thus, growth hormone treatment may help to cut back 
cardiovascular morbidity. 
 
Physical condition 
The transplanted child should be able to take up physical activity, more than before 
transplantation. Physical condition will typically decrease in the period of end-stage 
renal failure. For most patients, sports is not an option in the dialysis phase. Still, 
physical condition usually does not recover completely after transplantation, as 
demonstrated in adult patients.37 In a cross-sectional study in children several years 
after kidney or liver transplantation, all children’s physical fitness was significantly 
below that of age- and sex-matched controls.38 Even corrected for delayed growth 
and pubertal development, fitness level was alarmingly low.  
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In adult transplanted patients, increased and sustained physical training could 
improve cardiorespiratory fitness to normal values, as demonstrated by participants 
of the World Transplant Games.39,40 Some children will become overweight after 
transplantation, which obviously has an inhibitory effect on physical activity. Parents 
are pleased to see that their child finally starts eating with appetite, and 
corticosteroids trigger the weight gain. Together with habituation to little physical 
activity before transplantation, overweight will result in a downward spiral in which 
patients remain in their sedentary way of life. Furthermore, some types of medication, 
e.g. antihypertensives, may interfere with the capacity of physical activity.  
Low cardiorespiratory fitness is associated with cardiovascular morbidity and 
mortality in the general population, as shown in the Framingham study.41 The 
standard of care for transplanted patients who already are at increased 
cardiovascular risk should therefore include a meticulously designed and coached 
rehabilitation program. An additional advantage is that physical activity may improve 
bone condition in patients with osteopenia.42,43 
 
Bone disease 
A large proportion of young adult patients (18%) had crippling complaints of bone 
disease, in part caused by renal osteodystrophy prior to transplantation.43 Long 
duration of pre-transplant dialysis treatment contributes to this morbidity. Avascular 
bone disease and osteopenia, with its onset post-transplant, may be prevented by 
minimizing corticosteroids treatment. Osteopenia may be counteracted by 
alfacalcidol, intranasal calcitonin, in addition to the above mentioned increased 
physical activity.44 There are no effective treatment options for avascular bone 
disease in childhood. Total hip replacements have been performed in adults, with a 
cumulative implant survival of 99% at 10, and 64% at 20 years.45 
 
Cognitive development 
Children on renal replacement therapy may show impaired cognitive development in, 
the extent of which appears to be related to the duration of dialysis.46,47 It has been 
reported to catch up after transplantation.48,49 Again, shortening the duration of pre-
transplant dialysis is essential to limit cognitive impairment. It is recommended to 
assess cognitive function and development in an early stage and during follow-up. 
Testing should be at a general level in combination with additional testing for the 
more specific domains of attention, memory, executive function and visual-spatial 
skills in school-children.50 Educational support through individual educational plans, 
tutoring or special classes will likely optimize educational outcome for children with 
renal replacement therapy.  
 
Organisation of pediatric renal tranplantation in the Netherlands 
 
No more than 30 renal transplantations are performed in our country each year. This 
number has been stable for over 30 years now. Close collaboration between the four 
centers has obvious advantages. During the past 10 years we agreed on shared 
treatment protocols, discussed individual cases and considered further studies and 
improvements.  
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In adult transplanted patients, increased and sustained physical training could 
improve cardiorespiratory fitness to normal values, as demonstrated by participants 
of the World Transplant Games.39,40 Some children will become overweight after 
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cardiovascular risk should therefore include a meticulously designed and coached 
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Bone disease 
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minimizing corticosteroids treatment. Osteopenia may be counteracted by 
alfacalcidol, intranasal calcitonin, in addition to the above mentioned increased 
physical activity.44 There are no effective treatment options for avascular bone 
disease in childhood. Total hip replacements have been performed in adults, with a 
cumulative implant survival of 99% at 10, and 64% at 20 years.45 
 
Cognitive development 
Children on renal replacement therapy may show impaired cognitive development in, 
the extent of which appears to be related to the duration of dialysis.46,47 It has been 
reported to catch up after transplantation.48,49 Again, shortening the duration of pre-
transplant dialysis is essential to limit cognitive impairment. It is recommended to 
assess cognitive function and development in an early stage and during follow-up. 
Testing should be at a general level in combination with additional testing for the 
more specific domains of attention, memory, executive function and visual-spatial 
skills in school-children.50 Educational support through individual educational plans, 
tutoring or special classes will likely optimize educational outcome for children with 
renal replacement therapy.  
 
Organisation of pediatric renal tranplantation in the Netherlands 
 
No more than 30 renal transplantations are performed in our country each year. This 
number has been stable for over 30 years now. Close collaboration between the four 
centers has obvious advantages. During the past 10 years we agreed on shared 
treatment protocols, discussed individual cases and considered further studies and 
improvements.  
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In the years to come we should like to invite surgeons and urologists to participate in 
our meetings. This would be the way to develop and discuss perioperative surgical 
and urological protocols, including techniques, use of en bloc donor kidneys, 
perioperative fluid management, reduction of cold and warm ischemia times, among 
other things. Similarly, the social workers, teachers, psychologists and dieticians in 
the four centers could be encouraged to share their experiences on a more regular 
basis.  
 
In addition, we need to devise a strategy by which the expertise of the surgical teams 
can best be consolidated and guaranteed for the years to come. The low number of 
transplantations calls for close collaboration, either with the surgical teams of the 
other pediatric transplant centers or with the local transplant teams for adults.  
Establishing a single national pediatric renal transplantation team may even be a 
worthwhile option. Obvious advantages of this strategy are greater efficiency and 
experience in both operative and post-operative care. On the other hand, it would 
come with disadvantages as well. Patients and parents often have a history from 
early childhood in the local dialysis unit. They will have become familiar with pediatric 
nephrology staff, nurses on the ward, social workers, dieticians, laboratory and 
radiology personnel. Transfer to a different, centralized hospital with unknown staff at 
the critical moment of transplantation introduces risk of miscommunications and may 
have repercussions on the child’s further recovery. In addition, centralization would 
also artificially separate the centralized transplant team from the local follow up team.  
 
Study endpoints 
 
In future studies, effects of changes in treatment need to be assessed from suitable 
parameters. Clinical studies may be evaluated by clinical endpoints or laboratory 
markers, e.g. measuring immunologic or endothelial functions. Some remarks: 
One year graft survival has reached a 92% rate. Studies demonstrating higher rates 
will need vast numbers of patients to obtain adequate statistical power. As such 
numbers cannot be provided for in the Netherlands, these studies only could be 
performed in collaboration with neighbouring countries. Instead, surrogate endpoints 
may be considered in children, for example estimated glomerular filtration rate 1 year 
post-transplant.51  
Various endpoints may serve to study cardiovascular disease. At the vascular level, 
the effect of stiffening of the walls of the main arteries on blood flow patterns may be 
determined by pulse wave pattern analysis and measurement of transit times at the 
carotid and femoral arteries.52 These parameters have been evaluated for children as 
well as for adults.53 It is one of the endpoints of the Rich-Q study in Dutch and 
Belgian children on renal replacement therapy. The function of the endothelium may 
be studied in several ways, as performed by the group of Dr. M.R. Lilien, UMC 
Utrecht. In vivo flow mediated dilatation after an ischemic insult reflects endothelial 
function.54 In vitro, the number of endothelial precursor cells type I present in the 
peripheral blood, and the amount of endothelial precursor cells type II that can be 
cultured from peripheral blood monocytes are associated with the risk of 
cardiovascular disease.  
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Structural and functional disease of the myocardium may be visualized by imaging 
techniques, e.g. echocardiography including tissue Doppler examination.  
The optimal way to study exposure to calcineurin inhibitors is measuring the area 
under the concentration-time curve, which is a cumbersome method. While trough 
level does not adequately reflect the exposure, two hour postdose level has been 
shown to be a more reliable predictor of exposure.55,56 Fine-tuning of the treatment 
with calcineurin inhibitors in children is probably best done by therapeutic drug 
monitoring, e.g. by estimation of the area under the concentration time curve using 
population pharmacokinetics (as performed by Dr. R. Mathot, Erasmus MC 
Rotterdam). 
 
Summary 
 
Summarizing, a range of issues play a role in further improvement of pediatric kidney 
transplantation in the Netherlands. These are listed below, each with the objectives 
to be derived from them:  
1. Pre-transplant factors 
 Prevention and treatment of hypertension, bone metabolism, growth, 
development. The Rich-Q study is expected to contribute by setting 
evidence based standards of care (design Dr. J. Groothoff, AMC 
Amsterdam). 
 Shortening of pre-transplant dialysis treatment. 
2. Source of the allograft  
 Evaluation of potential higher yield of deceased pediatric donors in the 
Netherlands.  
 Considering transplantation of adult living donor kidneys in younger 
children, preferentially to be performed in one institution in the Netherlands 
so as to develop experience within a dedicated team of surgeons, 
anesthetists, intensive care physicians, and pediatric nephrologists. 
 Widening the criteria of the Eurotransplant ‘Young for young’ program, by 
raising the age limits of both recipient and donor from 6 and 10 years, 
respectively, to 16 years. 
 Participation in the national cross-over program in case of incompatible 
donor-recipient pairs. 
3. Outcome of transplantation 
 Minimizing immunosuppressive therapy one year after transplantation, in 
order to curb toxic effects (e.g. cardiovascular, bone, cosmetic, 
malignancy), notably of corticosteroids and calcineurin inhibitors.  
 Adaption of surgical schedules aimed at limiting cold ischemia time, as well 
as initiating more aggressive fluid management could prevent graft loss 
due to thrombosis. Coagulation function test should be added to 
pretransplant evaluation so as to identify high risk patients. 
 Surveillance biopsies at 3 and 12 months could be considered in young 
children with relatively large allografts to detect and treat subclinical acute 
rejection. 
 Transition care needs to be elaborated on.  
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4. Comorbidity 
 Retrospective evaluation of the effects of growth hormone therapy on final 
height, in relation to dosage and duration of treatment. Dependent on the 
results the treatment indication should be extended to transplanted patients 
with good graft function. 
 Effect of treatment with selected antihypertensives and/or statins on 
cardiovascular comorbidity.  
 Restricting corticosteroid administration could prevent bone disease .  
 Structural rehabilitation programs may improve the child’s physical 
condition after transplantation. Worth studying are the effects on cardiac 
structure and function, and on bone mineral density. 
5. Reaching these objectives requires our shared database to be maintained by 
a dedicated person fully responsible for data-collection and data-entry.  
 
Conclusion  
 
The collaboration between the departments of pediatric kidney transplantation in the 
four centers in the Netherlands and in Antwerp, Belgium, has been in place for 10 
years now. It no doubt has been instrumental in improving the outcome of pediatric 
kidney transplantation in the Netherlands. The studies documented in this thesis 
support this observation. Still, efforts should be directed at optimizing these children's 
life expectation and quality of life, as described in the general discussion. On the 
horizon, children with a functioning kidney transplant will enjoy optimal education, 
sports, having fun with friends, in anticipation of a normal adult life. 
General discussion 
189 
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Kidney transplantation is the optimal modality of renal replacement therapy in 
children. It restores renal functions, more and better than dialysis, and has the 
potential to reduce the comorbidity of end-stage renal disease. It provides better 
conditions for normal physical and psychosocial development. Nevertheless, a graft 
usually does not function for life, and brings along comorbidity of its own. This thesis 
comprises studies dealing with this objective. Most are collaborative efforts from five 
institutions for pediatric kidney transplantations, four in the Netherlands and one in 
Antwerp, Belgium. 
 
Chapter 1 gives an overview of the current state of affairs of pediatric kidney 
transplantation. Currently in the Netherlands, children with renal failure from the age 
of 3 years or a minimum body weight of 12 kg qualify for kidney transplantation. 
Yearly 25 to 30 children are transplanted in the Netherlands, distributed over four 
medical centers. After 10 years approximately 55% of kidneys are still functioning. 
Mortality rate is low at short term, but considerably higher in longer term follow up. 
Kidneys may be retrieved from living or from deceased donors. At this moment 30% 
of kidney grafts is from a living donor, and this figure is rising. Waiting times for 
children on the Eurotransplant waiting list for a deceased donor kidney are shorter 
than for adults, but have been increasing in recent years.  
 
Here we review differences between pediatric and adult transplantations, as well as 
immunological aspects, including immunosuppressive agents and their side effects. 
We also report on risk factors for graft failure, such as rejection of the graft, 
thrombosis, ischemia/reperfusion injury, chronic allograft nephropathy. Primary 
kidney disease may recur in the grafted kidney, leading to loss of the graft. Non-
compliance may contribute to deterioration of graft function. Unfortunately, 
immunosuppressive medication brings along comorbidity of its own, such as 
cardiovascular damage, bone disease, infections and malignancies. 
 
Part I aims to review the outcome of former kidney transplantations in children in the 
Netherlands. All centers worked independently at the time, and the low numbers of 
patients interfered with proper evaluation of protocols.  
Chapter 2 describes the outcome of the 269 transplantations performed between 
1985 and 1995. Immunosuppressive therapy consisted of different combinations of 
corticosteroids, cyclosporine and azathioprine. CMV prophylaxis and thrombosis 
prophylaxis was not prescribed in all centers yet. Early graft loss was caused by 
thrombosis in 4.5%, and by acute rejection in 6.9% of transplantations. Only 26% of 
all transplants were free from acute rejection. Graft loss at long term was associated 
with number of acute rejections early post-transplant, but even more with late 
occurrence of the first rejection episode. The graft survival at 1 year was 73%, at 5 
years 60%. 
 
Chapter 3 reviews the status of young adults who received a kidney transplant as a 
child between 1972 and 1992, the first cohort of pediatric transplantation in our 
country.  
Summary 
195 
The graft survival rate of all 397 transplants was 59%, 45%, 35% and 30% at 5, 10, 
15 and 20 years, respectively. In comparison with azathioprine, cyclosporine was 
associated with better graft survival in retransplantation, but not in first 
transplantation. Patients treated with cyclosporine showed more comorbidity than the 
other patients, including more hypertension, hypertrichosis, severe warts, general 
fatigue, and a history of epileptic insults. 
 
Part II contains reports of trials to improve immunosuppressive therapy in Dutch 
pediatric kidney transplantation.  
Chapter 4 describes the effects of the introduction of a shared initial 
immunosuppressive regimen in all centers, consisting of a combination of 
corticosteroids, cyclosporine and MMF, and comparing these to the findings in the 
historical cohort documented in Chapter 2. A spectacular improvement in one year 
graft survival of first kidney transplant recipients was noted: the 73% of chapter 3 had 
jumped to 92%. Proportions of patients who remained rejection free had increased 
from 28% to 63%. Rates of steroid resistance of acute rejections had dropped from 
30% to 16% (n.s.).  
 
Chapter 5: Having treated 100 patients with this shared immunosuppressive 
regimen, we adapted it by delaying the start of cyclosporine and by adding 
basiliximab. We hypothesized that, by avoiding the vasoconstrictive action of 
cyclosporine in the immediate post-transplant-phase, this would reduce the incidence 
of delayed onset of graft function. This change in initial immunosuppressive therapy 
was thought to improve 1 year graft survival.  
The outcome was compared to that of the cohort described in Chapter 4. Delayed 
graft function was measured in two ways: 1. the indication to dialyse in the immediate 
post-transplant period, and 2. the time period in which creatinine level reached half 
its pre-transplant value. We did not find an effect of the shift in initial 
immunosuppression on the incidence of delayed graft function, on estimated 
glomerular filtration rate at 1 year post-transplant, or on 1- and 2-year graft survival. 
The incidence of acute rejections had dropped significantly, though. 
 
Chapter 6 contains a report of a randomized clinical trial, starting at 1 year after 
transplantation, to examine safety and efficacy of MMF and prednisolone as 
maintenance immunosuppression. The triple immunosuppressive regimen of the first 
year after transplantation was reduced to a dual prophylactic therapy, by slow 
withdrawal of the third drug over a period of 3 months. Patients treated with 
prednisolone and MMF showed better preservation of glomerular filtration rate over 
the 2 years of follow-up than did those treated with prednisolone and cyclosporine. 
Cholesterol levels improved over the 1st year in the MMF group, but did not 
significantly differ from the cyclosporine group after 2 years. In the MMF group 2 out 
of 18 patients had a late first acute rejection episode in the second year of the study 
(third year after transplantation), leading to chronic allograft nephropathy and graft 
loss in one patient, and proteinuria and decreased glomerular filtration rate in the 
other. 
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Part III, Chapter 7 reports the effect of restricting the time on dialysis on the outcome 
of pediatric kidney transplantation. Since pre-emptive transplantation was not 
performed very often in the Netherlands, we extended the field of investigation to the 
Eurotransplant region. First kidney transplants performed between 1990 and 2000 
(n=1113) included 156 transplants without prior dialysis (14%), 70 with a graft from a 
deceased donors, and 86 from a living donor. Pre-emptive transplantation yielded the 
better graft survival, notably in the first 5 years, but also in the later 5 years of the 
study period. The effect was strongest in transplantations with kidneys from 
deceased donors. The favorable effect of pre-emptive transplants was absent when 
compared to transplantations preceded by less than 6 months dialysis. Patients with 
slowly progressive renal disease on the basis of congenital structural abnormalities 
who were enlisted before dialysis, had a 55% chance of being transplanted without 
dialysis. 
 
Part IV contains reports on pulmonary and cardiovascular comorbidity of patients 
with a functioning kidney transplant in the Netherlands.  
Chapter 8 describes findings in five patients with chronic respiratory complaints due 
to bronchiectasis, four after kidney transplantation and one after liver transplantation. 
These findings led to a cross-sectional study of respiratory complaints and pulmonary 
function of all children who had undergone kidney transplantation in the Netherlands, 
described in Chapter 9. More children than normal had respiratory complaints, 
possibly caused by a higher infectious load due to the immunosuppressive therapy, 
and more children had disturbed pulmonary function. To prevent bronchiectasis in 
the future, we recommend yearly check-ups with the pediatric pulmonologist and 
more aggressive treatment of respiratory infections.  
 
Chapter 10 is a report of the prevalence of diastolic dysfunction in a single center 
population of children on renal replacement therapy, either peritoneal dialysis or 
transplantation, as compared with healthy children. The diastolic function was 
measured both by regular echocardiography and by tissue Doppler. Both methods 
yielded abnormal values in patients, more deviating in the dialysis patients than in the 
transplanted patients. Diastolic dysfunction is an early finding of cardiac disease and 
is a reason for alarm when observed in young patients. 
 
Chapter 11, the general discussion, is focused on ways to further improve the 
outcome of these patients. These involve pre-transplant conditions, direct transplant 
results as well as comorbidity issues. A major objective is shortening of the time on 
dialysis, since end-stage renal failure and chronic dialysis are associated with 
decreased patient survival, worse graft survival, increased cardiovascular risk for the 
long term, growth failure, and bone disease. Moreover, longer dialysis seriously 
interferes with development, school performance and psychosocial skills. To limit 
time on dialysis, a larger pool of available donors is needed.  
Living donor transplantation can be further stimulated, and may be extended to 
younger recipients. Cross-over transplantation is an option for incompatible donor 
and recipient combinations. The Eurotransplant ‘young for young’ allocation program 
might be extended to recipients and donors up to the age of 16 years, since in the 
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current program (recipients younger than 6 and donors younger than 10) no 
transplants have been realized in almost a year. Graft losses due to thrombosis and 
the incidence of delayed graft function could be reduced by shortening cold ischemia 
times, for example by more effective scheduling of surgery. Graft survival in 
adolescents could be improved by more intensive coaching by social workers and 
psychologists to combat non-compliance. This is of special importance to prepare for 
transition from the pediatric to the adult medical system.  
A major effort should be made in the battle against cardiovascular disease. This is 
the number one cause of early death in our population. Parameters to be used as 
study endpoints are being discussed. Minimization of immunosuppressive therapy is 
indicated to treat or prevent long term toxicity, including cardiovascular disease, 
infections, malignancies and bone disease. This strategy is preferentially controlled 
by immunologic tests to control the risk of acute rejection. Finally, changes in two 
fields could improve general well-being of the transplanted children. First, offering 
growth hormone treatment to growth retarded children also with good graft function, 
in order to achieve more appropriate adult body height. Second, offering a structured 
physical rehabilitation program following transplantation in order to improve children’s 
cardiorespiratory function and fitness. 
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Als de nierfunctie van een kind door een ziekte verloren is gegaan, kan deze het best 
vervangen worden door een niertransplantatie. Een transplantaatnier kan veel meer 
functies van de eigen nieren vervangen dan dialyse, en doet dat ook beter. 
Eindstadium nierfalen, met of zonder dialyse, brengt ziekteverschijnselen met zich 
mee, die door een niertransplantatie teruggedrongen kunnen worden. Bovendien 
neemt door een niertransplantatie de kans op normale lichamelijke, psychische en 
sociale ontwikkeling toe. Dit proefschrift bevat studies die als doel hebben de 
omstandigheden voor kinderen met een niertransplantatie te verbeteren. De meeste 
zijn gezamenlijk uitgevoerd door de vier Nederlandse centra voor niertransplantaties 
bij kinderen en dat van Antwerpen. 
 
Hoofdstuk 1 geeft een overzicht van de huidige stand van zaken in 
niertransplantaties bij kinderen. Op dit moment kunnen kinderen vanaf de leeftijd van 
3 jaar of een lichaamsgewicht van 12 kg in aanmerking komen voor een 
niertransplantatie. Per jaar ondergaan in Nederland 25 tot 30 kinderen een 
niertransplantatie, verdeeld over 4 ziekenhuizen. Na 10 jaar werkt 55% van de 
getransplanteerde nieren nog. Het sterftecijfer is op korte termijn laag, maar op de 
langere termijn aanzienlijk. Transplantaatnieren kunnen afkomstig zijn van een 
levende of een overleden donor. Op het moment van schrijven is 30% van de nieren 
afkomstig van een levende donor, en dit percentage loopt nog op. De wachttijd voor 
kinderen op de wachtlijst van Eurotransplant voor een nier van een overleden donor 
is weliswaar korter dan voor volwassenen, maar neemt de laatste jaren toe. 
 
We beschrijven de verschillen tussen niertransplantaties bij kinderen en 
volwassenen, de immunologische processen, de medicatie die de afweer onderdrukt 
en de bijwerkingen ervan. Risicofactoren voor het verlies van transplantaatfunctie 
komen aan de orde, zoals acute afstoting, trombose, schade door zuurstofgebrek in 
de nier, chronisch transplantaatlijden. Sommige van de oorspronkelijke ziektes 
kunnen terugkeren in de nieuwe nier, en tot transplantaatverlies leiden. Een ander 
risico voor disfunctioneren van de nier vormt therapieontrouw die in de puberteit vaak 
voorkomt. Helaas brengt ook de niertransplantatie zelf en de immunosuppressieve 
medicatie ziekteverschijnselen met zich mee, zoals schade aan hart en vaten, aan 
de botten, het optreden van infecties, en maligniteiten. 
 
Deel I bevat twee studies die terugkijken op de geschiedenis van niertransplantaties 
bij kinderen in Nederland, voor het begin van de samenwerking tussen de centra. 
Hoofdstuk 2 beschrijft de resultaten van 269 niertransplantaties die tussen 1985 en 
1995 uitgevoerd zijn. De immunosuppressieve behandeling bestond toen uit 
verschillende combinaties van corticosteroïden, cyclosporine en azathioprine. In die 
tijd werd er nog niet door alle centra profylaxe gegeven ter preventie van CMV ziekte 
en trombose. In de eerste weken ging 4.5% van de nieren verloren aan trombose, en 
6.9% aan acute afstoting. Slechts in 26% van alle transplantaties werd geen acute 
afstoting gezien.  
Samenvatting 
201 
De transplantaatoverleving op de lange termijn was geassocieerd met het aantal 
acute afstotingen in de vroege fase na transplantatie, maar meer nog met het late 
optreden van de eerste afstotingsepisode. De transplantaatoverleving na 1 jaar was 
73%, en na 5 jaar 60%. 
 
Hoofdstuk 3 geeft een overzicht van jonge volwassenen die op kinderleeftijd een 
niertransplantatie hadden ondergaan. Deze jong volwassenen vormden het eerste 
cohort van getransplanteerde kinderen in Nederland. De transplantaat overleving van 
de hele groep van 397 transplantaties bedroeg 59%, 45%, 35% en 30% na 
respectievelijk 5, 10, 15 en 20 jaar. In vergelijking met azathioprine gaf initiële 
behandeling met cyclosporine een betere transplantaatoverleving alleen bij patiënten 
met een retransplantatie, maar niet in degenen met een eerste transplantatie. 
Patiënten die met cyclosporine behandeld werden toonden meer comorbiditeit dan 
anderen, onder andere hypertensie, sterkere lichaamsbeharing, wratten, 
vermoeidheid, en epileptische insulten. 
 
In Deel II worden studies beschreven met als gemeenschappelijk doel het verbeteren 
van de immunosuppressieve medicatie in niertransplantaties bij kinderen in 
Nederland. 
Hoofdstuk 4 beschrijft de effecten van een gemeenschappelijk immunosuppressief 
protocol in alle centra. Dit bestond uit corticosteroïden, cyclosporine en MMF. De 
resultaten werden vergeleken met die van de historische controlegroep beschreven 
in hoofdstuk 2. De transplantaatoverleving na 1 jaar was spectaculair verbeterd met 
het nieuwe regime, van 73% naar 92%. Het deel van de patiënten zonder acute 
afstoting was toegenomen van 28% naar 63%. Een groter deel van de 
afstotingsreacties kon afdoende behandeld worden met corticosteroïden, nl. 84%, in 
vergelijking tot 70% in de controlegroep. 
 
Hoofdstuk 5: Nadat 100 patiënten met het bovenbeschreven protocol behandeld 
waren, werd het aangepast door de start van behandeling met cyclosporine uit te 
stellen en basiliximab toe te voegen. Onze hypothese was dat, door het vermijden 
van het vasoconstrictieve effect van cyclosporine in de herstelfase van de 
getransplanteerde nier, het vertraagd op gang komen van de nier minder vaak zou 
voorkomen. We verwachtten dat dit de 1 jaars transplantaatoverleving zou 
verbeteren. De resultaten werden vergeleken met het cohort beschreven in 
hoofdstuk 4. Het vertraagd op gang komen van de nier werd op 2 manieren gemeten: 
1. door tijdelijke behandeling met dialyse in de eerste week na transplantatie, en 2. 
het aantal dagen dat nodig was om de helft van de kreatininewaarde voor 
transplantatie te bereiken. Helaas zagen we geen effect van het veranderde initiële 
immunosuppressieve protocol op het op gang komen van de nier, op de nierfunctie 
een jaar na transplantatie, of op de transplantaatoverleving na 1 en 2 jaar. Wel 
traden er minder acute rejecties op in de groep met basiliximab. 
 
In hoofdstuk 6 wordt een prospectieve, gerandomiseerde studie beschreven waarbij 
de effectiviteit en veiligheid van MMF werd vergeleken met cyclosporine in de 
onderhoudsfase, te beginnen 1 jaar na niertransplantatie.  
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Beide immunosuppressiva werden gegeven in combinatie met corticosteroïden. Het 
immunosuppressieve schema, dat in het eerste jaar uit 3 middelen bestond, werd 
over een periode van 3 maanden teruggebracht tot 2. Patiënten die behandeld 
werden met MMF en prednisolon behielden een betere nierfunctie gedurende 2 jaar 
dan de met CsA behandelde patiënten. De cholesterolconcentratie in het bloed 
verbeterde in de MMF groep over het 1e jaar, maar was niet significant verschillend 
van die in de CsA groep na het 2e studiejaar. Twee van de patiënten die met MMF 
behandeld werden, kregen echter een late acute afstoting, nl. in het 2e studiejaar. 
Deze leidde in de ene patiënt tot transplantaatverlies een half jaar later, en in de 
andere tot blijvend verlies van nierfunctie en eiwitverlies in de urine. 
 
Deel III, Hoofdstuk 7 beschrijft het effect van het beperken van dialysetijd vóór 
transplantatie op de resultaten van transplantatie. Omdat transplantatie zonder 
voorafgaande dialyse, zgn. pre-emptieve transplantatie, niet vaak werd uitgevoerd in 
Nederland, werd het onderzoeksgebied uitgebreid tot de Eurotransplant-regio. Van 
alle 1113 eerste niertransplantaties bij kinderen, die tussen 1990 en 2000 plaats 
hadden gevonden, waren er 156 (14%) zonder voorafgaande dialyse, 70 met een 
nier van een overleden donor, en 86 van een levende donor. Pre-emptieve 
transplantaties hadden een duidelijk betere transplantaatoverleving, vooral in de 1e 5 
jaar van de studieperiode, en vooral in de groep met nieren van een overleden 
donor. Er was geen verschil in transplantaatoverleving tussen kinderen 
getransplanteerd zonder, of na een korte periode van dialyse, maximaal 6 maanden. 
Van de patiënten met een langzaam progressieve nierziekte op basis van 
aangeboren anatomische afwijkingen, die op de wachtlijst geplaatst werden voor 
start van de dialyse, kon 55% ook daadwerkelijk getransplanteerd worden voordat 
dialyse nodig was. 
 
Deel IV bevat rapporten van complicaties op het gebied van hart en longen in 
kinderen met een niertransplantatie in Nederland. 
Hoofdstuk 8 beschrijft de bevinding van chronische longklachten ten gevolge van 
bronchiectasieën in 5 kinderen, 4 na een nier- en 1 na een levertransplantatie. Deze 
bevinding leidde tot het transversele onderzoek, beschreven in hoofdstuk 9, naar 
klachten van de luchtwegen en longfunctie bij kinderen met een functionerende 
transplantaatnier. Opvallend veel kinderen hadden klachten van de luchtwegen. Dit 
zou te verklaren zijn uit het grotere aantal luchtweginfecties dat kon ontstaan door de 
immunosuppressieve behandeling. Ook hadden meer kinderen dan normaal een 
afwijkend longfunctieonderzoek. Om bronchiectasieën in de toekomst te voorkomen 
adviseren we een jaarlijkse controle bij de longarts, en agressievere behandeling 
van, m.n. lagere, luchtweginfecties. 
 
In hoofdstuk 10 wordt het vóórkomen van een verminderde diastolische functie van 
de linker hartkamer beschreven in kinderen die nierfunctievervangende behandeling, 
peritoneaal dialyse of niertransplantatie, ondergaan in één behandelcentrum, in 
vergelijking tot gezonde kinderen. De diastolische functie werd gemeten met 
standaard echocardiografie, aangevuld met tissue-Doppler onderzoek, en vergeleken 
met gezonde kinderen.  
Samenvatting 
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Met beide methoden werden afwijkende gemiddelde waarden gevonden in zowel de 
groep peritoneaal dialyse patiënten, als de getransplanteerde patiënten. Diastolische 
disfunctie is een vroege uiting van verminderde hartfunctie, en een alarmteken bij 
jonge kinderen. 
 
Hoofdstuk 11, de algemene discussie, richt zich op manieren waarop het leven van 
kinderen met een niertransplantatie verder verbeterd kan worden. Het gaat om 
aspecten vóór transplantatie, directe transplantatieresultaten, en de aandoening van 
andere organen. Een belangrijk doel is het beperken van de duur van eindstadium 
nierfalen door beperking van de dialyseduur voor transplantatie, aangezien die 
periode geassocieerd is met hogere sterfte, slechtere transplantaatoverleving, groter 
risico op hart- en vaatziekte, slechtere groei, en botziekte. Bovendien heeft dialyse 
een duidelijke weerslag op de psychomotorische ontwikkeling van het kind, en de 
schoolprestaties. Om dialyse te kunnen beperken, zijn meer donoren of een andere 
verdeling van donoren nodig. 
Transplantatie met nieren van levende donoren kan verder gestimuleerd worden, 
waarbij de capaciteit voor deze transplantaties in de ziekenhuizen aangepast dient te 
worden. Misschien moeten ook de jongste kinderen een nier kunnen ontvangen van 
één van hun ouders. Het cross-over programma is een goede mogelijkheid om 
transplantatie met een levende donor ook in het geval van een niet passende donor-
ontvanger-combinatie mogelijk te maken. Het ‘young-for-young’ programma van 
Eurotransplant kan uitgebreid worden tot donoren en ontvangers van 16 jaar, 
aangezien het programma in de huidige versie nog niet tot transplantaties heeft 
geleid. Zo kunnen nieren van overleden kinderen getransplanteerd worden in 
kinderen, wat nu meestal niet gebeurt. Transplantaatverlies door trombose en het 
optreden van vertraagd op gang komen van de nier zou beperkt kunnen worden door 
het verkorten van koude ischemie tijd, bijvoorbeeld door het verlenen van voorrang 
op het operatieprogramma aan een niertransplantatie. Transplantaatoverleving in 
adolescenten zou bevorderd kunnen worden door een poging de therapietrouw te 
verbeteren door intensievere begeleiding door lotgenoten, psychologen en 
maatschappelijk werkenden. De overgangsfase van kinderziekenhuis naar 
‘volwassen’ ziekenhuis draagt extra risico voor afname van de therapietrouw. 
Een van de belangrijkste aspecten van comorbiditeit waar we de strijd tegen aan 
moeten binden is hart- en vaatziekte bij onze patiënten. Het is de belangrijkste 
doodsoorzaak. Daarvoor is terugbrengen van bepaalde immunosuppressieve 
medicijnen gewenst, maar ook om andere toxische effecten te beperken, o.a. het 
optreden van infecties, van maligniteiten en botziekte. Er zijn aanwijzingen dat dit 
terugbrengen gevolgd kan worden met immunologische bepalingen, die het risico op 
afstoting weer kunnen geven. Tenslotte zou het algemeen welbevinden van kinderen 
met een niertransplantatie door twee aspecten kunnen verbeteren. In de eerste 
plaats door een poging de volwassen lengte in een normalere range te brengen door 
behandeling met groeihormoon ook bij goede nierfunctie na transplantatie mogelijk te 
maken. In de tweede plaats zou het zinvol zijn om een revalidatieprogramma na 
transplantatie onderdeel van de behandeling te laten zijn, ter verbetering van de 
cardiorespiratoire functie en lichamelijke conditie.  
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Dankwoord 
 
Professor Van der Heijden, beste Bert, ik heb lang gedacht dat een promotie er bij 
mij nooit van zou komen. Maar jij vond de goede toon om me te motiveren tot het 
schrijven van een boekje. Hiervoor, voor je steun en voor je vriendschap wil ik je 
hartelijk bedanken. 
 
Jeroen Nauta, copromotor. Beste Jeroen, dank voor je altijd sprankelende gedachten 
ten aanzien van onderzoek in het algemeen, en dit proefschrift in het bijzonder. Jij 
bent de inspirator van onze groep kindernefrologie, als mens en als professional.  
 
Eric Wolff, beste Eric, in 1990 was ik blij te kunnen komen werken bij de leukste 
subafdeling in het Sophia, de kindernefrologie, die op dat moment uit Jeroen en jou 
bestond. Naast het feit dat ik ontzettend veel kindernefrologie van je geleerd heb, 
droeg je ook enorm bij aan mijn dagelijkse werkplezier gedurende vele jaren. Ik ben 
je daar heel dankbaar voor! 
 
De leden van de kleine commissie, Professor Willem Weimar, Professor Andries 
Hoitsma en Teun van Gelder, ben ik dankbaar voor het kritisch lezen van het 
manuscript. Dank ook dat ik altijd met vragen bij jullie terecht kan op het gebied van 
transplantatie en farmacotherapie. 
 
Professor Offner, dear Gisela, thank you for being so kind to participate in the 
ceremony. I appreciate your presence very much. I thank you for always having been 
an advocate for the rights of the children within Eurotransplant, and for convincing 
our German and Austrian colleagues to participate in the study on pre-emptive 
transplantations. 
 
Guido Persijn, beste Guido, voor mij was jij het gezicht van Eurotransplant. Dank 
voor je deelname aan de commissie, maar vooral ook voor je inzet voor alle mensen 
op de wachtlijst voor een transplantatie! 
 
Tenslotte, Professor de Jongste, beste Johan, ik ben blij dat je als vreemde eend in 
deze transplantatie-nefrologie-bijt in mijn commissie hebt willen plaats nemen.  
 
Collega kindernefrologen van de transplantatieclub, Marc Lilien, Marlies Cornelissen, 
Koen Van Hoeck, Jean Claude Davin en Tonny Bouts, ik ben blij met onze 
gezamenlijke inzet voor het verbeteren van de behandeling van onze 
transplantatiepatiënten, en voor de levendige discussies bij onze bijeenkomsten. 
Alleen door deze samenwerking hebben we de studies kunnen uitvoeren die de 
basis vormen van dit proefschrift. Ik denk met plezier terug aan de kleurrijke 
kindertransplantatiecongressen die we samen bezocht hebben in Venetië, Rio de 
Janeiro, Mexico. Laten we verder gaan, er is genoeg te doen! 
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Vele studenten hebben bijgedragen aan de totstandkoming van dit boek: Muriel 
Darby en Marjolijn Boendermaker, Femke Gijzen, Liesbeth de Vette, Floor Klee, 
Sanne Mertens, Esther Hornikx, en Maaike Lunstroot. Ik dank jullie voor je enorme 
inzet om telkens weer op reis te gaan om de voor het onderzoek essentiële 
gegevens boven water te krijgen, in alle 22 centra voor kinderniertransplantaties van 
Eurotransplant! Colette Wissink, verpleegkundige, ook jij reisde stad en land af om 
de patiëntengegevens voor de database te verzamelen; daarvoor veel dank! 
 
Theo Stijnen en Wim Hop, de statistische power achter dit proefschrift, ik dank jullie 
van harte voor jullie onmisbare hulp bij de verschillende studies, van A tot Z, en van 
B tot chi-kwadraat.  
 
Eiske Dorresteijn en Petra Hornstra-van Echtelt, stralende en bezielde collegae 
kindernefrologen in het Sophia, jullie wil ik bedanken voor de geweldige 
samenwerking binnen onze groep. Het was fantastisch om te merken hoe 
vanzelfsprekend Jeroen en jullie taken van me overnamen, waardoor ik ruimte kreeg 
om dit project af te ronden. Ik ben blij dat ik nu weer gewoon met jullie aan het werk 
kan (en gaan we nu eindelijk die borrel drinken?)! 
 
De kindernefrologie kan niet draaien zonder de bijzondere inzet van vele anderen. 
Een aantal wil ik met name noemen. Conny Groenendijk is de spil op de polikliniek: jij 
houdt alle protocollen draaiende. Samen met Corine Leemhuis, Heleen Warbout en 
Annette Bakker, sta jij altijd klaar voor de patiënten. Marja Kenselaar, Katinka van 
Linschoten, Caro Fonkert en Marjoleine van der Zijde, verpleegkundigen van de 
peritoneaal dialyse, jullie voeren de jaarlijkse ‘grote onderzoeken’ van de 
transplantatiepatiënten altijd zeer adequaat uit en zijn de patiënten heel toegewijd. 
Jullie, evenals de haemodialyseverpleegkundigen van de kinderkamer (Anjo Stoop, 
Anneke Lont, Cora Kornaat, Dymphna Dekker, Eliza Tol, Esther Bunk, Froukje de 
Bruin, Margot Brandon, Marijke Helberg, Patricia Biesheuvel en San Janssen) 
dragen een groot deel van de medische zorg voor de kinderen in de periode 
voorafgaand aan de transplantatie en doen dat met een warm hart! Ook Marianne 
van Zevenhuyzen, Boukje Smit, Angeline van der Pligt, Elles van der Louw, Elza van 
der Schee hebben allen een onmisbare inbreng in dit team, ieder vanuit haar eigen 
invalshoek. Het voelt goed om met jullie allen een team te vormen! 
 
De chirurgen, van wie Gerard Madern al jarenlang de centrale plaats bij de 
transplantaties inneemt, de urologen, en de anesthesisten dank ik voor hun inzet ten 
behoeve van de kinderen, die vaak niet beperkt blijft tot de directe (peri)operatieve 
zorg. De verpleegkundigen en artsen van de ICK en van 2MKG dragen een 
geweldige steen bij in de zorg direct na transplantatie en bij verdere opnames van de 
patiënten. Allen dank hiervoor! 
 
Hier wil ik ook de patiënten en hun ouders bedanken voor het vertrouwen dat ze in 
ons kindernefrologie-team stellen. Ik hoop van harte dat het onderzoek waarvan 
verslag is gedaan in dit boekje, gunstige gevolgen heeft ook voor jullie persoonlijk.  
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Ko Hagoort, beste Ko, op alle mogelijke momenten kon ik je vragen om mijn ‘Engels’ 
in echt Engels te vertalen. Of het nu middernacht was, en of je aan de andere kant 
van de wereld zat, binnen 12 uur had ik het altijd weer sterk verbeterd en 
leesbaarder terug. Heel veel dank! 
 
Willeke van der Bent, lieve Willeke, het leek Folkert een goed idee om jou te vragen 
mijn proefschrift in elkaar te timmeren. Hij wist dat je het kon en hij had gelijk, het is 
mooi geworden! Ik heb erg genoten van onze samenwerking, die, alhoewel voor het 
grootste deel per email, erg intensief was. Heel veel dank! 
 
Jan Kees Karelse, beste Jan Kees, wat ben ik blij met de omslag die je gemaakt hebt 
voor het boek!  
 
Dick Bruna, held van vele (volwassen geworden) kinderen, ben ik zeer erkentelijk 
voor het ‘uitlenen’ van Polletje Piekhaar voor deze gelegenheid. 
 
Ineke Polder, lieve Ine, dankzij jou heeft ons gezin de afgelopen 17 jaar zo goed 
kunnen draaien, en bleef het huis schoon en de kinderen blij, terwijl Folkert en ik 
werkten. Daar ben ik je enorm dankbaar voor! 
 
Nicoline van Voorst Vader-Boon, lieve Nicoline, met Jet en Hildegard werken we al 
jaren zeer harmonisch samen in ons kwartet; dank je van harte dat je me ook hier 
terzijde wilt staan. Je ziet dat er ook in niertransplantaties muziek zit! 
 
Petrien Uniken Venema, lieve Petrien, onze jarenlange vriendschap heeft de laatste 
tijd een dimensie erbij gekregen. Ik ben blij dat je mijn paranimf wilt zijn! 
 
Lieve papa en mama, dank voor de niet aflatende belangstelling voor mijn werk en 
de voortgang van dit boekje, het heeft geholpen! Ik zal je aanwezigheid bij de 
promotie missen, pap. 
 
Lieve overige familie en vrienden, zonder jullie was dit boekje er misschien eerder 
gekomen, maar had ik veel minder plezier gehad! 
 
Folkert, love, je brengt muziek in mijn hart. Hoogste tijd om achter de computer 
vandaan te komen en samen, en met onze fantastische kinderen, leuke dingen te 
gaan doen. Morgen zeilen!  
 
Lieve Jurriaan en Eva, jullie hadden gelijk: ‘het komt allemaal, allemaal, allemaal, 
allemaal heus wel weer goed’. Met jullie muziek, zingend, of spelend op piano, viool 
en zelfs drums, maken jullie me he-le-maal blij. Ik ben trots op jullie! 
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Curriculum Vitae 
 
1972   
eindexamen gymnasium beta, Rhedens Lyceum te Rozendaal (Gld) 
 
1972 – 1980  
studie medische biologie, RU Utrecht, doctoraalexamen cum laude. 
Doctoraalvakken: neurofysiologie (Nederlands Herseninstituut, Amsterdam), 
farmacologie (Rudolf Magnus Instituut, Utrecht), immunologie (Lab Immunologie van 
het Wilhelmina Kinderziekenhuis, Utrecht). Een deel van het vak farmacologie werd 
bewerkt aan de Addiction Research Foundation in Toronto, Canada.  
 
1980-1984  
studie geneeskunde, RU Utrecht, artsexamen in 1984 
 
1984-1988  
opleiding tot kinderarts, Wilhelmina Kinderziekenhuis, Utrecht (Prof Dr JW Stoop)  
 
1988-1990  
werkzaam als kinderarts bij de afdeling Intensive Care Chirurgie (Prof Dr J 
Molenaar), Erasmus MC Sophia, Rotterdam  
 
1990-heden  
werkzaam bij de subafdeling kindernefrologie van het Erasmus MC Sophia (Dr ED 
Wolff, opgevolgd door Dr J Nauta), de eerste jaren als fellow, vervolgens als 
kindernefroloog. Vanaf 1995 vormden niertransplantaties een aandachtsgebied. Een 
nationaal samenwerkingsverband werd opgezet en gecoördineerd. Daarnaast werd 
geparticipeerd in de landelijke transplantatieorganisaties Nederlandse Orgaan 
Transplantatie Registratie, Transplantatie Werkgroep Nederland en het Landelijk 
Orgaan voor NierTransplantaties. 
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Transplantatie Registratie, Transplantatie Werkgroep Nederland en het Landelijk 
Orgaan voor NierTransplantaties. 
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